<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:void="http://rdfs.org/ns/void#"
  xmlns:dcterms="http://purl.org/dc/terms/"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
  xmlns:foaf="http://xmlns.com/foaf/0.1/"
>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8276b4f9-deb2-4f36-b515-0b0b09d02a07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a2553ac-c081-4478-9073-b0422699a54d"/>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc28e1d8-5f75-4dc5-addb-3df7df78c0ea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9cdd8b81-2773-45f5-8593-f85deb05efbb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ee26c24-b54b-454b-bb49-ca4e7c99fe95">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28688703-ac46-472d-9674-a22ab8804521"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff">
        <rdfs:label>Hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
        <dc:identifier>ECO:0000352</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/246a5c65-dd9c-4912-b9e5-c8c569c3e55a">
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ac988235-cf88-4b99-ba7f-6723e4df0c65">
        <rdfs:label>LPIN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/9521a638-b49d-4d52-9433-385ddfc1e996">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1ce5e96-2ffe-48d0-a553-974033a4beee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46a5137a-db77-493a-802c-0f95ccf03121"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f495e800-ae1b-4440-89e1-2ba68f7a969c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05d4acfe-bfa6-4e86-ba50-efc345afde8e">
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a1b9a83-5de1-4697-8428-aebe1c86a405"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/190a2ccf-28be-4e9d-9a42-9bf098572388">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92275ab2-c104-4847-a3eb-78e418dd3b1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70c9243b-30d6-4314-b71f-c240af5f486d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cfc39c2-99af-4766-aa52-9551b04f84ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1813366a-769e-44b7-9dfe-4273606f66fd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>The study was terminated</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/860189f8-041c-4023-9869-960fe41917fd"/>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ac46306-ac13-4327-9de0-5fbe5fb02936">
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02aa1086-40ec-47ae-b17e-9919e9204fe0">
        <rdfs:label>PYGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/63880a7f-9326-4e19-ad0b-90268e3c4f8c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e87994b9-7dbe-4b10-aaf2-7d5a4af6e4d4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:label>Functional motor deficit</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5cafaa17-1083-4cf0-ba40-e5fe8b2b50ff"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6da6f6a3-2b12-4b0f-bb40-be37c68d39b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c072f54-5164-4e61-9ff1-0caa64c4f944">
        <rdfs:label>Cognitive impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/887aeafd-ce35-41ab-a501-fa20e0e9e016"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c4cd648-e838-4894-b909-5a7ffc790a13">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7b4f9b0-172b-4909-bb34-c9e60562dbea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025356</dc:identifier>
        <rdfs:label>Psychomotor retardation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/675ad02d-1575-4863-a809-fdd4716f2d23">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <rdfs:label>Petechiae</rdfs:label>
        <dc:identifier>HP:0000967</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e328d37e-191a-4850-85ab-1f405bb8f1ed">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7ae98fb-5085-4da4-8105-ef1978f71028">
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/24064803-7fb5-481a-9199-ed8d2ad43c02">
        <rdfs:label>SLC5A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/85eecdbc-dca3-4cd7-8e20-628a0c50ed8a">
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2982511f-2382-483a-be0f-641dd36cb709">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
        <rdfs:label>APOA5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein A5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f4469f4-29df-44a0-8e22-02366416f689">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/476ecd8c-0190-4394-a929-8d751809a1e0">
        <rdfs:label>HPD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86ddb188-4c1c-4d9c-9ba2-c1883297ecf8">
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd08eeb8-c1a9-404c-8e9e-ac07f30f6eef">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
        <rdfs:label>ALDH6A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eef5e219-d701-45a3-a25b-8162e394a02b">
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16ba1113-e039-49eb-b987-7666b07bbc5b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
        <rdfs:label>SLC6A19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e91f24e7-444c-495e-93fc-995e7aa18ea6">
        <rdfs:label>SLC36A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43cd5c79-d6d2-44ba-89b4-09bf17d00fc0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
        <rdfs:label>SLC6A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0b6848a8-6a29-4ab4-86c6-6a7649c8626b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebc36fa5-85fe-42f2-8512-e5c9e6f62d1e">
        <dc:identifier>HP:0000649</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9653c2b4-0fd9-40fb-a0c2-88c30580ac44">
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2c136f6-4454-4e72-a638-4cb6f834ddac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
        <dc:identifier>HP:0006958</dc:identifier>
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ff57eae-d52d-47ca-9c3f-88d56abde2f9"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5736d5f9-d827-4cfe-96ab-3fb568392665">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6016e1e-a8be-4e43-a7af-46864efbde33">
        <rdfs:label>Difficulty walking</rdfs:label>
        <dc:identifier>HP:0002355</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c91918ff-a49d-4c94-975e-be8b34e6d4af">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mental impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9dd94e8d-477b-40bb-9b33-46639078da3b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7e9e714-8348-4f0d-9a98-34461848590e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/84e60def-792d-427b-b25e-6d02c8a20974"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aec1fb24-78e4-46cc-b9fa-71e2fb05be74">
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dementia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdcf354c-1cae-499c-8e5e-e96f851ff6e7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <dc:identifier>HP:0012120</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a434aa2f-bc21-4687-aff9-54065ff3a190">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Emotional lability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/d7fee931-3fc9-4b4c-9f2f-d5dd8aee22e6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e99e2cd8-25c8-4414-a790-aab94858ff57"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbd06cbf-2249-4d69-a08f-e1676d42519f">
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/168590dd-cf7b-4f83-8ae9-0d361185e299">
        <dc:identifier>HP:0010893</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ff19fb1-c464-4802-85d0-c621f20d3471">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/29b43645-3cf1-4a1f-926d-1146c168f39b"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ececfbd-7e49-47bb-8f87-f13de36523a7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <dc:identifier>HP:0040086</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum  prolactin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67e85e6b-9e12-490b-93ce-0f7b5b9a7f8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9a18144-aa0e-4a91-a18f-0331883a1265"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000009>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6dc3d4ad-0227-49d6-be6a-eb32aa463d20">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60ff05d8-18c6-43f4-a777-24a3a8f3d6ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dd604edf-6220-41b2-8a56-8df649f58eac"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9663ab6-0a15-4bc1-a098-bc260f42719b">
        <rdfs:label>seizure</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/322a2426-1a16-4c90-881d-2656ac034101"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/48f75b1b-5d45-4582-91aa-134714332dd3">
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e77c9979-a509-440b-9681-4f05fa5a4848">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
        <rdfs:label>CRAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d463ddfd-37a6-4a87-ac1c-8c856fc11247">
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd337144-4043-482b-a1f9-9dadbd45c0c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c8817a9-5b3b-4d8d-8c8e-9ad708570a37"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28b58ed1-119d-4c80-969d-51ebafc23833">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53954d1d-e8ab-4ea3-b223-79b66f0574de"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbd06cbf-2249-4d69-a08f-e1676d42519f"/>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/19592c8b-7ac4-461c-9335-d392e5636784">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
        <rdfs:label>SLC1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db1270e9-6401-47e1-95e5-c1490ca0ee61">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2782116-685a-469e-b74a-3ecc1cdaae97">
        <rdfs:label>SLC7A7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/328b25e0-7168-40ca-b0ee-1b6d631a71ec">
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/08596620-7dec-4e61-a957-13f049476eeb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
        <rdfs:label>PIGT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4a8ac6d1-449f-4b1f-a3cf-ad47e783750c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c054ee2c-563f-48a4-94c1-c6e855db7bb3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06432aa2-8544-4499-a64e-64959a55d117">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53955de4-6cd0-47eb-b239-28b6649224db">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/56a8921e-4189-4957-86a1-6a52eaa94534">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/808ed7be-232d-433d-80f8-a8f7b8bcbb59">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a5efe4c-9030-4149-bf8d-bfe164b200af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a7e4e05-bdac-4206-9dde-298928019c97">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
        <rdfs:label>GNPTAB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c5095170-e4af-4be1-a3f1-b31c3d6826ec">
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e96950c0-d49b-4c49-8dff-bea38e3c71f3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
        <rdfs:label>GNMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e0743847-5f6a-42eb-96b2-7f4f5bc66fc3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26419a46-eff5-4033-aca0-65cc2c62dd47">
        <rdfs:label>Developmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/94c1c28c-bb8b-48cd-8c77-0d8ec0f004c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d67b18b6-1433-4f36-8e40-10c85a37c159"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f026a32-9bc7-49bd-8bef-582a9bf204cb">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/418fc420-0dae-4ef8-aee0-05e0bace33f5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010863</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:label>Delayed receptive language</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9fea9754-ed57-47d1-995b-a4fd578c85cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/493bcc49-ab4a-4146-a49f-43b9bd30e922">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/79f1e03f-e850-4345-8789-4a577de59a0a">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2072adc3-4db4-4299-8fff-8bd973853bfd">
        <rdfs:label>low muscle tone</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5519ba9e-7f3f-4a61-851b-5eadc6b4618d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48e9cc43-0084-4e1f-a1e8-ef0d62fbbd6b"/>
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c0cecba7-a02f-4608-8beb-07c211e3912a">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a9abb129-3c5c-4ef9-a1e4-12f159e83deb"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63600574-5939-423f-9eae-77308fb7c043">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cbcfe40b-428b-4dce-9ba0-e6ed816c68fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebdd6e09-1ad1-4330-93a5-7e96d8349e09">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b33a91f6-1921-4821-a467-96d8faef59cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c70dc0b2-1306-4024-800c-ed089d1a9b88">
        <rdfs:label>Slow recovery</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
        <dc:identifier>HP:0012823*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/381bc135-a348-4823-bfaa-199a6a414055"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ad77d5b6-e530-4b40-8195-1915e172420f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e067b8a-acf9-4871-8a94-f24185249f15">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06f62ce7-8914-49f4-9392-6c680d2571e2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
        <dc:identifier>HP:0030890</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b872fe3d-0243-47c9-b742-cb2d379cf60b"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cec1039b-a706-4718-8c6a-00c143c271dd"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5132b34e-1ea9-4213-9fc3-8dd7b1e550b4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6128cbc9-4eea-4b1c-ac5f-d53a1a222b21"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16b206fe-c2e1-465d-ba06-99b2970a2391"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b579ba3e-1af4-4e28-8ecb-a2ef8ed076d4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1bb76fac-f9ba-402b-b6a5-ea1b6ef1a2f8"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9cf08971-cff3-48a6-b99c-4960a532ab70"/>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/86a8940c-7247-4d1b-8fd8-daa96f1ebd3a"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dc8635a7-3f72-4873-ab9f-357ccd63745e"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a21e28b-9864-43b2-a255-c680642435ed">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecc992f6-dfdc-4b42-b666-19bf4f499863">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Stroke-like attacks</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebdd6e09-1ad1-4330-93a5-7e96d8349e09"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff536e06-90aa-4745-a88a-097707612b2e">
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a5eb3520-3d59-42d4-b756-f612ea545ea6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cd38fa90-11a9-4187-b0df-70d964e16f2a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4413dcf1-8755-4fb5-867c-cc9ecab61a09">
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff43ae32-cfc9-4199-ae0e-7c28aac71417">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/e7a8e0c3-4f63-43b2-b829-1d1aa8fe7523">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97f7d415-94ee-489b-846e-0f2a2c9d54a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ac582d3-3915-4643-98b1-dd75096bba66"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f026a32-9bc7-49bd-8bef-582a9bf204cb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e0d05edd-9883-4328-802a-a7f7950b4113"/>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6aeb9bbf-83a2-4f1a-9511-44eb7beb5418">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48eb383a-ae46-497f-b00d-553cc112552e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b883ce2e-1794-44ae-82d5-8b4bbeb87118"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44a5315a-0d2e-4994-9434-18dbb27492bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82ef51ab-413e-425a-8eb1-4559c1a14bbc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7cdfd959-984a-4dd8-8c3a-f7672e8f49da"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a52833a6-dfab-4e35-80d7-94bd8319cf57">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <dc:identifier>ECO:0001565</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/418ff31a-ce20-4793-8987-fcffddc7215c"/>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/949ca51f-1ad5-48e6-a1b2-d6c69b02c81b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af48ea38-6f9f-4779-a118-1e3f01616b8a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca44c2e7-dce6-4b2e-bffc-92a6f74114d5">
        <dc:identifier>HP:0012444</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
        <rdfs:label>brain atrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9082c40d-01b4-4efc-86fa-5085b3585552">
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57f11abc-52e6-4671-bb07-356d8654f0b6">
        <rdfs:label>POLG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75fd33a3-a3e8-4e22-af45-72a2ea7c5f5a">
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <rdfs:label>glutathione synthetase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff4425de-1564-4dce-9a70-d7ec9f218ddf">
        <rdfs:label>GSS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a63ca24e-809b-41e8-9fc9-4d059610091a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
        <rdfs:label>GALK1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fb19efdf-529c-4bbd-91b8-6b455cc01dce">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a406962f-1a6f-487d-906f-6e9c02bec894"/>
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf9689c3-9345-4149-984a-7048affa8575">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/940fad52-df38-4266-b6d6-8664b9a562ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd19cad3-bf59-4cf4-8ddc-a8abc89bfa2a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
        <dc:identifier>HP:0002664</dc:identifier>
        <rdfs:label>neoplastic growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b36f0d7f-4806-4df2-ae39-d99fbcb3c75a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5377516-8641-48f9-9338-aa803eb31634"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4bb933e8-e1b4-4b68-9d9a-12f573206bed">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d33ceb0e-5068-45db-81de-48f46c856414">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3d239f8-c2a1-4e73-97b7-46d42541c917"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
        <dc:identifier>ECO:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/753e88c3-b9b7-4412-bff3-794841e7799d"/>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f03809f7-614f-4891-9a7d-df0f556bc12e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <rdfs:label>Muscle dystrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006785</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ab4bf6a1-be98-4d2f-a585-064b6099e4cb">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b7aa867-b8be-4e9f-9633-9a57e78462a8">
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b3cd836c-c337-41d7-9ffc-8eae8970a747"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/632f6789-40e5-4248-a860-b4492fe34f8f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c06a12b5-0358-4b69-bcc2-b7598af940f1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f72970ac-356a-4803-aa9e-1041db89250e">
        <rdfs:label>Motor function impairment</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67a94138-a939-4695-8d68-f67456b5d92e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76baecde-58ad-4938-8b20-d58606a48504">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/929fa139-4970-48c8-bf9a-8c883125bd88">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2fdb7e71-2d3a-4970-bc5c-bbe300074873"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46578862-b762-4d82-aebc-68385141bca1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d66936f9-34da-47c7-bdab-6cc064c1159e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/130b91ce-f38a-4219-86e8-18807d0a4dd5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Splenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/46b36357-b6bb-4931-b86e-a049a25f7805">
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9f8555b8-6ae9-416f-9204-847b70be6b80">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
        <rdfs:label>ASL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e22eaa0e-0341-4ff3-b746-efbbc6e2e046">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
        <rdfs:label>MANBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/78c96482-6ae1-42a1-a345-fe5806a78b21">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21564044-58be-4ea5-a23b-f3f0b388e971">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
        <dc:identifier>HP:0003234*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4a6ebe10-4bb8-4cc6-8bb6-0f4900ee015c"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/26aad291-8305-4b70-8061-f9104ac7f823"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/021e6089-87d3-40ae-9c62-9221f3f0ee17"/>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9790428-a212-49e3-81b3-988a9278c7cd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f">
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Muscle weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/91461357-5d5a-46d2-af85-b0acaf593bbf">
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dfd2654d-bd41-4a0e-9031-bf9f3a359f0b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
        <rdfs:label>PCBD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8d808ce3-eb97-4645-8379-e1e151e0df8e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5b9a059e-94fe-4d8e-b76a-65ffe3994a6d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
        <rdfs:label>CP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <rdfs:label>Ferroxidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/439f5871-559c-411a-994d-e5ee523076bd">
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b25feea-3ab5-46fd-a9d2-147c02987765">
        <rdfs:label>GLUD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ea83756-36f8-41b1-a56e-49c5dc0ca497">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6cb1dcd0-1855-42b2-aec3-3d518c737daa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
        <rdfs:label>CYP17A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/37cc039d-901d-4b78-a689-c1a7c11500b3">
        <rdfs:label>LDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7a3cbeb9-a2c5-4623-9569-2857942ddd4d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a833785d-8550-49b1-9139-67417330062b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4f73c6e-55bd-4e39-8e10-776eefb18458"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4e128cd-9566-42dc-bf2a-19a0f1a0532b">
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/170c5c6e-6f9b-48a6-bcc5-ac80ef84ffd3"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b1e22b97-c3a3-4ba3-a914-912322396095"/>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d163a896-211e-41c7-8f83-4310b5852d69">
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/c8737009-c4ff-4f11-a63c-69e2b1b44e0f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a833785d-8550-49b1-9139-67417330062b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/884c49a5-7447-408d-ab54-03ce26c02a5c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <rdfs:label>Metabolic stress</rdfs:label>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d4b2f5b-1664-491e-aca5-f49be37afba8">
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26419a46-eff5-4033-aca0-65cc2c62dd47"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db72a65f-1d24-4bcc-b298-5440cd4297fe">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/017eb299-05dc-42dc-b859-228b907b687d"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5e11b77-6b12-4c8d-9025-d6adc3133a05">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:label>Metabolic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e5030848-87b3-4f72-bc67-8bdd01ac4952">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9f8555b8-6ae9-416f-9204-847b70be6b80"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6">
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>Hyperammonemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e65c5faf-69b2-467c-be7c-caaf7f151e38">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdb79641-2c71-44ea-9584-ad9e178b7ee3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4f5f4c4-8a00-45b4-9ebf-9cdb2d206234">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10ee8be4-d0ae-4bc5-98ff-271f9474ca33"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b02cfe1d-55df-4571-92c8-701f46af58d5">
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f445d143-01e2-4959-b940-50d896d32fb6">
        <rdfs:label>SLC12A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/04056e46-8f41-4e7c-8487-ff8d776e71c6">
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/93b2da91-eb5f-4157-bef0-6a0197e92739"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/493da7e6-3d62-4718-80aa-dd43b6974978"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49b340fe-6468-40d6-afee-2504daced046">
        <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f398bd6f-1e27-48d7-88a4-1528f4081b23">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6492a1af-250c-4ede-bbfe-2eb1e13032e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000015>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac66d331-845c-4da2-89b3-6db32f4bb711">
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad7cec19-111f-4c31-9ebe-01adf693e189">
        <rdfs:label>CTSA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4324fbd6-fa66-4008-87ce-8067a91f2967">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f25435b-10e1-4726-b3c8-b9e80ca99ad6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
        <rdfs:label>CYP27A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5eaa60c-9094-42a7-89ff-1e5e71644112">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f94b92c-579d-46ec-9148-9ff2851d115e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a957ab3-a844-44a3-b5b8-0739871eb84d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2eaa77f-592d-4137-b675-f30186fba1cb"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22452ff9-1234-4184-828e-588a7c621284">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11c3b432-88ce-45c5-a3dc-9df00c4a9abc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49daeb96-c37a-48d6-8fd6-8f7e3bfb99b5">
        <dc:identifier>HP:0001250*</dc:identifier>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe044a2a-da7d-4c9d-98b6-93da46b8c5db">
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4e090e2-db54-4af0-a6cd-d51909906fee">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
        <rdfs:label>APOB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d55df8b1-8354-4552-a0a9-ce3f973c90f6">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1162cef5-2a67-4a5b-873d-c544e69b1939">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80462ebf-f5e9-4eb9-be8e-97b21c8ded02"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73591acc-aaca-4d94-998b-051b7bc02693"/>
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c1b902b3-7b88-4d26-beb7-e65e5170f296">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b25fec0-c1b9-4675-9827-967769621fc4">
        <rdfs:label>FOLR1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
    <rdfs:label>Folate receptor alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b96b8d54-f6ac-4714-b582-bcaa75ec8e59">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8884c14a-466d-42d0-b76f-b83700df5de3">
        <rdfs:label>Dehydration</rdfs:label>
        <dc:identifier>HP:0001944</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1ce5e96-2ffe-48d0-a553-974033a4beee"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d658463b-ffd3-484f-abec-b82343babbc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90910d1f-e837-4741-bde5-078058707f43"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/24064803-7fb5-481a-9199-ed8d2ad43c02"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbbd3f6c-24e0-48af-8363-39c6b96260f8">
        <dc:identifier>HP:0002014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ee2e18b6-13af-4344-922c-9bfa1d496011">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/638c9e56-e17c-4000-81ba-5deb96d73fca">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
        <rdfs:label>SLC17A5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/952ad6c9-d5ac-4cf7-b2fd-982ee4f825c6">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e0c87aa9-169b-40c2-b80e-fd43c3d27b8e"/>
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6016e1e-a8be-4e43-a7af-46864efbde33"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8818a71d-316e-4750-aae0-234d58376664"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/281fac5c-99e2-4811-a697-97cf0ecf90be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39593b8d-673e-403e-98b5-9e4d6a8e6d3a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84b5b785-f374-4635-9737-05353dee88e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1388fd71-0653-47c2-b3ca-88c184721e24"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/89b7fee1-f930-4f39-8c4a-6510881ae623">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6bbc605-8547-4c4a-b3a4-4cf19f74a4ef">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
        <rdfs:label>DYSF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
    <rdfs:label>dysferlin</rdfs:label>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/759e9ad8-d453-4dcc-a9ac-b7104aef825b">
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4194c11-30ee-4638-9710-e3d89550768b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
        <rdfs:label>POMGNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b9ed622c-ac30-4e17-87fd-360a46923cd0">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fd8781dd-a2aa-4e3b-b7bb-055927baba42"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47138941-123b-480c-8ed0-cdc6f1347b96">
        <dc:identifier>HP:0012638</dc:identifier>
        <rdfs:label>Muscular abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e067b8a-acf9-4871-8a94-f24185249f15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/debd6209-2094-4de2-8ebf-78e6fda90067">
        <dc:identifier>HP:0000505</dc:identifier>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f75eab3-0012-4cb3-aaa9-88349904d654">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d49dff07-ed6f-448e-a7e0-8f79df68ddd5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6aa2f11-3950-41b6-bea8-57952df0fd6d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2db2c767-4267-40a6-861f-212b17d0e814">
        <rdfs:label>DBH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67266e8e-b35b-4b5e-b425-7d65635b3d9f">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a9abb129-3c5c-4ef9-a1e4-12f159e83deb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-ND4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c388aadb-473b-461f-abbe-5ff52c4963ed">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2982511f-2382-483a-be0f-641dd36cb709"/>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8abf5fbe-8cdf-4eed-b66b-8dc290b69a0b">
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4080e804-813d-462c-947f-4f81bcd7c92e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
        <rdfs:label>POMGNT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/60b8d88f-0b6d-4c54-9caa-ad8cb70bffa6">
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f711200-8f9e-4598-9d4f-e6a1541efd87">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
        <rdfs:label>PPT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f123702e-5ea7-4ffe-84fc-9afdcc7578a1">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/724d636a-7031-497f-bc13-da87d8986310"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36e27b09-da34-48a9-b220-fb83563a4139">
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <dc:identifier>HP:0031517*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c70e828-df6f-43f8-ab41-8631efec153e">
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Itchy skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb781d9c-211c-4f79-af68-f28faf7f7480">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007431</dc:identifier>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49c4c321-e075-4740-98b2-96df934560a0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>Scaling Skin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d01c2ab-9a52-4879-a89e-7b66fa0305b2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>VX‐like lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3685f7d-2440-4140-9ec5-3c15e5f9ea86">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <dc:identifier>HP:0010783</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f398bd6f-1e27-48d7-88a4-1528f4081b23"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ae77d57-a69f-41e4-a569-70f493efce5b">
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8bd67bc-1058-436e-a0f0-b6cca852d167">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
        <rdfs:label>MPI</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4413d843-e609-4a5c-9262-94ec946d174d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/933d5ac4-c22f-4e87-a0ee-6ad509fe7501">
        <rdfs:label>HJV</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d9bbcc6-fb37-466a-ac09-67d06bfbb400">
        <rdfs:label>HAMP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/50dc8126-1571-4ce1-a431-cb40964162e9">
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d2e15354-ee2d-431b-be03-49e514017134">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
        <rdfs:label>MVK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d708bc63-a536-4dd5-a941-4ebbf3e3b5c5">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b458ce23-fadd-4186-97be-0f5c63a06b09">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad23c817-48fc-461e-afb0-40d653988546">
        <rdfs:label>Bradykinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002067</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02316261-9420-4f8e-bd61-bef897df2ae1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4072cecb-28ce-4548-b59e-2b64779bd09b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09c408ec-4b85-4255-8f3c-722ee2968c5a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e">
        <rdfs:label>Dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/626c8bf9-2ba7-4d39-81c4-eed38fbe1862">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Kinetic tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
        <dc:identifier>HP:0030186</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f514d402-cc47-4442-bd22-1e9e4d378566">
        <dc:identifier>HP:0002174</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <rdfs:label>Postural tremor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28b58ed1-119d-4c80-969d-51ebafc23833"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef4aca57-7acb-4102-872f-40a4d8ae2187">
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e85adc0c-1aba-4af3-8104-0da2d5c6c80d">
        <rdfs:label>DHCR24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0457ca85-bff6-4729-8232-ff30417e76e2">
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d7f7df02-ada9-4cf4-b827-9d1a5124af17">
        <rdfs:label>CHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf792886-bca7-4e9f-84ef-3cccc357014a">
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20185e78-45fe-4105-9b4c-e484b85382e9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
        <rdfs:label>TWNK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/100eecef-0b63-48c9-bcc7-2074e11f744d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d36b748d-88e4-4c19-805b-16d9af5448e0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66b6a0b9-5fad-4ad2-aa35-a835905ed442">
        <rdfs:label>Glutaric acidemia</rdfs:label>
        <dc:identifier>HP:0003530</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ef9d6f4-eba3-4855-b168-a33c009bf410">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4eedeab4-47b6-4891-925d-98d9fa161b23"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e65c5faf-69b2-467c-be7c-caaf7f151e38"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4924f0b3-770e-48b8-80f0-b1971a5e065d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92bb383b-c113-4fda-a7dc-23858e82e7c2"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f0cf917a-b651-4977-9151-23a9fdc7ec29">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5dd929dd-2151-43b9-9188-2e6755094889"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/576f6f52-b193-4113-bf88-17397e3b670d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f98fa39a-835e-4c16-86a4-04006e37049c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ead683cf-3d68-45d0-b551-0af4631f7bd5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbed34d3-b91a-4f12-b309-3935795959fc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7856377b-4a7c-4098-9c1c-7219d5cb99c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short stature</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b7cb5eef-bad2-417e-8b84-567d438982b2">
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/793705ac-9348-407e-bbe6-fce9b3109eed">
        <rdfs:label>RPL35A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/861de82a-9027-4fee-94f5-ec6af14cb9f0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
        <rdfs:label>RPS19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21fc85b6-22b2-4a27-9fc6-31744a0a0380">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
        <rdfs:label>RPS17</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e611bb6e-12ff-4d76-8ec1-f5c8262e2adb">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
        <rdfs:label>and</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5ecfc5dc-af02-45f0-9e98-6fa34ef79dc0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
        <rdfs:label>RPL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1842b0e6-76f7-4c40-9d56-c48875aaf23a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
        <rdfs:label>GATA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b7243f30-b160-4c1f-a571-ed16b7ca3ee7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
        <rdfs:label>RPS7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33728497-27ef-443c-80a1-4ff126ec7e78">
        <rdfs:label>RPL11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3bec90e5-90b9-486f-a07d-0153fd0f9cb5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
        <rdfs:label>RPS26</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/845cd622-a245-470e-a815-a30fe93213ae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
        <rdfs:label>RPS24</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c8fa9d3a-22ff-4c67-8f33-a9bfb15cc1bd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
        <rdfs:label>RPS10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7c53a3b0-7325-46fe-aee2-1cd26b5f6610">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
        <rdfs:label>ALDH4A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <dc:date>4.10.19</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0c51bb15-14d9-4023-b17e-8c65ce17f0e5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7875d0a2-38ff-4068-9f9a-655fd0d4eb18">
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/752ffb20-1c5e-4c1e-8591-526bcfbed889"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92275ab2-c104-4847-a3eb-78e418dd3b1a"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6516933f-1aff-45dd-9e13-14cf5c58f2ce">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c13a8160-acdf-4531-9680-36a4b89fda0c">
        <rdfs:label>Abnormal liver function tests</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a5973f7a-bff7-4a7c-bf67-ce59bedafd50">
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5170203e-79e3-4b6a-8a3c-855dfadce947">
        <rdfs:label>HPRT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e41ddff3-a37b-41d9-adaf-85d540e3e6c8">
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc1ffe76-b879-4c13-8329-ca8e39145b38">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
        <rdfs:label>ATP7A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b2fa9aec-84fe-4c27-8284-799058a5c91c">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ccc94f1d-5903-478a-bbdb-e5fc6ad3dd1c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
        <rdfs:label>PSAP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>Prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/753e88c3-b9b7-4412-bff3-794841e7799d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
        <rdfs:label>POMT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5b8051af-4d94-4c92-ad11-b86b17b2624e">
    <rdfs:label>barttin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f6c3e6f4-a3c7-45b0-9216-2ca1e65ef550">
        <rdfs:label>BSND</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3df26b91-01a1-4704-a6d0-27d4110716f3">
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/724d636a-7031-497f-bc13-da87d8986310">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
        <rdfs:label>NSDHL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3fd7774c-9972-4d6e-979d-9d31cd92d815">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/994823bb-498f-44ce-aa8e-bcac7ffd38e1">
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:label>social interaction defect</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2782116-685a-469e-b74a-3ecc1cdaae97"/>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71c8dc0d-6baf-40db-b958-b1e9d8fb6954">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e629a614-d76a-45d0-930d-0b8dbf2836c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8c018e4-7007-4561-ba64-22a8007914f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ecd4c37-ee83-4c43-8e0a-00ca61b7b861">
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7209ab7-569b-4a82-8f62-17b74381896e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/652d81e9-1eec-4843-8394-6ffa07aa718f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d59ec338-3aad-4ccb-8a0c-0a71115ef5e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e8ff6b9b-1477-46f4-95b0-4e7263d5be4c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3bd38e1d-969a-4d59-bd88-89a6171dbf25">
        <rdfs:label>ABCC8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/55b7b488-1f0a-41bf-88cd-5fcc16f4fdeb">
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9554b9c3-4e35-4dc1-9152-4acb3d1d0a1c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
        <rdfs:label>FBP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cd10db2d-299e-44dd-a4fe-17f158006827">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/81d37d38-61f7-45f0-843f-202e441455d2"/>
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23694d9a-1bec-428b-8ee2-471f6096b366"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff1d3dff-9377-436d-91d2-0e695701cf63">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/074576ef-d393-45b6-ad56-3c75dbe6951d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/acb3e872-972d-46fa-99dd-10450ad9d1b8">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9653c2b4-0fd9-40fb-a0c2-88c30580ac44"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdcf354c-1cae-499c-8e5e-e96f851ff6e7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/74449e80-43fb-4d58-883e-86675b9a1e5f">
        <rdfs:label>MAN1B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/dceb10bf-8d86-4259-90ce-db83e985cbc9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43762c06-ef7f-42a1-ba7e-d58b38c45f18"/>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e31cd01c-c817-48c4-b89a-55b6133cc04f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3bde5216-aaf1-4578-b749-18e246b4e498"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6785375f-4e50-4e06-8882-7b0c686e6c1a">
        <dc:identifier>HP:0003162</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d31ca0be-daab-4247-8ad0-f940b97d4bfc">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/957ea850-5f08-4c0c-9a5c-9809aa439f42">
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3dd518b3-14b0-435e-a911-42b7b38af839">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/138ee07c-5270-4a65-94c8-6d2948ee905e">
        <dc:identifier>HP:0000991</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>xanthomas</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9df52a5f-fa28-4a66-9e60-9282a8329f31">
        <dc:identifier>HP:0001677</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b68eef9a-5c7d-4d5f-83aa-80fe3bc733ad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e8010c6-f0cb-4ee7-ab89-314ba7de3c6b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa4f2e96-0dc7-4c5f-9542-cbfce3df4538"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c93fd509-d496-414c-bb29-ed2e897ac3ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21353248-18d3-41cd-8f21-d6ea01f36578"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48e1e0cf-1186-47a1-8074-fefeb42f1f64">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>angina pectoris</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <dc:identifier>HP:0001681</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/620a1b73-bb64-473a-acef-90b7c56b3984">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c665d45-5cb8-4f2f-9796-c61e30779058">
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9da8a637-b31b-4d5d-8d79-7672dbfc020f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/550ce3ed-7e7f-4393-8e99-019cb08e6423">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3252bb1b-5ef5-41dd-ac63-046d28bffbfb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63600574-5939-423f-9eae-77308fb7c043"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fdfa17c3-9a6f-4415-b504-4f8d96dca82d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d7ecfbf3-b80c-42db-b92b-80314a215926">
        <rdfs:label>ECM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/68236440-45b1-42e3-b716-cbd2a3e7139c">
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6d98d94c-6a15-4922-80d8-7339c2d440ea">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
        <rdfs:label>HMBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/033db97a-d1c3-49ca-aa34-1c25ad16322f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9421dbf9-2760-4c58-8955-8636aa5e305b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16a4eb31-c7fb-407f-9ee6-dcf8246ccd66"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8990a6af-244f-4db3-aebe-a2f8f9f94ae8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypertriglycernemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/daed9aed-c019-49ba-8175-210e066dd14e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2fda124-dd92-4e03-801d-8ce273d51b5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4e87256-0396-478a-81a3-284911681b3f">
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2df01971-c3a0-40b2-b273-45f85d67b9ec">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
        <rdfs:label>ATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a7ccd1c-5092-4e3b-a29d-f8be743925fb">
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/57f11abc-52e6-4671-bb07-356d8654f0b6"/>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/21d10f3e-149d-4765-a831-f8f181afdfe6">
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b57c90b3-f209-4ca1-9820-c29831a65fb5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0010e6d5-6bf2-4773-a181-4a4c2859521e">
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/90fd04d0-4c32-4881-877d-d3a7b502531d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
        <rdfs:label>DGUOK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/26a88e9d-df30-4d1b-9111-9a165c122412">
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1ce5e96-2ffe-48d0-a553-974033a4beee"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5891217d-5234-4597-8817-d3aa434e8bca"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d08360e3-c658-4c4a-8a59-7ab686f37eed">
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <rdfs:label>AMP deaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/96d28e82-5789-431d-baeb-9dd86315f46b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
        <rdfs:label>AMPD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/466bc43b-809e-40fa-b8b9-bfc8f5cac86c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d457a7ae-ca3d-4088-b2fe-057b5b390bd3">
        <dc:identifier>HP:0003124</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypercholesterolemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3ffe442-8c83-437c-99d7-c54c62c7bfbf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bebd8686-b92a-4c09-9541-a3449e00f19f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4924f0b3-770e-48b8-80f0-b1971a5e065d"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/35407d1a-b0d6-42f0-b7a2-18e636b9bc4a">
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8279242-f879-4372-acd6-b3e4f9be728e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/315c1d5c-3442-4a21-9a5e-cb1c378c0c49"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fa9e117-faf6-46d3-8f42-2a43c6aae9bd">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9d920b9-52ca-4ef5-a188-4d3bff397e30">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>cognitive imapirment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/059e512c-c695-4c0d-8f13-ac4fc52a5fe0"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93b2448a-3b4a-4c32-afa1-38ecae33f03b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <dc:identifier>HP:0002354</dc:identifier>
        <rdfs:label>Memory impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14">
        <rdfs:label>Oxidative stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b6d6c0c-76fa-420b-99ab-56a2117e85ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86fa7cb0-e9ce-405c-86ea-3c67f093e3c0">
        <rdfs:label>Learning impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <dc:identifier>HP:0001328</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/69f3daca-3eb5-44e0-8f23-b21d1b270090">
        <rdfs:label>ENO3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/830b7d90-f2c9-4117-98bf-261f66018a2e">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <rdfs:label>prosaposin</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ccc94f1d-5903-478a-bbdb-e5fc6ad3dd1c"/>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6ebc24e-dd9d-4893-a9b7-8ce66e5f871c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/35de6bf9-e2fb-4307-ae09-252589a84133">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
        <rdfs:label>OPA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/e63fdb2a-f090-4937-8325-7621ad73ca6d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0ea3b4d-d969-4df5-b4f2-a4165fccfead">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/554bb998-00a1-4006-9571-69ef0c9eed50"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/890e349e-ad83-404b-b127-97ea84a6f7a4"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49bfdf5c-2a0b-48ec-ade1-0ff482e4257b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/37eeba86-e2b5-474e-a6de-c22634d21dbf">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c0ffbc06-2a50-4fdb-899a-b2f72b82e11a">
        <rdfs:label>CTNS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3642f2d8-f700-4798-89c4-2374bc580328">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b3e4307-3369-4dc8-9aad-b6f25b0d6dad">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
        <rdfs:label>AP2S1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6569e06e-a1f7-4d2c-92d5-e3aed2e6384e">
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/439ffeb7-a52f-4dd7-ad5d-aea326df326a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
        <rdfs:label>LMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/60dd8445-1787-45b1-b4c6-baa3fbe6ee8c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d"/>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da5b66fc-6371-4c00-92f0-0672ce85bf4a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>Impaired renal function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2496678-525b-4531-bea7-8dedf68fde78">
        <rdfs:label>Spasticity</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/198cfe84-594a-4eec-a42e-5248892bc258">
        <rdfs:label>Haemolysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdcf354c-1cae-499c-8e5e-e96f851ff6e7"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f63372ca-1f17-438f-b039-e1e7ca8c4692">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>Fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9653c2b4-0fd9-40fb-a0c2-88c30580ac44"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e2e3fdc-41b0-471e-8f43-c067e279acd5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:label>Anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf6c2d1a-de92-4283-9bfc-366d8f88d412">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012213</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b379253a-df62-4a03-8b79-e9b14c5a84aa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
        <dc:identifier>HP:0002395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d8b298a-27c6-4d46-904b-34dc58ec67f2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
        <dc:identifier>HP:0031258</dc:identifier>
        <rdfs:label>Delirium</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d68c89a5-653f-4595-86a3-00a839b9b886">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c46f80a8-5d02-44bb-b641-a06ba487f3f4">
        <rdfs:label>SPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f87d78e6-5a89-4ed8-ada7-3d758911f603">
        <rdfs:label>GCH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba80ee46-1c08-4647-a93c-83be39db3ed2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
        <rdfs:label>TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a285a82-d8b8-4be0-8c61-650f6fad3c0d">
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/720c4f5f-d051-4446-b436-abf1f9ffb8f1">
        <rdfs:label>GATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f45b93ba-4078-4e65-821d-0165ef68936c">
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25b5a865-7498-4ddc-b5cf-3d617b45543b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
        <rdfs:label>DPYS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8d67f5d2-3b87-441b-9a68-7e8c11f40205">
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b3cd836c-c337-41d7-9ffc-8eae8970a747">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fd8781dd-a2aa-4e3b-b7bb-055927baba42">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
        <rdfs:label>SAR1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0be60d77-abe9-4f52-b37e-316ae2378668">
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b5b1c072-457b-4ef6-ace6-e24c13451d48">
        <rdfs:label>HGD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/976246ea-f00e-410a-9c3d-0cbb550d21e1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/185d7b82-6bc2-4edc-b6e2-1eccbdcab05f">
        <rdfs:label>MAT1A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/59da9bdc-1f9f-4d9b-a5ff-405faa5c207c">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/692e9489-e7ef-48da-8d94-4f6f53621976">
        <rdfs:label>HSD3B7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24b5dd6b-479a-4c9e-ad7f-84c97be2dc69">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6910fb8-4b16-4a97-be57-973c06b71db3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6af03e60-df2a-40d7-839f-4bc0df44e447"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/291c5c36-a20d-46ee-a9a2-832d3e8d6538">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74d61ab7-b109-47fa-a8e3-b8e83bf97d82"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce47d227-40cb-4a06-89f3-07ff9026c7be">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80091ee7-4b2f-4860-81a9-3f89d11e786c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <dc:identifier>HP:0040088</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2df01971-c3a0-40b2-b273-45f85d67b9ec"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62f2da06-26f1-4d24-90b5-72f733360474">
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/26aad291-8305-4b70-8061-f9104ac7f823">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
        <rdfs:label>ETFB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/021e6089-87d3-40ae-9c62-9221f3f0ee17">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4a6ebe10-4bb8-4cc6-8bb6-0f4900ee015c">
        <rdfs:label>ETFDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e6185c2f-c1e8-42b6-912c-c97512daa9d1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cac13a80-ade4-472b-aa04-00d2e1bd5625">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <dc:identifier>HP:0025051</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low cerebral creatine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ad6b9a5-4920-438a-9f8b-2885122269e5">
        <rdfs:label>low brain creatine phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02330a5a-576f-48be-9fd1-24af213a0e80">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3b4e236-8d7d-452d-8247-ab1fb91433ed">
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8521710f-25d2-4273-b6d5-45c3deb2458c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
        <rdfs:label>abnormal coordination of movements</rdfs:label>
        <dc:identifier>HP:0011443</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6596b8fd-5bb2-4a3a-9279-3b4e2b768461"/>
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07732259-5e4e-4efc-85db-65e7fe9bc1a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a906de9e-0742-4713-9e22-4815088d152a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84b5b785-f374-4635-9737-05353dee88e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03767e6a-3e2b-46c6-b709-b0018616a480">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Epilepsy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebc9758c-74a6-43bd-99ab-ab301dd1e28b">
        <dc:identifier>HP:0012113</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87ad55c1-ee2e-439a-aa66-79d8bd0ad815">
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3cacf3d6-d955-4b54-bf21-abe291adb245">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
        <rdfs:label>SLC25A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c44145d-06b0-45d5-95c4-2b56f5b0da38">
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89b01278-75f6-4d53-829e-16a85a027d4a">
        <rdfs:label>DNAJC5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/70450684-b524-466e-ba01-9f660ebc8f92">
        <rdfs:label>RNASEH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/00cbf7b2-029c-4fc5-8263-b7507adfd798">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/059e512c-c695-4c0d-8f13-ac4fc52a5fe0">
        <rdfs:label>DLD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <void:Dataset rdf:about="http://ddiem.phenomebrowser.net/DDIEM">
    <void:sparqlEndpoint rdf:resource="http://ddiem.phenomebrowser.net/sparql"/>
    <dcterms:creator>
      <foaf:Person rdf:about="https://www.kaust.edu.sa/AllanKamau">
        <foaf:mbox rdf:resource="mailto:allan.kamau@kaust.edu.sa"/>
        <rdfs:label>Allan Kamau</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:creator>
      <foaf:Person rdf:about="https://www.kaust.edu.sa/MarwaAbdelhakim">
        <rdfs:label>Marwa Abdelhakim</rdfs:label>
        <foaf:mbox rdf:resource="mailto:marwa.abdelhakim@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:creator>
      <foaf:Person rdf:about="https://www.kaust.edu.sa/RobertHoehndorf">
        <foaf:mbox rdf:resource="mailto:robert.hoehndorf@kaust.edu.sa"/>
        <rdfs:label>Robert Hoehndorf</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:license rdf:resource="https://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:title>DDIEM - Drug Database for Inborn Error of Metabolism</dcterms:title>
    <dcterms:creator>
      <foaf:Person rdf:about="https://www.kaust.edu.sa/SenayKafkas">
        <foaf:mbox rdf:resource="mailto:senay.kafkas@kaust.edu.sa"/>
        <rdfs:label>Senay Kafkas</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:description>DDIEM - Drug database for inborn errors of metabolism is a database on therapeutic strategies
     for inborn errors of metabolism. These strategies are classified by mechanism and outcome in DDIEM Ontology. 
     DDIEM uses this ontology to categprise the experimental treatments that have been proposed or applied. It 
     includes descriptions of the phenotypes addressed by the treatment and drugs participating in treatment and procedures.</dcterms:description>
    <dcterms:contributor>
      <foaf:Organization rdf:about="https://www.kaust.edu.sa">
        <rdfs:label>King Abdullah University of Science and Technology</rdfs:label>
      </foaf:Organization>
    </dcterms:contributor>
    <void:feature rdf:resource="http://www.w3.org/ns/formats/RDF_XML"/>
    <dcterms:creator>
      <foaf:Person rdf:about="https://www.kaust.edu.sa/AliRazaSyed">
        <foaf:mbox rdf:resource="mailto:ali.syed@kaust.edu.sa"/>
        <rdfs:label>Ali Raza Syed</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <foaf:homepage rdf:resource="http://ddiem.phenomebrowser.net/"/>
    <dcterms:contributor>
      <foaf:Organization rdf:about="https://www.pdn.cam.ac.uk">
        <rdfs:label>University of Cambridge</rdfs:label>
      </foaf:Organization>
    </dcterms:contributor>
    <foaf:page rdf:resource="https://github.com/bio-ontology-research-group/DDIEM"/>
    <dcterms:modified>2019-11-19</dcterms:modified>
    <dcterms:creator>
      <foaf:Person rdf:about="https://www.pdn.cam.ac.uk/PaulSchofield">
        <rdfs:label>Dr Paul Schofield</rdfs:label>
        <foaf:mbox rdf:resource="mailto:pns12@cam.ac.uk"/>
      </foaf:Person>
    </dcterms:creator>
  </void:Dataset>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3abcb383-615e-4423-a242-bcaad34fb492">
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <rdfs:label>myosin heavy chain 2</rdfs:label>
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f513c4e5-0709-40e1-b9e4-345d9e6eeab1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
        <rdfs:label>MYH2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/25f8324a-e175-4eeb-9960-ae79ee562d8a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
        <dc:identifier>ECO:0007764</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c04b197-4a19-48f3-8d51-1fa76201cae3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:label>Nephropathy</rdfs:label>
        <dc:identifier>HP:0000112</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1a3c599f-834b-4867-93a7-5c652b3597cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f41de4bb-1c87-4f2a-bb0f-2dd69d5acc2d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66476764-b823-45fd-be4e-eb357be390a2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76b797f8-461c-4eaa-895d-6acb91ea3bca"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a5682d73-7b41-4a02-a9e2-0cfbfba13bc5">
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/692e9489-e7ef-48da-8d94-4f6f53621976"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29b2ff40-6f9c-4a8a-a8fc-69bf11ad9b06">
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/337c6e31-c163-43c0-b315-9fc57c8b8ab6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
        <rdfs:label>ALPL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b437e34b-a2b8-409e-b5ff-6e2b6fc4c7f9">
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/68b1c89f-9634-499e-ad0a-b718a71dcf8c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
        <rdfs:label>PFKM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4c5460e-b944-4cbf-a54c-27ab2b10f928">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4811390b-91ee-4677-908f-938bb36a110c">
        <rdfs:label>GLYCTK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <rdfs:label>d-glycerate kinase</rdfs:label>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d367ccb3-5e83-4468-8499-71d0468875c1">
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <rdfs:label>HMG-CoA lyase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b44313a3-259b-4d65-a8cf-83aca3ff63f3">
        <rdfs:label>HMGCL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3a70bb42-e066-4a2a-92ea-dd37b35a9d90">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bba77417-8493-4e7f-bcbf-ad700ec61005">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb5ce11c-195b-46c0-97c1-7b2cbeb2d8ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/439ffeb7-a52f-4dd7-ad5d-aea326df326a"/>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9853cddd-5ace-47dc-b227-f1fa361abbf2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f00f365-9121-4009-923f-68fc1acfd253"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2">
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6fbae4f8-8be7-474c-a922-043044699db9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6398f4b-d9d4-4cc2-af7a-52ccdc553b20">
        <dc:identifier>HP:0001877*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64ebc8dd-ae08-4f86-a0cb-6ed701255bd1"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41e2cddb-556f-42ea-a77d-713c1819d89c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed965c7c-a22f-47c8-9069-a062d46b1a2d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6403ef4-9506-4948-9d73-0b5665ebe2cd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/88c757ab-2805-490c-83fa-01eaf12c5ad3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7b56016-914d-4368-8675-750871988ee1">
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
        <rdfs:label>Osteoporosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9484536-ff3f-4c99-a972-e0f1e38df021"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d0abd1e7-c79c-493f-85c7-87aa65dba88f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2228d9e-5d4f-4341-87e3-445290e576e8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
        <rdfs:label>Chorea</rdfs:label>
        <dc:identifier>HP:0002072</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28b58ed1-119d-4c80-969d-51ebafc23833"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5170203e-79e3-4b6a-8a3c-855dfadce947"/>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25551f23-7f00-404e-b9ea-fc76ff25b57a">
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89054296-1d4d-402e-a076-77b2b03ade2d">
        <rdfs:label>AVP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fb944c33-8d58-490d-96af-df950d25be2a">
        <rdfs:label>COG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5145fc8d-67a2-44f4-9d0e-09d6748b3be0">
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cbf17fbd-ceb8-425b-a544-433ae8de260b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
        <rdfs:label>D2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae678948-5df1-4cb5-b475-d7f767ec4fba">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b57c90b3-f209-4ca1-9820-c29831a65fb5"/>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0624d895-f5b2-41b8-a7a0-4577c1d926c2">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/74449e80-43fb-4d58-883e-86675b9a1e5f"/>
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e71cd73-cd76-454b-8510-3a344cd6a230">
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d36b748d-88e4-4c19-805b-16d9af5448e0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
        <rdfs:label>GCDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3ccfbdd-7940-4f12-bee2-93a67b44804b">
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <rdfs:label>Arginase</rdfs:label>
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c470ca49-b8fc-40ed-8523-f0d2788b9bcd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
        <rdfs:label>ARG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d3e9e256-74f0-4bf6-8d3a-0841bfd5414d">
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a63ca24e-809b-41e8-9fc9-4d059610091a"/>
    <rdfs:label>galactokinase 1</rdfs:label>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/406baec5-0e4c-4381-8ed0-ec83e3aca9ab">
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/18135eb6-c29d-4d3d-8560-559082e99106">
        <rdfs:label>SCP2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/866f88bd-5907-4a90-88b9-0ccc35799486">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f03809f7-614f-4891-9a7d-df0f556bc12e"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d33ceb0e-5068-45db-81de-48f46c856414"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75365e86-7d26-4bee-b63b-8fdcc56447f8"/>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef23cf5e-00b4-4b12-a244-515110d799ab">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/090aaf5a-991c-4688-ae9d-701aa3ccbf74">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
        <rdfs:label>POMK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/455e4523-921d-4be5-9416-4e663c3ee888">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5087cd82-4050-464d-aa5e-632a77cc7737">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <dc:identifier>HP:0008315</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92f5dc4c-c672-4880-ae83-5faaf6fd1a60"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f120e42d-da2f-4eae-86fc-63c0a00782fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63600574-5939-423f-9eae-77308fb7c043"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b163e3c-efbe-4968-9b5c-02412ccc14b4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43cd5c79-d6d2-44ba-89b4-09bf17d00fc0"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16ba1113-e039-49eb-b987-7666b07bbc5b"/>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a2d4c5e5-4dcc-40a3-b829-1cfd8a5e5f97">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/85bb7fb9-efee-4cb7-a18a-1d61ee16f1cb"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae749b1c-b4ab-46b8-bfad-a206c20f2587">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/58349314-1aaa-4071-b08b-2b4ef7431a20">
        <rdfs:label>UROD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/309e1ca0-4d48-4c8a-b568-10ac36f4912a">
        <rdfs:label>HEF</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/HEF</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e337f59d-acd3-4069-add6-04d55a7cbb8f">
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/752ffb20-1c5e-4c1e-8591-526bcfbed889">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
        <rdfs:label>AKR1D1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
  </owl:Class>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/379966be-e2e1-4f21-85a5-bcfaa64529dd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4489c7ea-796d-4bc0-ba2d-e3aabdb56ec7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86d69a44-aeac-4632-9d0c-995d80afd5e3">
        <dc:identifier>HP:0003288</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6910fb8-4b16-4a97-be57-973c06b71db3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b872fe3d-0243-47c9-b742-cb2d379cf60b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
  </obo:DDIEM_0000007>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a826059-3724-4035-a0ac-683bb3998fed">
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d708bc63-a536-4dd5-a941-4ebbf3e3b5c5"/>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/516f3b17-0ffa-4be5-8d66-7abfe822e650">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45dcd73e-4507-4269-96d0-20bd5da53166">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
        <rdfs:label>ADA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Adenosine deaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5e44be9a-d788-42b0-a667-c2116dcef0f4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e29cf693-cbae-46f9-99ea-5b820b62399e"/>
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ff19fb1-c464-4802-85d0-c621f20d3471"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/401ebd31-dc38-4241-8256-3da01becec26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d656d29e-ef63-47d6-814c-f14006f97404">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec274b29-ada1-4f6d-89a5-8062deac3b42"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a07a9b53-0ede-447f-99b9-83ab3f956c16">
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f75eab3-0012-4cb3-aaa9-88349904d654"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5124078d-a225-44bb-9f6c-265dfcd9615b">
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/13be01af-da85-43b6-a973-4ea0385ff6eb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
        <rdfs:label>NAGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b904250-06bc-486d-8cfe-e8096734c585">
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43762c06-ef7f-42a1-ba7e-d58b38c45f18">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b0915acf-9c54-4a5b-bf87-4a22abac4326">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21564044-58be-4ea5-a23b-f3f0b388e971"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9338737e-138b-4ee1-9d5b-112be99105a6">
        <rdfs:label>Dysphagia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6016e1e-a8be-4e43-a7af-46864efbde33"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/afe0baff-6313-41f6-92fc-eb9345e2b7e4">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a04e1bff-55ce-4858-88f6-8107b1d06e78">
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:label>High desmosterol,cholesterol ratio</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/291c5c36-a20d-46ee-a9a2-832d3e8d6538"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e85adc0c-1aba-4af3-8104-0da2d5c6c80d"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6eb796f-ade7-4ef6-8232-41cc8d2d1603">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b063c759-a688-4c1a-be0a-61a1099eb0d9">
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1313017a-6803-4e4b-8e60-cc64b83161f4">
        <rdfs:label>PHKA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f4ca4fae-d21d-4576-bd27-b83db0674f22">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e067b8a-acf9-4871-8a94-f24185249f15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5546a7ba-4875-4cf2-9a14-a04849bc0b41">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42b075da-bf2a-4b8a-ace7-09dd2a569604">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3ec9e9d-600e-415c-9f27-51e03c435d3b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ded9ae2f-cfbc-42fa-8a06-e73defa5100a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89054296-1d4d-402e-a076-77b2b03ade2d"/>
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e80fc7e-6bf0-452b-818f-cf1a761810dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ed14b18-34b6-482a-bef4-fbd073bbfbd5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6ae16e0-fad9-46cd-a3ef-254188241950">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Polyuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff1d3dff-9377-436d-91d2-0e695701cf63"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ca293e1-6320-49a6-80fe-be0c8f8a30bd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62c56e15-c092-411a-a372-26fe839974cd">
        <rdfs:label>DPM3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6884835-138c-4f1a-9edf-887e6832cbe4">
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3ca01151-5955-49e0-badc-49529b568b62">
        <rdfs:label>ABCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73e74538-f01d-48d2-becd-7967bd5c2ebb">
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b677623-2361-472e-b7eb-bf202c741a88">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a87c94d0-ac7b-4f73-92c5-1a0326027cfd">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72a489df-48c6-4156-b963-e2862cfb9afb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c7daa13-9a1d-472d-b117-6fa4d82226f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec97b595-3d38-4ba4-8949-a84766f3011f">
        <dc:identifier>HP:0000793</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/621da6f9-ce1d-4107-adf0-24d3d4b42dca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/067e07c9-752b-4cfd-9a2c-d8da25a61dc8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5cb2c115-6caf-49c8-94d2-9e578016fde9">
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c808404-ef2f-4ef1-83b6-40e94c140a76">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
        <rdfs:label>LIAS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2ce52dd-97cf-4ab8-bac5-c803eb630af7">
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/942e5216-dc9f-4054-9e40-c48c84a47445">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c06d26e-f0b2-4cbe-9447-d010bc24473d">
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a34d12fb-8867-4e35-a99b-a894f38a6970">
        <rdfs:label>LBR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8c6cc7cd-4a1a-40c0-a82c-5ac2bed117f7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/919d204d-9c88-4039-a350-61e4041f3cd0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <dc:identifier>HP:0025065</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/125f43d5-cde4-407e-99e8-6b4307befd72">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <dc:identifier>HP:0025546</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/550ce3ed-7e7f-4393-8e99-019cb08e6423"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7c84781-5878-449c-b849-9495439d0a0e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6c53c39-34d1-40c6-bc0d-97a84aec770e">
        <rdfs:label>DNAJC19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3e728ada-1462-44e6-b366-2bc6942e69e4">
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6932d50f-162f-4493-97b9-fb471759a88a">
        <rdfs:label>BTD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>biotinidase</rdfs:label>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a34d12fb-8867-4e35-a99b-a894f38a6970"/>
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5d3becd-b96e-4fbe-943c-31c35f34e6c6">
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a4d4ffd-00d4-479b-a9e5-174f3ae62ffe">
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/66bf3506-fc0b-4130-9caa-fa37e28e5d63"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59d951ce-856a-42f4-b17e-9d03c80be428">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c810db58-3e62-4b5e-94d6-aba75e455fd4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>developmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1bb5b98-c3fb-451b-86a8-5bf099a9fc58">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc8635a7-3f72-4873-ab9f-357ccd63745e">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
        <rdfs:label>MT-TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6128cbc9-4eea-4b1c-ac5f-d53a1a222b21">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
        <rdfs:label>MTTC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1bb76fac-f9ba-402b-b6a5-ea1b6ef1a2f8">
        <rdfs:label>MT-ND5</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cec1039b-a706-4718-8c6a-00c143c271dd">
        <rdfs:label>MT-TQ</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/807a7861-b4f6-42bf-a164-7d76b9cc0f77">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
        <rdfs:label>MT-TE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b579ba3e-1af4-4e28-8ecb-a2ef8ed076d4">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
        <rdfs:label>MT-TS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9cf08971-cff3-48a6-b99c-4960a532ab70">
        <rdfs:label>MT-ND1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/86a8940c-7247-4d1b-8fd8-daa96f1ebd3a">
        <rdfs:label>MT-TS2</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16b206fe-c2e1-465d-ba06-99b2970a2391">
        <rdfs:label>MT-ND6</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b872fe3d-0243-47c9-b742-cb2d379cf60b">
        <rdfs:label>MT-TK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5132b34e-1ea9-4213-9fc3-8dd7b1e550b4">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
        <rdfs:label>MT-TL1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c26f38ad-25c7-4240-8058-5824f58f6cc0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2c35f85-d010-4787-8e35-d5256bcf08ab"/>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a283e196-1596-4ca8-824b-d6b13bb52704">
        <rdfs:label>Growth abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f2e763f5-0206-4363-9e44-147a9fa4343f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
        <rdfs:label>POGLUT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd0b204d-2732-4683-a571-cc0fa2e6f752">
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a8976f66-69fa-4ae0-9593-080613ef4c28">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fd7d0539-d7df-40c8-80cf-278ca60d5d3f">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e470a0b-736d-4373-b925-054a427e1d4b">
        <rdfs:label>Abnormal EEG</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebdd6e09-1ad1-4330-93a5-7e96d8349e09"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/218262a7-485d-4a16-8add-14be70ec40ae">
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/69afbfe6-df1e-4468-afb2-ac28d1996122">
        <rdfs:label>ABAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <rdfs:label>GABA-transaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae37c0bd-ba99-4dab-a2f9-4d78d5ed12bf">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dbd09cf2-9eb7-4583-9a07-0f7d55bfc1d5">
        <rdfs:label>TTPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79646a65-7c6f-4676-82ff-0232f356098b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4154d7d6-42fe-41b2-99f0-a76a1a76a671">
        <rdfs:label>Poor growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d80f9728-a621-4dd6-a01b-7f71d3bce64f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fc20028-2624-430c-ac18-534e0d78a387">
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e92624db-441f-4aea-b919-a71bff05f47f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
        <dc:identifier>HP:0001254</dc:identifier>
        <rdfs:label>lethargy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5eaee23a-479b-431b-9194-b821c3f34ef8">
        <rdfs:label>hyperammonemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8883d6e-0234-46cb-a7ba-2f947c408707">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <dc:identifier>HP:0011966</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e65c5faf-69b2-467c-be7c-caaf7f151e38"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e57df37-4214-44ba-a032-b234608607bb">
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>anorexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/be50cc60-8a18-4a21-a822-0e741373e045"/>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34cfe685-61c5-4885-9cb2-094fb44632fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0647d761-4e9a-4d13-ad5a-bbb60eb7e857"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d40188aa-09ee-4311-b264-6777477259d2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004337*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e35d365a-0d0a-46f6-96b4-8ddde6df10be">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e29cf693-cbae-46f9-99ea-5b820b62399e">
        <rdfs:label>MTTP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2deda4f0-88bf-4bd2-95a6-f8400800f53a">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/16b206fe-c2e1-465d-ba06-99b2970a2391"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/932f5621-c5b5-4177-ac45-a73545e88847">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
        <rdfs:label>MT-ND4L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9cf08971-cff3-48a6-b99c-4960a532ab70"/>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/4b67eb3f-bc3f-4a10-8e1d-e2aeff29da69">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/445505ee-0e2e-46aa-b13f-bf6beedc97fd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b5f37901-a176-45ae-99de-ff2e5003df39"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1ce5e96-2ffe-48d0-a553-974033a4beee"/>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/61ba65c5-b765-4015-b095-cd77173efbf4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a833785d-8550-49b1-9139-67417330062b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a2fb03c9-0ac5-4e06-9938-52f8375faf90">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7f7fd4b-d737-441e-aa0a-f4d6ffee23b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c04c52f-e877-4888-a645-b87c791c96f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79343775-8be3-4ccc-ac63-6819d377bd7b">
        <rdfs:label>low Hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3bec90e5-90b9-486f-a07d-0153fd0f9cb5"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c8fa9d3a-22ff-4c67-8f33-a9bfb15cc1bd"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/845cd622-a245-470e-a815-a30fe93213ae"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/793705ac-9348-407e-bbe6-fce9b3109eed"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5ecfc5dc-af02-45f0-9e98-6fa34ef79dc0"/>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/861de82a-9027-4fee-94f5-ec6af14cb9f0"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21fc85b6-22b2-4a27-9fc6-31744a0a0380"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1842b0e6-76f7-4c40-9d56-c48875aaf23a"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e611bb6e-12ff-4d76-8ec1-f5c8262e2adb"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33728497-27ef-443c-80a1-4ff126ec7e78"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b7243f30-b160-4c1f-a571-ed16b7ca3ee7"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09eb9b3c-8c59-4c25-8825-3e228ed37091">
        <dc:identifier>HP:0001896</dc:identifier>
        <rdfs:label>Reticulocytopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001896</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2503027</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1546717</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85ff1ce1-5d2e-4ce0-8f08-c579a15b0963">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8039f557-75d6-40bb-85bc-6add97b55e54"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3389144</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e2d4a516-af27-44e0-8489-251c203e76fd">
    <rdfs:label>atrophin 1</rdfs:label>
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9237ebd8-9069-4af9-89e4-6a48103345a0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
        <rdfs:label>ATN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67cf9b76-1b5c-41c3-9d05-94cf73afeb6a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2254c466-f4d3-4a28-93b5-da110c097123">
        <rdfs:label>CAPN3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <rdfs:label>calpain 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b431e3bb-fb47-447c-a6e6-3d7b1f8a68f1">
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/017eb299-05dc-42dc-b859-228b907b687d">
        <rdfs:label>IVD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eaa85349-5971-4b17-b5d2-fb5309478cae">
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <rdfs:label>Methionine synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25772345-216c-4da1-9f31-efb439b67dea">
        <rdfs:label>MTR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fca9feab-e2d3-4531-b8c8-e5952f8e21cb">
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/15735600-449e-41b8-8c0f-3b84938feddc">
        <rdfs:label>FUCA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <rdfs:label>a-L-fucosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3a8261a4-b972-4831-8f42-2fe29a911716">
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c32ee60f-35b5-44d8-97a4-258c83018647">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e484a85-7e77-446f-add3-ed450b07d32b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78094a95-8807-4ff3-ba03-1b67629941fe">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
        <rdfs:label>SLC2A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/34caef95-2a73-4713-ab02-21620011e2c2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
        <rdfs:label>LDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/05491bb8-1d65-4d94-bcf9-acb457deb020">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/debf03cc-ada7-4149-b29c-753d54e871d5">
        <rdfs:label>PGM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/42f37c12-4527-47e6-8146-9c2896d1ef0b">
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/88c757ab-2805-490c-83fa-01eaf12c5ad3">
        <rdfs:label>AGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cd557488-2669-44b3-b368-092be816254a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20bc603d-01d5-45fd-96f1-f0bf04d7c20d">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec0d76ce-c1a2-46c0-a4d3-fa0b45807a2a">
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6d99257-df99-4124-a7e6-092108304c66">
        <rdfs:label>CLN6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79c39990-446a-46b1-aa11-647b7aab0832">
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f87d78e6-5a89-4ed8-ada7-3d758911f603"/>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4eb3f852-19de-49a2-972f-1e8604bee626">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/337c6e31-c163-43c0-b315-9fc57c8b8ab6"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36352ed9-1222-4ae6-9b09-92a7c5b64669">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c572714-f37f-44f9-b117-ae14c42de3fa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
        <rdfs:label>CASR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/af2ddb00-0591-4a64-abf5-da89807251a1">
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/da372ac9-cc7a-439a-a46c-5477ec4db232">
        <rdfs:label>RRM2B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c8872d79-bda2-4d32-a6a6-247917532507">
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72c86a28-fdc4-4c68-9ee1-7b152cf494d5">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>fukutin</rdfs:label>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e822e3a8-d005-4d19-9bac-cf6aacfd171d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/96b52b8b-9435-4354-b2e8-ba36498afb00">
        <rdfs:label>MT-CO3</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a60b6a6c-dec9-4ac2-9da2-fbff92f30c68">
        <rdfs:label>MT-CO1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21e4d5f3-f36c-4151-bc6a-12bfd6c95cf9">
        <rdfs:label>MT-CYB</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0de0f043-8c2b-425d-abd4-1ee0c9c1c8b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e9a3b42-1ddd-4fdf-822e-5c344010c970">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c6250bd-8158-4853-b960-8e543d019a87"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6ea4ef8-778c-43e2-a20c-2ba081dba36e">
        <rdfs:label>hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24e0cd14-5985-45e5-86aa-6ffcf41f5349">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/659f450b-0a09-4a53-ade0-af5818393dae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b25feea-3ab5-46fd-a9d2-147c02987765"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc28e1d8-5f75-4dc5-addb-3df7df78c0ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5ca809ac-5892-4444-8c34-13b4019b4638">
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2210e953-39b4-428f-bd07-207b1f31645d">
        <rdfs:label>AUH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d2221555-3592-47f3-bb37-6fcd157b7a6b">
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b5f37901-a176-45ae-99de-ff2e5003df39">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
        <rdfs:label>PYGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/965ee01b-ad93-47be-a1d1-317d8222a596">
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e82b1eea-e53a-43dd-a255-d520d5c67876">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
        <rdfs:label>DARS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3b431a5-f170-470c-9fcc-94c6be09ef58">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aeac07e6-a1dd-40ee-bb5b-0bdaff38e9c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/864990f6-75c6-4744-9c54-a0bdc12317d7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a796ef1-9b90-4f03-a961-b78062765b20">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
        <dc:identifier>HP:0003452</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/649e9426-dd17-4482-bf92-87486740dc51"/>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c1506d4a-ae9f-47bf-86ba-b8f1d442a7c3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5a83bf0f-a298-461e-8b93-62bcadfc45d5">
        <rdfs:label>PNPO</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25259296-f029-4736-bc4c-7d4419a2fb5e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a349f857-1a93-406c-899b-621ea34b74c8">
        <rdfs:label>MAN2B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6717a661-2aa2-450e-8b3d-c24f944c4419">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de9922c5-ea25-4378-8b8f-9b00ec9b62f8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d7f22cb-aafd-40ba-8188-516d34de955d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2653e94-d8fd-4dbb-9854-a5716bf3d4a5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study is still recruiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/115f5132-344a-4d6d-9570-13b0a359ba32">
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
    <rdfs:label>anoctamin 5</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d2cbb92-d57b-48c1-9047-94837121051c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
        <rdfs:label>ANO5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/43254a26-ef9d-4657-8fc6-c6194dc415f0">
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5e30865b-1109-499f-bf72-97e58b928f05">
        <rdfs:label>MAGED2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/02b94fb8-874a-4970-a12e-277d3a4cf031">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75bb0d04-4c3e-4736-b9dc-9ab038a19140">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
        <rdfs:label>DPM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bae2acdd-6c80-4657-8e5c-9380e36b91c6">
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0aaa9491-8337-40d8-9aa3-d37637f7f673">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
        <rdfs:label>DBT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2ab1e386-50ea-43b3-9cf5-a3e091be2c13">
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9adbc433-24d8-42d6-95b7-424a00f2b03a">
        <rdfs:label>GLA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/488da816-5b8d-4aee-80fd-e862c0c3223b">
    <rdfs:label>battenin</rdfs:label>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20e4df74-d6b0-45be-85d9-1b8041231043">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75a42cd5-4ae9-4971-882d-08e0f0b88661">
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2ab36d02-dcaf-4088-9b79-f063114bd56c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
        <rdfs:label>RXYLT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/ce247954-ea4a-4518-92cd-c5101d0a4e80">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3b4e236-8d7d-452d-8247-ab1fb91433ed"/>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4f5f4c4-8a00-45b4-9ebf-9cdb2d206234"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07732259-5e4e-4efc-85db-65e7fe9bc1a6"/>
  </obo:DDIEM_0000009>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/23229a1c-08a7-4424-8e0c-0264594fae14">
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <rdfs:label>Glycerol kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/17cc0eb6-4519-45b4-b7fd-458be15cd6c6">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/10cd27bc-cbec-4249-8fcb-4e2cfb7925b3">
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a406962f-1a6f-487d-906f-6e9c02bec894">
        <rdfs:label>RET</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e97bfdd1-6828-44e5-b9cf-f4a04c15447b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9054ef6-822b-429e-aa5c-8d6891dfe5c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ec75377-48d8-41d3-bc55-8398f4f93af4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7f7fd4b-d737-441e-aa0a-f4d6ffee23b0"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79343775-8be3-4ccc-ac63-6819d377bd7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d130ab71-d4b5-48b3-9a2c-f01d4edf99be">
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a8cd6c6-373b-4455-a30d-0b787ed5bc7b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ADCK3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c3133ec5-142e-46df-9a2a-52fc4a30abf1">
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b949e0f-f8f9-4450-8fcb-29b7dbbbed71">
        <rdfs:label>GBE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6d560ff7-1747-4aed-bc4c-30a2732c4605">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50e50643-02ec-4f98-8635-c4e5f98613cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0cc6b68-0c00-4abe-a378-afcf4a87dec2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9229b917-6052-49ec-9f7f-5a1e0f73047c"/>
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/960f5da2-3ce8-4b4a-a100-ce025192d84d">
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <dc:identifier>done</dc:identifier>
        <rdfs:label>Hyperurecemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee8ad9cf-f161-4159-a44a-8f45fdb561ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b2ed23d-5526-476d-a490-2f9ad5328dd9"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6d8b3436-38f1-429a-b9c4-585142225ee5">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5087cd82-4050-464d-aa5e-632a77cc7737"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b163e3c-efbe-4968-9b5c-02412ccc14b4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63600574-5939-423f-9eae-77308fb7c043"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <rdfs:comment>Hypertryptophanemia should be regarded as a benign condition</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c32ee60f-35b5-44d8-97a4-258c83018647"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/65adaf1e-484b-45f4-a6bc-05ad9839c0ca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ca018ce-70eb-4e8b-adc3-f137d0010637">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003657</dc:identifier>
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cff6bce-8416-4a7f-847b-7c04a9339b06">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6348c217-a72b-4497-974c-1f2e75bc18a2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad709f54-f0af-4e5e-b428-59de731abd3c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f711200-8f9e-4598-9d4f-e6a1541efd87"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02c5bf45-0b5e-488d-bcbe-b7465c13c19d">
        <rdfs:label>irritability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93434b28-7f80-4dd8-96b3-cf6097273de8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <dc:identifier>HP:0004372</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected alertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c36efcc0-cf44-49dd-99dd-1663adc5a304">
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/88ab15b1-8276-4008-b18c-ab18777901be">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
        <rdfs:label>PIGN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/12d7125b-2fd4-47ea-8950-daff6a7ae216">
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9fe53061-9628-4db3-8e49-a3f20ee71e1e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
        <rdfs:label>FA2H</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ecd7827-bff4-48a8-98de-548b98ba9caa">
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fc83d585-7550-4894-9110-6eb06b13d3b1">
        <rdfs:label>SLC39A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25fb09fc-fb3d-447d-b52b-a38b4bae1c65">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
        <rdfs:label>B4GAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/44d588b2-b64b-44b9-b7b7-8636f37f8139">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1fe4e4d0-d249-4351-bb66-3a326d9f7c52">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3896da61-237a-4a6e-b8a0-04b348a5ab60"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86e79a2f-4a07-4ad8-8c92-3968b887f744">
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
    <rdfs:label>ferrochelatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe403c28-6471-4b0f-abcd-1f5f326d0b51">
        <rdfs:label>FECH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc144fd5-20b4-4450-8fac-5f6ca36f7862">
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e29ceb39-294d-4210-b0eb-0b2c57aa2d93">
        <rdfs:label>SLC2A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/55c75b17-0345-4690-a227-ca26a61d55c9">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/753e88c3-b9b7-4412-bff3-794841e7799d"/>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/baf22159-59f2-4293-b416-fd2d9a645be4">
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ca926f3-ad35-41de-9889-e56d1927e5d8">
        <rdfs:label>PTPS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/153fd62c-8ae4-4df2-b73a-68d4dd58c6c2">
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6ff57eae-d52d-47ca-9c3f-88d56abde2f9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
        <rdfs:label>MMACHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/56ff1c5f-de05-4560-9e63-6e9e8dd5ea3d">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e242f4dd-471f-4bea-b315-3bcc694c786c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f17a14d7-38ba-4d74-941e-3c8fc6425919"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20185e78-45fe-4105-9b4c-e484b85382e9"/>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:OGMS_0000112>
  <foaf:Person rdf:about="https://www.pdn.cam.ac.uk/EuniceMcMurray">
    <rdfs:label>Eunice McMurray</rdfs:label>
    <foaf:mbox rdf:resource="mailto:emm1@cam.ac.uk"/>
  </foaf:Person>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24ea6031-2f1c-432f-8da9-b2c8fd2f403f">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9550ea33-3ec0-45c7-b320-b3aa47363696">
        <rdfs:label>AASS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b84f0ab-630c-4e01-85a0-8fdb5d76db30">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/890e349e-ad83-404b-b127-97ea84a6f7a4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
        <rdfs:label>UGT1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79690963-ca66-4738-b553-36053b251185">
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48e9cc43-0084-4e1f-a1e8-ef0d62fbbd6b">
        <rdfs:label>MTHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3baecd9f-4432-4883-876b-108a72678243">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d2ec200a-f1dc-4c63-ba28-9288832c1635">
        <rdfs:label>GNE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3ed53d01-04ef-4879-9502-d6cb21f2632e">
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/48e9cc43-0084-4e1f-a1e8-ef0d62fbbd6b"/>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/240e10d4-5a62-421f-b5f8-c39f05d74b6d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0bbe4cd-cd3f-4fa3-bcd3-4547f908f7aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/40dae991-fa2a-4980-91df-3868ffed377e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eefea3d3-bac6-4e43-8fff-7413d72131c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5fc0073-caa4-407d-bfcc-06bad7b16a26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7856377b-4a7c-4098-9c1c-7219d5cb99c1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a5eb3520-3d59-42d4-b756-f612ea545ea6"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85d0668d-3ddb-40c8-af47-b3bbc3bf5038">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d54cc7a0-c93c-4f5b-902a-1dabead051d5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/61bbd9cb-523b-495b-a19b-c07d8c1baa1d">
        <rdfs:label>PIGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/174377e6-3257-48ed-ba5f-2c136d79c6ac">
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6a7e4e05-bdac-4206-9dde-298928019c97"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8e957dd0-8229-46f6-b8e2-3c677145636b">
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/961f4748-f8da-4402-ba80-61943928d419">
        <rdfs:label>FTCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4a2297f7-19c2-41fe-90f5-895255d9200b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9bcb73c3-c483-47c7-bf46-885f42739d82">
        <rdfs:label>KRT5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f2e763f5-0206-4363-9e44-147a9fa4343f"/>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d0f0e359-2cfc-4873-8fc5-ae3ab8113b8b">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/83d9581a-50c0-4ba1-a044-59028e7f62b4">
        <rdfs:label>LRPPRC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a4d6a4e-9e1d-4508-84e2-473bce24413e">
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4144eb9-2864-4f46-8570-f20820491415">
        <rdfs:label>PRPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e0b3cd79-9754-469e-9686-06f29e153ca2">
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/29b43645-3cf1-4a1f-926d-1146c168f39b">
        <rdfs:label>QDPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fba8dac0-4c20-4d79-b2ac-b72f28c6fa05">
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/34ea06a3-e838-4851-ab85-e4d2c80121b7">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9664062b-9107-465a-910b-6c6750a34cb1">
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25ade689-8195-46f2-b43b-94ad0acbf9fb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
        <rdfs:label>PLA2G6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/44045b3a-360b-4c56-beb5-f1bd97babc2e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3f33d82-46c8-4bf9-8cd0-576204697742">
        <rdfs:label>Sleep disturbance</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6785375f-4e50-4e06-8882-7b0c686e6c1a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e31cd01c-c817-48c4-b89a-55b6133cc04f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dffba834-6f6f-482c-8c09-711d6d1cbea7">
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <rdfs:label>kynureninase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6612b6bc-c699-48b6-8a53-d2f7ab5f71df">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
        <rdfs:label>KYNU</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/51639a09-de34-447f-bfb3-d4560d7ecf2a">
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d74cfa15-85fc-42a6-a07a-58d70503dd96">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df00f8eb-8ce0-4500-9be2-6afb11560569">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32cdb9eb-c46f-482d-b4b0-ecf54b506153">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <dc:identifier>HP:0001285</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03767e6a-3e2b-46c6-b709-b0018616a480"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/31ed4883-a2bf-4747-8c4e-c122e632aabe">
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <rdfs:label>uromodulin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9229b917-6052-49ec-9f7f-5a1e0f73047c">
        <rdfs:label>UMOD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1134adb-15f4-4df8-afac-936ff7b7152e">
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3a124391-07ff-41f1-9996-ba2fd5437c69">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
        <rdfs:label>HADH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2ab36d02-dcaf-4088-9b79-f063114bd56c"/>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6740344-6b0d-460a-bf67-ea6fb59feb23">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aaf76651-b3f6-467c-8fbc-bea3d4dc905f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/80d57a57-585f-47cd-84ac-81d0d67dd4a6">
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c0711bf-17ff-44fa-8b09-071b48674862">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
        <rdfs:label>ACADSB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f49550e5-37fc-4a1e-92c5-4577c8bc1341">
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5891217d-5234-4597-8817-d3aa434e8bca">
        <rdfs:label>G6PC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4194c11-30ee-4638-9710-e3d89550768b"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9201967-09c1-46da-95f9-1e7ab4ebe60b">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/25fb09fc-fb3d-447d-b52b-a38b4bae1c65"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b872fe3d-0243-47c9-b742-cb2d379cf60b"/>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a6f244fc-abe6-48ad-ac65-8c55f171ac26">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8cced984-7f4b-4545-a0b5-6487534aded3">
        <rdfs:label>CTSC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Dipeptidyl peptidase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd7b8ff2-3501-484f-9350-ca2dd124762a">
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/059e512c-c695-4c0d-8f13-ac4fc52a5fe0"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75bb0d04-4c3e-4736-b9dc-9ab038a19140"/>
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0117a263-6089-4829-a014-0c647c18cd78">
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2c35f85-d010-4787-8e35-d5256bcf08ab">
        <rdfs:label>ACAD8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/100bab90-8d7e-4b1c-bacc-efd287df0dfd">
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2ec8d0b-0a97-4d26-8488-240f91acb0ff">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
        <rdfs:label>KCNJ1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/15490441-7bfb-4932-807b-940b13d4bc2f">
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c35cdf76-d420-4aed-9849-6640abe339b9">
        <rdfs:label>CUBN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c918b3b-0a8e-4c7a-a0a3-22c9227bd6b1">
        <rdfs:label>AMN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c2fcf220-38ca-4b31-9b7a-8a943503da3f">
    <rdfs:label>Aprataxin</rdfs:label>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/38791c4a-8a8d-4ebe-8ff9-a569ac494caa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
        <rdfs:label>APTX</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/81f308b7-7b20-4fd1-9dd0-981ebc00c4a5">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/550ce3ed-7e7f-4393-8e99-019cb08e6423"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/050f8258-e8c9-45b2-bbd1-a2e9466cfb3b">
        <dc:identifier>HP:0001889</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Megaloblastic anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/961f4748-f8da-4402-ba80-61943928d419"/>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c3e5d467-b6e7-4c6e-819d-5d9db658a5e6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/127af02f-b19a-45e9-9a1d-e8f3833ed42d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003128</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:label>Lactic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a23f6e8-6540-4904-9ffc-bff7e7e196d5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a137c2bc-19c7-4753-9dae-0ef20e5b2478"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14765544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caaa85ea-4d8c-4e4a-9423-ccf44b221019">
        <dc:identifier>HP:0002572</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <rdfs:label>Repeated vomiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84b5b785-f374-4635-9737-05353dee88e0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40f05195-94ad-4178-895e-532f4e1be6ae">
        <dc:identifier>HP:0001298</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Encephalopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8e301bc7-acf6-4cc7-a15e-47ad9120ad88">
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8e6e416-9fff-43f0-bc61-4d196b4bc29b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d2cbb92-d57b-48c1-9047-94837121051c"/>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/452d4ccd-b0d7-4b7b-947e-af44791b15a0">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/649e9426-dd17-4482-bf92-87486740dc51">
        <rdfs:label>TFR2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fef0d66e-6fd0-472c-8116-860a450590ba">
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e22eaa0e-0341-4ff3-b746-efbbc6e2e046"/>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62bc1bb8-a245-4537-b535-10a99bdb4fd1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7e84ccbc-42bc-45de-aeb1-67a6bc3cd4e0">
        <rdfs:label>SLC19A3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>thiamine transporter</rdfs:label>
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62c56e15-c092-411a-a372-26fe839974cd"/>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/5c6feda8-d466-4fbc-9046-b75138460f94">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/761646f2-2887-4446-a926-718fdcf7506d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/384f7619-85da-438f-8479-639da52ed3ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21564044-58be-4ea5-a23b-f3f0b388e971"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e212bd72-bea7-41c5-a78e-74ffe0f1ad2f">
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:label>Disease progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ef9d6f4-eba3-4855-b168-a33c009bf410"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9df0542a-1bde-4545-8550-5c559e246c60">
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e0c87aa9-169b-40c2-b80e-fd43c3d27b8e">
        <rdfs:label>DNA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b510d39d-6b22-48eb-9195-8fd8fce0657d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d573f998-b7a0-4a2f-bed4-5cb0eee23ff6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
        <rdfs:label>TK2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c36564bd-e7b0-4bc9-9347-db1f3b3c460b">
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7c53a3b0-7325-46fe-aee2-1cd26b5f6610"/>
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86d596fc-3e5d-4b37-97a6-af2623a47fe4">
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d5d9e9d7-30c8-4c03-b2fc-76c3e0da0e8e">
        <rdfs:label>PAH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2fe5df26-5ad2-4f88-b141-3f7bf8379322">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9c59b279-b2bf-4baa-8d87-9cd010d2f01a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
        <rdfs:label>BCKDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7baacfd9-6258-4511-b55f-61ede0cadd66">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c94cb6c-3044-4578-a67f-0024474d7208">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9241fc12-145d-45f1-81a9-a6a5b069faf8">
        <rdfs:label>Myoclonus</rdfs:label>
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ad67411b-8711-4135-bf9d-8d02163372cd">
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7cdfd959-984a-4dd8-8c3a-f7672e8f49da">
        <rdfs:label>DOLK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dolichol kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67eb36b0-6030-49ec-9711-ee45fc8c62ac">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b1e22b97-c3a3-4ba3-a914-912322396095">
        <rdfs:label>MCCC1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/170c5c6e-6f9b-48a6-bcc5-ac80ef84ffd3">
        <rdfs:label>MCCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/15228d9d-6ff0-475f-a490-09315e15dea3">
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/793e3f56-dca7-40b4-b649-9164146f9ab6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
        <rdfs:label>UROS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ee3189ab-fc0b-444e-8e9c-208fbbbba080">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d416e1a-1d14-4dc0-a52b-29c0fcf4f0c6">
        <rdfs:label>GALT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9d516313-fab7-4ce2-ae50-2a7d4425834c">
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fab9ffe9-af73-4d10-bd0e-af16a6114bfb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
        <rdfs:label>CTH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/10c6680c-6f56-41b9-a8ff-d56c9e3b30c7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3f541954-865a-4488-b7e9-5f4f55908328">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
        <rdfs:label>TOP3A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3a4fc783-ac4a-4c4d-9403-01ba39805b43">
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <rdfs:label>glucokinase-4</rdfs:label>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a2553ac-c081-4478-9073-b0422699a54d">
        <rdfs:label>GCK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e498393-2156-49b3-a5ba-fcdb03de3b43">
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/61bbd9cb-523b-495b-a19b-c07d8c1baa1d"/>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c17fb2e7-09a5-4b52-9ced-edbb1e5a89d8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dd604edf-6220-41b2-8a56-8df649f58eac">
        <rdfs:label>DHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/642bf03a-dd2b-4133-a6b8-3313889b8c78">
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/72c86a28-fdc4-4c68-9ee1-7b152cf494d5"/>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <rdfs:label>Fukutin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/82037a85-d747-4dea-8377-4f0de47d1a3f">
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6045059-dc2f-41ea-a50f-441b0e1ff9d5">
        <rdfs:label>B3GALNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26fbbdf3-0c1c-4212-8a3e-dfe47dcc9267">
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/933190fe-a441-4bad-bc7f-ebf38bbb3c7c">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/46677f90-bc86-43c5-8cb7-1d2a2baf00c2">
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b9558af-2ec8-4050-9e6d-5846cf7d9acd">
        <rdfs:label>BCKDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd0893ec-cb87-4f59-9146-a7653eb4b1a8">
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4f437f6b-9203-43d9-9f7e-625b0a0ec49c">
        <rdfs:label>CPT1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c763bdb1-2396-476e-8f54-56a3871c49ab">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eff1d7de-9ac1-44b0-959a-2ce70907124f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GIF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/18135eb6-c29d-4d3d-8560-559082e99106"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/5cd8b23c-5815-4052-a1e8-beb45e60aa62">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07732259-5e4e-4efc-85db-65e7fe9bc1a6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3b4e236-8d7d-452d-8247-ab1fb91433ed"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2f35e32-692b-4818-8c63-1ca91d94e3fd">
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e629a614-d76a-45d0-930d-0b8dbf2836c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84b5b785-f374-4635-9737-05353dee88e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000015>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b677623-2361-472e-b7eb-bf202c741a88"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25b5a865-7498-4ddc-b5cf-3d617b45543b"/>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d00efd7c-7541-4855-bc81-d6ad4b35b8a1">
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5cafaa17-1083-4cf0-ba40-e5fe8b2b50ff">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
        <rdfs:label>ETHE1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/436b3153-0842-4386-82e3-e1c1be4d5bc8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3f95a537-e6f3-4e57-b5ee-a53b3ac22cb2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
        <rdfs:label>LIPC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dfc1eb88-2aa0-494a-ac32-711aba8328a7">
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/25ade689-8195-46f2-b43b-94ad0acbf9fb"/>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5715fac0-27fc-4f50-aa45-44ecf5556152">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/20185e78-45fe-4105-9b4c-e484b85382e9"/>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f32bd274-b177-41e0-9255-7b461c36968a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9148fc2b-466b-4feb-a0f1-1c5898b57d79">
        <rdfs:label>PRODH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9cfd816b-3f30-49aa-9c72-fb277f623cd0">
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ad5a75a-9c32-40cf-bfc9-dd1951000c4a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
        <rdfs:label>OCRL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9fe2b175-18c8-45f3-b735-0ac1970bd77b">
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c6b3f82-0cfe-4000-93e3-c6ac9a4cf82f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
        <rdfs:label>APRT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4480a143-f02a-41fc-96b1-0c584c5c9e92">
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/083a19e4-1b22-48b1-ab0d-e57994748f3b">
        <rdfs:label>PHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b60e3137-f3b8-44d9-8f94-d67e04ab5e8a">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/16ba1113-e039-49eb-b987-7666b07bbc5b"/>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <rdfs:label>Sodium-dependent neutral amino acid transporter B(0)AT1</rdfs:label>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2ce9c827-c956-430f-8f43-52da0c546ccc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9550ea33-3ec0-45c7-b320-b3aa47363696"/>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff1d3dff-9377-436d-91d2-0e695701cf63"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8d987e8-9a0d-4bcc-af44-c87fbdc9f81a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
        <dc:identifier>HP:0010818</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b27b449-36c1-4c0f-9a7a-c59e79d092bc">
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <rdfs:label>acid ceramidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4565975-985f-45c5-8ebc-cece90acd40c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
        <rdfs:label>ASAH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/23a9610d-7645-48b3-a94d-a8f23a36f8a8">
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
    <rdfs:label>Sar1b protein</rdfs:label>
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fd8781dd-a2aa-4e3b-b7bb-055927baba42"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/626a0287-5960-4236-acbe-5758ce2e5c6f">
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98a733bf-cdb9-44d3-92fb-82b3e90e64ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
        <rdfs:label>ABHD5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/420298bf-d71e-4252-8a4e-273d2b13513b">
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64ebc8dd-ae08-4f86-a0cb-6ed701255bd1">
        <rdfs:label>GLUL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0727c65c-4b7e-49c3-8704-3d869e763f7a">
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e0d05edd-9883-4328-802a-a7f7950b4113">
        <rdfs:label>L2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf801aac-e9f1-4385-b6fa-8f4db31933c2">
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/61738226-940c-4032-9b20-6b7785a7ec2c">
        <rdfs:label>HADHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2acc0b2c-3db2-4d7f-9161-70531a106453">
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e9ea8ca8-5a34-4a7a-b6cd-ad208b36907b">
        <rdfs:label>FKRP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/945d8cfc-452b-42b2-adeb-ec46be66b0ad">
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ceb47a87-bbe8-44b2-9adb-015382445cde">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
        <rdfs:label>MTRR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d819bc5b-2157-48b2-a8fe-e75c8f4cd558">
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/70450684-b524-466e-ba01-9f660ebc8f92"/>
    <rdfs:label>Ribonuclease H1</rdfs:label>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d197245f-8665-4a87-9deb-c5bbe26662eb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6785375f-4e50-4e06-8882-7b0c686e6c1a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e31cd01c-c817-48c4-b89a-55b6133cc04f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc212a43-b6f2-4798-8e74-b3e5e0f44462">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/957ea850-5f08-4c0c-9a5c-9809aa439f42"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/61f7f220-7138-4937-abab-675fac332953">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d33ceb0e-5068-45db-81de-48f46c856414"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e9ea8ca8-5a34-4a7a-b6cd-ad208b36907b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f03809f7-614f-4891-9a7d-df0f556bc12e"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f77d088-4dad-47fa-988a-0ec38a2d54b0">
        <rdfs:label>SUMF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/51f829fd-c345-427c-879b-3a3dadc74677">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e059043-e82c-40b1-9293-1d624c8b0e3c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f02a66a-4158-47e3-86ba-4780b9e4b43b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b72112cb-5a13-494a-9ae5-48a318f284ed">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <dc:identifier>HP:0003074</dc:identifier>
        <rdfs:label>Hyperglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9853cddd-5ace-47dc-b227-f1fa361abbf2"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bba77417-8493-4e7f-bcbf-ad700ec61005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6da5c813-f0f2-464f-9f19-700749052b41">
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25c53baa-5b87-486e-af1e-2c5154e85eab">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
        <rdfs:label>LMNA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/491c0d94-6472-4207-91ef-342bbbb6dc3a">
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ba80ee46-1c08-4647-a93c-83be39db3ed2"/>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25919b8f-dbc8-47dc-8e99-534d1c3966ec">
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fb684ee4-3277-4693-8b97-9e78704000d4">
        <rdfs:label>GLB1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-galactosidase</rdfs:label>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ca51cd89-e8ca-4fdc-857e-77cb2fa25262">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a1b9a83-5de1-4697-8428-aebe1c86a405">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
        <rdfs:label>PHKA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/c4048b46-361d-4fa5-8eac-8b7610539563">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1ce5e96-2ffe-48d0-a553-974033a4beee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/45553594-9a99-4db4-8524-41e4aec65a60"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c008e92-bdbc-4da4-b5f2-e5a17308a9e3">
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1dde6e3-ce97-414e-8509-14a50cdd5b2e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cystoid macular edema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <dc:identifier>HP:0011505</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/949ef2dc-95ec-4fed-8f02-c1a223e20bd5">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c054ee2c-563f-48a4-94c1-c6e855db7bb3"/>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a1c5377b-0d26-4483-a8c9-c8fa91866aca">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/890e349e-ad83-404b-b127-97ea84a6f7a4"/>
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5dae9c5d-7bcd-40a6-8f36-018ab547fc15">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b872fe3d-0243-47c9-b742-cb2d379cf60b"/>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0df9b264-e466-48d3-a8f3-2f9b4bca085a">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8dd3af09-9019-4661-b772-2a3db15f9e94">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
        <rdfs:label>NPC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NPC intracellular cholesterol transporter 2</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8596b418-9601-4b37-8b15-ce0f2ce2df80">
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0159ddc6-985e-4336-8d15-72310419ccc4">
        <rdfs:label>CDAN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>codanin 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c330a1a-33d8-4151-96a9-2ce579472cb3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2eaa77f-592d-4137-b675-f30186fba1cb">
        <rdfs:label>POLG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fca719ad-a8be-4e91-bd76-73943436c8fa">
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e3de2c89-ffda-4183-96bb-b2e2fd697578">
        <rdfs:label>LCAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c2cd7229-c3d9-456c-874f-a71a7feae261">
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/126e2271-6af9-4f43-b9c3-e5b40d392abe">
        <rdfs:label>PIGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4acd9846-7e6b-4dc9-ab98-ba07764fff1f">
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6c6159fb-6620-41e0-8f02-2d7473b76114">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
        <rdfs:label>SLC25A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9412896-0479-413e-bbc4-3d036aa4e8e9">
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8ec8953-b7cc-4bc6-a040-93bcb6435b1c">
        <rdfs:label>SERPINA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccc94f1d-5903-478a-bbdb-e5fc6ad3dd1c"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36c297f7-c507-43c6-b0a8-711b34db2a55">
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dd40c737-f17d-41ec-a106-75d95a23871d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
        <rdfs:label>FXN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:date>3.10.19</dc:date>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e05e596f-537f-45ed-b2ae-c97b08361ba6">
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/40db5f7d-e4f0-44b4-b94e-6089cb030f49">
        <rdfs:label>HFE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86bfaae7-4a5e-4f06-94d1-7941800ea796">
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45553594-9a99-4db4-8524-41e4aec65a60">
        <rdfs:label>OAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f4abc32-205c-497e-8725-d5cbf9cdc780">
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8963ccc-6cfa-40a8-bb75-c9edb64c5ccd">
        <rdfs:label>AGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a99e118-efc1-46be-b344-2f15f373b582">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/60d4e435-a072-43a1-b96e-b18ab3714e52">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
        <rdfs:label>SLC35C1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3bffb153-53f0-4423-8e5a-0720a622e62f">
        <rdfs:label>DAG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/35de6bf9-e2fb-4307-ae09-252589a84133"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d78b54cc-941b-47c6-a497-0c6a97ca4447">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aeba6a9b-28e9-4072-9e40-283dbfa4d051">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
        <rdfs:label>POMT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b357fd65-b2dd-4d23-98f0-bf08e5da6753">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81d37d38-61f7-45f0-843f-202e441455d2">
        <rdfs:label>DPYD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1e17dda-1662-4a54-8cdf-448705960d8c">
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3675fd8c-9a03-4378-9120-d216252414c5">
        <rdfs:label>BCS1L</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e5c5ecf5-6b0c-477f-8c21-4d3e6e79b746">
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78468c5a-56a2-424c-a94d-d5a9845af8c8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
        <rdfs:label>ABCD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89b01278-75f6-4d53-829e-16a85a027d4a"/>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/96b52b8b-9435-4354-b2e8-ba36498afb00"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd9390c5-da26-4ce3-b8a6-d18f3ccc4bff">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/60d4e435-a072-43a1-b96e-b18ab3714e52"/>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6eb330a7-fc59-4b51-bad1-aec656a4be5b">
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/860189f8-041c-4023-9869-960fe41917fd">
        <rdfs:label>HSD17B4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/090aaf5a-991c-4688-ae9d-701aa3ccbf74"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2e0e63a-2a14-4341-ab93-a3daac7f72bd">
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c10bbf4d-867a-4ba5-9f5a-21571d8539b2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b836c162-4c54-4632-b303-abb7b8185f56">
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/93b2da91-eb5f-4157-bef0-6a0197e92739">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
        <rdfs:label>SC5D</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/707f6004-ecdc-4bc3-82d0-897357e0365e">
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73591acc-aaca-4d94-998b-051b7bc02693">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
        <rdfs:label>SGCG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e91fe203-47fe-4d0f-8077-d3d55bbd1b32">
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5dd929dd-2151-43b9-9188-2e6755094889">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
        <rdfs:label>IGF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>insulin like growth factor 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6a8d3745-e8fd-4f65-8f4a-384b531ca32e">
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9fab77c9-a147-40d7-8d57-15aa05339da8">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8dc134d1-cbaa-4baa-bdbb-30c1e91454d7">
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/08dfd68f-2f9b-438c-9005-712dfef51a8b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fab78b6f-a934-4e7c-9b8c-ce2a7a21a5bc">
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3bffb153-53f0-4423-8e5a-0720a622e62f"/>
    <rdfs:label>Dystroglycan</rdfs:label>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/47077b11-7130-41c1-91c4-600f5638d5c2">
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2deb1f3-61fe-4767-a1ed-95e6409f47d8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
        <rdfs:label>PHKG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/37e1d20c-1cd5-413e-95f8-61e4926c6213">
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/29b43645-3cf1-4a1f-926d-1146c168f39b"/>
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da7614ed-369a-49df-92d1-0a5c18e369c7">
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <rdfs:label>enolase 3</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/69f3daca-3eb5-44e0-8f23-b21d1b270090"/>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/685579db-3c28-4f90-98d3-468d131d0f86">
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/cbf17fbd-ceb8-425b-a544-433ae8de260b"/>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/29604a8d-286e-40e0-a490-5d5aa43035ed">
        <rdfs:label>DPM2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/47171494-1344-449f-8445-7735b6c51903">
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/66bf3506-fc0b-4130-9caa-fa37e28e5d63">
        <rdfs:label>SLC25A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/68438909-444f-4021-a5dd-19e8a740ae57">
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/37cc039d-901d-4b78-a689-c1a7c11500b3"/>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/34caef95-2a73-4713-ab02-21620011e2c2"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29f36f98-f3a8-4667-9c2d-a7b60b494cbb">
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa4f2e96-0dc7-4c5f-9542-cbfce3df4538">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
        <rdfs:label>APOE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein E</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4588d651-37f6-4445-a528-b24fb99f4501">
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/85bb7fb9-efee-4cb7-a18a-1d61ee16f1cb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
        <rdfs:label>SUCLA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/912dea38-7d0b-4f51-aa31-66b80d49b6f8">
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6596b8fd-5bb2-4a3a-9279-3b4e2b768461">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
        <rdfs:label>GAMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aaf76651-b3f6-467c-8fbc-bea3d4dc905f"/>
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9bf337c-2c4b-4c62-bdf8-f3b5462fed9c">
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/29604a8d-286e-40e0-a490-5d5aa43035ed"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9543176c-a514-4b5e-a57b-463b34e173bc">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/19592c8b-7ac4-461c-9335-d392e5636784"/>
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <rdfs:label>Excitatory amino acid transporter 3</rdfs:label>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/181113e6-3d62-421f-a477-1bc982b546d4">
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aaaf38f1-6acd-490d-979d-6f7e795d25a2">
        <rdfs:label>CBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9abffa76-6730-4159-bf34-19c117683143">
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/418ff31a-ce20-4793-8987-fcffddc7215c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
        <rdfs:label>TPP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c8f89e2-8e8b-4bd5-86a7-301059bf6c46">
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a5eb3520-3d59-42d4-b756-f612ea545ea6"/>
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ecae9bf5-c8c1-4945-8e94-2c5380650050">
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/305fa49a-6b24-4ffa-ba0b-ae8a53d8019e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
        <rdfs:label>GGT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2cf2f29a-81bb-4230-8f67-4621f39232f5">
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/126e2271-6af9-4f43-b9c3-e5b40d392abe"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d59e3022-d653-4b93-8f86-b9d976350347">
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6f77d088-4dad-47fa-988a-0ec38a2d54b0"/>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5f2c3199-8582-4c55-9f52-9292ad7d48f1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/be50cc60-8a18-4a21-a822-0e741373e045">
        <rdfs:label>SLC25A13</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>citrin ( protein)</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/590b41c9-cb8b-437e-a6dc-3a27e293d664">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/35f96144-a3af-45ac-8c3d-0fdbf8495dc5">
        <rdfs:label>SGCA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>sarcoglycan alpha</rdfs:label>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/790d6bfc-2176-4e74-9d86-e7292b6950ce">
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e9ea8ca8-5a34-4a7a-b6cd-ad208b36907b"/>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <rdfs:label>Fukutin-related protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f9fe55e-7886-401d-998c-6f7fcf316281">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b4f27271-7d57-4e06-a7e6-3aa46692be3b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
        <rdfs:label>MLYCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da9db3c2-8359-4aeb-8d64-fd7c71369796">
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4f381eb-57c6-463f-a38e-3dbdb76b0de2">
        <rdfs:label>GNA11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87f8b189-86bd-4853-acb7-0cfa93f53193">
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fc117324-e576-4766-981d-d3bec9ceef8e">
        <rdfs:label>GYS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <rdfs:label>glycogen synthase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c6e7be1d-7764-4e6a-b71b-b54f0253fbb2">
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/712c497f-9e15-4f10-aaee-61cc8f290f69">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
        <rdfs:label>ANKH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/39f5b5e2-2944-4820-a3be-e5878f7a7021">
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fb944c33-8d58-490d-96af-df950d25be2a"/>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/945e5077-14f9-478b-8b18-31f43899fe94">
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/752ffb20-1c5e-4c1e-8591-526bcfbed889"/>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
  </owl:Ontology>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e0169f3-7966-4a43-b591-c23836f57d4c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75365e86-7d26-4bee-b63b-8fdcc56447f8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>LARGE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/44f9cbab-884d-4a2f-8b8b-ee9f9434e003">
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7130e42a-79ab-49d0-9240-7cbdfb82f559">
        <rdfs:label>DDC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f513c4e5-0709-40e1-b9e4-345d9e6eeab1"/>
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4fcd98ec-a72e-4e10-bbbc-d06541ccd584">
    <rdfs:label>transferrin</rdfs:label>
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2a24a5c9-acaf-4de3-bc44-9e2e6519ae29">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
        <rdfs:label>TF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a86435b-0804-42af-81b6-2368132a1e46">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/c621f6bd-4dc1-4249-be0b-b7d360e524a7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <rdfs:comment>Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31ce3532-6caf-48de-9f7a-79a81fd4814c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77572f95-a377-40e2-994b-ff93ed5b77a4"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Probucol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
    <dc:identifier>DB01599</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/85eedb92-29c6-4d09-a1a2-49203c78650b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa57f333-c711-41fb-a442-fcd1525094d0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004322</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>short stature</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/108d64c8-9d5a-4e80-8cbd-c43589861b5d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d96dbf1-925c-4507-8b02-3e2553e8667d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/75a2c86f-d7c4-4f72-9e17-a4e749ce35cd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8424e0f3-012d-452c-845e-9e4617b06885">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81c03bb5-d6e9-4421-800d-1f7bd572a53e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/807a7861-b4f6-42bf-a164-7d76b9cc0f77"/>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5132b34e-1ea9-4213-9fc3-8dd7b1e550b4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b872fe3d-0243-47c9-b742-cb2d379cf60b"/>
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22b4ae5c-f140-4e94-90af-cf5ee1c764e4">
        <rdfs:label>Epigastric pain</rdfs:label>
        <dc:identifier>HP:0410019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d097a4c0-b305-444a-9b84-4bea0c32bc1f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acid regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
        <dc:identifier>HP:0002020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9f45ec42-fbc9-4616-80df-bc60be3dd0f0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c890c3f3-2093-4b5b-8277-9b7187c282aa">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9adbc433-24d8-42d6-95b7-424a00f2b03a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <rdfs:label>FABRY DISEASE</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86cdeb50-4751-45e1-84d4-c02e2c09ba08">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07f8d25d-1861-4431-a0ac-b5454ec43063">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/520a4285-b50a-4fc3-9e03-ab89431d4cec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b61cc12-e79d-47c2-b205-05f945d62343">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001712</dc:identifier>
        <rdfs:label>Left ventricular hypertrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/685f6de5-e83c-4f4e-90b6-a91c895c44d5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d25ebfc-a0a8-4796-a96b-b29859e31a3c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
        <rdfs:label>bone weakness</rdfs:label>
        <dc:identifier>HP:0002749</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/337c6e31-c163-43c0-b315-9fc57c8b8ab6"/>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/780ec78e-84a7-4aa6-9258-32628bf340f4">
        <rdfs:label>bone fructure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
        <dc:identifier>HP:0002757</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10e19c70-6b0a-410c-b5f3-9cab4c5c91c8">
        <dc:identifier>HP:0031429</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone formation biomarkers</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c45504c-66fc-47ff-88a2-820d920caaea">
        <dc:identifier>HP:0004349</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
        <rdfs:label>low bone mineral density</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce2c5b27-9d21-47f6-8c51-5fd48bc518dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6cae887-f348-4189-b789-05a1323b5e48"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1cba1f4b-e1aa-4dd6-b188-0102392b514c">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f75eab3-0012-4cb3-aaa9-88349904d654"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cfb86a2-02e3-4893-ab66-4d1048f31d1a">
        <rdfs:label>Retinal degeneration</rdfs:label>
        <dc:identifier>HP:0000546</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3ec7470-3f3e-47a6-a4e8-d7ba8a8d3dbf">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f2a42e1-7aa8-4175-a594-74b59f67b59d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c6527af5-309f-4409-81df-1d4d7a7e5b49"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f18b61f4-8269-435f-97e7-c2ab62a4dee9">
        <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
        <dc:identifier>HP:0004387</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cc867f93-8c69-481d-bb3f-4a484cb24938">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2a24a5c9-acaf-4de3-bc44-9e2e6519ae29"/>
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/719b98b8-84f3-4cec-ab3c-91c2717eb552">
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0b602b2-c0aa-4711-9378-d2029e1929d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5846b0b-20e0-406d-a26c-5cdae435ac6e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a44f7c7-8e70-43bf-abf3-506f515d2ff4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>High ferritin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2fbab007-7147-480d-add4-ef9293776132">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/589fe5c8-464a-4bf5-8515-c17cecd49302">
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f706a76e-a340-42f8-8abd-d00741f9058e">
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd506f63-fb2b-41ec-892e-3da783394e7a">
        <rdfs:label>Reduced pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9dee73f-8360-46b4-955f-e859ad6f9d3d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d13dc500-7e7a-49ce-b60d-77b7816f2b90"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10117fad-3e8f-41b7-89f1-e7c70a248fbc">
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28b33352-6e2a-49b0-95de-2cf1d76923e7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0f0e126-6f84-4ec2-a1c4-547a655008b8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cognitive deficits</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a349f857-1a93-406c-899b-621ea34b74c8"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e06ebdd2-450d-47a4-8fae-314ad060b0c1">
        <dc:identifier>HP:0030878*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low FVC%</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0a42fe84-8a75-412f-8115-1847a90aeb89">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49baa587-6fc4-4168-8cec-aebe08b4a36c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002360*</dc:identifier>
        <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe32d04d-3ee2-45c9-bceb-115f05acea4a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
        <dc:identifier>HP:0001943*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e31cd01c-c817-48c4-b89a-55b6133cc04f"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fc117324-e576-4766-981d-d3bec9ceef8e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/183ca1ae-ebde-4526-bf15-227e9ee7bb2c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf9689c3-9345-4149-984a-7048affa8575"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/456d50d8-03fa-4c1c-bea4-3cb6a129497b">
        <dc:identifier>HP:0003199</dc:identifier>
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50eea66a-0e0b-490f-8d9d-4e10308286bd">
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28e37015-a3ef-4cc0-9f60-e8752e6394cb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
        <rdfs:label>Bone pain</rdfs:label>
        <dc:identifier>HP:0002653</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b982422-9a89-403f-afb6-42dcdb6d99b6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Progression-free survival</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/351d4d05-2ec8-454b-a833-2d214b414e20">
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bb03996-7884-4a74-8f57-4c5d858566fb">
        <rdfs:label>Weight loss</rdfs:label>
        <dc:identifier>HP:0001824</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73504d9c-57ce-457d-be29-747e596a98db">
        <dc:identifier>HP:0003528</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <rdfs:label>Elevated calcitonin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/853343bc-3a13-406c-adb3-b62a168a1a4d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69f16cb7-81ba-4413-aef9-c4090a9300d0">
        <dc:identifier>HP:0031029</dc:identifier>
        <rdfs:label>Increased plasma CEA</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c4f7978-2058-4ffb-ae69-29b086ae2ec0">
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb65ddbd-17d2-4631-b214-f215fa19cf27">
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
        <dc:identifier>HP:0040063</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32ee967c-7058-4961-9cc8-e56c262ffde2">
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
    <dc:identifier>HP:0004356</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a02cb601-5777-4efa-88f8-940ec9a69b60">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c10bbf4d-867a-4ba5-9f5a-21571d8539b2"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/30c9c90f-9408-4f29-bb74-97dde109fa76">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64b2ffad-b17e-491d-bcfc-f69e79526e31"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>Abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30ba2311-4679-4fb1-9f44-9f21a0faa58a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:label>Acidosis</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/d4ef804c-a655-43e9-a685-2f550df41f1e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c93fd509-d496-414c-bb29-ed2e897ac3ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e86429f7-20b3-4039-8cff-5e86629540d2">
    <rdfs:label>Gliosis</rdfs:label>
    <dc:identifier>HP:0002171</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002171</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/794d9673-8239-4cbf-86a7-2d61855ba702">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6348c217-a72b-4497-974c-1f2e75bc18a2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/837312bb-75f1-4ef7-b12b-2eb660356f3c">
        <dc:identifier>HP:0002344</dc:identifier>
        <rdfs:label>progression of neurodegeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc4b83c0-10b8-4f4d-b44f-ef89d09d0452">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011167*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
    <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b27b7bd-3058-4b8e-bed5-1bac6b65ff3f">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7002f2f5-bdfe-4092-bd78-024ddb138642">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/701aa5ad-a054-457e-b370-1be013523860"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffdb152a-6e33-4904-a571-ac0fce877f26"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21564044-58be-4ea5-a23b-f3f0b388e971"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36cd2e49-a76d-44e7-aa97-f29c5b481cb2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ef9d6f4-eba3-4855-b168-a33c009bf410"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
    <rdfs:label>Amino acids</rdfs:label>
    <dc:identifier>DB09393</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a539d6cd-f5a8-4804-8975-75929065eb0b">
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
    <dc:identifier>HP:0002123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b13b196a-5dde-4d85-b91a-73e6a6effd28">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/130b91ce-f38a-4219-86e8-18807d0a4dd5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20bc603d-01d5-45fd-96f1-f0bf04d7c20d"/>
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bee94aa0-8e3c-427e-975b-2f2406c82a96">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025547</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac2f7503-b979-4d57-ae05-9cb62eca1c1f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d98e258-d2af-499e-8667-ea180f382f06">
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>thrombocytopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca223bb0-7449-4cf3-b8ed-28d6fc0977da">
        <rdfs:label>anaemia</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0">
        <rdfs:label>Hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c86ac9b1-8a19-4dd9-b659-5880d37cf38b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46be25ed-18e9-4007-a016-a2f4fe316a48"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/198eabed-68d8-4a7a-9eac-56b9bbc1cdec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70b458f2-5702-4631-bb79-bed0a9341fdc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>Abnormal kidney function</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ef094a9-8ace-4671-8328-893dd976a23f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/316ed4d8-d363-42c2-8d5e-40fd55b13620"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e221822-dab7-4fae-a2d5-d8b404341ff0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d125601-5fa0-4b8c-a5ef-adeef056ac84"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a416e053-e5b4-4fb5-abd7-ef2d88724404">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d52fab0-167d-44cb-9f8c-7e870667f86e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:label>Low pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ca922d8-0894-43e7-bcba-c32e50cf4eb6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <dc:identifier>HP:0006517</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a17fc9dc-1be0-4934-a2d0-272d720cac7c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed557427-fd30-411e-8ffc-70203a5e7cb0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2b9ae963-08a4-4be1-b790-32293698f671">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e0cd14-5985-45e5-86aa-6ffcf41f5349"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db3f252a-ac19-47ab-995f-1689d9de7125">
        <dc:identifier>HP:0003546</dc:identifier>
        <rdfs:label>Exercise intolerance</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
        <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1313017a-6803-4e4b-8e60-cc64b83161f4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/dcfa2626-1da7-4b99-9607-bf86ade6357c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55740cd4-f273-47fe-bd08-cbf22d757e7f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3640013-ffe4-43ef-9d1a-6affaf5cb20f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
        <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6d99257-df99-4124-a7e6-092108304c66"/>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/50f95389-f5e9-40d5-b14e-2690f0c393b2">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edda7d00-40b3-49fc-bb78-d748e4c5c909">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f405118-e45d-4605-b280-761875bad6d2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e16943f-3a5d-48ae-82ba-3f705d2c941c">
        <rdfs:label>Movement Disability</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cec7d03a-7a72-4278-9e5a-89fec0cffd89">
        <rdfs:label>Behavioural Disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dacd7052-01f1-4ef3-aa97-3187869016fe">
        <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ca926f3-ad35-41de-9889-e56d1927e5d8"/>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/392eb090-a856-477b-9470-3ab7e7eb8b55">
        <dc:identifier>HP:0000870</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High prolactin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/abcfe6aa-96c3-48f7-9138-45af9ec8acc9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8143c0f5-7474-4e6e-a765-02e63e321dc7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Parkinsonism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f63372ca-1f17-438f-b039-e1e7ca8c4692"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba80ee46-1c08-4647-a93c-83be39db3ed2"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f87d78e6-5a89-4ed8-ada7-3d758911f603"/>
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c46f80a8-5d02-44bb-b641-a06ba487f3f4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8654c9b7-2367-4c0d-a2cd-444f4fedc319">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e99e2cd8-25c8-4414-a790-aab94858ff57"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53954d1d-e8ab-4ea3-b223-79b66f0574de"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ddc00d3-ac03-43c6-b35d-9ad2498f31ab">
        <rdfs:label>Cerebellar dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74728246-697c-4440-a7d5-3aba06093967">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003452</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
    <rdfs:label>High serum iron</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0504fe4-54e2-4e57-a3f7-b5ae0596c9e1">
    <dc:identifier>C04</dc:identifier>
    <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1cb430c2-23de-41c6-94ae-0fdbc388538c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3bcdf09d-f719-47f0-9994-d50d62220e8c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf5db4dc-9044-4b05-998b-7ceba18be612"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c029371-342f-4b10-8a6f-48147aa11476"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f7c2f4fc-8973-40c5-a242-6ee222bd1e76">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5232d86-dab0-46ee-a63d-27d1c6df9136">
        <dc:identifier>HP:0001945*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/703ebb30-9ed8-4606-8fbe-c7003de39a7c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7bdedc3-59e7-4d38-9f52-241ecbd2e743"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2fb42dc8-c4b8-429a-8bf3-2906825c474a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d26215d8-e725-4389-8a90-b0cead31d88c">
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8fad1eca-ed5a-4bf1-991d-bc9227cc39b6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc0282f4-191a-4d73-8088-c5407dc23604"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc1ffe76-b879-4c13-8329-ca8e39145b38"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42699940-486c-4a40-961e-e08938df17e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/26bf68a3-72aa-446c-ae84-4025f00c1151"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/bbb880ff-f364-465a-b8d2-42ff6caf8b50">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5749b1ea-ebdf-44d2-b235-c08c68984cd5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92fab497-b94b-4987-b62d-3ccf90765599"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7e9e714-8348-4f0d-9a98-34461848590e"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdb79641-2c71-44ea-9584-ad9e178b7ee3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dc17b85-81ec-43b8-9a16-6c5154c3deeb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypolysinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/419720ab-774d-45d0-a714-7e41add95301">
        <dc:identifier>HP:0005961</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>intracellular defect of arginine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f97c22c1-cd2d-4792-8101-149f962586e8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
        <dc:identifier>HP:0002152</dc:identifier>
        <rdfs:label>hyperproteinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec622c5d-dcf4-498f-a9ff-fb9f082e0eff">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <rdfs:label>orotic aciduria</rdfs:label>
        <dc:identifier>HP:0003218</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ed14b18-34b6-482a-bef4-fbd073bbfbd5">
    <rdfs:label>Chlorpropamide</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e4e90715-a6e3-4341-9bdc-1ef9c1beca84">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64314fcd-fef6-40c4-82fb-74dfde3aafcf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e80fc7e-6bf0-452b-818f-cf1a761810dc"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/900813d3-3af1-497c-9193-8f1269c59345">
    <dc:identifier>HP:0011018</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>extended G1 interval</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a60e6656-bc9a-4558-b389-a35680f8c736">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d2df6e1-95d9-4392-9ea2-0ca2b1056c93">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9814ff9d-0db2-4ebd-a2da-fbf45735e927"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/6e5dd289-dfc1-43e6-afeb-72d048a39822">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dc42e74-8ca6-4355-962c-dbf0ccf9c130">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>deambulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce9c3e1a-95d9-45b8-8462-a290669cc327">
        <rdfs:label>White matter alteration</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccc94f1d-5903-478a-bbdb-e5fc6ad3dd1c"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a2c30d9-982d-4f6c-8c07-3479dbc960ce">
        <rdfs:label>Low 5‐MTHF level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef3c4fc8-4963-4008-8eb8-50e710959f5e">
    <dc:identifier>HP:0002459</dc:identifier>
    <rdfs:label>Autonomic dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a5efe4c-9030-4149-bf8d-bfe164b200af">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c7192595-87ba-41ca-a8d6-c3542fddf34e">
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0ad31f9-90e7-4950-ba60-6e469e03e009"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/965a6a19-a15e-4da3-a0d3-a2543a2363c6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/100133a0-a779-49aa-885e-fa73db7d77d5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/808ed7be-232d-433d-80f8-a8f7b8bcbb59"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00916</dc:identifier>
    <rdfs:label>Metronidazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbd8c4fb-e017-4ad7-a242-3c6ae8cafe53">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011197</dc:identifier>
    <rdfs:label>EEG with focal spike waves</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e3a5735-451e-43fa-9114-b34846cc0701">
    <rdfs:label>Central nervous degeneration</rdfs:label>
    <dc:identifier>HP:0007009</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/56b0f634-89b5-4c0c-b934-5e4be955d7b3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77f8812b-a6cf-478f-8d31-98c54bfbf433">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Stroke-like episodes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f165335-598e-4273-99df-6f6e08703364">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
        <dc:identifier>HP:0006279</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b3f606f-8720-49bb-bd8f-7af810ac2e4f">
        <rdfs:label>Congestive heart failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59281149-5729-48ef-8f48-ef572837be0e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <dc:identifier>HP:0009830*</dc:identifier>
        <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e65c5faf-69b2-467c-be7c-caaf7f151e38"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c02e1102-df74-44ae-a7d1-c5306efd56a3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b285248-6dfc-4ab1-8532-778076e30e4c">
        <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
        <dc:identifier>HP:0003688</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2e3bfa76-f354-48e9-ae6d-1f4d5ecade8c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f0817ca5-d2f8-4e12-82f0-8a3fbc3568f3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b919d1a0-f190-47f4-ba78-76633115b0ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cbf17fbd-ceb8-425b-a544-433ae8de260b"/>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b742e52d-1188-4cd8-9b1e-ca6d1dd09a78">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a65813b9-6dab-4e47-bc79-3304445f93ca">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08e57b06-1bb3-4d47-b973-c742024f24de"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7a898c4-4ec7-4dc4-914b-cc357cd7723b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b487683e-060e-427e-a108-a97207771a3a"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB11251</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8cca228c-dd39-4381-8ba4-91469a7e6653">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/271e529c-eecc-4985-88dc-d558e78b66c5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08e57b06-1bb3-4d47-b973-c742024f24de"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38becd3f-9939-4b10-939e-4ccaea18ffa7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0f0e126-6f84-4ec2-a1c4-547a655008b8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cef8e8e4-cc40-467d-b61b-c94fea71c16f">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0f0e126-6f84-4ec2-a1c4-547a655008b8"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08e57b06-1bb3-4d47-b973-c742024f24de"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Tocopherol</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/9dd2ce1b-f615-48aa-b487-30a8eefbbbee">
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe403c28-6471-4b0f-abcd-1f5f326d0b51"/>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a05857ea-9578-4f3e-b9fd-a939ff0f222c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59a3984c-0a29-40e7-a57c-3e710c4b1512"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75df9b88-2bfc-4fff-811e-26b8b8e11457">
        <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c5d56e7-ea8c-4e2e-be89-054711177353">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f94b92c-579d-46ec-9148-9ff2851d115e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/88ab15b1-8276-4008-b18c-ab18777901be"/>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe8e146e-6eac-400b-b9c4-d09901e6e79d">
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:label>Low HDL-cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/fffdba44-3f5d-4a38-a0f0-94664499a742">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e465867-56d2-42d1-9545-a82f0b55de35">
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/363671ea-2599-42db-832d-268b150850e3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8dd3af09-9019-4661-b772-2a3db15f9e94"/>
        <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
        <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd36b117-5889-445e-9f21-a34ae47d5ad9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ddff2732-ed80-4221-ad2c-865a888bf107"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ea325eb-dc8f-4d5e-aa40-44ec43eb9568">
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46f3da56-e0aa-4a26-9fbd-650b33769b6a">
    <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8963ccc-6cfa-40a8-bb75-c9edb64c5ccd"/>
    <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
    <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
    <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/9949f97c-6a2d-482f-a7ef-6bd6d811d768">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c810db58-3e62-4b5e-94d6-aba75e455fd4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1569c42c-fbfd-4a1c-aa1c-cee6e2215882">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28b58ed1-119d-4c80-969d-51ebafc23833"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fc03dd7-23f8-452f-abfb-bc11b3433300">
        <rdfs:label>unalertencess</rdfs:label>
        <dc:identifier>HP:0002329*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5004e77-a943-4181-bb4a-fd7f151827ab">
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:label>Receptive language delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/45a37aac-b5cf-484a-ab8a-4f0b94a40d34">
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2982511f-2382-483a-be0f-641dd36cb709"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7193862c-ec77-447d-86e7-10418835514e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fe9af0f-a3dc-4c8e-8c32-90dd83cd2cb1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a27bceff-f743-4fb1-a6e7-fca388d4fbb3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97097396-8992-405f-a2b2-85e4ed42bdf9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82d976f5-a219-489b-85a5-9af9828cc8cb">
        <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fbf16b1-bd00-4836-aad8-3175a886294f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfde9845-87c1-40b5-bfcf-0b583416e702"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72a489df-48c6-4156-b963-e2862cfb9afb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba0f235f-84f2-4ae3-a9d7-5bc0cee7266e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00993</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cafabc9c-cc13-49e3-a4b1-ef45d226f295">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba0f235f-84f2-4ae3-a9d7-5bc0cee7266e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Azathioprine</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dc8d99c8-e564-4c3d-ab53-76af59998e46">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2c5e89a-ae0b-498f-9f69-ae3399a3d04d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebf51c0e-01c1-4fa0-8e23-b4721c47b7d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dee7343c-2cd5-4832-a43f-b6d0349b1154">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49011343-aaa7-4a76-802d-2e1e49b180ee">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
        <dc:identifier>HP:0007015</dc:identifier>
        <rdfs:label>gross motor dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/707b660f-4e24-4323-8c07-720e245e1813">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>muscle weakness</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11bdc57b-07ae-4c26-b07a-f59a1b8f531d">
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defect of bone mineralisation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/665dab89-1091-496b-814e-be2fa6543006">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000002</dc:identifier>
        <rdfs:label>delayed growth(stature)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/735db429-1348-4be4-84fb-791ce9ab829d">
        <dc:identifier>HP:0002748</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:label>rickets</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a2eaaeb-7b17-490f-83b8-25b019ab7a15">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <dc:identifier>HP:0006462</dc:identifier>
        <rdfs:label>poor skeletal mineralization</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d80f9728-a621-4dd6-a01b-7f71d3bce64f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20162ea4-2d9c-4a1e-9926-f00d7179281b">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>growth delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e568cd8-5f8e-44de-b195-e50d9ce08f8d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:label>fine motor dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5da1942-f783-403c-a65f-7cc78e252368">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
        <rdfs:label>respiratory insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b58f8538-e2e1-4f48-9b07-eec0a7ff5486">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
    <dc:identifier>HP:0000648</dc:identifier>
    <rdfs:label>Optic atrophy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55f9f454-8492-47cc-9f90-6cb31ac27bb0">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
    <rdfs:label>language impairment</rdfs:label>
    <dc:identifier>HP:0002463</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59a3984c-0a29-40e7-a57c-3e710c4b1512">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
    <rdfs:label>Isoniazid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9dd2ce1b-f615-48aa-b487-30a8eefbbbee"/>
    <dc:identifier>DB00951</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6c6bca2b-ac2c-4a1d-9340-7d0cbb8f8d01">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25588781-d771-456d-a414-f7d5c114984f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
        <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
        <dc:identifier>HP:0001874</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faeb7ce6-1249-4004-8b35-30a9d7f8ec11">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
        <dc:identifier>HP:0000556</dc:identifier>
        <rdfs:label>retinal dystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7a531ce-80d0-43a2-ac69-617c63859d2d">
        <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98fb5d7b-4ad4-482f-8695-e3ec2edd4d85">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007367</dc:identifier>
        <rdfs:label>CNS damage progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/730e59dd-db8a-4a1f-8785-d248161f0957">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a6e1596-0cfb-4f2a-9070-0db9724194df">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neutropenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92c23be3-8611-4043-8583-a921bffd2914">
        <rdfs:label>abnormal microtubule assembly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef483bb5-2430-4453-bca7-46adf7d9945a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a948180b-f0f5-4df5-a818-817d2445a2c5">
        <rdfs:label>Dorzolamide</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24e1a60b-682b-4e9a-a9e1-0c41dc30c0aa"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
        <dc:identifier>DB00869</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/e496ca02-2dd4-4036-be32-b470aaac638c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5d83d6e-fe6f-4aa8-9848-e9a3f5a70538">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fad6a25-c4a6-40ac-a5a9-ff7ebebcab2e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/130b91ce-f38a-4219-86e8-18807d0a4dd5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd28e60d-279a-4f77-b6ac-8a5d93a642c0">
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>Splenomegly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65b92dc9-0380-4699-af8d-48ddf7aa09fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>Anemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffc11c9f-292b-49fa-9d98-3fc62fa76610">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>hepatomegly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8505e090-e05f-4415-8633-8c31e04491dc">
        <rdfs:label>High chitotriosidase level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dc42739-51e3-414b-8edb-41835373a508">
        <rdfs:label>Thrombocytpenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <dc:identifier>HP:0001873</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/224d56e5-492c-4504-87ad-a8c75e0b6451">
    <dc:identifier>HP:0000819</dc:identifier>
    <rdfs:label>Diabetes mellitus</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1de6722-6a8d-4623-b5a7-8a82a0e6cafd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
    <dc:identifier>HP:0001738</dc:identifier>
    <rdfs:label>pancreatic dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7b15968-4012-4671-92fd-c5ae0e8c6b11">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
    <dc:identifier>HP:0010553</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Oculogyric crisis</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cfd42121-f28e-415b-b2fc-a26aec660d39">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c94efcde-f245-40b2-bcf7-aab28fa873e7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Increased reactive oxygen species production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24fae09a-332c-4f4b-9316-0d095421d9be">
        <rdfs:label>Low ATP synthesis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16fe9d90-8ffc-444c-a809-6c703fb8a73a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/551f3e45-a42c-4190-b3de-a205a77672fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b883ce2e-1794-44ae-82d5-8b4bbeb87118">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/69368856-e12b-49a9-97e4-5a7bd9b6c3b2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a539d6cd-f5a8-4804-8975-75929065eb0b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f2547200-263d-4261-ba80-33e0fed01c59"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Clonazepam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d97f282a-478e-4bb1-82ca-f2836571f662">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc5096b7-4d44-406d-a602-d2bb195317d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41b13ff0-02f1-48ba-a6b6-1a08f5c3026b">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48eb383a-ae46-497f-b00d-553cc112552e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8069ebd1-b0ce-45df-9d25-5b9fea65d85f"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9a31cd14-a7bf-40cd-ae65-a62e37c441bc">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc4b83c0-10b8-4f4d-b44f-ef89d09d0452"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48eb383a-ae46-497f-b00d-553cc112552e"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01068</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/74ea1ced-1761-459a-93db-9cbd880bb6eb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/742562eb-550e-4a39-bd14-16cefbaedd94"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dcf5035-9215-4280-9e38-fb8356f91908"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eefad780-2898-495f-8a40-f845e3ae406d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57718ed9-3dab-406c-8a4a-92ca2ed6c1b5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48eb383a-ae46-497f-b00d-553cc112552e"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2c7d5582-35f6-4e79-b3a9-fd51b0c55fe1">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d785342d-f514-4a31-8a36-152fba2aed4b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48eb383a-ae46-497f-b00d-553cc112552e"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb684ee4-3277-4693-8b97-9e78704000d4"/>
    <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df3c7947-59e7-4715-a00a-fad884ed3c2d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c0ffbc06-2a50-4fdb-899a-b2f72b82e11a"/>
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af980e22-67f6-4b62-bfaf-e0796b6ee203">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9452161b-276f-4ebe-acb0-5b72badf50eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91c2c67f-44a2-4b51-9b1b-07e3fd4391f2">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0000821</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:label>hypothyroidism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ccdd7715-411a-44d2-9335-8a7911c0f259">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ee26c24-b54b-454b-bb49-ca4e7c99fe95"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7f5bb53-486e-4772-a4b5-20d11dab8d12">
        <dc:identifier>HP:0001946</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <rdfs:label>Ketosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>Abstract</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cd3bcfef-fcda-45ba-b59d-78be0f611e4f">
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1add3c2d-fd5d-4cc3-8a9e-37d81c356af6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003455</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3ffe442-8c83-437c-99d7-c54c62c7bfbf"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
        <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
        <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/78468c5a-56a2-424c-a94d-d5a9845af8c8"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/411f9c07-012c-4b90-978f-4ea9e2f59755">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/24b9fe89-ab2e-4d0f-a408-8a4fb415eb67">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2d82ccc-fe4a-4a33-afd5-9e95e4a751f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb939cf0-5739-49c3-b8f5-5e998c42e094"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e242f4dd-471f-4bea-b315-3bcc694c786c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c808404-ef2f-4ef1-83b6-40e94c140a76"/>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c72456e-3104-42a7-bac1-f2d7d3ef1faa">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Microalbuminura</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
    <dc:identifier>HP:0012594</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae37504e-7ae2-41fa-9987-9685dcadd9dc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23633496</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca3d92ee-0041-4c62-8323-d7277753bc36">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglyceridemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c93fd509-d496-414c-bb29-ed2e897ac3ef"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2982511f-2382-483a-be0f-641dd36cb709"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12709436</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5703f1bc-48e6-4c09-8f03-306d860623b0">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>High total cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe8e146e-6eac-400b-b9c4-d09901e6e79d"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
        <dc:identifier>ECO:00007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d62a695-4424-49a8-8c00-a636ddf13c8c">
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7927093b-aa32-41cd-9555-c119022ddada">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37c2137b-8a25-4d28-a926-3ea542f69f47">
        <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
        <dc:identifier>C03D</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e533dec-db39-4a0a-b690-ba6d66db8012"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/eda3185d-7e9e-4870-8bbd-d3f4aefb8a0c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c271016-e725-4ce8-a985-a02379b8c93c">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a2a2ff2-510d-4387-a614-68ad4bf269f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e8010c6-f0cb-4ee7-ab89-314ba7de3c6b"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95f931af-c7e2-41bd-a153-03cbe3517968"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/747ec13b-f3e3-4433-b77b-449f8c17d12b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72003903-40c5-4d2b-b197-40267885dcdf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12cec2f8-31ca-4e26-bb6c-9cb968abc1ce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
        <dc:identifier>HP:0001298*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bfe4680-cd17-4b6c-b8e9-fbb6fd59c762">
        <rdfs:label>High blood ammonia level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58693b87-5c55-4ae3-9922-f9123baf6de2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011966</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <rdfs:label>High plasma citrulline levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3ddfad2-75a5-4f31-b61b-956bf9f2f65f">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79f5ceb9-7666-4752-b1f1-37c12146dabd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>Diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3abf5d8d-d21d-4686-97b2-c8c7592ce977">
        <rdfs:label>Alopecia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <dc:identifier>HP:0001596</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35a47cf6-8aeb-45ad-bb42-6921697c4e9f">
        <rdfs:label>Perioral dermatitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
        <dc:identifier>HP:0040181</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3ee758a1-6502-45bd-93f7-48cbce6d3880">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9ca3717-53d2-420c-a67d-9695786a1460"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5db95542-3f8d-4322-9859-5387855a5ab8">
        <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fc83d585-7550-4894-9110-6eb06b13d3b1"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/75b8d31a-4537-4daa-909b-01b9cf86cd4e">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebdd6e09-1ad1-4330-93a5-7e96d8349e09"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bff079c6-e7e3-4b58-af44-7538589ed68c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011925</dc:identifier>
        <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/285f062d-8058-496d-b147-a529ef771840">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
    <rdfs:label>Abnormal circulating insulin level</rdfs:label>
    <dc:identifier>HP:0040215</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/a36891a0-976a-48a1-b541-93988929cf96">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91b5aae8-b43b-43ad-8519-1bafd6aa0b00">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f026a32-9bc7-49bd-8bef-582a9bf204cb"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0fe0358-6341-4fa0-a35d-61f27ae9222e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <dc:identifier>HP:0002415</dc:identifier>
        <rdfs:label>Leukodystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97f7d415-94ee-489b-846e-0f2a2c9d54a4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841">
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:label>dystonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af3ab109-7f88-4ff2-9948-244cf61e625f">
        <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040144</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8115d455-f08e-4211-98b3-83c30576d742">
    <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002630*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/53b054cd-92ab-4069-be66-bacfcaac5c3c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b982422-9a89-403f-afb6-42dcdb6d99b6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51f54b7a-7a54-48b5-8e98-0fbada790332">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>phospholylation of RET</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a688991c-9108-41ad-8f19-7ef95a5d0716">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbb56630-2362-4e9b-ae99-5cf11c1ccb51"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54a03cf8-d644-4935-92e8-6df2f0f2adc4">
        <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
        <dc:identifier>MP:    ....</dc:identifier>
        <rdfs:label>overall survival( premature death)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac0fb727-3fe8-4da2-b603-5acdbfbcfb14">
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
        <rdfs:label>Low tumor response rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73504d9c-57ce-457d-be29-747e596a98db"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2328a99e-13eb-435e-88c8-5805b992d884">
    <rdfs:label>Low muscular tone</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001290</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e7afffe-a8a9-42e2-bc5e-5871c30b7dc0">
    <rdfs:label>Decreased body mass index</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <dc:identifier>HP:0045082</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3cda9a7c-4195-46b4-aeeb-fa154f5ed765">
    <dc:identifier>DB06372</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2fa7704f-f846-4213-b08b-787ad16fa362">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5007472b-7929-4ede-8077-ea22dcba4b2d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c09afd6-f880-424a-9641-d6a0e1a759ab"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
        <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Rilonacept</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bd2661c4-5b84-4f09-aca3-cb2efd6cd628">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb3f2a33-8365-436c-be24-acd5e92c47f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ececf35-f7be-41a2-88ab-9cac06109db8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b335d035-cbee-4e40-816d-2f2086782447">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/870cb774-2638-4066-88a7-e9e303be1887">
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8e6e416-9fff-43f0-bc61-4d196b4bc29b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/476ecd8c-0190-4394-a929-8d751809a1e0"/>
    <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
    <rdfs:label>HAWKINSINURIA</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3015242-72c9-43c5-9000-e82e7782e26c">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
        <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d7f7df02-ada9-4cf4-b827-9d1a5124af17"/>
        <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9efa9eec-b88f-42d9-87c5-aa37ad863a0f">
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/124ff624-dc1d-40e8-9f96-29d9a6a39a7d">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50bb9bbd-4f79-4d56-9a4a-8ba5bf62d506">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalitis</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/124a9186-6eb8-4516-a0e2-7bee51e91abd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
        <dc:identifier>HP:0100513*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8341ab2b-bd3e-4933-a45f-ce376b9fd2a2">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4439f227-6a09-4e6e-9e04-6b139a47fcdd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <rdfs:label>Ataxia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001251</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dbd09cf2-9eb7-4583-9a07-0f7d55bfc1d5"/>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/752ad2cf-a506-4c62-aabc-a2b2a4396113">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f79400f0-9f93-49a7-9aba-ded42df3cdc5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5aa86015-1375-47cd-bc53-4f8d917751f0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Psychiatric disturbance</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8ddd187-877a-4715-af0d-3c0cce19f5c2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5b81977-1026-4920-b8ec-b19d45abe55d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/349a34fc-f35b-4903-9d99-e14fc1960fe4">
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c5807b6-fc21-40d8-8cc5-2c2ac7f7014c">
        <rdfs:label>Abnormal mental status</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55bd8d7d-470f-42d8-a46b-8f0ef4a7ab6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a77b93f-d8fe-47c3-a71b-f366512dd898"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dfa2d9ac-86b6-4cfb-bc42-bd884d0bad06">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a83818e3-04de-4f5d-b9df-019555527aac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>High total plasma cholesterol</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb3f2a33-8365-436c-be24-acd5e92c47f0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c461a9dd-956c-473b-9885-d3e521c7dfd7">
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
        <dc:identifier>HP:0003362</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ed29c9a-ba4d-4bc3-b97a-b1790db1c8b7">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18001312</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca3d92ee-0041-4c62-8323-d7277753bc36"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4c831a6-4fad-4446-9d85-2131f4e0d575">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5679950</dc:provenance>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/1a2128d5-cc52-44c8-a5ad-711ebd542a75">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5df3f812-96c5-4400-bd7f-b9a347650044">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18516b05-581d-432e-8f62-ebf3a6ad656d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>waxy scaling plaques</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fb865ed-8fc6-48af-8b9e-a54b89c07ec7">
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a14975af-b8c1-446b-97fc-14481b99a943">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
        <rdfs:label>skin thickening</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100725</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/149d427c-6bf1-4b3b-b3d0-a7ccae4b95fb">
        <rdfs:label>inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
        <dc:identifier>MP:0001845</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000015>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d1ee0c7-9aaf-46ed-8f57-679a48088efe">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7aab40d3-920a-44a8-b5ea-891fa724fddf">
        <dc:identifier>DB00159</dc:identifier>
        <rdfs:label>Icosapent</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ec8c041-4667-40d2-9ba3-00aecc89c808"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63d7b663-b2f6-44ac-b056-3539d365b2f9">
    <rdfs:label>Galactose</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9fbf2eb7-0eb4-44fd-ba6f-944173e9f1d5">
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1d0c59e-81b2-496c-b428-801e9c910977"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607091"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/78ece4ee-0430-46e3-a901-fbbaf2a29ab9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7653f9ed-b787-4ad4-b6e2-584a949e5b92"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f38c3766-7d03-4b0f-ae98-bc4e52a94c89"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83ae0923-0cfc-4436-94c2-324cda6a6286"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0f54b3c-6493-4e4d-8ce0-109dbb762dd2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36288ad9-08d2-486b-8c57-ed0691e10236"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec5f50f8-3c8d-4187-8473-9917c0b4849d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b9c18a3-80f4-4ddf-a0cc-6c7fe703bfd4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614921"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29a034c2-fa9f-49f1-83ad-d74d4a1cbbbf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34617cb5-23dd-4b15-af43-28c8c92ef753"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1d0c59e-81b2-496c-b428-801e9c910977"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
    <dc:identifier>DB11735</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c63881ce-2f87-4f6d-97b4-812360f03d9e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a79eaf2-a4c8-4bb6-b7c9-e75940934d60">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8109684f-e82d-482e-ad2d-5080f8b13332">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18b9aca0-10a8-4bf5-b249-0b6f1b78cbe8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/424bdddb-6c72-42c1-ab6e-5b63305e4c34">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:label>recurrent infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5047a74a-b73b-464d-8d73-b63757a19bcc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>atypical psychomotor development</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/60d4e435-a072-43a1-b96e-b18ab3714e52"/>
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d2f5074-1c2f-43e4-8800-c17d79b1af93">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <rdfs:label>low neutrophil count</rdfs:label>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/395b2cb5-8772-4255-972b-5b04909867ae">
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e29473e-a2f8-4776-a249-6f213f1e0ad7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3417febd-1151-487e-9789-21eb4db250d4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defected phagocytic function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
        <dc:identifier>HP:0010977</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a6e1596-0cfb-4f2a-9070-0db9724194df"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d62a01a-e420-4bb7-9f88-3237434acb04">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/3e473ade-70cd-46e6-97f8-a8d9a6c64568">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9a5dd63-936a-4962-89ef-252b8ed63f86">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Failurre to thrive</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c4928da-b6c3-49fe-b65d-5f92e3055951">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003679</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
        <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
        <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b4f27271-7d57-4e06-a7e6-3aa46692be3b"/>
        <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f353996-79f2-421c-a825-e93edf34452c">
        <rdfs:label>High blood malonylcarnitine level</rdfs:label>
        <dc:identifier>HP:0031544</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04847bdc-ff05-4975-a673-b62d0464bbdb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Low endurance</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
  </obo:DDIEM_0000008>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fe06818-6cf2-4033-bcd4-cd41eff404f9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
    <dc:identifier>HP:0000841</dc:identifier>
    <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ccfeae75-51d7-4b8a-a8e9-998f25558615">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/942e5216-dc9f-4054-9e40-c48c84a47445"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff1d3dff-9377-436d-91d2-0e695701cf63"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2ca0c8a6-09b9-4f2b-a698-141b3d0cac10">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a85bd486-26fc-4b84-a222-f5451b11dbbb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13fb59a9-ccb1-497f-b0e8-1ef816572849"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/769a5b93-a64d-4557-aa7a-0b2b1cc2abaa">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6be854a-77b2-420a-9803-21a548e1a1b4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
        <dc:identifier>HP:0012647</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e57ad49-d80b-456c-a31b-4ab8a8dd02ad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b9d98c3-92c4-46c3-b51c-96e74b2eea9e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2cba554e-e28a-4996-b366-6ab1f8ec68a3">
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24787057</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10944c34-191e-4505-a06e-3a38c4fa90da">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
        <rdfs:label>schizophrenia</rdfs:label>
        <rdfs:comment>The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.</rdfs:comment>
        <dc:identifier>HP:0100753</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9148fc2b-466b-4feb-a0f1-1c5898b57d79"/>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4c311ad5-1a46-434c-9421-c09851f27bb3">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/69afbfe6-df1e-4468-afb2-ac28d1996122"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e6d1e78-f301-436d-bb8b-2fae7ffb7549">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d68f365e-86cb-46ac-9518-067abeb8c65b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e48cf669-3fab-4966-a69d-e90d958d9367">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated CSF GHB levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9174fbf-d714-43cb-8e4c-ab3becd9b018">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>oxidative stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9a57092c-86de-4ca6-857e-28772d21aac4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cba823fa-81dd-4789-aa46-08a30e734d91">
        <rdfs:label>Unstable AGA enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <obo:RO_0003304>T122K</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89db0ba2-aeb6-43d9-a8ec-b3849bd5b67c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low AGA activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74680f92-646e-41f6-88a0-3ae8fc099d0c">
        <rdfs:label>Misfolded AGA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a924cc0e-f4b4-4e76-9710-0df2a9a6ed90">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal AGA processing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/51ae0d3d-5359-47c8-9919-093479caef4f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2dfbe571-fb86-41d3-8061-6dd96c2fa52d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87c5bdae-dd64-4855-aab1-870fd8421496"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/890e349e-ad83-404b-b127-97ea84a6f7a4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4c4720b-6ce9-451a-912e-b31ee07fd3bb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012100</dc:identifier>
    <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/401ebd31-dc38-4241-8256-3da01becec26">
    <obo:RO_0000056>
      <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/43c58ed8-bb6e-4edf-affc-dc492eedbede">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/960f5da2-3ce8-4b4a-a100-ce025192d84d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db780100-48b8-4f1c-bcb7-dac436992a7c"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
      </obo:DDIEM_0000010>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/747ec13b-f3e3-4433-b77b-449f8c17d12b"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ffb4a06-3fd1-4113-a444-1f44e41a0f33">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bf7b990-d74c-49fb-9f57-b69c7993994c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f3bcee-d68c-413d-9a11-5fa38ff535d0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79f5ceb9-7666-4752-b1f1-37c12146dabd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a8837d57-6c62-41b5-850f-f295ae99d8c4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4568f246-fa19-4629-abd9-8134f74d7063"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20162ea4-2d9c-4a1e-9926-f00d7179281b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5d9663c-98b1-4e4d-8f08-1b43f323977f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64145cff-ea9b-46f5-8b95-81a58e9a735e"/>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e708ef60-6ce7-4811-989d-158397092f5b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c689f8f0-3a53-4e90-aff4-165b557df696"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4c6db7f3-39a6-4708-8b07-28056ef4b6e3">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c894d5a-a6d7-462c-aa8a-84a781320954"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601987"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6ea4ef8-778c-43e2-a20c-2ba081dba36e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a47e99c4-3fb1-4a8a-81e3-a2611a20fd47">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac21895b-0a51-4a67-b7a4-40f0c6029d97"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db780100-48b8-4f1c-bcb7-dac436992a7c"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e473ade-70cd-46e6-97f8-a8d9a6c64568"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d2657e98-c69d-4339-aae1-f5d7e5649061">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c810db58-3e62-4b5e-94d6-aba75e455fd4"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f882e07-0048-46d2-ac2a-c236da048325"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <dc:identifier>DB13959</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a766eeb4-5d5f-4f68-ad02-d262ed12d174">
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f87d78e6-5a89-4ed8-ada7-3d758911f603"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3a3d21a-6d97-4c80-82ed-9a994534ef87">
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a01a3d1e-b5f6-4c9b-86fa-2809356886b4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11c5178c-cb49-46ee-8223-62b2eca1e3e7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecc7cc62-4fb7-4352-8cd5-1f5be9991192">
        <dc:identifier>HP:0008222</dc:identifier>
        <rdfs:label>Female infertility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b626206-f74a-46a1-82d6-c176c2849574">
    <rdfs:label>dermatitis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <dc:identifier>HP:0011123</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c3b63b8-d508-4c6b-af42-7a3072da4f96">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000787</dc:identifier>
    <rdfs:label>urolithiasis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f6887625-4072-42c3-9a99-ef42adcc7e45">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b44313a3-259b-4d65-a8cf-83aca3ff63f3"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e212bd72-bea7-41c5-a78e-74ffe0f1ad2f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d621a633-a61e-473d-a107-f131f18bae30">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:label>Decreased plasma carnitine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/59f5c7ed-3afc-44d5-9586-a65f7e87fc6d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71d62211-f40b-4b34-ab7c-e1c3579637bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e32925a9-1b3e-42db-b9f4-0290abf3cd48"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c41bb84b-cb67-49cb-9b16-e5f39664f75f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f19eecea-8a76-4a0a-87d9-9c2125818022">
        <dc:identifier>DB12537</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af11a3fa-7927-41ab-bac2-8383a0c45289"/>
        <rdfs:label>Benzodiazepine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99b96592-7687-4e47-8b8c-e11f54bd6298">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af11a3fa-7927-41ab-bac2-8383a0c45289"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
        <dc:identifier>DB00182</dc:identifier>
        <rdfs:label>Amphetamine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee47b75c-55d0-448f-b65f-79cd153d270d">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dc22536-dec0-40c6-8ce7-e0b9f15153bc"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af11a3fa-7927-41ab-bac2-8383a0c45289"/>
        <rdfs:label>Trihexyphenidyl</rdfs:label>
        <dc:identifier>DB00376</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac0ac517-5119-4ac8-af97-6ca80e3fa753">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
        <rdfs:label>Dantrolene</rdfs:label>
        <dc:identifier>DB01219</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af11a3fa-7927-41ab-bac2-8383a0c45289"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1df46a4-5290-41ad-b303-9643e5c682c4">
        <dc:identifier>DB00697</dc:identifier>
        <rdfs:label>Tizanidine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af11a3fa-7927-41ab-bac2-8383a0c45289"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a4008a40-cea9-49f6-a18c-ceef5298c3da">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e629a614-d76a-45d0-930d-0b8dbf2836c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eaee23a-479b-431b-9194-b821c3f34ef8"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/33fa077b-41ab-49b1-ae6d-5ada6ed2df19">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6d98d94c-6a15-4922-80d8-7339c2d440ea"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2f672b2-85b3-4f2a-bd53-4212a7bd98a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fee65030-8212-4f30-a1d6-ddfa22cceb6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e544a0db-5304-42fc-bec2-0a3542f8e255">
        <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010472</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/927721c9-d1ed-4682-871e-a986ab23e91a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/149f0534-9617-4984-9083-b0a8d54a0f56">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal liver function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/783003cd-86b6-412c-a4c2-d1a24e68c722">
        <rdfs:label>hepatomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1853b34-646d-4e00-9f7e-6a31a88926dc">
        <rdfs:label>Abnormal liver function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e97d682-6896-4f89-aac2-a3dd91297758">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
    <rdfs:label>low calcium urine excretion</rdfs:label>
    <dc:identifier>HP:0003127</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3a682a7-7844-47b7-af4d-c6423d4e3b09">
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012120</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/473933d5-7110-4622-a688-d4009306269b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9f6c78f8-1ca6-45fa-b86e-45095946af83">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26930d1e-93c5-4bb1-8ff2-aefae5582e7e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c52bd00-d51e-429f-b8c6-61f7cf8bf8e0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c09afd6-f880-424a-9641-d6a0e1a759ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/309db5cd-3885-4989-a05f-20b4c1f5aef2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/094c0311-da78-4612-91de-d981c1cbc062"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Canakinumab</rdfs:label>
    <dc:identifier>DB06168</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5a8a61b2-203a-4b72-a4bb-912642d3b602">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a407695d-5afe-49e2-b805-aa3d77334057"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d7986ec-fde4-4fbc-92fa-e5caf2d2ec7f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7219853-e288-44b9-ac8d-fa421a562592"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/150eef7d-b4d3-447d-b667-74620d84df0f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a1cfa32-f793-46d2-b0d0-19fed95c3a00">
    <rdfs:label>Acute attack</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011009</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4d7b9d0d-a40a-494c-98a7-7a5591a68582">
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25ade689-8195-46f2-b43b-94ad0acbf9fb"/>
        <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0e5959e-0152-407f-beee-fdb1432ff47b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:label>parkinsonism</rdfs:label>
        <dc:identifier>HP:0001300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b01272b-ab58-4970-92e2-03a05474f1d7">
    <rdfs:label>Six Minute Walk Test</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ee8c85e-1583-4dd6-9fc8-1288fb99a4eb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0159ddc6-985e-4336-8d15-72310419ccc4"/>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/445ccf27-0e9a-419c-97ff-c92d52a8a6a9">
        <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24a5e2b9-77d8-41d3-a055-b1385b1c5e95">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/444001c5-5b09-4239-acb4-fd8a379c0508"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e8e5139c-3a56-4a3d-aee7-545e77fcecb1">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cd966819-7a10-4e76-b057-6dab62ba5162">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63fe020d-3612-4dfd-a4a2-5bd19c17ea68"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2802d0d-06ad-45ce-abfb-42641a9e41a4"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff2b933f-a3ae-46ad-9b28-14c1e5434aa5"/>
        <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c3b63b8-d508-4c6b-af42-7a3072da4f96"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a12cea-f87a-4090-90ae-a29a1308e12d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8f3f257-8604-4e5f-afe1-b9267bd340ef"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/676334ef-2d07-4732-b5fc-fbf7daf74e31"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/807e4898-fb1c-4fb0-b2b7-2df0b52db046"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Febuxostat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
    <dc:identifier>DB04854</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/797c5fed-670b-43ee-83ec-ac23d7dbfb1b">
    <dc:identifier>DB00169</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dea789be-eb50-4641-8d1d-5b4a6af8bdce">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a4ea69d6-d1bc-465b-aeba-27d6aecb4b58"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed965c7c-a22f-47c8-9069-a062d46b1a2d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7b56016-914d-4368-8675-750871988ee1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
    <rdfs:label>Cholecalciferol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42b40c5f-056c-42ba-a34d-7cb519eb4c45">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011729</dc:identifier>
    <rdfs:label>Abnormality of joint mobility</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd357210-31eb-4b68-b593-9420ea6572e5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a916d2db-2388-4f37-a476-ee45d65dd7f1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5455685-361d-4265-aa5c-4c7e6d131e2e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum GDF15 level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24dc1fda-4fab-4573-b5ab-05a92f7e3c5b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d3eeae3-0bed-4b15-a7a7-55906b9c2205">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11c64218-db3e-4eeb-8a29-132a287fe16d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
        <rdfs:label>Elevated serum lactate level</rdfs:label>
        <dc:identifier>HP:0002151</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34cfe685-61c5-4885-9cb2-094fb44632fc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3003433f-5699-4e49-91e9-3c03535c2fba">
        <dc:identifier>HP:0200125</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f0269237-11a5-42b4-a850-da0c29d47028">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31cdabc9-f525-4f2e-9a8e-557077a99951">
        <rdfs:label>Developmetal delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e167778-e7bb-48fe-b5e6-d79c735a7e86">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bcf9be3c-31d4-4af1-a5e4-6c9769e2deb1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa48a7a8-240a-43a4-be74-0e63dc49d2dd">
        <rdfs:label>Abormal liver size</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b99646db-a35e-4321-a762-a3cefc33ebf0">
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>Cardiomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64cde555-e0df-48f9-a38c-290c2cbb35ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20c1d857-a57a-4c08-9c94-3884d21891a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1605697c-1a0f-458a-a653-a1513a992118">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e27bef0a-4769-4678-b1a8-1d6cc96bbb3a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9ee131b-3668-489e-9bc7-1a868546eaa8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced ejection fraction</rdfs:label>
        <dc:identifier>HP:0012664</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/933190fe-a441-4bad-bc7f-ebf38bbb3c7c"/>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6819f9b0-f387-4198-955c-608e244c861c">
    <rdfs:label>Tanespimycin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/34359ce6-b90d-44f8-9577-fde015ad14b3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc6f46cc-6425-47d2-8aa2-1a18388533d2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed941595-baab-4b89-b44d-199d60b14966"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec5b2926-d2b3-4a71-9e5a-5aa470987fd2"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9860778e-6cbb-4c4f-90c1-8a234e3d7965"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fd16d4f-0aa0-44c0-8b96-48ef733aa77a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/06f8b658-2452-4c2c-9b76-c4e71838c744"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cf0d49b-812d-4294-b2cd-edfb71838b83"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB05134</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c9465de3-d486-41f6-ba6b-573af71d1f2d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03988153-1ccb-4482-8832-0c9e390d8d3a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PL-induced cytotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/83d9581a-50c0-4ba1-a044-59028e7f62b4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/951b8733-91f4-4fb0-893c-742760f7e1cb">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1dbe07e-977f-4633-9d51-ff78fdf8d95b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Failure to thrive</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c66812f4-41d6-42ca-b73c-7045638b4a31">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Carnitine deficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c966759-5ac8-4644-beff-a6e39d00583d">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/859a4d5c-dde6-4b3e-b800-630d71c0fed1">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21a0a2bd-b1c1-470b-9102-db383532621f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1baf68e0-2b40-4757-a23e-fe717d97fbf1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/23a82ca0-83cd-4875-9679-1ffa7cde62c3">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17b8afd9-b557-481b-a7d3-e41f47848e2f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ganglioside accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8417b2c-6bb1-40d1-b0f6-84d3ca389d54">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:label>ataxic gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002066</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46578862-b762-4d82-aebc-68385141bca1"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0bb27f7-67ec-4436-bcc9-4e8fc5d83568">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0030353</dc:identifier>
    <rdfs:label>Decreased serum IGF‐1</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53d9c15a-653a-4c2c-9423-d23272e2f2c7">
    <rdfs:label>Thiram</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/86d74820-b80e-4fbb-aaa5-db28571bb30d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/825974d0-2398-47a4-a126-7203c4b29f27"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f77e8cde-39e1-47a8-acdd-d86c2485a195"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8fad1eca-ed5a-4bf1-991d-bc9227cc39b6"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9d82ec4-89e4-41a1-acb6-aeeeeda91f38"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26bc56ea-aa15-4415-93fd-725fdc83131a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB13245</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/59032ac1-82e5-4ac2-b4b0-218381c3eec0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7f7fd4b-d737-441e-aa0a-f4d6ffee23b0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a72cae8d-1bf5-4f0b-807a-752c3776ef93">
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d564b71-3ff7-498f-b741-373f554098ca">
        <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3a124391-07ff-41f1-9996-ba2fd5437c69"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e46a43de-cb2a-4bd3-b3e5-8ae21731e8af">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040129</dc:identifier>
        <rdfs:label>Impaired nerve conduction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f63372ca-1f17-438f-b039-e1e7ca8c4692"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82dac0d3-ea0c-4ad6-baa1-a586f681fbf1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma MCP-1</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/73891d1b-66bd-4ad2-9b63-233d1c1bdff9">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cb12933-bdfd-4119-9e18-3c177b8dc477">
        <dc:identifier>HP:0012040</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Corneal Oedema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ecad38e-8f8b-46a3-94cf-d71a3014b01a">
    <dc:identifier>HP:0004355</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/ee0a5089-d755-41c9-ac04-610bcfe5608a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84b5b785-f374-4635-9737-05353dee88e0"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18652077</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8e1d2ec-c38f-422e-97f9-a5c3dec7d4fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
        <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
        <dc:identifier>HP:0002071</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ea61c88a-faf0-4f86-8b63-677727b77d02">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e96dba6-b8e4-41f3-ad50-7a2d00be58a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf461ca8-eeb7-4ea0-88ac-c09ca87cd190"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aaaf38f1-6acd-490d-979d-6f7e795d25a2"/>
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60f994fa-9f5d-420e-82b4-21b59b0b13db">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3206fa4d-050c-4c1e-8a40-4fddb3665d3a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ece83f0-c7bb-4440-9609-6a8b0a0e8c18">
        <dc:identifier>DB14681</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f229d92-3ee5-48b6-b660-25f77853f2a2"/>
        <rdfs:label>Cortisone</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ac51f2be-17af-43b9-9e14-f3aed50bda8d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40a6e49a-e539-4014-97d0-aacd64d1b178">
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>Enlarged size of the liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78893f38-e03e-4645-916b-5a07137f718f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000002*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f29efd2-6f09-42bf-9478-c3b328a5cfb5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
        <rdfs:label>hypoglycemic seizures</rdfs:label>
        <dc:identifier>HP:0002173</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fee65030-8212-4f30-a1d6-ddfa22cceb6f">
    <rdfs:label>Givosiran</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <dc:identifier>DB15066</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33fa077b-41ab-49b1-ae6d-5ada6ed2df19"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a3604a8-1255-42a8-82fc-7b9a970a42cf">
    <rdfs:label>ARC-AAT</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/03a64b69-c526-4cdd-abc5-11c6e9dca312">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a15d7b5-fd32-4628-b670-76a0e80385d1"/>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f08c24fe-e259-4039-9721-a137d1529735">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <dc:identifier>HP:0003128</dc:identifier>
    <rdfs:label>hyperlactatemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c6c5f3c-9420-4ea2-ae5a-ceb5b99c9e05">
    <rdfs:label>Hydrocortisone</rdfs:label>
    <dc:identifier>DB00741</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/af81f566-3f9f-463d-81cd-dcf7b0b7d6c8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1b693b8-458b-4e68-9c72-20c35e086606"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aabf3241-6f82-4993-8a30-2f22d1fb2fe6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0413d6e-88f9-437f-b93e-cd738b566ee6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92c1f9c2-bb6e-4903-b241-7f70cf04e0da"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment></rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b4a52aa-700b-4d28-9117-32a04b4b0ae1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f3b1375-4dc1-46b6-8f02-904fa1bc1fcd">
    <rdfs:label>Testosterone</rdfs:label>
    <dc:identifier>DB00624</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e9b462ac-50ec-44d3-8200-a54be2eaafc2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7b8e702-026d-4af5-a6a8-aa320f831296"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/347c65a4-8a52-4c5f-aa0e-71d35b855532"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <rdfs:comment></rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b22e73a0-52ee-4a5e-9420-680d84ac3bea">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a81ec3d0-5c74-4572-8845-b7267fdbfefa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31deefad-ab88-4f9b-b375-fc017dbfc430"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/347c65a4-8a52-4c5f-aa0e-71d35b855532"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2da825fa-b4e1-4d45-baa5-6d8d99b05242"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ebfbf2ba-5e53-4704-9cde-29cce61af01c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccabb8dd-704a-4764-ad6e-ad907c6390ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/347c65a4-8a52-4c5f-aa0e-71d35b855532"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a80e40f1-4502-4d80-930c-08386254f431">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a5a9720-3051-4ad4-9559-7200b328b5b9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
        <dc:identifier>HP:0100660*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9a4cb45-7e2c-4a47-a3a9-043fa9edd935">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe0fb7be-5eb0-4e9e-944e-f5c381100017"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b3e6b400-f94a-4a94-93c5-58ac2c2b9530">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24dc1fda-4fab-4573-b5ab-05a92f7e3c5b"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdfa56c0-52d2-4efc-b8d3-e02beb1a18cf">
        <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34cfe685-61c5-4885-9cb2-094fb44632fc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5455685-361d-4265-aa5c-4c7e6d131e2e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11c64218-db3e-4eeb-8a29-132a287fe16d"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/653a7597-6bc8-45da-a2b5-954483137308">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001332</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <rdfs:label>Limb dystonia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/56f48263-f396-41d7-85fd-729cfa337c57">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c9dcddb-13d9-49b4-bfb1-7b3c71e13a33">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f6e0f1ac-12f4-4b84-8934-8ab18fe6c7a2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/009b995a-fdb1-45ab-af86-e1c69f9b358c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum renin level</rdfs:label>
        <dc:identifier>HP:0040084</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/662f7cfb-07f7-461d-8228-76c674dc9b6e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Refractory hypokalemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cd38fa90-11a9-4187-b0df-70d964e16f2a"/>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a5eb3520-3d59-42d4-b756-f612ea545ea6"/>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b416a32c-5a55-4464-896a-1f195ae7ce1e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <dc:identifier>HP:0004319</dc:identifier>
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3a78267-1c36-4b7c-bf3d-9386ccf4c719">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96b0b768-f5dc-4c7f-a575-8626684b540d">
        <dc:identifier>HP:0011015</dc:identifier>
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2345338-f5b0-4c0d-9747-36bc3aad1812">
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1dbe07e-977f-4633-9d51-ff78fdf8d95b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa57f333-c711-41fb-a442-fcd1525094d0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/445505ee-0e2e-46aa-b13f-bf6beedc97fd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70d82e9f-d56f-4788-a9f0-21afba63f518">
    <dc:identifier>HP:0003254</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c0ffbc06-2a50-4fdb-899a-b2f72b82e11a"/>
    <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e75749d9-59af-4366-a6b1-cc4d0bda8a12">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b626206-f74a-46a1-82d6-c176c2849574"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6612b6bc-c699-48b6-8a53-d2f7ab5f71df"/>
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb3f2a33-8365-436c-be24-acd5e92c47f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8df44480-8fcf-4819-81f6-417bf77e7e8c">
        <dc:identifier>HP:0000992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>sensitivity to sunlight</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666ef3ed-c9ee-4c09-9cf2-8c42c5f17061">
        <dc:identifier>HP:0000726</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:label>dementia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3607753a-bbe1-4a90-84b5-50245ef4aeb8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>diarrhoea</rdfs:label>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22afe2fe-e24e-460b-8d13-d14a3dc9451d">
    <rdfs:label>Hyperpigmentation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000953</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19252979-5ba1-4e27-ab63-6f8fb5899c0b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6016e1e-a8be-4e43-a7af-46864efbde33"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/02aa1086-40ec-47ae-b17e-9919e9204fe0"/>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f6b112f-e830-4e59-85ca-e48839270f06">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a2d55fec-1ac6-4c15-8cfe-40d114b075b2">
        <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07b22438-d150-4bce-8ecb-cf58accd691e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66555cbf-be75-4823-8b38-b9a95994e93d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <dc:identifier>DB08909</dc:identifier>
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1383711d-42a3-45f3-9f80-7e9e7fe8c876">
    <rdfs:label>white matter abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002500</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e0519a2-79d4-47da-a3cc-9355a2fb0725">
    <dc:identifier>HP:0000789</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
    <rdfs:label>infertility</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8b2c7ee9-c064-493b-a792-a7e5874a1b77">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a834c6f3-7383-490c-b70b-a4c67a886244">
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfcdea75-8a79-4523-88be-0c392687b5ef">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0baa223-aec9-41f4-b358-9dbf792de656">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
        <dc:identifier>HP:0012389</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6b84c81-66fa-460f-a580-1698de632d6d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurologic burden</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <dc:identifier>HP:0002344</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fb6d73f-af0a-4ea3-b5f9-8eb17b32481c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
        <rdfs:label>Woolly hair</rdfs:label>
        <dc:identifier>HP:0002224</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83fcd52b-945c-4ae6-94ec-39b6bb35fe4e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
        <rdfs:label>Hypopigmented skin</rdfs:label>
        <dc:identifier>HP:0001010</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16332fca-65b8-4d42-88bf-c66c54877513">
        <rdfs:label>Rapid disease progression</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f50dacf7-a794-4dc0-a75f-df7b9e4f812d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:label>Poor weight gain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/323ea5f9-b8ce-4ff1-9e82-5a2cfd7c953d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
        <dc:identifier>HP:0025373</dc:identifier>
        <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2328a99e-13eb-435e-88c8-5805b992d884"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd0f3715-a4b3-4484-9874-2eef3c7e6c45">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormalities.</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b180215-201c-4e11-a5b5-f39b924449a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6bcf96fe-2dba-49c7-8830-e96f0f4f80a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/328a969e-5769-42b3-ac50-b5cb05a3283f">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6e8f21d-3e6e-458c-b81e-30e2859d50fa">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:label>Hyperlipidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff43ae32-cfc9-4199-ae0e-7c28aac71417"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
        <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a0614d83-a96b-446e-8015-75801db39e63">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98a733bf-cdb9-44d3-92fb-82b3e90e64ba"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b79ec80-8cf4-4a5e-9633-5a32afa4bfdf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdc8944f-1ec3-437c-8fbc-6a7e9dbb9739"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b4a0256-47b3-4e60-a2f5-50a567b6fafd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ichthyosis</rdfs:label>
        <dc:identifier>HP:0008064</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0072f1f8-05a0-4c7e-945f-883c3729a013">
        <rdfs:label>scaling</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4721c16b-f622-438a-838b-23ceb880169a">
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Pruritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/421c1093-7cda-450b-bb7c-345b0c5aed77">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010783</dc:identifier>
        <rdfs:label>erythema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
    <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c470ca49-b8fc-40ed-8523-f0d2788b9bcd"/>
    <rdfs:label>ARGININEMIA</rdfs:label>
    <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
    <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
    <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ac988235-cf88-4b99-ba7f-6723e4df0c65"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9da4d1ec-2423-4900-ad19-adb793f0c224">
    <rdfs:label>Decreased muscle mass</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/ef6661b5-18af-4a5e-8242-8bffad2edab9">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94c1c28c-bb8b-48cd-8c77-0d8ec0f004c4"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2afd82cf-a531-4902-b601-9f7bd5acaa17">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum folate</rdfs:label>
        <dc:identifier>HP:0040087</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1b31c10a-4cbd-4ec5-b970-8164e16d02ad">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a786ba0b-17be-4f30-b54b-e3299ecf4995">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f098221-f297-454e-8634-aa7435638885"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3880a74-b60c-4d32-bc4e-38d2e4ce29c7">
        <dc:identifier>MP:00011911</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9d82ec4-89e4-41a1-acb6-aeeeeda91f38">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <dc:identifier>HP:0010836*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c15d8537-74e3-4d8f-9655-6a870dc5cf88">
    <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67e85e6b-9e12-490b-93ce-0f7b5b9a7f8e">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/87fe55be-0bb4-49df-8c3c-4d9492f81c6a">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d707c6d-cd28-47c6-9e11-5983b2628146"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/493bcc49-ab4a-4146-a49f-43b9bd30e922"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e71e4f4-c834-4064-8dcc-6d43998d7d76"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e067b8a-acf9-4871-8a94-f24185249f15"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42b075da-bf2a-4b8a-ace7-09dd2a569604"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90a120ed-3c98-442a-9603-affeec51c55b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/3946e6f1-4bb7-4559-9005-476877a5f577">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37d007de-9aa8-425c-99a7-06420f6c1a9b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bbb8a55c-de4c-4517-bb44-2e567aff6b69"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/951dd891-ae7b-42e9-8a95-3491a58a5bfe">
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1eba47ae-bb49-49de-9d02-15b1c1f6e676"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42b075da-bf2a-4b8a-ace7-09dd2a569604"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB02959</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <rdfs:label>Oxitriptan</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d23eda5c-77b7-4c35-a537-a8019626e248">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3610f4e9-6158-4827-92c3-a07ad8474fae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdbd47f8-f6dc-4b74-9fc4-cb23cf3dc984"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0407d98e-d400-4395-b2e3-c567e9cb32e5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d6841f9-1af8-4e3c-9cfb-4c99b6361dc3">
        <rdfs:label>Abnormal cellular proliferation</rdfs:label>
        <dc:identifier>HP:0031377</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f93b89a2-ba25-4e62-817b-704baa6c40c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e31f96f0-4571-4e93-b497-af7b909b1dd9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11924e7d-8d53-4172-9382-0ae49701c5ed">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4565975-985f-45c5-8ebc-cece90acd40c"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
    <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
    <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9f68006-8c4a-459a-9c81-c0fa4cc8d991">
    <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031884</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/309db5cd-3885-4989-a05f-20b4c1f5aef2">
    <dc:identifier>HP:0031375</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Refractory Arthritis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/af4c4da7-93ff-449c-b8d9-6255bcf85436">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/39ce0f42-4382-437e-b595-e59965d6c7c6">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caf6c9a0-dad4-4cf1-adf3-b274abcbec9c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002148</dc:identifier>
        <rdfs:label>Hypophosphatemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3e2b581-2a6c-4ec1-8b38-9fb59f5a3698">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/68767ad3-660e-4c90-8c0a-dd6bcbd572e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab6de101-019a-4f23-8f51-f7f4f3aba61e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lack of emotional expressions</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
    <dc:identifier>HP:0030213</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69dd2590-fca9-4856-87e1-1d411e4e80b9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:label>high serum bilirubin level</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2710a8d0-6904-44d5-a707-a69eebfb57eb">
    <dc:identifier>HP:0002155</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>Increased plasma triglycerides</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dcae384b-d864-4818-a7d3-bb4b9b339341">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70b458f2-5702-4631-bb79-bed0a9341fdc"/>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e221822-dab7-4fae-a2d5-d8b404341ff0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae098ba0-07ed-41d0-bbbb-7cd8b9545391">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a310e86-b924-4678-a33a-8210f500a039">
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:label>acute hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e9a3b42-1ddd-4fdf-822e-5c344010c970"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1dab5d67-1783-48d7-80e5-72432ace7031">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ba3c368-1ea7-4d38-aadd-fa5357cea157">
        <rdfs:label>high ornithine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012026</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17565677</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7028650</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5fbef4cb-a0d8-4c47-9b3a-84e83f74bd77">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c0784f80-e579-4ac8-acd3-516dbfc22cba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d090e5c1-25ec-45f9-9a28-44759dfe61cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/545a86e4-a3dc-4d7b-8fae-c091b9e1c7e9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
        <dc:identifier>HP:0001410</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88450dee-d6d4-4e68-8a41-f4969795dd27">
        <rdfs:label>tissue damage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1de6722-6a8d-4623-b5a7-8a82a0e6cafd"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5b9a059e-94fe-4d8e-b76a-65ffe3994a6d"/>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56b6b42c-6231-472e-8a49-02d86ab3c051">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>brain ventricular dilatation</rdfs:label>
    <dc:identifier>HP:0002119</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c2d23b9d-e40f-4d63-94cf-ff53a8800622">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8de8b586-f1a5-4d6e-8b6c-7d33c17fa757">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ddb5457-0b57-4d3f-a0a2-733f98cee623"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/974ceed6-752b-4a8c-af83-729883e290a3">
        <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <dc:identifier>HP:0011031*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/790758cf-bb3f-4c26-b958-76d188c7b348">
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e11c18b-a8df-47ae-b22a-3ca5249e3cfd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/603031b1-249b-4caa-8f1a-e1cc0825ec32"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d2ec200a-f1dc-4c63-ba28-9288832c1635"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad0c1f46-b777-48a0-9a63-73883b20ba34">
    <dc:identifier>HP:0012217</dc:identifier>
    <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a21e37d8-2ff6-48d8-99a3-26c678022c83">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1605697c-1a0f-458a-a653-a1513a992118"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/feacfbb5-4e9b-45b7-910b-1ac09672625e">
        <dc:identifier>HP:0012664</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <rdfs:label>Low ejection fraction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64cde555-e0df-48f9-a38c-290c2cbb35ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66476764-b823-45fd-be4e-eb357be390a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6c53c39-34d1-40c6-bc0d-97a84aec770e"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be77fb07-4d6d-422a-8796-03f8ebca6a2e">
    <dc:identifier>HP:0004302*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>disability(Functional motor problems)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/19444866-9e00-493e-b450-ccca1f6eac02">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4236cb1-8278-4015-b261-ab1702692f44">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b9aedef-78a6-41f2-866f-4589c6c96f76"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a78d033-ddab-4244-bc3e-c771d97d3f9f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <dc:identifier>HP:0004910*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9fb3780e-463c-4af3-94d1-0125a00f583a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/112ee59c-299d-405f-84d8-2205618cd221">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28261de0-93f6-4110-a31f-2c30cecce574"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/08596620-7dec-4e61-a957-13f049476eeb"/>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc4b83c0-10b8-4f4d-b44f-ef89d09d0452"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea6fcfae-1148-4adb-9216-2f9b3eb927c3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:label>Increased ROS production</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025464</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8c5810f1-3d81-4a0e-90ef-9c55a49e9368">
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
        <dc:identifier>EC:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9860778e-6cbb-4c4f-90c1-8a234e3d7965">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200114</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <rdfs:label>Metabolic alkalosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f445d143-01e2-4959-b940-50d896d32fb6"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f07d186f-945a-4b0f-abd3-55e7616146ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c40278ae-f7c8-47d7-a421-86fa2bb5cf5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/356f15d7-0113-404a-8609-bf3930a5d581">
        <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb2aad12-2eed-44f3-b31f-24e230ec8f5a">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d0b019e-97a4-41dc-9f02-e481ca9af2bb">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ee66590-a4c7-4235-adc4-dac2ace4f7ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69904507-70c2-4c52-92bf-7e4d10436203"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Quinethazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <dc:identifier>DB01325</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fda910b-6cbd-431e-979f-9e964fd98fdc">
    <dc:identifier>HP:0000572</dc:identifier>
    <rdfs:label>Functional loss of vision</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48e9cc43-0084-4e1f-a1e8-ef0d62fbbd6b"/>
    <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/da37d10e-0146-4ba7-a751-a7c1d2a452c0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5f139c3f-e91e-47bc-9beb-da064901cc79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e456d8a9-a329-4174-9fb3-80db0d8574c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bb596ed-b7f7-4ada-b963-5ab56bd1ac92">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6fe400e9-1715-4228-b2cf-e4c6a4abac27">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c3d7cce-d4d0-4de8-81bf-ef008b7fa563">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8729189c-09e7-459a-b295-6f9bb4c7e827">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor head control</rdfs:label>
        <dc:identifier>HP:0002421</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19c0a710-28cc-46af-ba3f-d51a810c1d4b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a3fdd025-07b4-49d4-917b-4c72023dd189"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25a72b2d-7ace-41f6-8067-f0cd35dd8cc2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>choreoathetosis</rdfs:label>
        <dc:identifier>HP:0001266</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54a2f18c-fa96-4fbc-9704-c7582a053bd1">
        <dc:identifier>HP:0010553</dc:identifier>
        <rdfs:label>Oculogyric crises</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0c6ec29-8e98-4e79-8ff9-b3c4097bf9d2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
        <rdfs:label>axial hypotonia</rdfs:label>
        <dc:identifier>HP:0008936</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef3c4fc8-4963-4008-8eb8-50e710959f5e"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/410274e7-7db9-4533-b227-240517fee122">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:label>hypokinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7130e42a-79ab-49d0-9240-7cbdfb82f559"/>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa6ca9cb-c989-448f-ba06-c2bff07fc9a0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>limb hypertonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
        <dc:identifier>HP:0002509</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18715265-eba3-4742-bdf9-69df63ebd818">
    <dc:identifier>HP:0003236</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
    <rdfs:label>Elevation of creatine kinase</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/80565c9a-d7e3-4783-963d-fde4ee618312">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eaee23a-479b-431b-9194-b821c3f34ef8"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4f5f4c4-8a00-45b4-9ebf-9cdb2d206234"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/09db3881-b71a-4378-897b-c0b0d8caea95">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93e05956-986a-4f58-a15d-a32027a3d9a5">
        <rdfs:label>lipid peroxidation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f33e15df-3cfd-4f69-8209-5a926f24606f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
        <rdfs:label>oxidative injury*</rdfs:label>
        <dc:identifier>HP:0025463</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a4046e9-581f-4a7f-8188-cff2216e5267">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <dc:identifier>HP:0003254*</dc:identifier>
        <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa8ac9ce-349b-46f4-9b28-53895e111d4c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Protein oxidation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
        <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
        <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
        <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cbf17fbd-ceb8-425b-a544-433ae8de260b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/124e885f-713a-4299-bc51-fcc167476b65">
    <rdfs:label>ochronosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0030764</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49be7e1b-4d31-4dc8-b5f1-4f42826b3324">
    <dc:identifier>HP:0001889</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
    <rdfs:label>Megalobalstic anaemia</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1e821dc-bc6b-43d7-97fc-1ca99e0635c4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bcff6565-b45a-4df4-9f1b-be502ddd90e2">
        <rdfs:label>Complex Carbohydrates</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf41e619-eede-42a3-8eba-7514c7f10825"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c05b3a20-cc8b-4c0f-b75c-6b6e886e8ee0">
    <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <dc:identifier>HP:0002630</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/bf41e619-eede-42a3-8eba-7514c7f10825">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/083a19e4-1b22-48b1-ab0d-e57994748f3b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d4acfe-bfa6-4e86-ba50-efc345afde8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1e821dc-bc6b-43d7-97fc-1ca99e0635c4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5497e954-b42f-45b0-9a01-655b922cbbb6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Stature</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/697739e9-98f8-416d-aefd-e8f72e4258f8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc1c288e-319c-474c-85bf-37add63ce866">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>cognitive dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/707b660f-4e24-4323-8c07-720e245e1813"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1c7d643-60d0-4bc7-85e5-f994a095f515">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <rdfs:label>Low cerebral creatine content</rdfs:label>
        <dc:identifier>HP:0012113*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e4d7689-e756-4bbb-a6a1-2bbd7a152a8e">
        <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/720c4f5f-d051-4446-b436-abf1f9ffb8f1"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
        <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/035499b9-1264-4b5d-9def-3b2cae46c725">
        <rdfs:label>Low developmental score</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aadb09ff-bca4-41be-808a-e74e95c4fb5e">
        <dc:identifier>HP:0002474*</dc:identifier>
        <rdfs:label>communicative skills abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/139c50c7-fed3-4851-8f0f-b01e1560a0e4">
        <rdfs:label>Low IQ score</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2bba211-c75a-42fe-8f23-13d300ed18f5">
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavior al abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55f9f454-8492-47cc-9f90-6cb31ac27bb0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b2339ed-561e-472c-b0d1-70d3f6f8be01">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1388fd71-0653-47c2-b3ca-88c184721e24"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6230162f-c85c-41bc-b5e5-28152d08ae4f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98d611d0-7064-4edb-b2ed-892c3722ae25">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>psychomotor retardation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/309638e7-5161-40c4-9379-0e0967e9a727">
        <rdfs:label>neurodevelopmental delay</rdfs:label>
        <dc:identifier>HP:0012758</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7287cbe-6461-43e4-86cb-a10d325f4792">
    <dc:identifier>HP:0000722</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
    <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c6250bd-8158-4853-b960-8e543d019a87">
    <rdfs:label>Carglumic acid</rdfs:label>
    <dc:identifier>DB06775</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae098ba0-07ed-41d0-bbbb-7cd8b9545391"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/03370c38-8c49-4eb6-86c5-48434de64f20">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e9a3b42-1ddd-4fdf-822e-5c344010c970"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/815d6577-1046-4862-b2af-d40c9826ff93">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4f5f4c4-8a00-45b4-9ebf-9cdb2d206234"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9cdb42a-47e1-4ccb-ab92-33fdd69c2739">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
        <dc:identifier>HP:0008344</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0aaa9491-8337-40d8-9aa3-d37637f7f673"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/422ddcde-c917-47f9-9de5-68d158c6222e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma branched chain keto acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/412e84c2-0e33-4ff5-bfd7-de0eb575dd5b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40641329-ca76-4b29-bbc4-cf25929066dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/032df2ea-8f44-4047-a789-33dfaf87afac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d4acfe-bfa6-4e86-ba50-efc345afde8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fdcac6c-fefd-4b0f-97eb-3b8f5661588a">
    <rdfs:label>verrucous lesions</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012500</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1537681-1618-478e-8bdd-1d300a55e79b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hyponatremia</rdfs:label>
    <dc:identifier>HP:0002902</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/77571f82-0abd-404b-9c97-4a9bb49f3af2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6348c217-a72b-4497-974c-1f2e75bc18a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7aa56ac-aad9-4607-86fc-1832d5a537ba">
        <rdfs:label>corneal crystals</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <dc:identifier>HP:0000531</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5dce4ed0-c8a1-4608-890e-27c694662fcc">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b44e6cbd-efe0-46fa-9581-c0f634281678">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bc91b52-916a-4c78-b767-33605ff5376f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0003304>R125Q</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>R266K</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94dda678-c701-40dc-8c6d-5e7a2f69dc7f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71f45386-532f-4841-8f31-c76b02cef039"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <dc:identifier>DB00855</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e9c538ca-4ac3-48ad-9b9c-3720abb25e32">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9eb5c914-ace3-46d8-a01c-50f414b07428">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11449034</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2d2a7b4-a914-48b2-9fd8-0706c3cc520f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/189c0e94-a048-44b2-9083-d87f9391c52e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ce41f7d-afe1-44a6-b606-9e679a608755"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00502</dc:identifier>
    <rdfs:label>Haloperidol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/623ac604-ede5-4c9c-8f22-3eda8be7b25f">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1095954b-aa20-463b-a3fc-c67415768057">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c52293df-7b6f-48d4-93ab-c6f3b3e71544"/>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15adf047-c5d9-4885-9923-f8e1ee399144"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
    <rdfs:label>Benserazide</rdfs:label>
    <dc:identifier>DB12783</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11e043a1-c61b-42e9-af96-a404e06d9315">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <dc:identifier>DB01186</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a310fba4-6654-4afe-ae2d-58d46c9a3f23">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6817b284-c31c-4e04-b20c-9d2ee8ba7cbd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0e5959e-0152-407f-beee-fdb1432ff47b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fce3732f-872d-49bf-b4c8-203c3139faa9">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6817b284-c31c-4e04-b20c-9d2ee8ba7cbd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7b15968-4012-4671-92fd-c5ae0e8c6b11"/>
        <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8729189c-09e7-459a-b295-6f9bb4c7e827"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c72ecf5e-2a7e-4716-8658-6ef7970692a3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef3c4fc8-4963-4008-8eb8-50e710959f5e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0ad31f9-90e7-4950-ba60-6e469e03e009"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Pergolide</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/04a5c102-7f94-410a-be9d-3b78eb064c95">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5f25435b-10e1-4726-b3c8-b9e80ca99ad6"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/707b660f-4e24-4323-8c07-720e245e1813"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/37b10c5b-0941-43da-97df-1a0455763c3c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17ec62d5-b8af-44c8-88aa-4d7d9d3c0e54">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12bce9fb-3ea1-4f9d-a168-a13fbb08a766"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d4acfe-bfa6-4e86-ba50-efc345afde8e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3eb233a-5e80-44e3-96a6-fb61dbe44e67">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07732259-5e4e-4efc-85db-65e7fe9bc1a6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f6d22bb-7451-46ee-afc7-e4e63802562b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9686828</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c1476c4-7b8d-42cc-8532-b0681d00bf24">
        <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002453*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bee289ab-6442-4ddc-a824-1b000aced553">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Epileptic seizures</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3532b2c6-525a-4255-9d1a-acfb8a69b093">
    <rdfs:label>abnormal motor development</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <dc:identifier>HP:0001270</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/fd20cc35-021e-4774-8fae-a586f8d5b91d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c447adf-c436-4fb0-bbab-60e91fadeb7d">
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor appetite</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90a120ed-3c98-442a-9603-affeec51c55b">
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12f3610f-a126-47c0-8a2b-5bde88c482ca">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
        <dc:identifier>HP:0012449</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed mylination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dee82787-cd84-4fc2-81fa-1f5cf893c21c">
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ad713e-1b47-467f-bfe2-260cf9184115">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67c80583-85b8-498d-bcae-46def5601e5f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fed6b1c2-10e0-4ddd-ae08-f24713d49644">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed motor milestone</rdfs:label>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ded5ff9-d834-4ad3-8393-abc07302be9e">
        <rdfs:label>Low IQ</rdfs:label>
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83325131-992f-4add-ae9e-bfcc22278b31">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor traction response</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7495333a-0948-4516-9b31-6d1502a240c9">
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc8bdbfd-16f0-4d0f-bc1e-7a44a59bb980">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001347</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:label>Hyperreflexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f50dacf7-a794-4dc0-a75f-df7b9e4f812d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2d52945-a405-4f9e-9a10-e25a3f52d822">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Irritability</rdfs:label>
        <dc:identifier>HP:0000737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f038896b-032f-4c0b-9d5a-80d40bffc1d0">
        <rdfs:label>Behavioural abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e96dba6-b8e4-41f3-ad50-7a2d00be58a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30f6f242-d7ad-4193-b15a-2bd6c57f5690">
        <rdfs:label>Foot clouns</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011448</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/185d7b82-6bc2-4edc-b6e2-1eccbdcab05f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c20d576-a9d3-4c85-960f-28f0662e1274">
        <rdfs:label>Delayed development</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7445c9e9-4cee-4bd4-9107-1dd88a52cc5d">
        <rdfs:label>Brain demylination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007266</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/348cf8b0-6c71-490f-9896-fc7988c3fe4b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal Awake EEG</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
  </obo:DDIEM_0000011>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e5b67d52-e09b-4392-9573-c41e2704e2d0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a117723-c729-4588-9b3d-536c1891e699">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02a32af5-9dfe-43ca-a726-6de2ea7c4a95"/>
        <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22576252-ccf2-4e78-913e-18f03b61ac90">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025201*</dc:identifier>
    <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/2f0d5323-86d6-47dc-a7f2-6b45a76ff399">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/929fa139-4970-48c8-bf9a-8c883125bd88"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46578862-b762-4d82-aebc-68385141bca1"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/016d0797-5af9-4b53-8c80-34f0bcc19680">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8ee990e6-7589-4998-bcc2-d430b9cae67a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85ff1ce1-5d2e-4ce0-8f08-c579a15b0963"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5397745c-9cf3-459a-a84b-b6b9acd31118">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4dbad90-711b-448e-9c6e-fff83622eed1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21464603-262b-43f1-855b-0f753303d729">
        <dc:identifier>HP:0012410</dc:identifier>
        <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff68b816-484b-4c64-8bf2-254fe8f68f76">
    <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7d6b15e8-ba02-46a0-bcb4-18a2b50adaa4">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff590526-cfdb-4dd3-9c82-3f8a566efa38">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bcb9ebeb-0434-4e84-ac36-4b412f349022"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e74675a-45dc-45cb-8141-cc1fce47ec79">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5818273d-745d-42ca-bcfb-370b68987198">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e886d96-d44e-4da6-96c0-27ba6b292083"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a86f6078-59b7-436c-a506-39312b358df1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
        <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53955de4-6cd0-47eb-b239-28b6649224db"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02096fb9-ae11-46e5-8352-cf6aed1bcc51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/edf70ac8-e1a8-4884-bb7f-10693faa6d65"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/013b4c79-7cca-4084-a048-7cbf0df143cf">
        <dc:identifier>HP:0003326</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
        <rdfs:label>muscle pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe80023b-b083-4b84-9110-78085592a058">
        <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68e1f6b4-df34-4c6a-a984-1ab28d4923d6">
        <rdfs:label>rhabdomyolysis</rdfs:label>
        <dc:identifier>HP:0003201</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01cea7ae-5c98-43d7-b46e-b9d905655fda">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <dc:identifier>HP:0001290</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Generalized muscular hypotonia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5eff083-3e2d-44db-99af-48f49b66dedb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c164f4b3-e831-4579-bf30-cdd1c9de2904">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8e76452-2eff-4cce-a8c2-c51ae8c0c3f7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>hypocupraemia</rdfs:label>
        <dc:identifier>HP:0010836</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/890e349e-ad83-404b-b127-97ea84a6f7a4"/>
        <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8fad1eca-ed5a-4bf1-991d-bc9227cc39b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/682f1bb8-5917-480f-8971-d1950b1ae182">
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b4a52aa-700b-4d28-9117-32a04b4b0ae1">
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:label>Hypertension</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b3a35a1-cb8d-4069-965e-ab81d5b6abfa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c14d6e7-4d93-4639-b11f-cb2149721697"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6cb1dcd0-1855-42b2-aec3-3d518c737daa"/>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca4285a9-2acd-4d14-96b3-1dd76d225963">
        <dc:identifier>HP:0000855</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Insulin resistance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e54e2a56-6594-4076-bc77-120bb3b59a71">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69dd2590-fca9-4856-87e1-1d411e4e80b9"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbfa96a9-9c76-448f-93f4-cb1080983019">
    <rdfs:label>Joint inflammation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccabb8dd-704a-4764-ad6e-ad907c6390ab">
    <rdfs:label>Low serum testosterone levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:004017</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0bccbb3-0796-4e86-b52b-82d90a1a1fd4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>motor malperformance</rdfs:label>
    <dc:identifier>HP:0002275</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/f13a9a86-45e3-43f5-9bcb-25cb515ee6b7">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9e1c002-6277-400f-80d2-abc6a2530251">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ddcacb9-219c-4332-a767-7fdccda88c79"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5563e65a-5888-4bb2-b5bb-f3fbb8c8512e">
        <dc:identifier>HP:0003165</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
        <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4f381eb-57c6-463f-a38e-3dbdb76b0de2"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b39460f-62d4-4b88-98e9-5f7a715ad066">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <dc:identifier>HP:0003072*</dc:identifier>
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/2cd94337-571f-4dd1-9c63-3f8ff6d8bcb2">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b36f0d7f-4806-4df2-ae39-d99fbcb3c75a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71f45386-532f-4841-8f31-c76b02cef039">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
        <dc:identifier>HP:0012379*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <obo:RO_0003304>I278T</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/500881b2-c335-4438-9382-a059696d4d50">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d9041ab-ceeb-4f64-9e9d-1210daa73940">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a864e066-6bce-4622-b066-86fc145fdbe2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6513c327-08ac-4ca2-a20b-79e134f6e700">
    <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18f1e9da-febd-4584-94fc-52afe435ab11">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f765f777-0dc3-446b-94b4-6b68473426b9">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87b09f7d-7bab-42a5-b5f2-ab5a5f68e7f6"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c635aec2-e9ec-4cc3-a5ff-0e19835c7104"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cfa95e2e-d341-48ff-b92f-90fcb969d466">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c071cf5d-3f67-49d1-8f3d-e7548903badf">
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3ffe442-8c83-437c-99d7-c54c62c7bfbf"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae13ebe8-f4aa-44a6-84cf-af8b3a9ff885">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3685f7d-2440-4140-9ec5-3c15e5f9ea86"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2617a88-77ed-4dae-b8e4-f00d7cf77a50">
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>Cutaneous photosensitivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b049c230-09ef-4c5e-8b20-eb3bf4047ba4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/501ee339-83db-4300-b00c-81ec973b33cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a3bd06f1-2988-4ea2-a1a1-2ea013b1655e">
    <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
        <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd08eeb8-c1a9-404c-8e9e-ac07f30f6eef"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab764556-b981-45bf-abbc-3819380ba01f">
        <rdfs:label>acidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82d09855-326b-42db-81c5-06d7f36b7f42">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5da881df-440a-4701-963a-be46e7762bb1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e9ca709-296d-4a2b-8708-882539d60ba8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e74675a-45dc-45cb-8141-cc1fce47ec79"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/51400d4e-fd44-4bf2-ab37-45e38c5bd9b8">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a87a76cc-d94c-47a6-a7ec-0d258d971d3d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/443afe04-fbdd-4e87-ace6-b742f3d2eb5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/405c9bf7-852b-494c-90f6-2c08be90ffeb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>urinary tract infection</rdfs:label>
        <dc:identifier>HP:0000010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96b4739f-f0b8-47e1-8487-dcf094a771be">
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccf14b92-85e7-41e4-baf4-0e66a984df55">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002243</dc:identifier>
        <rdfs:label>protein-losing enteropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b4f7a76-c7f2-4e40-b2f2-2ec20da98c5e">
        <rdfs:label>hypoproteinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
        <dc:identifier>MP:0005567</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a59eceb6-36ec-4ef5-8435-dc58386ecdfb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
        <dc:identifier>HP:0001928</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>blood coagulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8bd67bc-1058-436e-a0f0-b6cca852d167"/>
        <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5af3856b-954b-44ed-88bc-3feafb104580">
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypoglycaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c73bcda4-d56b-4947-904b-19386d61b015">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolism abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/18af33b0-6038-4d3e-b97f-7603fe765f21">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf3b5037-4e05-4257-9846-ec2f0aa534c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e0549be-76c4-4b2f-a539-8cff85fdbee2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/30c9c90f-9408-4f29-bb74-97dde109fa76"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dff1f92b-eb56-40c4-becb-ace3775807c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52b96535-8df7-43a7-8632-c37d5e922731"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/edf70ac8-e1a8-4884-bb7f-10693faa6d65">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f60f874c-e334-431f-aa51-1bb6325c6581">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f63372ca-1f17-438f-b039-e1e7ca8c4692"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f79cd8f4-2f6e-4b6b-9e71-48cf36821161"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02096fb9-ae11-46e5-8352-cf6aed1bcc51"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bb10cf4-86fc-4244-944d-f7451dad5c38"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5121bfc6-84b9-4b00-88f7-ce1d145a9433">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263570"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02096fb9-ae11-46e5-8352-cf6aed1bcc51"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bd25438-bd4b-4c3a-8705-c92c07e7926e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/013b4c79-7cca-4084-a048-7cbf0df143cf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31b21ef7-fe1a-4863-9a03-286ce3849b68"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6fd32753-b579-4fde-a2d9-975e42ad718d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c93dcb5-1603-4fd3-86c9-56d1f7eb8ab1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bbb7d36-88cd-4e61-8193-cc85cecd2baf"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4f1ff45-5d8e-457e-a4c0-4fc77fa13686"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbd8c4fb-e017-4ad7-a242-3c6ae8cafe53"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02096fb9-ae11-46e5-8352-cf6aed1bcc51"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/48751547-13f8-4f1d-8dcc-ee134f6a8adb">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa1e34a8-2328-4e1f-b2cd-9d1c61456c93"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02096fb9-ae11-46e5-8352-cf6aed1bcc51"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b542c9b-0d55-4409-9abc-1d1e1a1c2828"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a86f6078-59b7-436c-a506-39312b358df1"/>
    <rdfs:label>Triheptanoin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8e6e3459-f828-4702-a7ea-9d928ecee9ef">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02096fb9-ae11-46e5-8352-cf6aed1bcc51"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1f17e5e-e065-4dd3-87db-358b397d6a84"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/18274d4f-9d4d-4915-a209-4df6a3c0d3ff">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12122118</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1299b1e9-50b6-4d3e-9548-bb273d2cbe39"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a148142d-0094-4a0c-91d2-db92caed7108"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16763896</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02046f8a-116c-4133-b04f-009cf6668f67"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02096fb9-ae11-46e5-8352-cf6aed1bcc51"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB11677</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/423f4d6d-1090-4269-8d2f-69d9e80da84d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ed29c9a-ba4d-4bc3-b97a-b1790db1c8b7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4c831a6-4fad-4446-9d85-2131f4e0d575"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c461a9dd-956c-473b-9885-d3e521c7dfd7"/>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de708a5e-33db-4f18-8a85-587041511f70">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001013*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
        <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d362645b-19ef-499a-aa9f-16967b7f172e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High total plasma cholesterol leve</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bba77417-8493-4e7f-bcbf-ad700ec61005"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42095566-8c97-4a48-8881-412acfc07dc7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
        <rdfs:label>Hyperchylomicronemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012238</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc0b3330-607f-4abe-b57e-d1b877b05efa">
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:label>Impaired fine motor skillls</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aa0acee5-5240-4751-b230-d609fb71a2c4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6910fb8-4b16-4a97-be57-973c06b71db3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/416fa56d-bac9-46f2-99fc-aa9d7a68b7f1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002529</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
        <rdfs:label>Neuronal death</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93d502d7-b27b-44f7-9f09-e499cd0ba21f">
    <dc:identifier>HP:0010885</dc:identifier>
    <rdfs:label>avascular osteonecrosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9eaaceca-5e11-48ba-8bea-50f66c95d96e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42456910-7bf9-4eff-b2bb-b24ede453f92">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002572</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <rdfs:label>Recurrent vomiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f90d9a50-6433-4b7f-be1f-6f1e55751ef6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ptosis</rdfs:label>
        <dc:identifier>HP:0000508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000508</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652410</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a956dfc2-2cfd-4063-abc6-6ef169c61ae3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
        <dc:identifier>HP:0003750</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased muscle fatiguability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>p.I480M</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b097c4b-7dad-4c91-ba0b-b9744150dd32">
    <rdfs:label>High blood ammonia levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001987</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be7a2826-36ba-4d25-92ae-d533212e244d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8341ab2b-bd3e-4933-a45f-ce376b9fd2a2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
    <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/815448d2-ad99-4a2a-893a-52f3110c518f">
        <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ecad38e-8f8b-46a3-94cf-d71a3014b01a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b5b1c072-457b-4ef6-ace6-e24c13451d48"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20832970-aa43-42fb-9474-57ecbe2cfc76">
    <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
    <dc:identifier>HP:0003358</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/15c27fb9-82f5-40ee-a95f-4783a7a455ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f32c0d7-cc99-42ad-adc1-c5bc3b52b16d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d5483f1-8894-483b-bed8-96ea36188465"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2a2e2080-4fd7-4a11-bf57-f87bdf46718d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22452ff9-1234-4184-828e-588a7c621284"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e7d30d7-4459-43a1-b9e0-07afdbf46d56">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa6bdfd3-0de6-4908-a26c-2ee14289fdcb">
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:label>Cardiac dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db3f252a-ac19-47ab-995f-1689d9de7125"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2792f94d-d726-453d-91ad-e37fccd67864">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95f931af-c7e2-41bd-a153-03cbe3517968"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f49597d1-6dd8-4a00-82b1-1df17f8194aa">
    <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/20772090-b0c5-4f1e-84d5-2bd4836725b2">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da98e1f0-e7d8-40f1-80bf-1b14e516e7c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f6c01a9-6efe-4aec-9c15-570e4cc2a29c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b32f6979-73ee-4e47-b2a4-58869554152a">
        <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
        <dc:identifier>HP:0012654</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0bccbb3-0796-4e86-b52b-82d90a1a1fd4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bbd05b50-e985-4fc0-818b-8fc0034e95b0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/639a2871-2d07-43b6-93cd-2c73b73eebd1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80312320-b207-4de7-975d-0a3e6afb91f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b83a2807-c684-432c-8c04-e21c15d92c67">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>exercise intolerance</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65071a8d-089e-4141-837f-82df778cf2d7">
    <rdfs:label>Thalidomide</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c3f11d42-366a-4744-bc82-8fd64fae1bdc">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e27d7aee-d9b7-49bd-8adc-b8a5851a16f5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51216c86-d1d5-497b-ae7e-9b138b9004d2"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b6fe60a-d11c-40f0-81f7-09f22a00b23f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/32a30bd8-1b00-4bb2-b70c-a76bc61bf631">
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/581a1cdd-8d7e-48a0-abf3-d565b419af71"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51216c86-d1d5-497b-ae7e-9b138b9004d2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01041</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/872e0d49-4de4-4df9-938f-85cfdecef9e1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fdb1567-31c2-4a4d-b65e-5bb2cc80fe98">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Sulfide toxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0d6ae81-41c8-4065-bf33-e931fab2727b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00552f93-b336-43b9-ad11-3d8aba3d4fcd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98a7b186-aadc-4984-a882-8a8f964b9a62">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/825b636b-47f4-49ff-8ab6-519db09dfc25">
        <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
        <rdfs:label>Siagoside</rdfs:label>
        <dc:identifier>DB12351</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6bbf977-d906-48a0-9949-63c4798b87ec"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7cc5486b-3b6d-4c57-b4ed-81e36f65e3a5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1981616a-ad50-4833-b38d-7b1851f5bb1f">
        <rdfs:label>AAV2/5-PBGD</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29e017d5-f388-4255-bc0b-7aaea34b82b2"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b65d65d1-c903-4b12-9888-49feb3f34e0b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e99052f9-020b-4291-8032-d331db3365f0">
        <rdfs:label>affected functional activity</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33626dc1-277b-466c-b10f-51607567b16a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd16f145-1553-4494-9fde-6bf60ee594a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/016a7678-b52c-4844-8cb5-7b86453fc9b3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d7dfa62d-e02e-4db9-a457-0f743060826e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd2315e8-4072-4d69-bfcf-3f4d334d01d2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
        <rdfs:label>Low energy level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003473</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2150d8d0-8cad-4519-8d09-60f0496f2456">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
        <dc:identifier>HP:0003737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/85dd1957-9026-4470-ba9d-c96c48ebbb63">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/245c1558-6a3a-468f-9298-ddbeabb7f812">
        <dc:identifier>HP:0000867</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
        <rdfs:label>secondary hyperparathyrodism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7865902b-4e2e-4b4a-81fb-5be375eb9cfd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/268321a0-00c6-42d4-9b74-6736c98a50a6">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23d00816-d18e-41a2-b1ef-b0b31fc4c137"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6be854a-77b2-420a-9803-21a548e1a1b4"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01329</dc:identifier>
    <rdfs:label>Cefoperazone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d68f365e-86cb-46ac-9518-067abeb8c65b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c311ad5-1a46-434c-9421-c09851f27bb3"/>
    <rdfs:label>Sirolimus</rdfs:label>
    <dc:identifier>DB00877</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/62a44d92-ad49-4bce-b11c-66f707b19c2e">
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6e6d1e78-f301-436d-bb8b-2fae7ffb7549"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1d63245-0015-4d9e-8546-e88a5250d13a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62e2a7dc-da9e-4d8a-b7a2-4c99431dc28a"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff2b933f-a3ae-46ad-9b28-14c1e5434aa5">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
    <dc:identifier>HP:0012622</dc:identifier>
    <rdfs:label>Chronic kidney disease</rdfs:label>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/3dc2f810-90fc-4702-be64-d04d65d86105">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d9d43d8a-f93b-432e-aedc-d483aa95f9af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e22e363-df78-4cd6-96f3-35a01c7f3995"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bb596ed-b7f7-4ada-b963-5ab56bd1ac92"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a427794-7154-43d6-9744-ce9a3ee40e3a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d090e5c1-25ec-45f9-9a28-44759dfe61cb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <rdfs:label>Zinc</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5fbef4cb-a0d8-4c47-9b3a-84e83f74bd77"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d33d15d7-8274-4dd8-bed0-e859f6bd4fe4">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08dc00f5-1e70-43f9-93bf-bd5eac7ea12e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0784f80-e579-4ac8-acd3-516dbfc22cba"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01593</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/a2abcc14-24bb-4ce4-9f55-d1cd728fb656">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d23823b-b7c4-49b0-82dd-49f7521b9ca0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4e42178-c14e-4742-9557-429b509c0c49"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/029d80d2-cb02-48ef-9bcb-44eff0d76cc8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02c5bf45-0b5e-488d-bcbe-b7465c13c19d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/965a6a19-a15e-4da3-a0d3-a2543a2363c6"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0784f80-e579-4ac8-acd3-516dbfc22cba"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3abf5d8d-d21d-4686-97b2-c8c7592ce977"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/addabc34-d272-485f-8149-34c5400baa6f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a148351e-a8ed-4341-b553-863195f672cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c359364-1b06-4b03-aa33-cf3edd3f9456"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a8976f66-69fa-4ae0-9593-080613ef4c28"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb5ce11c-195b-46c0-97c1-7b2cbeb2d8ef">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6c45b548-588e-44f1-9f36-baae9b541f3e">
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bba77417-8493-4e7f-bcbf-ad700ec61005"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/321180c9-2e79-4e8f-b056-6cb2fc18a0dc">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b335d035-cbee-4e40-816d-2f2086782447"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bba77417-8493-4e7f-bcbf-ad700ec61005"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/35e5339f-b2d6-4595-a515-38a1b96e1ac2">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bba77417-8493-4e7f-bcbf-ad700ec61005"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c071cf5d-3f67-49d1-8f3d-e7548903badf"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63b2ac35-72a0-40dc-a1cc-c9e48714987b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/423f4d6d-1090-4269-8d2f-69d9e80da84d"/>
    <dc:identifier>DB01241</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/402e5ed0-da52-474d-8a2e-5adbcf25c70f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0fe1f90c-7952-482a-894d-8da7638c9f22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7a78fc4-f4ed-4a80-9510-c5577905ecea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26419a46-eff5-4033-aca0-65cc2c62dd47"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5a83bf0f-a298-461e-8b93-62bcadfc45d5"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26930d1e-93c5-4bb1-8ff2-aefae5582e7e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001369</dc:identifier>
    <rdfs:label>Arthritis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83a65119-3951-47d2-95c7-bff1fa41a1fa">
    <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <dc:identifier>HP:0010472*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07e1be15-2b50-4c00-a5fd-6fcb3b76507b">
    <dc:identifier>DB00133</dc:identifier>
    <rdfs:label>Serine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9d4f459b-9a0e-4815-a232-01085306867b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a2b4cca-97cd-4a05-97b9-472bdbb02384"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5fce2dc-c9a7-4fed-a813-b450a283809b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/52d97a32-a0cf-4f3b-84a0-8966d1355905">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b75f3665-afa2-4d86-b02c-8763d46f4f68"/>
        <ddiem:failedToContributeToCondition>C-1131</ddiem:failedToContributeToCondition>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19530961</dc:provenance>
        <obo:RO_0003304>TT-1131</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca3d92ee-0041-4c62-8323-d7277753bc36"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pitavastatin</rdfs:label>
    <dc:identifier>DB08860</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79ce5118-e2dc-4639-b731-118b60ec05c8">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b3e4307-3369-4dc8-9aad-b6f25b0d6dad"/>
        <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e97d682-6896-4f89-aac2-a3dd91297758"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5563e65a-5888-4bb2-b5bb-f3fbb8c8512e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9e1c002-6277-400f-80d2-abc6a2530251"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b39460f-62d4-4b88-98e9-5f7a715ad066"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2cac432-d41f-49ce-8c20-e5b1927644f2">
    <rdfs:label>Neurological abnormalties</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1b9ee7da-679d-43bf-bebc-e4289dbb21bb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bdce4644-6df8-456e-8c8f-b38fb6fc6cb8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1276115f-a14e-46a9-b048-991e1222d524"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761646f2-2887-4446-a926-718fdcf7506d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7bfea45-786b-4c8e-85f7-1baecd50e9d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5dd810e0-0721-463a-94a7-f477fbcb93cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/272899b4-c7ee-4cdc-acb8-ed7ff75470a8">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec8f9cc6-26d2-486a-adf8-bb04b9b36f0e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>Movement disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c45f29b-6b46-4081-ae8b-c1e6d64f3707">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>Myoclonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9663ab6-0a15-4bc1-a098-bc260f42719b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613068"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c8c02dc-6273-4019-823b-790d4c07b624">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
        <rdfs:label>astatic seizures</rdfs:label>
        <dc:identifier>HP:0010819</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/240ef70c-154e-432d-8005-c7afbd7b3e20">
        <dc:identifier>HP:0000735</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>Impaired social interaction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e804bed3-56d8-421d-9ccb-69d079faa24e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f75eab3-0012-4cb3-aaa9-88349904d654"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39be9d78-de99-4b4a-9e80-b71625285af1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000488</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15fd4381-8b56-4482-be94-726097d4b08c">
        <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4e090e2-db54-4af0-a6cd-d51909906fee"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
        <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c05b3a20-cc8b-4c0f-b75c-6b6e886e8ee0"/>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c0b607a9-35fe-447d-af94-fb8cbfd64b6f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b108055-aaa6-49a4-a4ab-87ae1268e6de">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fe80e64-c673-40b3-8936-5db9001dd731"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2254c466-f4d3-4a28-93b5-da110c097123"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ee02530-64a5-4746-b6e3-cf4897a5547e">
        <rdfs:label>Low muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/484ad0c2-ebc5-4b89-975f-cb84d50f5d66">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fe62ec7-8016-48ed-a10d-ba361e4692ee">
        <dc:identifier>HP:0003146</dc:identifier>
        <rdfs:label>hypocholesterolaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a6e1596-0cfb-4f2a-9070-0db9724194df"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e89da0f8-7c71-420b-8361-ab1b34b09488">
        <dc:identifier>HP:0005135</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>T wave abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c14e590c-7e37-4885-8836-2873a17aa2a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50d81e36-0412-41ee-966b-b617de613d06"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b9f4d0b-0839-4ec6-b8af-7518e0353942">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperuricaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f828081-ecda-4e96-af66-e2b4b84502c2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>Delayed Growth</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a7098d7-8515-4a43-a384-789d544a1947">
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:label>Low myocardial function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28c4664c-877f-422e-a084-17bdbaba35be">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
    <dc:identifier>HP:0004818</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e87671b9-a00c-45b5-9451-f1bb8f6a11a3">
    <dc:identifier>HP:0004356*</dc:identifier>
    <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1bcd57e-0912-462b-b998-7f4577e1c78e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31ae9ff4-8337-4de1-a527-a1c4a8536a93">
        <rdfs:label>mortality</rdfs:label>
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c83b4d8-db89-4c9a-ad7b-0a1adc5e000d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c4b236f-e128-47b2-bcb2-77f054e178b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bb03996-7884-4a74-8f57-4c5d858566fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <dc:identifier>ECO:0000305</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8398c62d-e6a5-4990-9683-a68506807ace">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c726eff-ed99-42b6-af3e-a5511d4e5f80">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Developmental abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf0de577-83e3-4e14-a7e7-4f19424755ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2cd83c1d-5fa4-4f5e-86d8-71fb1907b654"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/194279c1-90cf-4b5b-b7ef-c61e7b0caf9a">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
    <rdfs:label>High total cysteine levels</rdfs:label>
    <dc:identifier>HP:0010918</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b7704294-2e4a-4f4f-b4b1-898c2e124155">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a30cefc9-02ef-4ece-89f5-e21746976a0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ea30a72-e1ba-4890-8af5-cb94932589b9"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbdab353-c3cc-4229-8f2f-51c8d2750540"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b74f86a1-da57-49bf-87fb-a312cc864575"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3018468c-8874-4249-8b0a-1bad6e0990e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13d8d4f0-3381-4a2c-854a-19ed8afffed7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/662f7cfb-07f7-461d-8228-76c674dc9b6e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/848bb669-678b-4251-827b-fb25543f70da">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eaf9c31e-d769-4c03-87bb-d533bcf5931c">
        <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
        <dc:identifier>HP:0003165</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
        <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c572714-f37f-44f9-b117-ae14c42de3fa"/>
        <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aecbaa8d-ef9e-4f94-a621-afb679fbf460">
        <rdfs:label>Hypercalcemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <dc:identifier>HP:0003072</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1835a15-0b59-47bf-9dc9-1d749dc777ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <dc:identifier>HP:0001959</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Polydipsia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9e1c002-6277-400f-80d2-abc6a2530251"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28fb04a7-37f7-4d9a-9637-ffbb97ef476c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
        <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
        <dc:identifier>HP:0004732</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ff5d0d5e-94bf-4fda-a037-058aa1f53036">
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f09d128-7e6f-47e3-bfc4-80eeb9ff3976">
        <dc:identifier>HP:0100512*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>concommitant low vit D level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24137761</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6543a8f5-3ad8-4bee-9e6d-f40a116cf929">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7ef780b-8c77-4f45-add6-1a59f17f7c0d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:label>metabolic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/8359b919-4238-4a66-9ce2-c70c4240cc51">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa24760d-4a3d-4570-9a12-be3bf128a68b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6106a1aa-4532-4cd1-9d0c-02c202290512">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>spasticity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3532b2c6-525a-4255-9d1a-acfb8a69b093"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/67dcd10d-1739-4034-9541-8f40d9f73abe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/abfa4010-e8b8-4a4a-a4d7-41ee95b7a290"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3f33d82-46c8-4bf9-8cd0-576204697742"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ba02764-3e74-4a25-904f-b1719e9796fa">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma ferritin</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ed2e0576-aa23-4451-9bf8-6e06d558df53">
    <rdfs:comment>"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ce41f7d-afe1-44a6-b606-9e679a608755">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
        <dc:identifier>HP:0000709</dc:identifier>
        <rdfs:label>Psychosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11d13339-90bc-4c22-87bd-fe82d5c04001">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Auditory hallucinations</rdfs:label>
        <dc:identifier>HP:0008765</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5c57fe4-8892-437f-9bbf-14039c7362a8">
        <rdfs:label>Hallucinatory-paranoid state</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
        <dc:identifier>HP:0011999*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9237ebd8-9069-4af9-89e4-6a48103345a0"/>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/373f66d9-a13d-47fe-9e82-cf58fad42e5d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fcc84f0b-e476-433d-ac57-567fc408fbfc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e2d3c1e-1f48-4fec-9f19-29feb30b46e9">
    <rdfs:label>Fine motor impairment</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1099973f-f586-401d-925c-b13f97c12400">
    <dc:identifier>HP:0002625</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
    <rdfs:label>Deep venous thrombosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9567066d-180f-42be-a4d3-8e5deb90b283">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/291c5c36-a20d-46ee-a9a2-832d3e8d6538"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b33f4564-a818-4b0f-ae71-0197543ca9a6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3affb1dd-934f-4021-9ada-fe2fd9abdbea">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ad72b47-9733-4cc2-a86b-601526e1a776">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal gait</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8115d455-f08e-4211-98b3-83c30576d742"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f75eab3-0012-4cb3-aaa9-88349904d654"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/692e9489-e7ef-48da-8d94-4f6f53621976"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2bf82092-839d-44c0-a6b2-ebd07297a9fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cbde157c-dd87-4bcc-aa65-87c80c403db6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a74580d8-21f6-4c43-bb6c-88ce6a2769fa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13f9ea03-c53e-4a08-af8b-37746592774c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dfc528b-4c21-4ccc-9cbc-1a53075a3346">
    <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
    <dc:identifier>HP:0012321</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed4fdc68-0c10-4cdc-a534-89e3526acc03">
    <dc:identifier>HP:0012029</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f9c11633-c55c-4ba8-86f3-a3920713a868">
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f828081-ecda-4e96-af66-e2b4b84502c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2210e953-39b4-428f-bd07-207b1f31645d"/>
        <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f77c0942-dfb9-4c4c-b27d-84b278fc4aad">
        <rdfs:label>Metabolic Decompensation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35a7a77c-ff2e-4e17-8749-8b9c433c9ddc">
        <rdfs:label>Abnormality of movement</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5377516-8641-48f9-9338-aa803eb31634">
    <rdfs:label>Bortezomib</rdfs:label>
    <dc:identifier>DB00188</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cd94337-571f-4dd1-9c63-3f8ff6d8bcb2"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6fcfbcc2-2ea0-40b2-9897-e6188d8277a6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3e92349-7fd9-4f5d-ab4c-83e640056bb4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/337674a3-bfca-448d-94d4-fab663a6d43c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6513c327-08ac-4ca2-a20b-79e134f6e700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b36f0d7f-4806-4df2-ae39-d99fbcb3c75a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263700"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/822d1ce5-a6fe-442d-a0ca-31e4ef9c2340"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8d2cf1f-2b0e-4845-a907-b99c47a30b56">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3f541954-865a-4488-b7e9-5f4f55908328"/>
        <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/112881bb-19e0-476d-976e-489b042c60cc">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b2a4188-4911-4be1-9651-cc286695dacf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000010>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc5096b7-4d44-406d-a602-d2bb195317d7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23694d9a-1bec-428b-8ee2-471f6096b366">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c60a132d-982b-48f9-af9b-bcd06249fd49"/>
        <dc:identifier>DB00313</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a27bceff-f743-4fb1-a6e7-fca388d4fbb3"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fed74e3-0942-4bfa-b7df-a37ba07a0255"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d97f282a-478e-4bb1-82ca-f2836571f662"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a12d7982-5f40-4f2a-a881-cf8e3278f027"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b117c24-3429-44e9-97df-2c39981351dc"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19252979-5ba1-4e27-ab63-6f8fb5899c0b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed0e888c-b5ad-4ca5-a817-b4116c70ec11"/>
        <rdfs:label>Valproic Acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b883ce2e-1794-44ae-82d5-8b4bbeb87118"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/922abf0d-b8ee-4376-be63-63b5806c572e">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d97f282a-478e-4bb1-82ca-f2836571f662"/>
        <dc:identifier>DB00683</dc:identifier>
        <rdfs:label>Midazolam</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60ff05d8-18c6-43f4-a777-24a3a8f3d6ad">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d3749ad-7c7a-49c2-b424-9d7dac53b31c"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07ecb5a6-214a-47e7-8433-58b38eb21ea3"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3121b104-b3f4-4bc0-860d-5f18b79b7391"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ecabf769-c260-4e67-9eba-5c2f583cd11e"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d97f282a-478e-4bb1-82ca-f2836571f662"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcfea03e-b22d-4e97-9290-9e6b3ec00f74"/>
        <dc:identifier>DB01174</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e54e2a56-6594-4076-bc77-120bb3b59a71"/>
        <rdfs:label>Phenobarbital</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/99f126c5-be24-4aa8-a5e7-4222ce280b15">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcac568b-7bca-450d-9c27-d45f1dc6e942">
        <dc:identifier>HP:0002160</dc:identifier>
        <rdfs:label>High total homocysteine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/194279c1-90cf-4b5b-b7ef-c61e7b0caf9a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be9640b9-060a-4f5a-8b1e-d320e3ad895b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73eaf10d-44a6-4457-9419-6e39e71a0dff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9da8a637-b31b-4d5d-8d79-7672dbfc020f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9dd94e8d-477b-40bb-9b33-46639078da3b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1979e8c-70ed-4abf-8c9a-05083f609fae">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low plasma serine levels</rdfs:label>
        <dc:identifier>HP:0012279</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1d63245-0015-4d9e-8546-e88a5250d13a">
    <rdfs:label>liver fibrosis progression</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
    <dc:identifier>HP:0001395</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5091d2f6-c7d1-4071-963b-44111db38163">
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb781d9c-211c-4f79-af68-f28faf7f7480"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3880a74-b60c-4d32-bc4e-38d2e4ce29c7"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3ffe442-8c83-437c-99d7-c54c62c7bfbf"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f398bd6f-1e27-48d7-88a4-1528f4081b23"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24e1a60b-682b-4e9a-a9e1-0c41dc30c0aa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f07d186f-945a-4b0f-abd3-55e7616146ce"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1dde6e3-ce97-414e-8509-14a50cdd5b2e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef483bb5-2430-4453-bca7-46adf7d9945a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a9fce680-d351-4bac-9b95-9cf5466fd71d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85ff1ce1-5d2e-4ce0-8f08-c579a15b0963"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e212bd72-bea7-41c5-a78e-74ffe0f1ad2f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
    <rdfs:label>FUCOSIDOSIS</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/15735600-449e-41b8-8c0f-3b84938feddc"/>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/517e8b4e-3c1d-4b6f-a8a6-d34b24318e2c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc3652a5-51d7-4415-b406-7494023d2b3b">
        <dc:identifier>HP:0003281*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high brain and liver iron stores</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1a6a1eb-bb4c-42bd-9e6e-28b44f2b24b5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>high serum ferritin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/df0427d1-4ed4-4338-ae15-95533aba2969">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c1288fd-280d-4142-a074-d3655c3b3ed2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b542c9b-0d55-4409-9abc-1d1e1a1c2828">
    <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011013</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5dd810e0-0721-463a-94a7-f477fbcb93cb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
    <dc:identifier>DB01563</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b9ee7da-679d-43bf-bebc-e4289dbb21bb"/>
    <rdfs:label>Chloral hydrate</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4c1ea9fd-6553-45d7-a8e4-0b73e867d520">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c660cdbb-7894-45c1-bde7-63b0e9c44d57">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c0b804aa-3094-4931-9e15-1ed9b7b94088">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/178fa760-653f-4128-8292-365a6959f888"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b949e0f-f8f9-4450-8fcb-29b7dbbbed71"/>
    <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
    <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/198799cb-9816-46e7-963a-a3dedbf66549">
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:label>Speech problem</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f9c46a2-ffdc-45b8-9e54-fb9991cc7af4">
    <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003455</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcfcff93-0d81-4acf-8cbe-cbc4733db396">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012759</dc:identifier>
    <rdfs:label>Abnormal developmental milestones</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e4ed0799-9fe1-494a-83cc-7c388dedddab">
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f398bd6f-1e27-48d7-88a4-1528f4081b23"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e54821e5-a264-4f0d-ab96-080af0e4fa3b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031517</dc:identifier>
        <rdfs:label>verruciform xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51ba69cd-b886-40c3-ac0b-79b632f45644">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92029b44-5811-4ac6-85dc-aeb2eb1b91b3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3ffe442-8c83-437c-99d7-c54c62c7bfbf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6a23641b-b158-4f87-80c9-9cfa4227fb89">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4de342e-cd52-4433-91de-b0e80b3dc53a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>Recurrent infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7596d5c4-4839-4d5a-8278-ec66e06a512f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76e0094d-401e-4db9-a37e-aa44bba99f9b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5339ecaa-c761-4bdf-b23f-49c029bdf8ba">
        <rdfs:label>Decreased lung function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8ec8953-b7cc-4bc6-a040-93bcb6435b1c"/>
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e34475bb-814c-45ba-9584-365f295416e4">
        <dc:identifier>HP:0002097</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
        <rdfs:label>Progressive emphysema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ed742dca-dedc-4ff3-aca2-28c5a28bd6bd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e985268-e1d2-4de2-9c39-7cd81f7c090c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:label>hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f6c3e6f4-a3c7-45b0-9216-2ca1e65ef550"/>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2072f2d-3491-43cb-9572-44a501b4dd96">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78867b26-3dd0-473d-bf39-7cceec7a78e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/43b56c30-9b9a-469b-aeeb-355555e3281d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8cf391f-d2dc-49e4-a4ac-ff0693666695">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dyslipidemia</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2b0084e-135c-4000-818e-84f3af56784a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5265beb7-9b99-4af5-973b-c2c9850e810a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1853b34-646d-4e00-9f7e-6a31a88926dc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
    <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
    <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e29ceb39-294d-4210-b0eb-0b2c57aa2d93"/>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d497ca35-e2ba-4273-ab5c-8927b378f9f2">
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/35816ce6-cfd7-481f-ab58-eac7defbde2d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6230162f-c85c-41bc-b5e5-28152d08ae4f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e8b90af-384e-4142-9ef1-e2ede086ffc5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <dc:identifier>HP:0011025</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc2947a3-9704-45c0-9000-6d9729fa90e3">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e215c58-caab-44d9-b05c-b078f409d111">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
        <dc:identifier>HP:0008972*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad3d195d-d295-408a-9aa3-5fa9a41b870b">
        <rdfs:label>Myopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003198</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c8a912b-4150-4aed-9505-7451806908d0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24fae09a-332c-4f4b-9316-0d095421d9be"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b58f8538-e2e1-4f48-9b07-eec0a7ff5486"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bad1ae05-7117-41a3-b980-7ec63e8768c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e3ddb8a-9258-47a5-ae66-cc6152612d25"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8258ee6-8859-4a4b-8460-82f92a490496">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <dc:identifier>HP:0030532</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/eb66e84f-1ecb-4d13-9ea8-1b0597ec69be">
    <obo:RO_0003304>delSer1387</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc28e1d8-5f75-4dc5-addb-3df7df78c0ea"/>
    <obo:RO_0003304>E1506K</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6ea4ef8-778c-43e2-a20c-2ba081dba36e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0003304>R1353H</obo:RO_0003304>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3bd38e1d-969a-4d59-bd88-89a6171dbf25"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f66227f-e495-4c07-bb30-9572c4f214f1">
    <rdfs:label>Desipramine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/10b6e8da-a523-447c-aa5b-ad40038a2cca">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32ee967c-7058-4961-9cc8-e56c262ffde2"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/267c69f5-0489-4bcd-8a94-0fca4497f3f7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e20bcf83-2125-4883-baae-987cddb82d89"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ca9dbb4e-1003-4cd2-b12e-f6d3ec6eea2b">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/269920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e20bcf83-2125-4883-baae-987cddb82d89"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01151</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/08c136ae-45b6-4262-9ec5-93c14b90482a">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b43b939c-fdea-4d72-8083-c51139227df3">
        <dc:identifier>HP:0002013</dc:identifier>
        <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf1af3dd-1ea0-4bef-a140-1cce994928aa">
        <rdfs:label>Bacterial glutric acid production</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/08dfd68f-2f9b-438c-9005-712dfef51a8b"/>
        <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5b9e3ba-31ae-42f3-b699-ab5c5758df27">
    <dc:identifier>HP:0003128</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <rdfs:label>lactic acidosis</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9d4cce0-ad34-4d4d-85c6-c148e1de9ee5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b8869ab-5925-4ccb-9928-ce3645571eed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a79a0bf-3fdf-48ee-922d-98eeb1f32306"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
        <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/34ea06a3-e838-4851-ab85-e4d2c80121b7"/>
        <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e5abc18-df80-4c2a-801f-d10ba4dbcd3f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>constipation</rdfs:label>
        <dc:identifier>HP:0002019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fc1d9ae-da2b-42d7-897a-b9bf057be5f7">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c4399dfc-0fc4-477c-a45d-07edd51570e8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed02ed35-5f67-4704-a3c7-ae938c7a0a38"/>
        <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72ec2655-9d9f-4de8-a5ab-0544ac53663c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17755cd5-891e-47e3-99a7-6239be5d827b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
    <dc:identifier>L04</dc:identifier>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/28722c43-e543-49db-89d5-f0ec7715f702">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6113a0ce-2626-4e10-bd44-356f4051804b">
        <rdfs:label>Kidney stones</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/676334ef-2d07-4732-b5fc-fbf7daf74e31">
        <rdfs:label>Hematuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
        <dc:identifier>HP:0000790</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/807e4898-fb1c-4fb0-b2b7-2df0b52db046">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <dc:identifier>HP:0100518</dc:identifier>
        <rdfs:label>Dysuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c3b63b8-d508-4c6b-af42-7a3072da4f96"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c6b3f82-0cfe-4000-93e3-c6ac9a4cf82f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8f3f257-8604-4e5f-afe1-b9267bd340ef">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63fe020d-3612-4dfd-a4a2-5bd19c17ea68">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50e50643-02ec-4f98-8635-c4e5f98613cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2802d0d-06ad-45ce-abfb-42641a9e41a4">
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:label>crystalline nephropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff2b933f-a3ae-46ad-9b28-14c1e5434aa5"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2db2c767-4267-40a6-861f-212b17d0e814"/>
    <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
    <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf461ca8-eeb7-4ea0-88ac-c09ca87cd190">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9035e31b-cc61-437b-860a-e51704af55a5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b63325-3d68-4ea8-a36d-6c09cd9947b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e96dba6-b8e4-41f3-ad50-7a2d00be58a5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17657a04-f4bc-45e7-9159-ef0bb4fcbdd7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00118</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1fb1cdca-5f11-4c6c-b575-7bd7a03060f5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4de342e-cd52-4433-91de-b0e80b3dc53a"/>
        <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28e9b592-5fe6-47b3-b3a5-cd152ee01cec"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d09ee8f-6922-4960-bf21-6a752c3f75ba"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e96dba6-b8e4-41f3-ad50-7a2d00be58a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d82aa760-7086-4bdd-a006-a4ebf851c523"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38bc3b4e-59cd-4ee4-949c-d4ea20b3c94c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2572d05e-c84d-4979-ae87-4c1e2a44c83a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301835"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5163fb2c-b239-4f61-a211-35e765c5ebd1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea61c88a-faf0-4f86-8b63-677727b77d02"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <rdfs:label>Ademetionine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd20cc35-021e-4774-8fae-a586f8d5b91d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f6b3546-80a4-42a1-bbe8-8591c409c072">
    <dc:identifier>C09</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
    <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d4119c5-90db-4ef1-9bbe-ad5db91d0fe4">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea71e02c-ab70-455b-87a8-895ccde42719"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a148142d-0094-4a0c-91d2-db92caed7108"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d143412-aa22-4c28-bf71-16fa590e5d0f"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7f4432e-a8b8-4632-a7f1-4db53c659bd0">
    <rdfs:label>Growth Failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c132989-fd6b-48d7-a905-ff7e65c39236">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
    <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012130*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d707c6d-cd28-47c6-9e11-5983b2628146">
    <dc:identifier>HP:0002188</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
    <rdfs:label>Delayed CNS mylinaton</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d445503b-7f44-4148-a16d-af0f4dbdaf43">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e0519a2-79d4-47da-a3cc-9355a2fb0725"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6af0761-dcdc-47fa-b65f-ac34716e4745">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>edematous</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a728fa3f-f30d-4f30-a086-95c344b9c767">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15a212a6-ea9e-42db-a92b-0aa6338cf755"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0778c6ad-a575-40fa-b16f-09d8bb426066">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:label>gait abnormality</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad7cec19-111f-4c31-9ebe-01adf693e189"/>
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe29c8c1-48de-425e-bbb8-9cdfac572662">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:label>incoordination</rdfs:label>
        <dc:identifier>HP:0002311</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/61fc47f4-d288-4191-a6b5-64d19c913372">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e3de2c89-ffda-4183-96bb-b2e2fd697578"/>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cbd54da-6aac-4f14-a7ae-15efe639e4f0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ef2b71d-bfb9-4830-95d0-79510cd269ec">
        <rdfs:label>Proteinuria</rdfs:label>
        <dc:identifier>HP:0000093</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb8a2d32-234d-46ca-8d1b-2ab3e5164c5c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal renal function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66476764-b823-45fd-be4e-eb357be390a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a2e7bc1-f88e-44df-bd72-7b17a3edcbd8">
        <dc:identifier>HP:0010979</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53954d1d-e8ab-4ea3-b223-79b66f0574de">
    <rdfs:label>Carbidopa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/2289daa2-f551-48f6-8416-34767fa16910">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42b075da-bf2a-4b8a-ace7-09dd2a569604"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28b58ed1-119d-4c80-969d-51ebafc23833"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9949f97c-6a2d-482f-a7ef-6bd6d811d768"/>
    <dc:identifier>DB00190</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abcfe6aa-96c3-48f7-9138-45af9ec8acc9"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c48b7855-3964-47b4-87ef-8c7ee20fa6c6">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28b58ed1-119d-4c80-969d-51ebafc23833"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c0d08f4-fec7-4688-9aa3-ca588c8c8d24"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/4276a2e8-77d7-4161-b470-106be9f2f1c0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db3f252a-ac19-47ab-995f-1689d9de7125"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeb15c1c-4c06-451f-a72e-f95ba0a657a9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
        <dc:identifier>HP:0003750</dc:identifier>
        <rdfs:label>Fatiguability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/127af02f-b19a-45e9-9a1d-e8f3833ed42d"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01f51df6-0293-4ddc-9c4f-d368d7e1e6e5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
        <dc:identifier>HP:0003200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad3d195d-d295-408a-9aa3-5fa9a41b870b"/>
  </obo:DDIEM_0000012>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c054ee2c-563f-48a4-94c1-c6e855db7bb3"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
    <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/759fb870-5d35-47d8-80a0-b27ea8a0f707">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f3eae11-1fc1-4ec7-bc27-ade5d2f4eb77">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df63ba58-0239-4638-9e89-cde02ba46fce"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8613f4e-f451-48f5-9e30-4b87d04158bb"/>
        <dc:identifier>DB00459</dc:identifier>
        <rdfs:label>Acitretin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b9d3f3e-35b1-42dd-91c1-a9454ba74886"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85022841-e1d4-4e8f-a94e-e69e5da1bd89">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <dc:identifier>DB01015)</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/88fb4928-e69a-4c61-92e8-8d87a51c544a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/df919f49-3ade-4c53-870c-3030f6b3b8a0"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/959bda31-8956-4159-a9e8-9c712fe31333"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/759fb870-5d35-47d8-80a0-b27ea8a0f707"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18a24340-2f71-431a-b6cc-ec2400a32e56"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e25a8c9f-0b20-4867-819c-451b485e465d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46be25ed-18e9-4007-a016-a2f4fe316a48">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b13b196a-5dde-4d85-b91a-73e6a6effd28"/>
    <dc:identifier>DB08876</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c06f6f45-9196-497a-a91d-9f57f9f5e1a1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ead683cf-3d68-45d0-b551-0af4631f7bd5"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5497e954-b42f-45b0-9a01-655b922cbbb6"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd542a19-6f7a-433f-8e90-f1d1261367d9">
    <rdfs:label>Xanthoma</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
    <dc:identifier>HP:0001114</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/faf6aedc-424e-4e18-bc38-d54bfe1cb726">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04106917-a41c-4b0e-9752-c7e87126660f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001997</dc:identifier>
        <rdfs:label>gouty arthritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc8d6e88-96de-47b4-87f2-9a933299e7c8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <rdfs:label>hyperuricemia</rdfs:label>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50e50643-02ec-4f98-8635-c4e5f98613cd"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/959bda31-8956-4159-a9e8-9c712fe31333">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000982</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/debf03cc-ada7-4149-b29c-753d54e871d5"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19886453-377a-4eb7-825b-71944bcc9e81">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a3e4e33-b89e-48c8-91c4-baf9b3500c2f">
        <dc:identifier>HP:0000093</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>proteinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d2944e6-b66f-4116-b012-e290152dfad0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:label>hypertension</rdfs:label>
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/286fa40f-e65b-4694-8e78-55a3ddb59535">
        <dc:identifier>HP:0000083</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
        <rdfs:label>Kidney failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6817413-a24d-49bb-91ee-84e4db511174">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c08dc99d-f730-41c1-9faa-2c3800395be3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/119c12f9-491d-4c3c-bffa-839d8638c9d1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
    <dc:identifier>HP:0003287*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aba5dfcd-81e0-41a2-a814-5638949d17f1">
    <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
    <dc:identifier>HP:0002086</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1ba5e82-c34a-4655-b01b-22b8cee756b9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0a97028-d71f-47d8-b2c1-f9f4dd84e713">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e8b6e0b-49d4-4cb9-9069-dec8b4bac36d">
        <rdfs:label>neutropenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7c4bf98d-9965-44b8-99f2-0ec3e966f8b8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f63372ca-1f17-438f-b039-e1e7ca8c4692"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9174fbf-d714-43cb-8e4c-ab3becd9b018"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/16fe9d90-8ffc-444c-a809-6c703fb8a73a"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfef5dc1-02f5-49f4-a628-9726b16d845c">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87859c13-3933-4f32-b961-1eb07c0758b4">
    <dc:identifier>DB03614</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <rdfs:label>Methylcobalamin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0e607ab9-fa86-45ed-bdcf-5e36cacf6a5f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49be7e1b-4d31-4dc8-b5f1-4f42826b3324"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc03fd6a-09ee-427b-a9f0-516cc2ad8ffd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ff19fb1-c464-4802-85d0-c621f20d3471"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ea0cd8f-a26b-475c-9d74-50bab9a39ee1"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83d948d0-a338-48c6-a6a8-3af5719e230b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e05ab7c-7cb1-42a7-b87a-70691c171948"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61c51e8c-dfab-439c-905a-e1d4b5d5949c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22afe2fe-e24e-460b-8d13-d14a3dc9451d"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d5c93f1-7731-4d4c-bff6-a832a7cccd20">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9c4b927-3545-44df-a299-e06814f649da">
        <dc:identifier>DB00458</dc:identifier>
        <rdfs:label>Imipramine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31057d35-95e8-4adc-b185-234b24b03350"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e9ea8ca8-5a34-4a7a-b6cd-ad208b36907b"/>
    <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2fda124-dd92-4e03-801d-8ce273d51b5d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/c0c307ae-286a-4599-9615-4a2ced25f753">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bca8777-c157-40db-9088-f0b4c62e323e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0003304>R219K</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b335d035-cbee-4e40-816d-2f2086782447"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/daed9aed-c019-49ba-8175-210e066dd14e"/>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/870cb774-2638-4066-88a7-e9e303be1887"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB00175</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/24a3f89b-df80-4314-8fc0-5b278ae34f1d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e212bd72-bea7-41c5-a78e-74ffe0f1ad2f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd542a19-6f7a-433f-8e90-f1d1261367d9"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e38f9ea-0b16-4fa3-9456-ac4df0bd8f1b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/daed9aed-c019-49ba-8175-210e066dd14e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/328e78d0-5b8c-46cf-b502-ff4151d1a749">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f8eb2b8-a291-4d7d-bfed-557982bc589d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/daed9aed-c019-49ba-8175-210e066dd14e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pravastatin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64314fcd-fef6-40c4-82fb-74dfde3aafcf">
    <rdfs:label>Polyurea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
    <dc:identifier>HP:0000103</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8f73202-9d9e-40a6-8c2f-32575e328ed0">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/508d9a3e-319a-49eb-a9b1-c748d4538c52">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17c944f6-2f0f-46af-bf54-2efd87f4b744"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/848bf089-28e5-4b89-abcb-d033fb3c5004"/>
        <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b7694e5-8bc0-4ce1-b4bf-77f59565ac2a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/94e43cd9-5ea8-4970-9f65-094985e240c8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/291c5c36-a20d-46ee-a9a2-832d3e8d6538"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de0b4e3e-4b43-420e-b7c9-95a3c36d0fa1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/723b0220-036c-42cf-9d9d-c03b96fde2d2">
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29278307-284a-4570-b219-88b7986f2bc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74d027e3-95a7-403b-8c7f-2ea8a2086406"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56772156-31ce-424a-b2dc-2338c1a921be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <dc:identifier>HP:0008282</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6da6f6a3-2b12-4b0f-bb40-be37c68d39b5">
    <rdfs:label>Riboflavin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/79b62abf-69b8-4ebd-897e-98a4a7829893">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9efa9eec-b88f-42d9-87c5-aa37ad863a0f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/0282e336-12bc-47ff-9614-36bda5731de0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4276a2e8-77d7-4161-b470-106be9f2f1c0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08c136ae-45b6-4262-9ec5-93c14b90482a"/>
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9b11e341-bb7d-4d82-8894-6e092377c6fa">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc965da1-538b-4cc0-bc47-1f806e8abe69"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c072f54-5164-4e61-9ff1-0caa64c4f944"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ab3f561-8e08-48a6-bacd-8e499d9d8709"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af3ab109-7f88-4ff2-9948-244cf61e625f"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/13ad5633-0063-4be2-97c7-daa825eae156">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef9629cd-95d4-4d36-b41c-b5dd27985df5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e89de4fa-fb27-4a37-8e4c-0911bc4d2bee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c929cd67-11f3-4b63-89d1-62ef625d93ec">
        <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f9c46a2-ffdc-45b8-9e54-fb9991cc7af4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e212bd72-bea7-41c5-a78e-74ffe0f1ad2f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
    <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c3da865d-8813-48b4-b954-c07cc72c1977">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5972043d-5376-45ba-b046-59fb3527a3c1">
        <rdfs:label>Neutropenia with IBD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
        <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/869fd436-6446-4685-8d26-0477c467552e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/226dc85b-71e5-4b9a-b9d4-004dc884a2f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f98a68fe-81b5-4b30-b0d6-c047f419301c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/646d5e2b-1bcb-49ba-9353-3b8468c9d26b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba185dd7-2542-43df-9043-7b250f9d4fa3">
    <rdfs:label>subclinical hypothyroidism</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000821</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c124e8f-cbe9-4e52-801f-4148e0b355cd">
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ed32d2c-2357-4e52-a10f-14034272d1cc">
        <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b60c549-72d7-45c8-874d-4330e033606a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ee2de93-7cf3-440d-a2a1-3f566aa62b97"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dc772cc2-d1b0-499a-b110-bf023399b3bf">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/929fa139-4970-48c8-bf9a-8c883125bd88"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a45d25f1-f602-4f75-9c0f-0b0531fa3d4f">
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mortality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/029a6286-4e9c-4b0c-b0ce-591a1c4844d7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003495</dc:identifier>
        <rdfs:label>cortical GM2 ganglioside accumulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003495</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208706</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e212bd72-bea7-41c5-a78e-74ffe0f1ad2f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1447e06-5fff-4b61-8292-64b041276cd7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004345</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GM3 ganglioside accumulation (Ganglioside accumulation )*</rdfs:label>
        <dc:identifier>HP:0004345</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/bfa1c6c3-c637-44b1-8fb0-322f666ed8f0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a80379bf-12f3-4850-b5a5-25ed3b38b5db">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b0f8901-2fcf-4688-b0c7-e9474b5cfbf4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bb596ed-b7f7-4ada-b963-5ab56bd1ac92"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/35f96144-a3af-45ac-8c3d-0fdbf8495dc5"/>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e3308f77-192b-48a1-83f1-57e6dea4beed">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1d204e5-a872-4e29-b29b-153113fa3ab6">
        <rdfs:label>Rimmed vacuoles</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
        <dc:identifier>HP:0003805</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/112bd614-d02d-4f8a-9324-76bd8dffc27a">
        <dc:identifier>HP:0003216*</dc:identifier>
        <rdfs:label>Amyloid deposition</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f675081f-6970-4859-827a-7fe8577fb24a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27aa38df-078a-4112-9599-a56ef34af1ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f391c3e8-e7ac-42ba-83b5-6025010819e8">
        <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
        <dc:identifier>HP:0012363</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04f1c617-efd0-484e-9b95-4a82e88bb175">
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
        <dc:identifier>HP:0012350</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/730e40f7-f488-4b3a-b7b9-05cb29bf24f3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ad5a75a-9c32-40cf-bfc9-dd1951000c4a"/>
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a01bc31b-7e24-41cd-a551-826a09cb11a8">
        <rdfs:label>Proximal tubular dysfunction</rdfs:label>
        <dc:identifier>HP:0000114</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9db0ad83-c136-4f77-b9fd-d10ea5a02ba5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d52645a9-9f09-4b39-af68-3c5bae311606">
        <dc:identifier>HP:0009830</dc:identifier>
        <rdfs:label>Neuropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d338d5eb-0ae9-48d5-a944-60097561bea0">
        <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
        <dc:identifier>HP:0045010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72ec2655-9d9f-4de8-a5ab-0544ac53663c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81752c87-56ea-4789-b849-6779ae8a1947">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
        <dc:identifier>S01EC</dc:identifier>
        <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4399dfc-0fc4-477c-a45d-07edd51570e8"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eda1e2d4-e130-4e3b-a798-fecfddc6d474">
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>behavioral abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e32925a9-1b3e-42db-b9f4-0290abf3cd48">
    <rdfs:label>Glutathione</rdfs:label>
    <dc:identifier>DB00143</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59f5c7ed-3afc-44d5-9586-a65f7e87fc6d"/>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/894dc9ab-6c2b-440c-9467-92cc857be941">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71ba0eb6-f533-4d6a-b871-126bd9dcc02c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002574</dc:identifier>
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/750879c9-36da-4305-83ad-91fa20d47cb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6fbb2f46-d13c-4d60-8e8b-7fb3010a5318"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/309e1ca0-4d48-4c8a-b568-10ac36f4912a"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
        <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/58349314-1aaa-4071-b08b-2b4ef7431a20"/>
        <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01fea52a-9387-4dea-ba75-ea91f2d2e25b">
        <rdfs:label>Low pancreatic zymogens</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24175354</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25772345-216c-4da1-9f31-efb439b67dea"/>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
    <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0460c193-da0e-4bc2-8133-5dfdb4fc9b60">
    <dc:identifier>HP:0012378*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1df921f7-8b40-4eec-be70-7b1edeb1b3df">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/890e349e-ad83-404b-b127-97ea84a6f7a4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1853b34-646d-4e00-9f7e-6a31a88926dc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1276115f-a14e-46a9-b048-991e1222d524">
    <dc:identifier>DB00679</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b9ee7da-679d-43bf-bebc-e4289dbb21bb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <rdfs:label>Thioridazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94dda678-c701-40dc-8c6d-5e7a2f69dc7f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Homocystinuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
    <dc:identifier>HP:0002156</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dfad9467-235f-4097-b0cd-30a513452510">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be77fb07-4d6d-422a-8796-03f8ebca6a2e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e43b88ad-83b9-4015-9530-414f54bc5ea9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal exercise physiology</rdfs:label>
        <dc:identifier>HP:0009020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6e3b3ed-fbfb-4a17-9dd3-07d8852d1b5c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b65b0f63-f5e0-43b9-959b-554e885dfbe7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39a80636-48f2-4660-9caa-ffeaf00931ca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23ef0fb7-437d-401a-9cea-bbf0d20d8d70">
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72dd30af-c2bd-471a-b175-4841b8d59ae3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71cbb69d-ad23-4e39-9d5b-f35e752acb61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b57c90b3-f209-4ca1-9820-c29831a65fb5"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ab7c0250-1aeb-4da3-adc5-57c881b8b9e6">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a65e818f-8918-4efe-b87d-e3c0486ba291">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3ecefeb-f45d-4647-8b44-65bd4f2a3a79"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29684566</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>(c.356+3&gt;C)</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/144e9daf-f024-43a2-a812-591fbedd32a3">
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:label>Thrombocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79343775-8be3-4ccc-ac63-6819d377bd7b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c0db91b2-40e3-42a1-8615-8144e7489038">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca3a2072-2ad0-41c1-9873-af075364b850">
        <rdfs:label>shorter life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7aa56ac-aad9-4607-86fc-1832d5a537ba"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6348c217-a72b-4497-974c-1f2e75bc18a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20832970-aa43-42fb-9474-57ecbe2cfc76"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62f2feb2-df28-4312-9d90-32d98b011c11">
        <dc:identifier>HP:0010918*</dc:identifier>
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c0f3448-55c6-40da-91f7-272f0c7a3453">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>Delayed growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91c2c67f-44a2-4b51-9b1b-07e3fd4391f2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bb1287f-9902-470c-b82f-4eda1270e464">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:label>Photophobia</rdfs:label>
        <dc:identifier>HP:0000613</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77c4f8b8-b8cf-40ee-96d1-e72cbfc950a7">
        <rdfs:label>renal function declines</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9f78c73-5ec1-4003-a520-2073014b9d87">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
        <rdfs:label>glomerular damage</rdfs:label>
        <dc:identifier>HP:0000095*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e682b66c-d109-4f7a-a472-b62465be1128">
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fa096a2-5d00-4b3d-abcb-37b1a52e829c">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02ad6ade-3742-4dc3-b4d7-63c9e15f9564">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83f57403-df90-4f0d-81be-15c632eb28c9">
    <rdfs:label>Rapid progression</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3896828f-3b01-4bf0-bc02-ead7f49d1561">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <dc:identifier>HP:0000982</dc:identifier>
    <rdfs:label>Keratoderma</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e8613f4e-f451-48f5-9e30-4b87d04158bb">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0fa37d6-ded7-4d17-9d7b-2c9a19af586b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
        <dc:identifier>HP:0040189*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b79ec80-8cf4-4a5e-9633-5a32afa4bfdf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3685f7d-2440-4140-9ec5-3c15e5f9ea86"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b8f6897-17ca-45e0-b0d9-cfed7500e283">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007479*</dc:identifier>
        <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/759fb870-5d35-47d8-80a0-b27ea8a0f707"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b4a0256-47b3-4e60-a2f5-50a567b6fafd"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74f596c6-8436-4fe4-9d4b-cd01c2c299ef">
        <rdfs:label>Erythroderma</rdfs:label>
        <dc:identifier>HP:0001019</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f041dbfe-b455-43fe-93ab-027ff5fae809">
        <rdfs:label>Scaling</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdf872e4-5b6d-4e62-8339-0a78eabb88db">
    <rdfs:label>Joint disesae</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
    <dc:identifier>HP:0001367</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08fad2df-4f59-47a9-a381-10af07fbb706">
    <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
    <dc:identifier>HP:0009020</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d3caca9e-935b-4c5a-83f1-72b9e5134ada">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea1a72aa-8d48-4f64-84f9-13f020a8f487">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001941*</dc:identifier>
        <rdfs:label>high-anion gap acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16691ac2-486d-4866-89dd-f3bb31e4913e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06b1b258-7e8c-4f38-8b20-10474497d46f">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
        <rdfs:label>Warfarin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57ad8b34-c532-4407-81c8-8fcce3cc029a"/>
        <dc:identifier>DB00682</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/524b37eb-fb89-438e-8b86-fbd61eeab40a">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9efa9eec-b88f-42d9-87c5-aa37ad863a0f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17657a04-f4bc-45e7-9159-ef0bb4fcbdd7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000718</dc:identifier>
    <rdfs:label>Aggressive behavior</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/76ebd45c-ce25-4ada-bca4-d266b950c93f">
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e0cd14-5985-45e5-86aa-6ffcf41f5349"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ce62dde-c5c7-4759-8d85-c62a80748226">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute decompensation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39645f68-cb0a-4e38-9028-d069ef9d4500">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
        <dc:identifier>HP:0001958</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
  </obo:DDIEM_0000009>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c540cf98-a177-4980-82c0-99a675d57899">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae2ee397-a45d-48e1-a5c4-5db6b53de1f2">
        <rdfs:label>neurological malfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34ea0678-eb21-471b-a4b8-d023f1dd7ba4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4bc5e92c-2ef1-49cd-9de3-6a6cd9ababbd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/279e2e23-1b5a-4feb-9b63-4494f3c2a621">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
        <dc:identifier>HP:0002715</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>immune dysfunctions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5604ec00-cbb8-4eec-bf05-fc35a1103237">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1b202077-5199-4592-8300-1c1ad2437f7c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f5a87c2-748f-42b4-91ed-abe59d660161"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ea94744-39bd-465c-a395-65b0ef5eef08">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>Renal salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
        <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5e30865b-1109-499f-bf72-97e58b928f05"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e71a71b-eedc-490b-8e57-37b78888c721">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/314763e2-802c-4435-98c8-fd714b9827c0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2b50ebe-a359-4d99-8f3e-bcf14f711bdd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/931e0f15-33b0-418a-a8c5-9b2f79461f4b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04067a75-ce89-4798-ba27-66acd0193aa0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5736d5f9-d827-4cfe-96ab-3fb568392665"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <dc:identifier>A11EA</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f171d3c-689a-4a00-ada7-99eaf2456ae2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7412eab1-b391-4cd6-922d-5143d92bcb5a">
        <rdfs:label>AAV-GLUT1</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/472f50b0-3a16-410c-a56e-18934f175dac"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d64d9f4-3d50-4823-8a8c-fed59b7e1dd2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Daytime somnolence</rdfs:label>
    <dc:identifier>HP:0002189</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9b188aa-ee0c-4c76-92b9-749ec2075076">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7c457034-e551-44d5-89a8-4438b124a3d3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37dd416c-49d9-4c5e-84b4-69d5163c73b0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57054856-12ea-48c0-b291-c77f0530d37d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
        <obo:RO_0003304>G11778A</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61dd9889-b74a-47b7-943e-06d44ba34c84"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/81c123a6-27bc-4293-a597-55c3e368647e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aba5dfcd-81e0-41a2-a814-5638949d17f1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e249150-8cbb-43b2-8451-b91c9ae9632b">
        <rdfs:label>Difficulty breathing</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002098</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7870811e-c61f-4361-9aca-c2d86a8080bc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
        <dc:identifier>HP:0006530</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d9bd371-f129-4c6f-90b1-91060ef8347f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20eb230b-a8f4-48ec-87f6-a6c0a36fd29e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
    <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/793e3f56-dca7-40b4-b649-9164146f9ab6"/>
    <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
    <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/30581c38-52d4-4110-8f71-7e3b9205c29c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df91fa55-acbb-4d11-931f-1e35033d1582">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8729189c-09e7-459a-b295-6f9bb4c7e827"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
        <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25ade689-8195-46f2-b43b-94ad0acbf9fb"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4211dfc-241e-4499-986b-ba214c20c0cd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012450</dc:identifier>
        <rdfs:label>Chronic constipation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59295682-f389-44c0-9d0e-b6f1a9007ff1">
        <dc:identifier>HP:0000496</dc:identifier>
        <rdfs:label>Defective eye motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/739bd71b-da80-4a14-9893-52e5d7d582ff">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bulbar dysfunction</rdfs:label>
        <dc:identifier>HP:0001283</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c0b8ba0-2fc2-4b51-a054-eb9ff76ee82c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2bcf374d-3e7c-4810-b8b3-be17578619cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/603031b1-249b-4caa-8f1a-e1cc0825ec32">
    <dc:identifier>CHEBI_17012</dc:identifier>
    <rdfs:label>NeuAc</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/78b9d9bc-ee72-4bde-92ec-0ecff49e884e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04f1c617-efd0-484e-9b95-4a82e88bb175"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f675081f-6970-4859-827a-7fe8577fb24a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e11c18b-a8df-47ae-b22a-3ca5249e3cfd"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/790758cf-bb3f-4c26-b958-76d188c7b348"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cfeeab3f-d0bc-4dd7-b75e-71305de0dc30">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3e711fe-083d-45e9-a76f-5bdb5d7884fb">
        <rdfs:label>Decreased niacinamide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff0cf920-a3c9-4d1c-aff2-cd13d8ce4a84">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63db562d-65f1-4289-8888-45998e57d8d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/788c92fc-4f6f-4922-9acc-8066852c3959">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d6c761c-457f-454c-ae68-5056c1cca20d">
        <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9142bf6-78b5-440c-a18c-63b73f76b53c"/>
        <dc:identifier>S01BC</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be754f8f-996b-4445-90cc-95341186709d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2518680d-a1d4-461e-8e83-df9ae86e4f51">
        <rdfs:label>Sleep apnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <dc:identifier>HP:0010535</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d1c9e12-2a7d-4156-9889-920cb9caa758">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0699683d-5a40-4747-83f4-bc434cb1cf86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1383711d-42a3-45f3-9f80-7e9e7fe8c876"/>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78805d88-93fd-40df-80d9-25999e642040">
        <dc:identifier>HP:0010444</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pulmonary regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f439c89-4460-4745-93cb-1800cd10cd2a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
        <rdfs:label>dyspnea at rest</rdfs:label>
        <dc:identifier>HP:0012763</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d59ec338-3aad-4ccb-8a0c-0a71115ef5e1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/811dfc12-5e1d-4629-8688-7e3f5b18ae35">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low exercise endurance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dad7b33-b5db-447f-985c-78f5244bc44c">
        <rdfs:label>pitting edema</rdfs:label>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d64d9f4-3d50-4823-8a8c-fed59b7e1dd2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90ccfee5-2ef4-43a7-af0b-7a5cffab2c98">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <dc:identifier>HP:0002500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain MRI abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e6aabe7-e8b4-4a63-983e-6301c20dd565">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>photophobia</rdfs:label>
        <dc:identifier>HP:0000613</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c939aeb-72af-4dc6-b4db-88b4eea4ec6d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:label>tricuspid regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ac817cb-42d2-4d65-8d94-86e9a3b040bd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
        <dc:identifier>HP:0002877</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0939111c-db0b-48d2-9ee7-0ee84410f53a">
        <rdfs:label>low quality of sleep</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08ecbd9b-b3f5-4213-99e7-e6a7f193bba5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
        <rdfs:label>conjunctival irritation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030953</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9da9cfad-9bef-42c1-ae2c-760d1d481210">
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42b40c5f-056c-42ba-a34d-7cb519eb4c45"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56b6b42c-6231-472e-8a49-02d86ab3c051"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b57c90b3-f209-4ca1-9820-c29831a65fb5"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31630958</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c2f6c32-0885-4664-bbca-d9026094c889">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e47a24a0-897e-4529-bd7b-9bac412ebcfd">
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <dc:identifier>HP:0003541</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2c888c6e-a989-4b3b-bcaa-c763cf221d90">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f94b92c-579d-46ec-9148-9ff2851d115e"/>
    <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9caf99a6-19fd-4c24-8757-d561f6f3fef9">
        <dc:identifier>HP:0031951</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd3da14d-9f31-4006-b34c-102edeed5e0a">
    <dc:identifier>HP:0010832*</dc:identifier>
    <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1cadcad2-e580-41aa-a29a-e1e7d92acd43">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eaee23a-479b-431b-9194-b821c3f34ef8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e629a614-d76a-45d0-930d-0b8dbf2836c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/635b3114-1d55-486e-9b03-24111916ed9d">
    <rdfs:label>Salicylic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <dc:identifier>DB00936</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cfb2e9f0-315e-4d2b-9878-a0a615d72ce8">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d199e02-8238-423e-bc65-a0036086ca14"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22538ae6-697f-4d47-9ad7-877cd7e931a7"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5353fde6-dfaf-4a56-a3d3-8025ffff492c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5fc0073-caa4-407d-bfcc-06bad7b16a26">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6c486b66-bece-4ca8-a9cc-237293dbd7b6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eefea3d3-bac6-4e43-8fff-7413d72131c6"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae78217e-2864-4753-b302-88f55041c7db">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/797622d0-a392-4853-9a88-d0b887c66c51"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/009b995a-fdb1-45ab-af86-e1c69f9b358c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c810db58-3e62-4b5e-94d6-aba75e455fd4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eefea3d3-bac6-4e43-8fff-7413d72131c6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b416a32c-5a55-4464-896a-1f195ae7ce1e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00328</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ba72547c-f995-43ba-94ca-e52ec9d50cdd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eefea3d3-bac6-4e43-8fff-7413d72131c6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4916d40-ba9d-42cc-a732-393c59ddc093"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28e893d1-45fe-4e82-a9e0-c330ca40d4b4"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e014eab0-aae9-464f-acc2-53d85cebabe9"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/49966f18-51aa-4793-b0f7-daef9afdea20">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/009d2391-c9d4-485d-8311-ba2c66f5634a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/794b4b64-b8d9-49bd-8dde-a5c5e79f44c2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eefea3d3-bac6-4e43-8fff-7413d72131c6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb63ecd2-c213-4bb1-b64e-ee9df61a5636"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33626dc1-277b-466c-b10f-51607567b16a"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Indometacin</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cba06df1-4032-4b4b-ba29-b0b616e26a52">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6173993</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22985607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de269d69-d171-4d57-aeb9-575d75d1e7c1">
        <dc:identifier>HP:0012463</dc:identifier>
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fe615b3-30b4-4a58-8e4b-d470309803be">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>Increased serum ferritin</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4811840</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9044298-0f84-494e-b80d-cef8af8d2f1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65db7ed2-82ed-49d8-8052-a9562f13c7b6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2274b67a-84b7-4e21-ae85-28b7f1c3cb28">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
        <rdfs:label>Increased liver iron level</rdfs:label>
        <dc:identifier>HP:0012465</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac4c65a6-fda4-4c32-87d3-83b78dae7354">
        <dc:identifier>HP:0010472*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa44f440-aeb6-418f-bff3-569d85690a89">
        <dc:identifier>HP:0003452</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased serum iron</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1853b34-646d-4e00-9f7e-6a31a88926dc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec4e055a-252a-4952-8a5b-2309417a096b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb3f2a33-8365-436c-be24-acd5e92c47f0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99468ffd-ab61-4f95-9ace-93c1dbe0a10a">
    <rdfs:label>neurological disease</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e0538677-fe56-4b1c-a3bd-33ef3d3d3a46">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac690927-7f34-42de-9c13-1ed32b9a53ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/809e0771-24b0-415c-95af-cb89cfcb5d85"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d954988e-0769-4f48-ba7c-0e21c182922c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
        <dc:identifier>HP:0012187</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/8e0cffde-c726-412c-91ea-0b70406b76cb">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c1eb1c9-594f-4765-b630-5086c9504380">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:label>hyperlipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003077</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6ea4ef8-778c-43e2-a20c-2ba081dba36e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69189f15-4d3d-4921-83aa-767f78bd98c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>lactic acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62095846-dfd7-465f-8a73-563aa148e0fe">
        <dc:identifier>HP:0000855*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a779c938-5a6e-47a8-bf20-c55775ba1927">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b41dd322-dc57-41a5-aa35-8cfdd9da8645"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/886f60aa-a899-419f-9ef3-7e8fcf826430">
        <dc:identifier>HP:0001513</dc:identifier>
        <rdfs:label>obesity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc8d6e88-96de-47b4-87f2-9a933299e7c8"/>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/67c8b290-f3e2-48a6-923b-d429ffc67771">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb684ee4-3277-4693-8b97-9e78704000d4"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a10b5da-4c23-4b9c-a44f-7cfc928db632">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:label>Brain pathology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/130854b2-93d4-44bf-86a8-450944251fb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ab1db91-3d28-4743-a93a-bd292829be67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d36b969a-2a42-4490-b0a8-b0fd229dc1ea">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68befe56-cdf5-452e-a421-2f8a7494d235">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
        <dc:identifier>HP:0001980</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3eb42541-4408-4dfb-a73c-60bc193f18c8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
        <dc:identifier>HP:0025454*</dc:identifier>
        <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a4ae332-25a2-4b22-b288-f07fcc92b963">
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:label>Low 5-MTHF level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/050f8258-e8c9-45b2-bbd1-a2e9466cfb3b"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a381b56f-4c05-44e3-ba5a-3c6586e4ceec">
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:label>Abnormal CSF folate level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ed8cb32-efc6-4fff-859c-dfdae0752355">
        <rdfs:label>Low total RBC folate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040087</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc0e9872-40dc-40cb-a03b-c27dfdd35963">
    <dc:identifier>HP:0001386</dc:identifier>
    <rdfs:label>joint swelling</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0df478fc-e73d-450e-9266-8471de0364d1">
    <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
    <dc:identifier>HP:0011923</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78867b26-3dd0-473d-bf39-7cceec7a78e1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <dc:identifier>DB00788</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed742dca-dedc-4ff3-aca2-28c5a28bd6bd"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1df328ca-1729-4fd8-b3f0-8e15a5ba9809">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/940034c6-2aa8-48ef-88a7-178f48cd2b8f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c09afd6-f880-424a-9641-d6a0e1a759ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2072f2d-3491-43cb-9572-44a501b4dd96"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Naproxen</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f4091b1c-b9b0-4fd5-b8ee-9a2c46fd1b5c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2072f2d-3491-43cb-9572-44a501b4dd96"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/572f8c07-abf0-4cde-b972-6b9deb5e389d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118610"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4883f257-0dad-4997-be34-1d0e93fd86ae">
    <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3bde5216-aaf1-4578-b749-18e246b4e498">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a42fe84-8a75-412f-8115-1847a90aeb89"/>
    <rdfs:label>Glycosade</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6366d67c-e46e-478b-bbc5-280ce45dcbfa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7193862c-ec77-447d-86e7-10418835514e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2710a8d0-6904-44d5-a707-a69eebfb57eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e27ec53-e128-4573-9a1f-ed88e7e899f5">
    <dc:identifier>HP:0004325</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low weight</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/61cf57a9-a429-49ce-8962-e51a8f4f3e41">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a05592b-a62c-4787-a74f-ff19bf7e6ce9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high creatine kinase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0207b78-4438-48c8-897e-99c01ef3c4e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:label>cardiomyopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d39774cb-33e2-4f84-83f5-9d244eb8d419">
        <dc:identifier>HP:0011025*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a22d735c-ee12-4782-b565-1f4813f39c48">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/307686bb-57ca-4d50-a98a-487a668290ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c210781d-9ec7-4d5d-83cb-8d15d6e8e258">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78969916-7942-4263-b816-eba634f0ef69">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/083ff32e-3a12-456a-9156-69355e1c82df">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
        <dc:identifier>HP:0004359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6fd9255-1873-4195-9f92-689d285f2353">
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000008>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4dd9cff5-e0c1-4f1e-92fe-26bc0db3f3f4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c072f54-5164-4e61-9ff1-0caa64c4f944"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b0240f9-500c-4d44-886b-ab9273139c3c">
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal gait</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a892d9d-6040-40e9-ae83-1c715dac83e7">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>EEG abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9663ab6-0a15-4bc1-a098-bc260f42719b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd4eff58-7577-4932-88d9-fe0703bed15e">
        <rdfs:label>neurological dysfunctions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/291370c8-c5f1-4b2d-b69f-28f40dcb5076">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001665</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
        <rdfs:label>chronic diarrhoea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/770833b3-0ce4-41f0-9036-fe73fa3f760c">
        <dc:identifier>HP:0040129</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e38f9ea-0b16-4fa3-9456-ac4df0bd8f1b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd542a19-6f7a-433f-8e90-f1d1261367d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3ace474-9140-4b1a-94d3-385b10786b02">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cataracts</rdfs:label>
        <dc:identifier>HP:0000518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97ce14be-2c89-4af2-834e-3c656e20046e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Incoordination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec8f9cc6-26d2-486a-adf8-bb04b9b36f0e"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f111efa-8b64-4b38-a90f-9279be2ce393">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
    <dc:identifier>HP:0040081</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/2fac5b7b-2b0c-423f-8acf-3e72c0b59958">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4924f0b3-770e-48b8-80f0-b1971a5e065d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c071cf5d-3f67-49d1-8f3d-e7548903badf"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9eea98c7-9917-4d56-96ea-02db4edcf1ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ec568f3-0127-4fb1-b797-dae7a50313ab">
        <dc:identifier>MP:0013277</dc:identifier>
        <rdfs:label>abnormal fasting glucose</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1759ab44-d29f-4ac7-bf20-1643064efb19">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2fd14756-0ddb-42e4-a98c-ec0aaeba5414"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4ef3724-f6f5-4388-a324-35e09a837dfb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <dc:identifier>HP:0040300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dddc9c8a-402c-4c39-936b-e68939f795dc">
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <dc:identifier>HP:0040217</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25c53baa-5b87-486e-af1e-2c5154e85eab"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00b06fa0-1e80-4f0f-a816-716a56fbea89">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high facial soft tissue volume</rdfs:label>
        <dc:identifier>HP:0000287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1f8d20bf-0f45-4b4d-8cf9-24a438b8b856">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7135396c-47ed-4cf5-a7a7-ff609c0a068e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2cb7b9b9-a08d-4c1c-b58c-8514a2ea2a12"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cc9b771-e7bb-49da-a361-e2b19a88653c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012026</dc:identifier>
        <rdfs:label>High ornithine plasma level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d108ea14-879a-43de-b88d-e80204e9b847">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a45d25f1-f602-4f75-9c0f-0b0531fa3d4f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/960f5da2-3ce8-4b4a-a100-ce025192d84d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c02a2517-dcb2-4747-8591-8c1bcbbe419b">
        <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50e50643-02ec-4f98-8635-c4e5f98613cd"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76b797f8-461c-4eaa-895d-6acb91ea3bca">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a21e37d8-2ff6-48d8-99a3-26c678022c83"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61fc47f4-d288-4191-a6b5-64d19c913372"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <dc:identifier>C09C</dc:identifier>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1dc3666e-413a-4807-abea-ce68488f791d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd79cf47-81fa-4ea8-9be1-6c6d1d9a55a3"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66476764-b823-45fd-be4e-eb357be390a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c9ae306-d5ba-400e-a0a3-a2ccfcbb2142">
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/bb3222e2-666e-4a0a-a913-53c1069b7c9f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7287cbe-6461-43e4-86cb-a10d325f4792"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37d007de-9aa8-425c-99a7-06420f6c1a9b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01008385-242d-4754-93d7-8b9d054ce51a"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <dc:identifier>N06AB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ebbff019-c444-493b-98ea-b3d2d8a408cf">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92de8fc2-668c-4a0f-b683-75f1666178c5">
        <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeeefd58-0055-43d9-a86a-4775e9d54603">
        <rdfs:label>Cardiac hypertrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d2944e6-b66f-4116-b012-e290152dfad0"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed721c41-edab-4887-a8be-72e05c7676c7">
        <rdfs:label>endothelial dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41c209cc-085e-478a-9030-12f46b07c369">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98087a41-e4da-4051-830f-17494bcdd4ff"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/61bbd9cb-523b-495b-a19b-c07d8c1baa1d"/>
    <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
    <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71769896-0c61-40cb-af49-2fa44d9fdf07">
    <dc:identifier>HP:0002630</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc9b15ca-c02e-4d0a-a1d4-ec3ccfbcfd82">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69de1626-03db-4a5a-aadf-c5b882137ff1">
        <rdfs:label>leucine-restricted diet</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba4305a2-e1e0-4a18-be05-5ce27b13e1a4"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1e533dec-db39-4a0a-b690-ba6d66db8012">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b70d507-6cf5-46da-bc99-e2519ed6eb34">
        <rdfs:label>Decreased life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e014eab0-aae9-464f-acc2-53d85cebabe9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deleterious prognosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7927093b-aa32-41cd-9555-c119022ddada"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28e893d1-45fe-4e82-a9e0-c330ca40d4b4">
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>Salt wasting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/328f49d5-5253-458a-a5eb-dc353f75bcb9">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth retardation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39233ca4-5065-4138-b67f-6bf1b8af3225">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <dc:identifier>HP:0003676</dc:identifier>
    <rdfs:label>Disease progresssion</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bfa349c1-ff57-47c9-8c81-277452f66b50">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4811390b-91ee-4677-908f-938bb36a110c"/>
        <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44ef5dc1-ed91-4829-90ef-0386fdfe0d7a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6808ac70-38b1-40c4-9c1f-bbfcd9ef7299">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fbf16b1-bd00-4836-aad8-3175a886294f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/faa1166c-f63c-4f8c-a869-0e4b4fd39ac2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9528f1e4-5278-4b15-a09a-f147400f4dc2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB14644</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cfe6c412-9e05-4387-8547-f49e432668da">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b487683e-060e-427e-a108-a97207771a3a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/82b1318b-e7e6-4f3d-aa1e-20153aa336e3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/90c1f869-ee9f-430b-8ed6-1ea9deab6da7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/988595fb-e4ac-4acf-aaa5-b2dcb5ee9264"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73000a54-ca9f-44da-9c88-1428eecaa5fb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:label>acidosis</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec97233e-8452-49ef-bb44-cb245a2832fc">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89a3ca4b-a207-4f4c-8fe8-cb225cda352d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9872a869-6f3e-4e3e-827b-9eb46e918d2e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aec1fb24-78e4-46cc-b9fa-71e2fb05be74"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f20e2b50-65dc-4124-8744-d0661e677500">
        <dc:identifier>HP:0002160</dc:identifier>
        <rdfs:label>Elevated blood homocystine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/050f8258-e8c9-45b2-bbd1-a2e9466cfb3b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28a32a7a-cc8d-40b5-a2c6-5f4df5ab549f">
        <rdfs:label>Myelopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002196</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2b50ebe-a359-4d99-8f3e-bcf14f711bdd">
        <rdfs:label>Gait instability</rdfs:label>
        <dc:identifier>HP:0002317</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3a682a7-7844-47b7-af4d-c6423d4e3b09"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b469820-2834-48ee-b878-9ef99c217f2d">
    <rdfs:label>Oprozomib</rdfs:label>
    <dc:identifier>DB11991</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4b85fffb-03f9-468a-9aac-8399462aa026">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94dda678-c701-40dc-8c6d-5e7a2f69dc7f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f7640a2-8ba9-4e6e-9d21-ed56d0aad977"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49e4db8e-1bc1-4fda-935d-d13afc1f0eb9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1388fd71-0653-47c2-b3ca-88c184721e24">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/697739e9-98f8-416d-aefd-e8f72e4258f8"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df303c69-b8c9-48be-a7dd-97f0fb2f6e12">
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84b5b785-f374-4635-9737-05353dee88e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b83a2807-c684-432c-8c04-e21c15d92c67"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/be5225f5-2c2c-4063-b767-cc78a7fef149">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84b5b785-f374-4635-9737-05353dee88e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9236654-157b-4e3d-894d-fd49a7c9ea60"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee0a5089-d755-41c9-ac04-610bcfe5608a"/>
    <rdfs:label>Creatine</rdfs:label>
    <dc:identifier>DB00148</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2668928b-d7dc-4b4c-8223-9687137c947a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
        <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
        <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6932d50f-162f-4493-97b9-fb471759a88a"/>
        <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761646f2-2887-4446-a926-718fdcf7506d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2496678-525b-4531-bea7-8dedf68fde78"/>
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/724e96f0-c04a-4620-b2a2-346fa97ce236">
    <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/029d80d2-cb02-48ef-9bcb-44eff0d76cc8">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <rdfs:label>skin inflammation</rdfs:label>
    <dc:identifier>HP:0011123</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3ecefeb-f45d-4647-8b44-65bd4f2a3a79">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab7c0250-1aeb-4da3-adc5-57c881b8b9e6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
    <rdfs:label>Eltrombopag</rdfs:label>
    <dc:identifier>DB06210</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c1e3e00e-73fb-479f-a488-c54d1dffabf4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb49b8f5-dea3-4ecb-8771-a08dff9aa7fd">
        <dc:identifier>HP:0002123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <rdfs:label>myoclonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79a9303f-8f84-4190-9106-45b79c60f889">
        <rdfs:label>inability to walk</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002540</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6377b7f8-de1e-4bbd-a143-6cbb81cbedca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97f7937f-95f2-4996-96d6-aeccd683833f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3aa75eb8-d0a0-45bc-b3c3-0858e4fd42d7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:label>Diminished intellectual abilities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/abe34805-a98d-4003-805e-89b21d52bf66">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af3ab109-7f88-4ff2-9948-244cf61e625f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a1b544c-e08c-4118-8ace-0bdc3d7063a2">
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dff1f92b-eb56-40c4-becb-ace3775807c8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3cacf3d6-d955-4b54-bf21-abe291adb245"/>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71100f05-a3b3-46c4-a242-b8b069176168">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
        <dc:identifier>HP:0012405</dc:identifier>
        <rdfs:label>Hypocitraturia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dfc528b-4c21-4ccc-9cbc-1a53075a3346"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6b9357a7-bfe3-416a-9b41-f5e23530d0a5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e25e975d-cecc-45e6-9086-8f0ce0a5f962">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma uric acid levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50e50643-02ec-4f98-8635-c4e5f98613cd"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6ba8050b-857f-4c2a-93d7-6935845dc4da">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42881b45-dc14-49fd-b31a-19c25ef74f09">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ce320ea-1b91-432b-bd03-0b30f85973cb">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc957b96-18c9-4c19-8f39-3c6e7e509516">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <rdfs:label>Increased inflammatory response</rdfs:label>
        <dc:identifier>HP:0012649</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1853b34-646d-4e00-9f7e-6a31a88926dc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d7d96eb-4eb7-4835-b1a0-8683fe226b4f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d54f5745-b829-4f45-b65d-82888977d9ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1195d345-36e6-4bc1-807a-fe5c9eaa4f4b">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f07d186f-945a-4b0f-abd3-55e7616146ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce2507e1-cede-4a83-a35e-d3a26bb01414">
        <rdfs:label>hypomagnesemia</rdfs:label>
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
        <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2ec8d0b-0a97-4d26-8488-240f91acb0ff"/>
        <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/4bd52c70-dd8a-45f4-8506-fcbae5b8c171">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d487b03b-3449-47eb-9742-c74bd261e329">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44b94d85-e5b6-4938-a9e8-82af89e4e418"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3d2d070-887d-4dde-8404-4c3ad91ea828">
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2388f92b-4d80-420b-9db3-d667e20692ab">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c608471-b569-4d4d-835a-507deff66869">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7eb77978-4c3d-4798-b222-cb86f8575f07"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ad31f9-90e7-4950-ba60-6e469e03e009">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>Hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39377296-46cb-473a-8595-3e7ffe1a91fc">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1dbe07e-977f-4633-9d51-ff78fdf8d95b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8c4a71cb-fbad-48ab-b199-0af7f6e2899f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/da372ac9-cc7a-439a-a46c-5477ec4db232"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c0d08f4-fec7-4688-9aa3-ca588c8c8d24">
    <dc:identifier>HP:0001337</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>tremor</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cf9cee23-a145-4f93-8d93-21661b1a0823">
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/973ebfb1-b8a7-485c-a509-43466ed5f84c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3701a85-4c01-4a93-824f-e064599150ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5711b93-a815-4951-aa00-a69d05c5289c">
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
        <dc:identifier>HP:0004371</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8bbd744-3f28-4b1c-8ae0-7878900b6a4b">
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2e106d3e-a31b-47cb-982a-4c41bd375195">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/949ca51f-1ad5-48e6-a1b2-d6c69b02c81b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca44c2e7-dce6-4b2e-bffc-92a6f74114d5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/797622d0-a392-4853-9a88-d0b887c66c51">
    <dc:identifier>HP:0000847*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
    <rdfs:label>high plasma RAAS activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0db60fa5-cd49-4996-bc7d-fd61f1805710">
    <dc:identifier>DB12273</dc:identifier>
    <rdfs:label>Ecopipam</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/be8a61df-53b4-499a-b030-a37e1ed2d7a5">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1ab17b0-b5a1-43b0-913c-c3791f538787"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c62d88af-ceac-4cab-bca7-671d55bbf537"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/da65f7f9-f4ac-4ef5-93d5-7a0330978c75">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d586617-76e5-445c-a61f-6bf86a0f4dfc">
        <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004364</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/30c9c90f-9408-4f29-bb74-97dde109fa76"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5be6a18f-519d-440b-984f-b66f2f752c2f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002570</dc:identifier>
    <rdfs:label>increased fecal fat excretion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68cace00-c7ca-4c67-afec-eaf6632b7376">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <rdfs:label>speech impairment</rdfs:label>
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e71e4f4-c834-4064-8dcc-6d43998d7d76">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:label>Intellectual disability</rdfs:label>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13f9ea03-c53e-4a08-af8b-37746592774c">
    <rdfs:label>Phylloquinone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/52eee92e-c382-4ab8-80d0-8c7240a243ec">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a74580d8-21f6-4c43-bb6c-88ce6a2769fa"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e40457e4-82ae-4b67-a8f9-7449ae9ee98a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/416151cd-7f42-4bbf-beee-0a2ecf0098e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3affb1dd-934f-4021-9ada-fe2fd9abdbea"/>
    <dc:identifier>DB01022</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7b8e702-026d-4af5-a6a8-aa320f831296">
    <rdfs:label>Puberty and gonadal disorders</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008373</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3b341e30-d294-486b-9e57-bf1d5f4452b4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
        <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20bc603d-01d5-45fd-96f1-f0bf04d7c20d"/>
        <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbd12dea-a3cb-4069-8423-8d5eba26988e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1b59104-b79c-41e5-9917-4ed69a831e68"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b422ddac-0fbb-4d46-816a-7f779104c840">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result is  added</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c049725e-3e34-48b3-8223-01445ac76b91">
    <rdfs:label>neurologic deficits</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/03ccf189-088c-4578-a852-342472c8971f">
    <rdfs:label>HDAd-G6Pase</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4f6fe977-1dda-4d80-95e6-e1b12b09721e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd3a8f78-e073-4ce5-b098-3e38c49b6e2a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/219c8f85-0b8a-46dd-9cdd-3ced94554b73">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/712c497f-9e15-4f10-aaee-61cc8f290f69"/>
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57901a4c-89a5-464b-a7c8-315cade5b476">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>swollen joint</rdfs:label>
        <dc:identifier>HP:0001386</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bba62500-f9b8-4bb3-98f5-3e2f3cbb0154">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91e4e1b6-f1c3-4ca6-8740-a8f18c96e34e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/940034c6-2aa8-48ef-88a7-178f48cd2b8f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:label>Arthralgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b4910613-b779-40a4-875f-0680e61307f3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88fb4928-e69a-4c61-92e8-8d87a51c544a"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
    <dc:identifier>(DB00440</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9da8a637-b31b-4d5d-8d79-7672dbfc020f">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0df06d07-60d4-40a6-8add-c90b0462c860">
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be0218ab-0972-4faf-88fc-70a31cc05e1f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/552224d5-e587-49a2-9c7f-dad4cbafbd20">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0003304>R229W</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fdbde11-f97d-4c4e-b378-732dc301a98c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0305f18-0148-4229-a2f1-5b52d608c801"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/07bff160-9647-47f3-84c7-8cc4080488ae">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5bc31c1-c693-4d0d-ab5b-fde0c753ba4d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b83a2807-c684-432c-8c04-e21c15d92c67"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a53ea1dd-a02f-4236-b6a3-78626bc181f6"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pyridoxine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3926bb01-2b15-4b23-925c-00fa11f87668">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/338b71ab-8c56-4443-8c0a-55f44fc46857">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80f08790-c7b0-44eb-8412-d47ff1c41c32"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5bee9a3a-368e-406c-b3b6-3a18cb22c0f4">
        <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71f45386-532f-4841-8f31-c76b02cef039"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/4679e0b2-f590-476b-95d8-a12bdbff11cd">
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d88cf1fa-ab85-4709-bcd4-83c923cb0db4"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99f126c5-be24-4aa8-a5e7-4222ce280b15"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3f0cfd8-e1fa-4c82-9f94-c155aa1544e0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71e298aa-bf66-4b21-9252-236134276741"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/192e1f89-67d4-4c46-989e-d3a4d1976f0c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10012e8e-0a48-4fa7-924b-653f73052707"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc0b3330-607f-4abe-b57e-d1b877b05efa"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/713774a5-508b-418f-9ac2-a3ceccb7093c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
    <dc:identifier>DB00165</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec97233e-8452-49ef-bb44-cb245a2832fc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1dab5d67-1783-48d7-80e5-72432ace7031"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a74261f8-a2b6-4f74-9e76-c547b084289c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/791573b5-af0b-4ce1-b10d-38fa8a8cc99c">
        <rdfs:label>Hypoxanthine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f2717b12-df7f-412d-a27c-0aeed52964b6"/>
        <dc:identifier>DB04076</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8801813e-291a-4e81-bc58-cdc352e23639">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/126e2271-6af9-4f43-b9c3-e5b40d392abe"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9421dbf9-2760-4c58-8955-8636aa5e305b"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/406e8f34-702d-460f-9bad-057b5e279110">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd3da14d-9f31-4006-b34c-102edeed5e0a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5173855e-44bb-48d6-8123-8626af323311">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c440df4a-0480-40e1-afb4-3ad70941cfed"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/a2d1bc1d-a096-4b40-8503-2ef5faf9d8fc">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6eb796f-ade7-4ef6-8232-41cc8d2d1603"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f398bd6f-1e27-48d7-88a4-1528f4081b23"/>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aa3c4959-fb61-4794-a3dc-118b63405f64">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17213282</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40bcdcac-0d57-45e9-bc4d-21c067b8d2a9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100036</dc:identifier>
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/150845ae-935f-48f4-8f98-39d1bfb90e05">
        <dc:identifier>HP:0003260*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High bone turnover markers</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26245849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22218563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/696603d3-3e5f-4f2e-b04c-295839f1795a">
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:label>mobility problems</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b8addb9-17a2-4b9c-869e-de4f2c68d930">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
        <dc:identifier>HP:0002756*</dc:identifier>
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b10b95f-9c2a-4bfe-9e52-1ea97dcbcd92">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <dc:identifier>HP:0001832</dc:identifier>
        <rdfs:label>metatarsal stress fractures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6855ef8-6f68-4316-9a21-c2c3e47b91b2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006462</dc:identifier>
        <rdfs:label>defect in skeletal mineralization</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50eea66a-0e0b-490f-8d9d-4e10308286bd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e028c695-c31e-4626-8fce-bf68c1cc3100">
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
        <dc:identifier>HP:0003239</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69f2e420-1f38-4b59-9395-ed80e08a3960">
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d33edf61-e08d-44c5-aee1-77ca60cfd512">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1dd8b433-4a35-4c40-b74a-577476b4ca87"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/20f6ea7d-5a00-491c-9e81-92db3cdb2c14">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e55f4f51-775d-4fc3-b0f0-4f0390e6cb04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d078ab5c-d8f3-47f9-abb7-404765599454"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1d0c59e-81b2-496c-b428-801e9c910977">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63d7b663-b2f6-44ac-b056-3539d365b2f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99e979df-13fa-4aab-a3ff-2521960178be">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
        <dc:identifier>HP:0011990</dc:identifier>
        <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
    <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/78094a95-8807-4ff3-ba03-1b67629941fe"/>
    <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
    <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8f229d92-3ee5-48b6-b660-25f77853f2a2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d76944e-6d6d-4949-844b-09c1b6a06810">
        <dc:identifier>HP:0001252</dc:identifier>
        <rdfs:label>Muscular hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3206fa4d-050c-4c1e-8a40-4fddb3665d3a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b4e0925-c27b-4368-9893-ae24836c1313">
    <rdfs:label>Etretinate</rdfs:label>
    <dc:identifier>DB00926</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1cba4f97-2964-464f-b69a-fc49308d1d6b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/429e2b1a-2d0f-4df2-9240-f77fbc845b0d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3896828f-3b01-4bf0-bc02-ead7f49d1561"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc875ae8-5230-4987-9085-583a5129a466"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a46bf20d-501d-40ba-9c67-76d620f83c1b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>epileptic seizures</rdfs:label>
    <dc:identifier>HP:0001250</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4063ab12-3106-4b7a-8ba8-928ac25fcbd7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7b56016-914d-4368-8675-750871988ee1"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ead683cf-3d68-45d0-b551-0af4631f7bd5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4230446b-f202-426e-8caa-a7c7f5825e6b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:label>Hypophosphatasia</rdfs:label>
        <dc:identifier>HP:0002148</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/883dce12-6a2c-4ef0-bc47-7473ba77f459">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/484d2f22-7a19-4640-b407-e0a2afb226bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/95f931af-c7e2-41bd-a153-03cbe3517968">
    <rdfs:label>Bezafibrate</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/92dffc6d-23f2-4c67-a53f-f827b33b4e99">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6066d4d-d859-4c8c-82d6-e27a78dd03c7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad3d195d-d295-408a-9aa3-5fa9a41b870b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2792f94d-d726-453d-91ad-e37fccd67864"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65b6cbf4-086d-4d11-8412-098f7aa6d4f9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c6d45e2-5ff3-4f14-9b1b-fe7080ce9945"/>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/707b660f-4e24-4323-8c07-720e245e1813"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eda3185d-7e9e-4870-8bbd-d3f4aefb8a0c"/>
    <dc:identifier>DB01393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e7d30d7-4459-43a1-b9e0-07afdbf46d56"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1abbeb90-729f-46bb-b530-7c65466704d2">
        <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a3d29f5-1d69-4860-bf8b-12da3f8e9560"/>
        <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
        <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bb1d464-7b0e-424f-8137-0f08503ef37f"/>
        <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2792f94d-d726-453d-91ad-e37fccd67864"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
    <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4f437f6b-9203-43d9-9f7e-625b0a0ec49c"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8831d90-6a07-4f12-82fd-de4c6c9291cd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
    <rdfs:label>Clioquinol</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2b91ed1b-926d-4f31-873e-e46c7455058f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be0fa6ab-a63a-4f73-aab3-2ae07f84d3b7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b9c4068-5de1-4a7c-a28c-1b6dba5c53d8"/>
        <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB04815</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4243631c-ef63-4b85-9f07-f3db62cb5185">
    <rdfs:label>Hypersomnia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100786</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3945ae38-ce22-4ca1-a495-ab67320a071f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6418873</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69189f15-4d3d-4921-83aa-767f78bd98c6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6910fb8-4b16-4a97-be57-973c06b71db3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34f6efa6-4b18-4ab8-85f9-fa33dbac0ec3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pyruvic acidemia</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8ea429f5-894c-40ed-b783-285a73e675fd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c34231b3-7ef2-4604-8e91-3dcd2cd56baf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21f75252-1218-4d3e-8c1d-0b47ec583b5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ff49a58-958f-4ab5-a26c-64e3fbef6ad3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
        <dc:identifier>HP:0001129</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Large central visual field defect</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf5db4dc-9044-4b05-998b-7ceba18be612">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8c40fa1-326e-4ff6-80e9-f6aeec263a14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/02a32af5-9dfe-43ca-a726-6de2ea7c4a95">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/416cf80e-0091-4441-bd0e-96ec6a600e62">
        <dc:identifier>HP:0010909*</dc:identifier>
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8341ab2b-bd3e-4933-a45f-ce376b9fd2a2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd34f898-f42b-4744-8da5-2717ce6d8e7b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707*</dc:identifier>
        <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b67d52-e09b-4392-9573-c41e2704e2d0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/652d81e9-1eec-4843-8394-6ffa07aa718f">
    <dc:identifier>DB00155</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e0307685-3d33-4594-b3aa-df5f00b9cc31">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7209ab7-569b-4a82-8f62-17b74381896e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>L-Citrulline</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/67689a9d-11d7-4584-a378-42cc4294e2e1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b2a0ffc-36ed-49a4-88f4-1a6007b4a7e7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Abnormality of muscle physiology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0df992b1-0841-484f-8f7e-71fea0500654">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>secondary carnitine deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08c12ef4-a10c-45be-9bdd-8669410bd03d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aaac5823-0eec-4a59-82b8-ad352858f662">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/307d9bc7-53e9-4c95-8e4d-f03ca9faa631">
        <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/836fd8b3-67d3-404c-b1c5-3a3dc348035c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2016570-761e-4066-aef8-d4ab894db785">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23713b1b-0f3e-47e0-99ea-f00077cebb46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6ea4ef8-778c-43e2-a20c-2ba081dba36e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d98f0409-5399-4059-bc99-ce59b62a0d5a">
        <rdfs:label>Low serum ICFBP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c2d41033-ebe7-4be8-9d60-9868829f8864">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96d6edf8-e71f-4567-a42d-8630bd4edd6e">
        <rdfs:label>Behavioral abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/030cecdc-4100-4f65-9b8c-1e0d50b71ba6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
        <rdfs:label>Personality disorder</rdfs:label>
        <dc:identifier>HP:0012075</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/493bcc49-ab4a-4146-a49f-43b9bd30e922"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4e34ca3-c9dc-44fe-88b3-24b968627e3f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011122</dc:identifier>
    <rdfs:label>Skin lesion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9352005-d816-4afd-a85d-e2047e8ad0d2">
    <dc:identifier>HP:0001653</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
    <rdfs:label>Mitral incomptence</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2237319-d221-457e-8b58-87f9153d939a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:label>anemia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/edbd47b6-8af6-40a0-b3e1-37722bcde58e">
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf704ce6-0220-4f30-8920-d4d4654e341a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a1e191f-d281-4842-9b65-c6c383146d79"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5749ddbb-9278-4634-8cad-bf7f2519a40e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55e71b38-7a93-48e1-8fe4-8fc14bf153c4">
        <dc:identifier>HP:0001877</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:label>low RBC count</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb81f851-3e44-4948-a65b-4a437580ec8c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6d113f1-8fde-4f4e-a9d4-4e7e878d84f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/25e46988-79e7-49b5-aec3-5fdd7a279543">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8f47406-4175-460b-8bd0-e6857ff13562">
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003111</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c50c0b12-4678-49e3-9bd7-ffcc836fe1a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13c0194f-2eaf-4645-81f1-2d8fc08a4556"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85d0668d-3ddb-40c8-af47-b3bbc3bf5038"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0bbe4cd-cd3f-4fa3-bcd3-4547f908f7aa"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43e85b6a-149f-4745-bdb9-bd50aea82a9c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:label>Acute hyperammonemia</rdfs:label>
    <dc:identifier>HP:0008281</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/84c45b5a-fa7f-4ef2-b0de-04b31cf764ea">
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e65c5faf-69b2-467c-be7c-caaf7f151e38"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40f05195-94ad-4178-895e-532f4e1be6ae"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8341ab2b-bd3e-4933-a45f-ce376b9fd2a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eaee23a-479b-431b-9194-b821c3f34ef8"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24c09029-e641-4835-bbb7-5670b53baef0">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b585e08e-727d-4da7-9b8c-bc397af4a724">
        <dc:identifier>HP:0000488</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <rdfs:label>Retinopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc9e8f64-e958-4898-97f6-89a0b8c48731">
        <dc:identifier>HP:0002011</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>nervous system abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d405a71-1ee9-443c-8966-7edb17ca139c">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurologic dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc1965a5-6a1b-4bb3-b3d1-9f9d2f41398a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <dc:identifier>HP:0007663</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased visual acuity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b7c586b-1d9e-4026-8bb4-15742394cec4">
    <rdfs:label>Salbutamol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3107aab2-e365-4457-afb5-a04865f0ea24">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e212bd72-bea7-41c5-a78e-74ffe0f1ad2f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f172ac76-4755-4558-a27d-9e4998b914fc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce433fa3-9b45-4edf-9fc8-5c32065569ab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0684c11-652c-49c0-8ab1-018f86873082"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01001</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29a034c2-fa9f-49f1-83ad-d74d4a1cbbbf">
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal aspartate transaminase</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d2866732-89bb-41e5-8d14-7d6bd278991d">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/341bc17c-ffdb-4dc6-8227-7c857f2a9e15">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b097c4b-7dad-4c91-ba0b-b9744150dd32"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77055033-fc03-4aea-8a00-08aab7555aab"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a84c2898-ce2d-42e1-875f-e0c2801c03b6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9663ab6-0a15-4bc1-a098-bc260f42719b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2401373d-3c37-4e11-83e0-c7cad03837b5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4439f227-6a09-4e6e-9e04-6b139a47fcdd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3623f42-fe31-4bc6-aaa6-9d0769429b16">
        <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
        <dc:identifier>HP:0010438*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e067b8a-acf9-4871-8a94-f24185249f15"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebdd6e09-1ad1-4330-93a5-7e96d8349e09"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d57f530-4c8b-4ac6-bf02-f7096754e18c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/593d577f-0efe-4584-aa08-24d29cb475d4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
        <rdfs:label>Nystagmus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000639</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dd40c737-f17d-41ec-a106-75d95a23871d"/>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ddc00d3-ac03-43c6-b35d-9ad2498f31ab"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebcfbdb1-cd4c-4314-952b-688d3acf7694">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
        <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
        <dc:identifier>HP:0000570</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c7e5d24-c5eb-4624-9ace-6f4951999023">
        <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001712*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccaa81d5-c0bd-45a5-943b-1a13fecc7dcf">
    <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
    <dc:identifier>HP:0030390*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1d0d95af-6381-4430-9722-2f8a02532824">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0e5959e-0152-407f-beee-fdb1432ff47b"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4439f227-6a09-4e6e-9e04-6b139a47fcdd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a031e4fb-c418-48d8-bb4f-e15de4874f60">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:label>involuntary movements</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9a4cb45-7e2c-4a47-a3a9-043fa9edd935"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
    <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
    <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba80ee46-1c08-4647-a93c-83be39db3ed2"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8c018e4-7007-4561-ba64-22a8007914f0">
    <dc:identifier>DB03793</dc:identifier>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cadcad2-e580-41aa-a29a-e1e7d92acd43"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5f7c6315-15f7-428c-ba4e-ef91c6e6a2f5">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e629a614-d76a-45d0-930d-0b8dbf2836c9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4008a40-cea9-49f6-a18c-ceef5298c3da"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0cc6b68-0c00-4abe-a378-afcf4a87dec2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/faf6aedc-424e-4e18-bc38-d54bfe1cb726"/>
    <dc:identifier>DB00437</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b9357a7-bfe3-416a-9b41-f5e23530d0a5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28722c43-e543-49db-89d5-f0ec7715f702"/>
    <rdfs:label>Allopurinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d108ea14-879a-43de-b88d-e80204e9b847"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bb10cf4-86fc-4244-944d-f7451dad5c38">
    <dc:identifier>HP:0003326</dc:identifier>
    <rdfs:label>Myalgia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dcf1bcf2-9396-4160-9ef5-96d6c50c2ed4">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85d0668d-3ddb-40c8-af47-b3bbc3bf5038"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cf0d49b-812d-4294-b2cd-edfb71838b83">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:label>Hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae5da945-9e77-4cd3-a79c-d3c1fa2de242">
    <dc:identifier>HP:0012446</dc:identifier>
    <rdfs:label>cerebral folate depletion</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e9731920-9cd3-408b-8a55-b33ef75f386e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d98e258-d2af-499e-8667-ea180f382f06"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02511fae-2ffc-4d6b-b642-c1e2bdc366cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>High spleen volume</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/719b98b8-84f3-4cec-ab3c-91c2717eb552"/>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5c2fdb8-93e6-46d8-b259-98a23ae9ce84">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high liver volume</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20bc603d-01d5-45fd-96f1-f0bf04d7c20d"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53f59901-6e1b-4358-b343-714961d0a95e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe9f7cf7-f1a2-4f2a-93a0-aa45a052515d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3843832-8012-4575-85d0-cff725767972">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
    <rdfs:label>neck muscle weakness</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000467</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc83bfc5-9526-4cfb-a591-1a755584dbaa">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e97ded1-a2c9-466c-a121-c3dcfc983804">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f69e8884-9b17-4e15-9b88-d9b0319696bc"/>
        <dc:identifier>DB00509</dc:identifier>
        <rdfs:label>Dextrothyroxine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b491e88-3226-48e6-9f76-63f00dafb9ec"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
    <dc:identifier>EC0:0005542</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
  </ddiem:Evidence>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7d14403b-c1df-4be2-888d-556ee9487b03">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cf0d49b-812d-4294-b2cd-edfb71838b83"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a09b089-89c0-455d-a2d6-f58601de60a8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
        <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
        <dc:identifier>HP:0004918</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dff1f92b-eb56-40c4-becb-ace3775807c8"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb421ffa-343a-4777-ab66-b9be4f8a8c8f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:label>High serum total cholesterol</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6af25ab2-0fa8-4764-bad4-231449be3ad2">
    <rdfs:label>Low lean body mass</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <dc:identifier>HP:0045082</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bd25438-bd4b-4c3a-8705-c92c07e7926e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>defective heart function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c7daa13-9a1d-472d-b117-6fa4d82226f7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
    <rdfs:label>Prednisolone</rdfs:label>
    <dc:identifier>DB00860</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/accfa26b-1de3-4643-b345-ed884756b084">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72a489df-48c6-4156-b963-e2862cfb9afb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6da43da-0f50-4d08-8bea-e68d0192da36"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82d976f5-a219-489b-85a5-9af9828cc8cb"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9dedc7da-58e3-444e-a1a9-0487b08ddf89">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6016e1e-a8be-4e43-a7af-46864efbde33"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f111efa-8b64-4b38-a90f-9279be2ce393"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607155"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67a3029a-5cb7-4f0e-b433-841dc42f874d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72a489df-48c6-4156-b963-e2862cfb9afb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53823a91-b8ed-4511-949a-4c5a5bee0a69"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f03809f7-614f-4891-9a7d-df0f556bc12e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f57403-df90-4f0d-81be-15c632eb28c9"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f2717b12-df7f-412d-a27c-0aeed52964b6">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e963059-5507-432b-9cd9-afa89be21b22">
        <rdfs:label>No result was accessible</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a74261f8-a2b6-4f74-9e76-c547b084289c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b4d02e75-0f50-4e7a-9f2a-117b73861ae8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a46bf20d-501d-40ba-9c67-76d620f83c1b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc28e1d8-5f75-4dc5-addb-3df7df78c0ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eed36d32-d848-4389-b2bb-664f588c2ddb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000842</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <rdfs:label>Hyperinsulinism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6ea4ef8-778c-43e2-a20c-2ba081dba36e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8818a71d-316e-4750-aae0-234d58376664">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1ba5e82-c34a-4655-b01b-22b8cee756b9"/>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9db0ad83-c136-4f77-b9fd-d10ea5a02ba5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24c09029-e641-4835-bbb7-5670b53baef0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfe6c412-9e05-4387-8547-f49e432668da"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e5842bb0-fd9f-49c3-b34c-d21a29df4339">
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0277a778-4e11-4c5f-a793-18de640d6580"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00163</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/124ff624-dc1d-40e8-9f96-29d9a6a39a7d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c6bca2b-ac2c-4a1d-9340-7d0cbb8f8d01"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/469491cb-f23e-42f5-a755-60bdc60cb18a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e3a5735-451e-43fa-9114-b34846cc0701"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3230a364-c6f6-47df-b1ed-d51d5aa79fb8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/788e89e7-67f3-4bb0-8e8b-497a76f5d262"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cfb86a2-02e3-4893-ab66-4d1048f31d1a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5a5fe535-92a2-477c-b637-a2a59a4a1431">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0460c193-da0e-4bc2-8133-5dfdb4fc9b60"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f4c18ee-4d2e-44be-9f3f-d09b8cfd11ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d8a29b0-8749-4071-9dff-030edd754ebc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60021451-7d5a-4a17-b435-51747e11828b">
    <rdfs:label>hyperbilirunbinemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002904</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f7640a2-8ba9-4e6e-9d21-ed56d0aad977">
    <dc:identifier>HP:0010919*</dc:identifier>
    <rdfs:label>Abnormal Hcy level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5353fde6-dfaf-4a56-a3d3-8025ffff492c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
    <dc:identifier>HP:0000972</dc:identifier>
    <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d49dff07-ed6f-448e-a7e0-8f79df68ddd5">
    <rdfs:label>Vitamin A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e804bed3-56d8-421d-9ccb-69d079faa24e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <dc:identifier>DB00162</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cba1f4b-e1aa-4dd6-b188-0102392b514c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d967e28-729e-4a19-8a39-8ac9d6e2f6af">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <dc:identifier>HP:0001263</dc:identifier>
    <rdfs:label>Delayed mental development</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/779e32a7-c8d9-4c6e-ad27-55f2f7dd82f1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Thrombosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
    <dc:identifier>HP:0001977</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13302134-1249-4064-838b-f110d9206624">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
    <rdfs:label>Rifampicin</rdfs:label>
    <dc:identifier>DB01045</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/da73acf6-357f-4f71-b2ee-2d3a6f0f8731">
        <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47e91f80-c98b-4095-b99a-d4b3cf5a1361"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2bf82092-839d-44c0-a6b2-ebd07297a9fc"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/827e5f5f-85db-4967-a9f2-003e8dd73d6e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c36a8ac-2f4d-4a9c-83e8-ea5a24c5e83a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fb7c1fb-e113-4192-95be-258270468a14"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60021451-7d5a-4a17-b435-51747e11828b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1aedfca8-8e84-42ad-8f7b-743b5cb2e21f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237500"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1903a73-60e0-48f7-a677-5bd22326f3ea">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
    <dc:identifier>HP:0000103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased urine output</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0fe5143f-aab7-496c-8590-710ec9080c82">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ca08ad8-d99a-4461-8708-ea44167da840">
        <rdfs:label>high ornithine level		HP:0012026</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f4193862-dc1d-4813-8973-d9b13cc36420">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92fab497-b94b-4987-b62d-3ccf90765599"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/67f3522f-9284-4115-bd93-598795419e78">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301530</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/960f5da2-3ce8-4b4a-a100-ce025192d84d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee8ad9cf-f161-4159-a44a-8f45fdb561ff"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7e433554-1c46-4575-983b-c4acc8c9c8f8">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e3de2c89-ffda-4183-96bb-b2e2fd697578"/>
        <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
        <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
        <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6ae4d9d-b47f-48d6-ace1-aa0619ac5016">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low APO A level</rdfs:label>
        <dc:identifier>HP:0025201*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9887eaba-14fb-4e6b-972d-256a2753c6ca">
        <dc:identifier>HP:0003119</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal plasma lipids levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5428e77b-390c-4229-ab3d-4655ed1b22cf">
        <rdfs:label>Low Apo B protein level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <dc:identifier>HP:0025201*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84c98aee-cf34-4e6e-9b92-3c15fa87e2c2">
        <dc:identifier>MP:0003949</dc:identifier>
        <rdfs:label>dyslipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ade0ca3a-626a-47e7-8641-8332ad0b76a0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low HDL-C level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36c65123-3e31-41e4-adf6-b64e5c8e1e28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6cc7c450-9f5d-46f9-93c4-b2e2278b5301"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8598693c-b0f2-4274-a297-669d0701490e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0011598</dc:identifier>
        <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b7b7d1d-3633-492a-8ca6-a9664f29e996">
        <dc:identifier>MP:0003193</dc:identifier>
        <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a3e4e33-b89e-48c8-91c4-baf9b3500c2f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2237319-d221-457e-8b58-87f9153d939a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/712c40a3-c466-4675-a5aa-bcd8ade0b9ce">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low HDL level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3c538a5c-63be-498b-8905-20f71a7b335a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef3c4fc8-4963-4008-8eb8-50e710959f5e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02316261-9420-4f8e-bd61-bef897df2ae1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8729189c-09e7-459a-b295-6f9bb4c7e827"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c72ecf5e-2a7e-4716-8658-6ef7970692a3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <dc:identifier>HP:0100022*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0ad31f9-90e7-4950-ba60-6e469e03e009"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7b15968-4012-4671-92fd-c5ae0e8c6b11"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24baa860-b133-4eb4-a6b8-637567cf116a">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/800caa0b-81e3-470d-8417-3cd8e975430d">
        <dc:identifier>HP:0002872*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
        <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f07d186f-945a-4b0f-abd3-55e7616146ce"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0457a024-ffb9-4f87-b6ff-08cfbc296a6f">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac0ce715-5070-48d3-967e-26209645bc09">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce96fc90-1137-46a9-ad89-efd7961eda39"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37d007de-9aa8-425c-99a7-06420f6c1a9b">
        <dc:identifier>HP:0000716</dc:identifier>
        <rdfs:label>Depression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2c6d6896-36b8-4e96-8015-0b4a65262d84">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
        <rdfs:label>GRACILE SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3675fd8c-9a03-4378-9120-d216252414c5"/>
        <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
        <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5b9e3ba-31ae-42f3-b699-ab5c5758df27"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f69e8884-9b17-4e15-9b88-d9b0319696bc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e6e5dd6-836e-4233-a44c-b5f8c59a9581">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatomeglay</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc83bfc5-9526-4cfb-a591-1a755584dbaa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b86b1384-832d-4acd-8d64-c612bd4f38d3">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1dbe07e-977f-4633-9d51-ff78fdf8d95b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/445505ee-0e2e-46aa-b13f-bf6beedc97fd"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3b117c24-3429-44e9-97df-2c39981351dc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01cea7ae-5c98-43d7-b46e-b9d905655fda"/>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40f7be66-e5a9-4282-9f75-8a13431c7eee">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
        <dc:identifier>HP:0012011</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a90a263-24e2-4843-ae13-d76722b6115a">
        <rdfs:label>Speech and languague delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>HP:0000750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb849906-cf64-462f-b0bc-42f246ec69c8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:label>Developmental impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9fea9754-ed57-47d1-995b-a4fd578c85cc">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8ffcd9b-dd9e-4131-8c1e-e2b1efcb6403">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a5ad17f-0a89-4ef8-be5f-240699045ec2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d9898bc6-4eb8-4b83-a63f-ab67d932fd47">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db780100-48b8-4f1c-bcb7-dac436992a7c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/493bcc49-ab4a-4146-a49f-43b9bd30e922"/>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1bc7290-045b-431f-a2e9-5d4c42f113e0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d76944e-6d6d-4949-844b-09c1b6a06810"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2d41033-ebe7-4be8-9d60-9868829f8864"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/74c68868-c694-4365-8d5a-498d47eddf9d">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e0a75c-3744-4de0-bc45-24b2e00f1232"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e067b8a-acf9-4871-8a94-f24185249f15"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c218f070-4da2-42a2-8e25-32c9a64beba6">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4215d1db-358e-4134-887b-d20a9213edd8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1555ce13-ec57-4004-967a-baa930943d83">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
        <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/493bcc49-ab4a-4146-a49f-43b9bd30e922"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
        <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <dc:identifier>DB00360</dc:identifier>
    <rdfs:label>Sapropterin</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d37204cd-77b5-448b-b50d-28a650a4c8d1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6efc32dd-1d87-4f30-b76b-6caa14138495">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/934780db-650f-45d9-8050-4d0a8f585cfc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fe069f2-8cb7-41ee-9fc7-373432caa755">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rickets</rdfs:label>
        <dc:identifier>HP:0002748</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de14a043-acc9-453b-8f31-c61516efc038">
    <dc:identifier>HP:0003656</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal glucocerebroside level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1257e5a2-d206-4a97-ba9a-b2197358badc">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b40acc5-6fe4-4ece-a606-209eb8f8b57c">
        <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
        <rdfs:label>Propanoic acid</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1dddc903-ae4e-48f1-9fa0-7bb43fae4043"/>
        <dc:identifier>DB03766</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/de768d3e-989d-45a2-9697-3133a02cbc68">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d2df6e1-95d9-4392-9ea2-0ca2b1056c93"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
        <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9fab77c9-a147-40d7-8d57-15aa05339da8"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2269f67a-84a8-4624-b9f5-fcf0502975c5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e40e614d-0aac-4f1f-b9b8-b2848311c7eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1532c9ac-c4d3-4e92-b309-989078f38dc8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26930d1e-93c5-4bb1-8ff2-aefae5582e7e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/940034c6-2aa8-48ef-88a7-178f48cd2b8f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d7a7280-946a-4241-b372-a2821eb2c684">
    <rdfs:label>Abnormal muscle tone</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003808</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b19bdacc-8bf2-4b8c-972f-3653c089ae5f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>progressive leukodystrophy</rdfs:label>
    <dc:identifier>HP:0002415</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6af3de4d-ca87-4f84-b60d-889bef52fabe">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ead683cf-3d68-45d0-b551-0af4631f7bd5"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0bb27f7-67ec-4436-bcc9-4e8fc5d83568"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7856377b-4a7c-4098-9c1c-7219d5cb99c1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1dbe07e-977f-4633-9d51-ff78fdf8d95b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32205ff6-fb20-4ab8-9579-8dc1af228e12">
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <rdfs:label>Low plasma arginine levels</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/62841848-33bd-4576-a4d4-800ac2aac937">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12d5dd31-d47e-445f-bb4f-3b0b0a24ef0a">
        <dc:identifier>DB00151</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c19e0d9-9cbb-492a-be26-bf9ca7adc16d"/>
        <rdfs:label>L-Cysteine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74d027e3-95a7-403b-8c7f-2ea8a2086406">
    <rdfs:label>Orlistat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/723b0220-036c-42cf-9d9d-c03b96fde2d2"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/76735078-fd87-42f8-9e36-1d327b6baf4d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5be6a18f-519d-440b-984f-b66f2f752c2f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/169d5002-c1aa-49eb-8829-5f5c79f28714"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29278307-284a-4570-b219-88b7986f2bc5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56772156-31ce-424a-b2dc-2338c1a921be"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB01083</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e2772b4-6798-4414-a93b-ee556fb139ef">
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbb56630-2362-4e9b-ae99-5cf11c1ccb51">
    <rdfs:label>Cabozantinib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/53b054cd-92ab-4069-be66-bacfcaac5c3c"/>
    <dc:identifier>DB08875</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9cd63027-c89f-4128-9410-6fc7b3f8de77">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
        <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2deb1f3-61fe-4767-a1ed-95e6409f47d8"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d4acfe-bfa6-4e86-ba50-efc345afde8e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2be3bac1-b426-4a7c-b31f-631162261c4f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e65a306-8deb-4861-9b05-4bf960a5ba65"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/864ead78-9b61-4cf6-a158-92a34804b1ad">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e51e03d1-1650-4fb0-9edb-b85a0b9cf3ba">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34e1a2df-3e05-4b41-b932-f9b8d5ed551f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
        <dc:identifier>done</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb0a9997-a1f9-4f2b-bfd0-95872ed2ed6f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1660351f-e1ff-44ad-b6b5-5d54f98decf4"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c0373c0-bc77-4cb0-a185-43dc83db9b24">
    <rdfs:label>Hypoalbuminemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
    <dc:identifier>HP:0003073</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ebce5da-c96e-455b-836c-b0f8013b0ff3">
    <rdfs:label>Muscle necrosis</rdfs:label>
    <dc:identifier>HP:0003713</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f6c01a9-6efe-4aec-9c15-570e4cc2a29c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20772090-b0c5-4f1e-84d5-2bd4836725b2"/>
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4ad9c126-b87b-4d83-b02c-1de979831e09">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2228d9e-5d4f-4341-87e3-445290e576e8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b88fe7b-bc62-43ba-8024-d02cddb1c2b6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e0ecad2f-2d46-49a7-9753-3effb3aac820"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8817cc30-1283-403b-b0da-6be4356d1d32">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bce4d8db-49c0-4574-9824-58eac5799fea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5c78d6b-0ef4-4e9a-b50a-289240c40019"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a150b99-c6bd-4f72-a137-2f74fadefe94">
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Pruritus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50eea66a-0e0b-490f-8d9d-4e10308286bd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2adb602d-58ad-4012-89b4-80cc6301bb11">
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d967e28-729e-4a19-8a39-8ac9d6e2f6af"/>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9185c97-fdc2-4a9d-863f-71053792c810">
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89472ed3-80be-4175-8726-fe5ca5693d16">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:label>lack of eye contact</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/432d810c-5bb6-4165-9feb-73917448f0b6">
        <dc:identifier>HP:0002194</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605407"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9764ff95-16fa-44c8-aeb9-1fb23815eb3e">
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001336</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e6218ff-b6b2-4be5-b99f-eb7b0fe30414">
        <rdfs:label>Hypokinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd337144-4043-482b-a1f9-9dadbd45c0c5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bd6a252-c4e2-439b-aaa6-34abea2dd39f">
        <dc:identifier>HP:0003785</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8729189c-09e7-459a-b295-6f9bb4c7e827"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b1a33e1-bef3-4128-81dc-a61f8bb17b15">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002194</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:label>lack of gross motor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/911d575a-7739-41c6-8b93-336d0aa9dc4b">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14206878</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26226126</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0010dac4-d6e8-42c9-bc61-31958cbd44c9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/887aeafd-ce35-41ab-a501-fa20e0e9e016">
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7810a5ce-edd7-4d29-bd6c-1f089008458b">
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2c2ec5c-acdc-43b0-9a20-2db51a19fb7a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc2947a3-9704-45c0-9000-6d9729fa90e3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7dfa62d-e02e-4db9-a457-0f743060826e"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5d1f52dc-4c93-4913-85af-9f217fd8b416">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1df921f7-8b40-4eec-be70-7b1edeb1b3df"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d3caca9e-935b-4c5a-83f1-72b9e5134ada"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b775c526-8e73-4e07-a1c6-164c72f5b594">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/510b7e23-86cd-481e-aa31-895b61b69bcf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/198799cb-9816-46e7-963a-a3dedbf66549"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6aa952e5-d723-4652-9566-b7474681d7bd"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9241fc12-145d-45f1-81a9-a6a5b069faf8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ef6e618-bc9b-4df3-9a42-7834e389031b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f08c24fe-e259-4039-9721-a137d1529735"/>
        <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
        <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
        <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f63372ca-1f17-438f-b039-e1e7ca8c4692"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c0d08f4-fec7-4688-9aa3-ca588c8c8d24"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b83a2807-c684-432c-8c04-e21c15d92c67"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19d7d03d-1ee7-4f79-89c6-15a309d1e572"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de9456de-d6c0-4ebd-b1de-5dd6a3315800"/>
        <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be749a8d-3165-4fa3-a66e-9ccc9c9ec548"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8417b2c-6bb1-40d1-b0f6-84d3ca389d54"/>
        <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f9d80280-d4a5-466b-8ec5-191f92eb0a06">
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e59f859-b7bf-49a7-b7b7-74012cfe4dd0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c14f5c20-57b6-43f1-ad6c-81ee43c10210"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/536eea0b-4bcc-4164-b189-46f0c09637dd"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB09270</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04a5c102-7f94-410a-be9d-3b78eb064c95"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/73891d1b-66bd-4ad2-9b63-233d1c1bdff9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44b5dcab-3013-49d6-b7fa-d2a37380f43e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000002</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/43190f8a-aa17-4032-b9aa-19d2b68c85ee">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3bbd3077-73c9-4a15-82be-0ed6aa7102af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/842d0f00-ad26-412e-8060-be10004c3627"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/272b3a9b-8911-4d37-a3cc-4bf106f5c3e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4e46084-6704-41c8-a0f5-051680451b07">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82e51566-db5f-4652-9d89-3c924b6928c7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002181</dc:identifier>
    <rdfs:label>Brain oedema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/67a75e0e-2b73-40af-a1a3-4132037cf793">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1903a73-60e0-48f7-a677-5bd22326f3ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd16f145-1553-4494-9fde-6bf60ee594a6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33626dc1-277b-466c-b10f-51607567b16a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e71ea84b-fff1-4bcd-8dbf-ee9b76761a17">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Microgliosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
    <dc:identifier>HP:0100708</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/18772f79-1bfe-45fd-ae31-40ffea23cdf5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71ddb19b-9ba3-44dc-b71d-6ab4c8e36c76">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba3e26ad-21ea-41aa-80d5-f423e78148d2"/>
        <rdfs:label>Tocilizumab</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
        <dc:identifier>DB06273</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/871e6c38-e930-4c8a-98fa-0d3a33795acc"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d6bbf977-d906-48a0-9949-63c4798b87ec">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
        <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d74cfa15-85fc-42a6-a07a-58d70503dd96"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
        <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
        <dc:identifier>EC0:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98a7b186-aadc-4984-a882-8a8f964b9a62"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/451b5410-c4f9-4061-909f-4df6bebbaeb4">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>Delayed Develoment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e53fa840-15ff-42fe-847a-1ec0252173d5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed4fdc68-0c10-4cdc-a534-89e3526acc03"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a150b99-c6bd-4f72-a137-2f74fadefe94"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76202e8e-58c4-4540-bae0-acd4bede634d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84c814a6-1e2c-45ab-8d36-33a6dc814b87">
        <dc:identifier>HP:0012030</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
        <rdfs:label>Abnormal urinary steroid level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c13a8160-acdf-4531-9680-36a4b89fda0c"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38b23e37-b432-4008-817e-8d3cdcf58221">
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/568044ac-bb9e-42fb-a904-08e6681be9b9">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8143c0f5-7474-4e6e-a765-02e63e321dc7"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20185e78-45fe-4105-9b4c-e484b85382e9"/>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61dd9889-b74a-47b7-943e-06d44ba34c84">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
    <dc:identifier>HP:0012103</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6a1e1da2-1eda-4d8e-a182-9f08a18bcc61">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e87273a0-6590-4e4d-ac27-e1c136a1cd5b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55d1ae0c-f123-42de-9007-d42ac09a4b82"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13c0194f-2eaf-4645-81f1-2d8fc08a4556"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb3c3d2a-872d-44c6-a4c3-c488c3fcb197"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c324bab5-5322-4291-9ed9-5a3e8665ce1a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9ed0dd1-bdaa-456b-866d-3fda1cfb7dfa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:label>Heart failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe8d5f5d-fd6d-4bb3-a6ec-6588d9325f0b">
    <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
    <dc:identifier>HP:0005978*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/dc31cce6-fb69-4d59-9075-f8501f118c49">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07f8d25d-1861-4431-a0ac-b5454ec43063"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/13be01af-da85-43b6-a973-4ea0385ff6eb"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a61f6173-faf8-4e99-a98a-bda61602da3d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d57ec92d-3f6b-44b2-b229-ea03494637c4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
        <dc:identifier>HP:0000479*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b26990e-b145-4646-8d49-da721b4d856c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/abb067ac-67dc-4801-a7d3-3bb8de44eb10"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9452161b-276f-4ebe-acb0-5b72badf50eb">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2a455428-80ec-4849-ac54-453253288950">
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba185dd7-2542-43df-9043-7b250f9d4fa3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af980e22-67f6-4b62-bfaf-e0796b6ee203"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Levothyroxine</rdfs:label>
    <dc:identifier>DB00451</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df3c7947-59e7-4715-a00a-fad884ed3c2d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9de719a6-948b-46ca-b8f1-2ae494640e0b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ead683cf-3d68-45d0-b551-0af4631f7bd5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7856377b-4a7c-4098-9c1c-7219d5cb99c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/967b6781-70f6-499b-8b2b-dcac97d4f278">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e60564bb-e158-47e8-ae9f-d924bf13f76c">
        <dc:identifier>HP:0012187</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d775e5e-ca0e-4139-8d5b-5ec5f276c500">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b8587f1-a0be-4aaa-a721-e7a7b5c4ee8d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1f2616a-e551-4bd8-934a-791e484fca4a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Atypical bile acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1aedfca8-8e84-42ad-8f7b-743b5cb2e21f">
    <dc:identifier>HP:0012202</dc:identifier>
    <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec3a69fe-24fa-44b8-b596-5d29c0bd82c1">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce320ea-1b91-432b-bd03-0b30f85973cb"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de9922c5-ea25-4378-8b8f-9b00ec9b62f8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3121b104-b3f4-4bc0-860d-5f18b79b7391">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc4b83c0-10b8-4f4d-b44f-ef89d09d0452"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccc94f1d-5903-478a-bbdb-e5fc6ad3dd1c"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
    <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
    <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80312320-b207-4de7-975d-0a3e6afb91f6">
    <rdfs:label>Sucrose</rdfs:label>
    <dc:identifier>DB02772</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bbd05b50-e985-4fc0-818b-8fc0034e95b0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6cae887-f348-4189-b789-05a1323b5e48">
    <rdfs:label>Setrusumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/685f6de5-e83c-4f4e-90b6-a91c895c44d5"/>
    <dc:identifier>DB14778</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec5f50f8-3c8d-4187-8473-9917c0b4849d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d2910be-ef3f-4c8f-91c4-9af3be719958">
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a833785d-8550-49b1-9139-67417330062b"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89db0ba2-aeb6-43d9-a8ec-b3849bd5b67c"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5aef24b1-5aac-497e-809b-27939d2533b0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10012e8e-0a48-4fa7-924b-653f73052707">
        <rdfs:label>EEG abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68669995-af4f-468d-9158-862bae58dcef">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f6ff0e8-092a-43ac-856e-37c84bf059aa">
        <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff0844e1-7ef4-485f-9ceb-5cc8c6cb0515">
        <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44a5315a-0d2e-4994-9434-18dbb27492bd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/e6df842d-010a-48f8-8aca-3623a7b24a39">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac0dc3d0-d17a-4fc5-a546-17e8f277655c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040210</ddiem:url>
        <rdfs:label>Low tetrahydrobiopterin level</rdfs:label>
        <dc:identifier>HP:0040210</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb0c0523-4a98-4469-9f55-0018468ba6a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/366faf9d-f79d-4bf5-8a0f-f2331afcc5df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad709f54-f0af-4e5e-b428-59de731abd3c">
    <rdfs:label>Cysteamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <dc:identifier>DB00847</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/794d9673-8239-4cbf-86a7-2d61855ba702"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ca913b57-a84b-4ecf-b58b-2b1e1dde1cb1">
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6348c217-a72b-4497-974c-1f2e75bc18a2"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9144e907-8706-47e0-8dd3-0dfd43cad2fe"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0db91b2-40e3-42a1-8615-8144e7489038"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/77571f82-0abd-404b-9c97-4a9bb49f3af2"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bb1d464-7b0e-424f-8137-0f08503ef37f">
    <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57968767-9be5-4f8a-a2d7-09c04931b5a4">
    <dc:identifier>HP:0000486</dc:identifier>
    <rdfs:label>strabismus</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/343c7d8a-60ac-4049-aa8b-21e0d3fc892d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8258ee6-8859-4a4b-8460-82f92a490496"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/249183ff-eaa7-4b53-9668-5f41422e1f36">
        <dc:identifier>HP:0000479</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Retinal ganglion loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0249240-9e75-460e-b544-1d231b0fbef2">
        <dc:identifier>HP:0000572</dc:identifier>
        <rdfs:label>Visual loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d2df6e1-95d9-4392-9ea2-0ca2b1056c93"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8341ab2b-bd3e-4933-a45f-ce376b9fd2a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7acf94ac-9eef-487a-a115-868462928862">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f56f1192-1722-47df-9816-f9ae527d7536">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99888c09-1d90-4344-bfef-7a651cd378aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e74675a-45dc-45cb-8141-cc1fce47ec79"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b50aab6f-3ffc-4a07-b430-4c51f80c2265">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000657</dc:identifier>
    <rdfs:label>Oculomotor apraxia</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4746237f-9249-4997-aa03-b9fac374182b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b8869ab-5925-4ccb-9928-ce3645571eed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed3fcdff-933c-422d-8d31-d4b0de01907f">
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypomagnesemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa1e34a8-2328-4e1f-b2cd-9d1c61456c93">
    <rdfs:label>abnormal fat metabolism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <dc:identifier>HP:0004359</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b3d3a10-8146-4ab0-bc02-375c305fe3f2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>cardiac dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3d71ca39-1fe7-4b7e-ba0d-de58238263d0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7dc0bd16-4a98-402e-8017-dcbf6acc87cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11583ad2-b42a-488b-843b-14d0604652db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bdf5160-27f1-44fa-9f63-748e60fcb5ee">
        <rdfs:label>No Studies were done on this drug.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/848b2440-1975-447f-af9e-d3024e2b700f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/493eaeed-9fce-4ad9-bce3-03568bda6462">
        <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
        <dc:identifier>B01</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/312d5ac3-1528-4019-84a3-e413bc585aa0"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a32cb814-dacd-4812-ad28-683a443bc50a">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83ce4649-686e-4b78-8a62-e623f7d6ce10">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/516ec830-21df-440e-9774-d1abeb825175">
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
        <dc:identifier>HP:0012213</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cff6d3e1-fd83-4fad-81fe-367a0476d383">
        <rdfs:label>cardiomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ef094a9-8ace-4671-8328-893dd976a23f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70670ed7-41cd-4f20-927f-9aa1d0824cac">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <rdfs:label>sleep cycle disturbance</rdfs:label>
    <dc:identifier>HP:0002360</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cdbe31be-e8e3-49a5-8924-77c2833be04e">
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2cc7ecd8-80af-4e10-b3aa-f008740d24ef">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e87671b9-a00c-45b5-9451-f1bb8f6a11a3"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81aa90f2-d6a3-4674-8779-d171f014a1b8"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a77b93f-d8fe-47c3-a71b-f366512dd898">
    <dc:identifier>DB00186</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/349a34fc-f35b-4903-9d99-e14fc1960fe4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
    <rdfs:label>Lorazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ea17686-8a5a-4956-bc05-45ad93306723">
    <rdfs:label>Pathological apoptosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abe9b423-01a7-4f82-b701-005382c16d6a">
    <rdfs:label>abnormal mental status</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100543</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ee66590-a4c7-4235-adc4-dac2ace4f7ee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb2aad12-2eed-44f3-b31f-24e230ec8f5a"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8e7bfcbb-4a58-4774-a5b1-f40b4b5faeef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d09f366a-99db-439b-8eff-ca5d9acb5359">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b60061f0-0c82-4eff-9f16-3bee1afd24b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/01be7229-0928-411c-bc80-4141b3adb846">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dddc9c8a-402c-4c39-936b-e68939f795dc"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ec568f3-0127-4fb1-b797-dae7a50313ab"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74aa8678-eee2-40b0-83f9-b39fcf6a9d5a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8c5dedb3-c66a-4232-8ab4-02eda2579475"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fcc0d0c7-668f-489f-bd70-0296e036dfa1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0fe1f90c-7952-482a-894d-8da7638c9f22"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d88cf1fa-ab85-4709-bcd4-83c923cb0db4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c334f704-108d-4345-a7a2-a81dc05ff4ae">
    <dc:identifier>HP:0000559</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Corneal scar</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eb71c29b-ffac-4ac1-bdad-ea9ffb581be8">
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63b2ac35-72a0-40dc-a1cc-c9e48714987b">
        <rdfs:label>High VLDL triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c071cf5d-3f67-49d1-8f3d-e7548903badf"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa8c47a9-149e-4fa3-8af9-2f432c6b9955">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal neuromotor function</rdfs:label>
    <dc:identifier>HP:0002333</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36a92f46-075b-4b53-90be-a703f2f31e24">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9e938e73-a332-41ac-bbd3-43dd8497bd66">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fec1ab7-7402-4bf4-85ef-553f9bd95269"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e2af13a-5b31-492a-a9df-2c0089009e69"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16214240</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8375ec9-727a-438b-a67c-1c9af17c9564"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f57e66c5-b168-4b7a-8248-696aee255429"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4883f257-0dad-4997-be34-1d0e93fd86ae"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB14476</dc:identifier>
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f69dedc9-fad2-4f24-9fd3-4224db8a7c53">
    <rdfs:label>Abnormal motor function</rdfs:label>
    <dc:identifier>HP:0004302</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ccaed853-7e79-4b6c-9607-57c17bc7eb68">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4924f0b3-770e-48b8-80f0-b1971a5e065d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce320ea-1b91-432b-bd03-0b30f85973cb"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9ec8c041-4667-40d2-9ba3-00aecc89c808">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7193862c-ec77-447d-86e7-10418835514e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d1ee0c7-9aaf-46ed-8f57-679a48088efe"/>
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9853cddd-5ace-47dc-b227-f1fa361abbf2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34b3039b-743e-462c-afeb-b1c83ac79c38">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cc954f65-3f85-465f-aa72-c1a2da1f69a2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8f648156-7dcf-4ba8-ac6b-799690de8335">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e61baaa-fa11-4942-b78f-60ff1899b3df">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001347</dc:identifier>
        <rdfs:label>Abnormal reflexes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7e84ccbc-42bc-45de-aeb1-67a6bc3cd4e0"/>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fff23e3-5411-4808-9450-6a16dc55266d">
        <rdfs:label>signal abnormality of the cortex</rdfs:label>
        <dc:identifier>HP:0030178</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cb8c8a5-9f08-45ca-862b-ba31aeb7b36e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Abnormal movement</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a23f6e8-6540-4904-9ffc-bff7e7e196d5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ec5d55-260c-41ce-abb0-0909baa0259e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6523c384-ca31-4a48-86f7-f4f546b5feea">
        <rdfs:label>encephalopathy</rdfs:label>
        <dc:identifier>HP:0001298</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/322a2426-1a16-4c90-881d-2656ac034101">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <rdfs:label>Levetiracetam</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/46b3fa00-0390-4c7a-b7a9-3f69816cb562">
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/21c757d6-4f17-4ca1-95de-9855aca34fe5">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/74a8647e-f610-468d-9e35-257ad2f2b41e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01202</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4f4ace92-1503-4bfa-8720-f8d457372e0c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10012e8e-0a48-4fa7-924b-653f73052707"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bee289ab-6442-4ddc-a824-1b000aced553"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02046f8a-116c-4133-b04f-009cf6668f67"/>
        <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a93a860a-622f-45be-9bbb-bac0247665d4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9241fc12-145d-45f1-81a9-a6a5b069faf8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c447adf-c436-4fb0-bbab-60e91fadeb7d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1432bcd8-9f1b-49cc-a48c-ada75d890150">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b517147c-7012-41df-b643-6cd7b6a52b5b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46f3da56-e0aa-4a26-9fbd-650b33769b6a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69368856-e12b-49a9-97e4-5a7bd9b6c3b2"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a2f102c9-62ed-4179-91f0-02af725530d2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9663ab6-0a15-4bc1-a098-bc260f42719b"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a23f6e8-6540-4904-9ffc-bff7e7e196d5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7219853-e288-44b9-ac8d-fa421a562592">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001945</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
    <rdfs:label>Fever</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c96e27d8-c8db-4135-ab3f-df80de672f4e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cde82f53-4a69-4c2f-abe5-7304f4e3c514">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7193862c-ec77-447d-86e7-10418835514e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/cc4f5013-6f2c-4f33-8b00-995ee5fe79ae">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/309d7521-bbfe-418a-a4db-2e5842e1463b">
        <rdfs:label>Organic aciduria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c0a0c87a-21e6-4e95-981a-cddd0d34a277">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4de342e-cd52-4433-91de-b0e80b3dc53a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a6e1596-0cfb-4f2a-9070-0db9724194df"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f767462-a6fe-4748-a6d1-0d31f9c2751f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a24546a1-f507-4d8e-99c1-52a0bcde2cb2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ea58721a-792a-4195-81d0-b92d74a00a93">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbd0c976-d2cd-4686-9309-3d39833f8ccf">
        <rdfs:label>High serum ferritin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
        <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/40db5f7d-e4f0-44b4-b94e-6089cb030f49"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d553259-37f3-4b14-80f0-93f90fa913b6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad401cfa-e479-454d-aaad-c64cb13b04c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf677c87-611c-4e31-817f-54a794c126cf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal number of b cells</rdfs:label>
    <dc:identifier>HP:0010975</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9814ff9d-0db2-4ebd-a2da-fbf45735e927">
    <dc:identifier>DB11917</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <rdfs:label>Vatiquinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a60e6656-bc9a-4558-b389-a35680f8c736"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de768d3e-989d-45a2-9697-3133a02cbc68"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/343c7d8a-60ac-4049-aa8b-21e0d3fc892d"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0b491e88-3226-48e6-9f76-63f00dafb9ec">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc83bfc5-9526-4cfb-a591-1a755584dbaa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/310199bb-3fde-4ec6-b421-6e279c614c45">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d4acfe-bfa6-4e86-ba50-efc345afde8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b16a507f-1975-4657-abf8-0c8d7efb2a64">
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6ea4ef8-778c-43e2-a20c-2ba081dba36e"/>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d59364c-585d-4fd2-80f9-3b1b9438080e">
        <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc28e1d8-5f75-4dc5-addb-3df7df78c0ea"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19c832bf-e792-44c5-9e63-50bef39e295c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c0f20af-5569-4b2d-b831-6f73c584b897">
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e0762cea-19fe-4c69-b4aa-cf442e8dd343">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1daba10f-7bc4-486a-a26a-b52f9f33605a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed21356e-8167-4f27-8b79-6240ab7556b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f2a42e1-7aa8-4175-a594-74b59f67b59d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfde9845-87c1-40b5-bfcf-0b583416e702">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <dc:identifier>HP:0001954</dc:identifier>
        <rdfs:label>periodic fever</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d2e15354-ee2d-431b-be03-49e514017134"/>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/388dd3f8-b72f-4ba7-8445-d59cbfb54661">
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>Abnormality of immune system physiology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf53c2f5-ba22-4eee-b15f-fc4ff34bc57b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor eye contact</rdfs:label>
    <dc:identifier>HP:0000817</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0b3f607a-c1e9-48f6-8bf9-e534ed6a6164">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79f79245-3f45-4135-b9f0-2524470ebe56">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf0a02bf-e136-4a1f-bb96-5be791936a54"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea6fcfae-1148-4adb-9216-2f9b3eb927c3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0df478fc-e73d-450e-9266-8471de0364d1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab4429b9-616e-4c1f-9980-73db814c1a9a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
        <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
        <dc:identifier>HP:0008347</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bebd8686-b92a-4c09-9541-a3449e00f19f">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fef9b7b9-9389-4bd7-b250-1fba76abdee0">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3ffe442-8c83-437c-99d7-c54c62c7bfbf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03d5cbeb-614e-47a6-a2be-225512f1e1c2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90751f57-ade9-4028-b6a6-c7c0229dc0ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2710a8d0-6904-44d5-a707-a69eebfb57eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41eeee59-8c4e-4975-86ea-32c5fcae05db"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB00227</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfa95e2e-d341-48ff-b92f-90fcb969d466"/>
    <rdfs:label>Lovastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd3bcfef-fcda-45ba-b59d-78be0f611e4f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/520a4285-b50a-4fc3-9e03-ab89431d4cec">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc31cce6-fb69-4d59-9075-f8501f118c49"/>
    <dc:identifier>DB05018</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f45ec42-fbc9-4616-80df-bc60be3dd0f0"/>
    <rdfs:label>Migalastat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
    <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb684ee4-3277-4693-8b97-9e78704000d4"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c243b4c-cdf1-4487-b45d-dba6fe74ed83">
    <rdfs:label>defected excertion of 3- MCG</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd528ef4-43a0-4624-803a-a7b09556ac4e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
    <dc:identifier>HP:0001878</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hemolysis</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bff9a640-4b5b-459f-9d5e-9ff8f723ed6f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92275ab2-c104-4847-a3eb-78e418dd3b1a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1813366a-769e-44b7-9dfe-4273606f66fd"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9c5c255-3abb-411e-9c4a-426653343750">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b96c9d3-0d27-4860-ba55-6aa8ccdf8d7d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f26f9e0c-0b80-4ee0-b2ac-39f79d26493d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74728246-697c-4440-a7d5-3aba06093967"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/647f99ec-494f-46d0-9d13-059ceb27b91f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c2e1a6e-e01e-42f5-8ca2-c48e26be728f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/918bfdc8-043d-41b8-b72c-12c45f6565fe">
    <rdfs:label>polydipsia</rdfs:label>
    <dc:identifier>MP:0001426</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93df6250-51e6-4392-b962-2610724c2060">
    <dc:identifier>HP:0000938</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>osteopenia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3dd497a-2389-4e14-b72c-72879ec985b4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e74675a-45dc-45cb-8141-cc1fce47ec79"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2068b37-9a3a-4975-bfbe-cd533bd954a6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c15d8537-74e3-4d8f-9655-6a870dc5cf88"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/667efcf9-99dc-4d02-9a14-bb3c1f75a663">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/709ef93f-dcef-4da9-a02b-3f6fb0a08e30"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9c2980b-35aa-4179-93d8-96324805547c">
    <dc:identifier>DB01025</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
    <rdfs:label>Amlexanox</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4a001a52-7edc-4b6f-ba04-a3c53cebfed7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89db0ba2-aeb6-43d9-a8ec-b3849bd5b67c"/>
        <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99bfd0cb-67b8-483f-916b-8616cc88592e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
        <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2b96b44-1a12-4164-aafe-92498fc61adf">
    <rdfs:label>Low height velocity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
    <dc:identifier>HP:0004322</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c59bb06-5f30-4c85-8c1f-f20a906130bd">
    <rdfs:label>myopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
    <dc:identifier>HP:0003198</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/501ee339-83db-4300-b00c-81ec973b33cb">
    <dc:identifier>DB04931</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae13ebe8-f4aa-44a6-84cf-af8b3a9ff885"/>
    <rdfs:label>Afamelanotide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c4657e7-abe9-4b55-ac73-7603babe48a0">
    <dc:identifier>HP:0040006*</dc:identifier>
    <rdfs:label>Low life span (Mortality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cfc39c2-99af-4766-aa52-9551b04f84ba">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af4c4da7-93ff-449c-b8d9-6255bcf85436"/>
    <dc:identifier>DB06777</dc:identifier>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/927721c9-d1ed-4682-871e-a986ab23e91a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e53fa840-15ff-42fe-847a-1ec0252173d5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4dd9cff5-e0c1-4f1e-92fe-26bc0db3f3f4"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6b03948c-8579-49be-b008-b7e5bcbd40a6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a23f6e8-6540-4904-9ffc-bff7e7e196d5"/>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cce17a3-7964-47c4-b753-e6a181ac27a8">
        <rdfs:label>Hypsarrhythmia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
        <dc:identifier>HP:0002521</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10012e8e-0a48-4fa7-924b-653f73052707"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/309d7521-bbfe-418a-a4db-2e5842e1463b"/>
    <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38becd3f-9939-4b10-939e-4ccaea18ffa7">
    <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
    <dc:identifier>HP:0004356*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4b9ed28-7b15-461d-a628-861ddb1e6e8d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
    <dc:identifier>HP:0012335</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4fc085ef-dddf-4167-92c7-d13634f19540">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0bd8b7cc-7ec9-4d31-b89b-2441a3f8b1b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e659ba26-e82e-4864-b787-ca8d7935cada"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f07b760c-1e56-4b37-9906-566c32f49163">
        <rdfs:label>No result was added</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34617cb5-23dd-4b15-af43-28c8c92ef753">
    <dc:identifier>HP:0001976</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bccb94b7-126e-4da9-a19a-6454c8a97e53">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2d038de-5fe5-4bd8-9652-849bf8146a58">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf1c1786-0ddf-4d62-873c-90b0f9a94d49"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2398e007-4b55-4110-ba1a-5b7a5e4632a4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:label>acute congestive heart failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45f0572b-3e5c-48ff-923f-0b77c5a30110">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5afc6b51-4df3-4197-85bc-9eabfa5b8171"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/480ce2b1-b47a-405f-88f1-74e855d82a39">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3b044bd-9a4f-4b8b-b788-49dfa171838b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a6b05552-8817-4ead-9b12-c1988faf8a3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a318a291-eff1-45a1-a78f-606bacc086ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7dcbc81b-4f42-462f-91a7-5232789950b6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80d87bc4-67f4-4333-bc08-55a9aea8a82f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
        <dc:identifier>HP:0031851</dc:identifier>
        <rdfs:label>Reduced hematocrit</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9054ef6-822b-429e-aa5c-8d6891dfe5c3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79343775-8be3-4ccc-ac63-6819d377bd7b"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f386b78c-23db-4cf2-9914-1e82522c3459">
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c35b7bb5-e46e-4b18-88e8-c3853e7fbd46">
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/62b66c95-6af7-4b18-bfc7-23d8e4bd3726">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3f5d92e-5df7-42df-bef0-fde8cc430b16"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8503b8bb-3630-4885-b1c7-172f6351b1ff">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
    <dc:identifier>HP:0006670</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Impaired myocardial contractility</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04b4e5fb-18bc-4fa2-981b-9e1c0139faa4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c09fe5c8-047a-4401-a5b9-053bc56467d6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6aa04c1a-6cae-439b-b2e8-463a47a52cc1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4cf289c-0942-40bd-b727-ac0c8f1c3377"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b595838c-95f9-4ae8-8e51-1ac51ebcdf72">
    <dc:identifier>HP:0011031*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a798e4a0-d223-4d96-bc8d-42439e75dccb">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34cfe685-61c5-4885-9cb2-094fb44632fc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eaee23a-479b-431b-9194-b821c3f34ef8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2907d2d-bca1-4331-81bc-e57e84f2ea0b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e80fc7e-6bf0-452b-818f-cf1a761810dc"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4865551-5db2-4e7e-95f2-732319505963">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5540dfb8-33cc-41cd-8f5f-aba57a2879cd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7ab7278-fe8a-40cf-a981-95072c5275a1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>Ployuria</rdfs:label>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/493da7e6-3d62-4718-80aa-dd43b6974978">
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb71c29b-ffac-4ac1-bdad-ea9ffb581be8"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0bf8017f-9127-4547-a192-6ffbb75b87bf">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0eef612b-6951-4a4e-87c4-4c9e7573c23d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a2128d5-cc52-44c8-a5ad-711ebd542a75"/>
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/328a969e-5769-42b3-ac50-b5cb05a3283f"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/7fccab52-e8a9-480d-a861-34c3790908c6">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee09af5d-92e4-4a92-a4fb-bc4dac2df994"/>
        <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
        <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26419a46-eff5-4033-aca0-65cc2c62dd47"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49b340fe-6468-40d6-afee-2504daced046"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13c0194f-2eaf-4645-81f1-2d8fc08a4556">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cb430c2-23de-41c6-94ae-0fdbc388538c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25e46988-79e7-49b5-aec3-5fdd7a279543"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a1e1da2-1eda-4d8e-a182-9f08a18bcc61"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
    <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
    <dc:identifier>C09A</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9bc2caf3-d766-448c-ab49-39de43df8820">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1fbf16b1-bd00-4836-aad8-3175a886294f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9874a620-7905-4043-bba7-c3d20861d6df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4de342e-cd52-4433-91de-b0e80b3dc53a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/91f00429-0d9f-45a0-a26f-b707aba12346">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8865e60b-07bc-4f7a-ae2f-29f99592ec8a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <rdfs:label>Acute pancreatitis</rdfs:label>
        <dc:identifier>HP:0001735</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d99d544f-2a6a-43cd-9f09-c0ce7e347f09">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/302e0ebe-9752-4530-832e-8a39f17371d2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/caadfa09-bcd3-4b5a-a755-dc69ac2c9c09">
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/25f852de-d8db-442a-b848-38db8a182278">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78eeeb2d-f5ea-49d9-8998-c7d47fcef259"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ae9671f-60cc-4781-ad76-221dab2d3e20"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB03227</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abaef7f9-fee4-4eff-bb3a-cdea12fc33c5">
    <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004356</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14b0e1a9-cb44-4896-a0ff-cb6f9f875a5d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <dc:identifier>HP:0004348</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/29e017d5-f388-4255-bc0b-7aaea34b82b2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/454c2861-75aa-4753-943b-afc6fe10de39">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7cc5486b-3b6d-4c57-b4ed-81e36f65e3a5"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/f078f53c-bf3e-4629-9197-210c723bf907">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66708463-d067-40fd-8357-9445fadd8621">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:label>unalertness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002329</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26419a46-eff5-4033-aca0-65cc2c62dd47"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e87994b9-7dbe-4b10-aaf2-7d5a4af6e4d4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b50aab6f-3ffc-4a07-b430-4c51f80c2265"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1497bab-7c9e-456e-b3b2-8ac47d9c7936">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca753c3d-70a8-49f8-8044-2dacd24e81fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2f57704-4913-4e60-8405-e46163f5a31b">
        <rdfs:label>excessive adventitious movements</rdfs:label>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6437b879-045d-435b-a064-2c0f72205f65">
        <rdfs:label>hypersomnolence</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100786</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10012e8e-0a48-4fa7-924b-653f73052707"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/978b33b7-85f3-4989-ac8b-f71f931bdf74">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>orthostatic hypotension</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
    <dc:identifier>HP:0001278</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/712ae54b-9f26-47aa-a598-21e20253298f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:label>Decreased pulmonary function</rdfs:label>
    <dc:identifier>HP:0005952</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
    <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/305fa49a-6b24-4ffa-ba0b-ae8a53d8019e"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLUTATHIONURIA</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d30c0e7c-e1bb-4651-95f9-968c0246a621">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/abf55cac-d02d-439f-aca3-e1a653186382">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31f668dc-98ac-4363-8901-18d0ad71d7b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/249900"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/53a45212-68ff-4f9e-8aad-6ce3fd526760">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/091821ba-3e85-427c-9404-2e4125e891dd">
        <rdfs:label>Hypomyelination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
        <dc:identifier>MP:0013438</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fe53cf2-38ff-4e26-a467-83f850d3e994">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal neurololgical function</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/529f7e63-5847-474e-83bb-22bcd090df31">
        <rdfs:label>Neuronal vacuolation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e71ea84b-fff1-4bcd-8dbf-ee9b76761a17"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91e90fad-ecc1-4cc3-9f1e-ca1ae74bdc03">
        <dc:identifier>HP:0002062*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pyramidal neuron loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4f3b30b-34fc-4a29-859c-3228b420805f">
        <rdfs:label>Oligodendrocyte loss</rdfs:label>
        <dc:identifier>HP:0100709</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a726de5-b9d8-4389-9bca-0b49e13d0e12">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3aac75df-d6e2-470f-a671-ada0af4509a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62c7731c-eb30-4f7b-b6e8-632ee13fc2e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89e0082b-90c5-4fac-a415-e06114e343c6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bca32ffb-5c25-4ce9-9e6d-10fbce3ad255">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Astrocytosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
        <dc:identifier>MP:0003354</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11990815-0ac6-4bf8-945e-9cecb0ebeb59">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5dc6e7b-9865-4a9a-8129-7cfbc2a13fc4">
        <dc:identifier>MP:0000880</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c113bfb3-4364-4f70-ae65-c50539a9b1ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
        <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
        <dc:identifier>HP:0002446</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5f072b7e-102a-4f79-a309-60cba72e39fc">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c72456e-3104-42a7-bac1-f2d7d3ef1faa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/144e9daf-f024-43a2-a812-591fbedd32a3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f81a4f6-bb0b-4c05-b630-82a7bca805a4">
        <dc:identifier>HP:0002907</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
        <rdfs:label>Microhematuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65b92dc9-0380-4699-af8d-48ddf7aa09fe"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/400ba23c-d911-49f1-a996-33bf0404f17a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9f2e2da-c196-4012-9fea-4ec61c02bec0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f885fd4e-17b2-473a-92e9-c75939831f6b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e6af9477-1036-48a8-99da-6bc1339e028c">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15017f8f-8d12-43be-98c5-7673816f3966">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurologic abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb4290d8-571e-49d9-96e9-cfbb9536e492">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0adb1513-3e8a-4492-bb9e-f78851334d66"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c06a12b5-0358-4b69-bcc2-b7598af940f1">
    <rdfs:label>cyclodextrins</rdfs:label>
    <dc:identifier>CHEBI_23456</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/927a5162-d67e-41ba-8e6e-11bf9fa13d26">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6937c442-9575-4bef-a4d5-5d096f116059"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff68b816-484b-4c64-8bf2-254fe8f68f76"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/632f6789-40e5-4248-a860-b4492fe34f8f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79d2c91b-49d1-4bbd-98fb-630557ba73e7">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae5da945-9e77-4cd3-a79c-d3c1fa2de242"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8c75998c-c981-485f-8b60-d2b3d4b9ccc3">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d658463b-ffd3-484f-abec-b82343babbc5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b83a2807-c684-432c-8c04-e21c15d92c67"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9554b9c3-4e35-4dc1-9152-4acb3d1d0a1c"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16a4eb31-c7fb-407f-9ee6-dcf8246ccd66">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ece2edc8-112f-4b22-97a0-b548d6f2a014">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9421dbf9-2760-4c58-8955-8636aa5e305b"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d9082be3-05f6-4dc4-bb78-1cc8db924624">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9421dbf9-2760-4c58-8955-8636aa5e305b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62fc0890-926f-45a7-a205-4c3e8203d156"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52d97a32-a0cf-4f3b-84a0-8966d1355905"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1b81fb91-f0b0-47ff-875a-f6be0ac0a927">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9421dbf9-2760-4c58-8955-8636aa5e305b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5703f1bc-48e6-4c09-8f03-306d860623b0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca3d92ee-0041-4c62-8323-d7277753bc36"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62fc0890-926f-45a7-a205-4c3e8203d156"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22576252-ccf2-4e78-913e-18f03b61ac90"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Rosuvastatin</rdfs:label>
    <dc:identifier>DB01098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8801813e-291a-4e81-bc58-cdc352e23639"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/747b6969-929b-46e7-a3c2-3a2563c0dd70">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/415ae071-acd8-429e-aa91-737e235e6a3e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03c79ed7-ba82-4199-8408-d462449832a3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26194979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0879b21f-614d-4678-900e-f7dcd4439b08"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151670"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9421dbf9-2760-4c58-8955-8636aa5e305b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/92bfc802-cefc-436a-8551-64735a79b1ae">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ac801c3-3bbf-4b2a-b5c7-5d1f2f4752c2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5f6a25d-3858-42a1-a948-680bbd08e3fe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/918bfdc8-043d-41b8-b72c-12c45f6565fe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a894932-fbf1-42bd-94c6-6265ee12c7d4">
        <rdfs:label>thirst</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <dc:identifier>HP:0001959</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84886372-3abf-4f01-89b0-dad8ccbaea8e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
    <rdfs:label>Abnormal reticulocyte count</rdfs:label>
    <dc:identifier>HP:0004312</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3bfe3db-3cd7-43db-9e1b-3ceb20c76b3d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a6d1a7a-65f1-4345-8145-b1355b1b0c10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d762b50-5889-4441-873f-724d99262f87"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48f3bcee-d68c-413d-9a11-5fa38ff535d0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
        <dc:identifier>HP:0004395</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Malnutrition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/781d0ffa-6ad8-4078-ae3b-6c48396f8146">
    <rdfs:label>Abnormal spleen size</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001744</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc0282f4-191a-4d73-8088-c5407dc23604">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c164f4b3-e831-4579-bf30-cdd1c9de2904"/>
    <dc:identifier>DB09130</dc:identifier>
    <rdfs:label>Copper</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cbde157c-dd87-4bcc-aa65-87c80c403db6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0aa94ae1-6bd5-483a-9f2f-d9f279bf8d53">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c13a8160-acdf-4531-9680-36a4b89fda0c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2bf82092-839d-44c0-a6b2-ebd07297a9fc"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB01586</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/72719c44-c208-4c02-86d3-d82162740f5e">
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2bf82092-839d-44c0-a6b2-ebd07297a9fc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0277a778-4e11-4c5f-a793-18de640d6580"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9b7eb557-8acc-486b-b3fc-5327e3e6f00a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2015ea8b-e795-4e42-a4ef-f94dd40ff0c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a8a6041-8771-47c3-b734-87b4ef0bc9dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1537681-1618-478e-8bdd-1d300a55e79b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00c0e7c4-b51b-4ed7-877d-78886d5404d5">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
    <dc:identifier>MP:0020582*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High intracellular cermaid level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e1d370d-8d96-456d-83b6-1d2c5857b442">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001992*</dc:identifier>
    <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d4580544-607c-412e-80fd-9ecbc91f450b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3018468c-8874-4249-8b0a-1bad6e0990e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e985268-e1d2-4de2-9c39-7cd81f7c090c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05586586-02f9-4bf4-b89a-668cd24590ba">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
    <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0009587</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73e21795-ef72-48bc-82dd-4a7e70530cf4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low physical capacity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb63ecd2-c213-4bb1-b64e-ee9df61a5636">
    <dc:identifier>HP:0004324</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
    <rdfs:label>weight gain</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/31e62928-1423-4277-920b-d8e9498a6e7c">
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f720ad5c-1a99-414d-9928-97f0f11032a4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee8ad9cf-f161-4159-a44a-8f45fdb561ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b7d4f2b-70ac-4c3c-a605-209d19c822a3">
    <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100502</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b06f75b6-75d8-4109-b103-81d2fadf1408">
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
    <dc:identifier>CHEBI_113373</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a321f603-6c90-4cf6-b560-6d13416550ee">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/794b6d21-9ced-449a-9d18-2339967b7569"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8503b8bb-3630-4885-b1c7-172f6351b1ff"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b19bdacc-8bf2-4b8c-972f-3653c089ae5f"/>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0207b78-4438-48c8-897e-99c01ef3c4e1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/404d3b0c-129c-4716-b10b-9bf1ce0ef09f"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f57ddc9e-0e01-436b-9023-050d36a2139f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
    <dc:identifier>DB01124</dc:identifier>
    <rdfs:label>Tolbutamide</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b26c63d5-8ecf-464e-848e-0641bf9d086d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4cb5e280-2ee9-4904-b837-319be38c9697"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe8d5f5d-fd6d-4bb3-a6ec-6588d9325f0b"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/316ed4d8-d363-42c2-8d5e-40fd55b13620">
    <rdfs:label>Agalsidase beta</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/198eabed-68d8-4a7a-9eac-56b9bbc1cdec"/>
    <dc:identifier>DB00103</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a32cb814-dacd-4812-ad28-683a443bc50a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/ba4305a2-e1e0-4a18-be05-5ce27b13e1a4">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65d0e863-1fc7-4fbc-8ef8-8ac7734e1e7d">
        <dc:identifier>HP:0007103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>White matter changes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc9b15ca-c02e-4d0a-a1d4-ec3ccfbcfd82"/>
  </obo:DDIEM_0000009>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29fbd61b-c3d5-4ea9-b1f5-2f8695c1404c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8863d997-9d76-4bac-9a9d-82e04b718d50">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/170669a7-966d-42df-9bfa-2a9134c448a7"/>
        <rdfs:label>Norleucine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/694c96c6-fe34-4c3e-ac80-84652c8538a4">
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a6fdfb9e-0087-4734-9ad6-3040dbd09c7e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f0b06eb-6a80-49d5-b703-5d69dc9e8332"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/31057d35-95e8-4adc-b185-234b24b03350">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d5c93f1-7731-4d4c-bff6-a832a7cccd20"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0736ffa6-b67d-4268-997b-a43ff9c14a25">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Diabetic polyneuropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
        <dc:identifier>HP:0001271</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63600574-5939-423f-9eae-77308fb7c043"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/68767ad3-660e-4c90-8c0a-dd6bcbd572e9">
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39ce0f42-4382-437e-b595-e59965d6c7c6"/>
    <dc:identifier>DB14573</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/10f51280-bccc-4b12-979c-9b0dd8297a4b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba4a3c1b-78e8-48e6-8fe3-d1a4ee4fc042">
        <rdfs:label>anxiety</rdfs:label>
        <dc:identifier>HP:0000739</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0003304>Spa</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49ddf618-930c-4d29-a9b7-61d910af209f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c283793a-21f6-4939-beba-3bbb79c31156"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8c6d91c8-9f20-4214-ba6f-82847778ae98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d7a7280-946a-4241-b372-a2821eb2c684"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/794b4b64-b8d9-49bd-8dde-a5c5e79f44c2">
    <rdfs:label>renal salt wasting</rdfs:label>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/60b21848-c7d1-4cfc-8797-66a4066bb6fa">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12ef9b03-0a1a-407d-9052-ffdb80a247d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d198b6f-cfd2-4b08-8ab9-f5214d9c550f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0784f80-e579-4ac8-acd3-516dbfc22cba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000011>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/347c65a4-8a52-4c5f-aa0e-71d35b855532">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f3b1375-4dc1-46b6-8f02-904fa1bc1fcd"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2fd7583e-4f48-473f-af51-b526ff36da81">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f38f095b-22f1-40a3-b6f2-f828a2c9965e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f6e9d31-8317-4540-914f-b51796cf432c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d9eda76-502b-4296-bc48-8b614d79da1c">
        <rdfs:label>psychotic  disorder</rdfs:label>
        <dc:identifier>HP:0000725</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6389689d-b085-4b7e-ab42-509569728b9c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8279242-f879-4372-acd6-b3e4f9be728e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ba02764-3e74-4a25-904f-b1719e9796fa"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7216f6e7-e9b3-429a-86be-5bb527a65a5e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/578fcb98-ef9b-4db0-89d8-dbb0e7d55178">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1162cef5-2a67-4a5b-873d-c544e69b1939"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608099"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9da4d1ec-2423-4900-ad19-adb793f0c224"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d82aa760-7086-4bdd-a006-a4ebf851c523">
    <rdfs:label>low levels of purines</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d4f2ad0c-c804-4b63-a8da-38cc6175cd5d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7b8e702-026d-4af5-a6a8-aa320f831296"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f56f1192-1722-47df-9816-f9ae527d7536"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f405118-e45d-4605-b280-761875bad6d2">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c19ba582-e324-4ffe-be4f-48ac76b853f0">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9311daf0-d5d2-40a8-ba88-a4e489209bf8"/>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edda7d00-40b3-49fc-bb78-d748e4c5c909"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/185d2c34-b2d1-43be-8d48-83fe2f7788e7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0ca1088-4f09-4b79-af93-db6df0bc32ab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92e791d6-c064-4879-bab5-3e33b6af62a6"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00413</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50f95389-f5e9-40d5-b14e-2690f0c393b2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
    <rdfs:label>Pramipexole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99888c09-1d90-4344-bfef-7a651cd378aa">
    <dc:identifier>DB00783</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7acf94ac-9eef-487a-a115-868462928862"/>
    <rdfs:label>Estradiol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4f2ad0c-c804-4b63-a8da-38cc6175cd5d"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c30e7ecd-324e-41aa-9669-a7f5aaa2d3b1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d775e5e-ca0e-4139-8d5b-5ec5f276c500"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/550ce3ed-7e7f-4393-8e99-019cb08e6423"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/693cf238-c112-4f4f-9a15-6b2814adb8ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fa0fa85d-c534-420b-b467-a2c66a60d7f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca223bb0-7449-4cf3-b8ed-28d6fc0977da"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/10d01746-99c4-4d11-b82d-c0e7a92ae5de">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26419a46-eff5-4033-aca0-65cc2c62dd47"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/144e9daf-f024-43a2-a812-591fbedd32a3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26d023d1-cad3-4ce2-a636-c1f334e017ab">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
        <dc:identifier>HP:0001913</dc:identifier>
        <rdfs:label>Granulocytopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e067b8a-acf9-4871-8a94-f24185249f15"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/050f8258-e8c9-45b2-bbd1-a2e9466cfb3b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f81a4f6-bb0b-4c05-b630-82a7bca805a4"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ac6bea4-6a60-407d-91ff-4ec8ab817bbb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
    <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d7ecfbf3-b80c-42db-b92b-80314a215926"/>
    <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/689e9398-aeba-4666-9c9c-bf8863ef7773">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3f7905-ed5e-49ec-8ef5-ab3975c75b04"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/513e158c-afa8-458e-9ca4-c0f66a1106f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c552c7a5-1e97-4211-92ac-4d58151b3f33"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/725f7c33-33fc-4477-af4f-ea1c57d77672"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbd06cbf-2249-4d69-a08f-e1676d42519f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3149fe0-9d4e-47ce-a292-829ae8850a89">
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e2772b4-6798-4414-a93b-ee556fb139ef"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1606d4d2-a492-4635-8b80-6bc21350b9eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e7e52af-3c06-47ad-90e5-3d90c2f7c4ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/777c2e92-2aad-4c55-8961-5abaacb14eb6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0ea3b4d-d969-4df5-b4f2-a4165fccfead"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce320ea-1b91-432b-bd03-0b30f85973cb"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/805b0c25-db23-403d-953a-701bae9041af">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43e85b6a-149f-4745-bdb9-bd50aea82a9c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e65c5faf-69b2-467c-be7c-caaf7f151e38"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81bf3b80-022a-41cd-91e9-c076d1e44a5b">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>abnormal hepatic function tests</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32205ff6-fb20-4ab8-9579-8dc1af228e12"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e1fa3d38-9d50-4726-8306-9de1046f9737">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7792ee2-ef60-4046-9085-abf5626145ea">
        <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/85f57dbc-0054-4de4-8479-0dfa4554b9cd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27b68446-fe63-4349-8c5e-9b4257243169">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008166</dc:identifier>
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52d0b3e2-e0a2-4dce-a78f-0eabcc89dc21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f2fd615-70f6-4f29-a7ed-06dfa469c419"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92f5dc4c-c672-4880-ae83-5faaf6fd1a60">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1a7debf2-d19b-4337-80bf-13b76dca43be">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bdae8d81-c824-4197-b1b9-f3eb24b99969"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/730e40f7-f488-4b3a-b7b9-05cb29bf24f3"/>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6543a8f5-3ad8-4bee-9e6d-f40a116cf929"/>
    <dc:identifier>DB01390</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8c3f9738-f2ee-4f24-bcdb-4a8f4b6490a4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2c6d6896-36b8-4e96-8015-0b4a65262d84"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfa349c1-ff57-47c9-8c81-277452f66b50"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9bc91b52-916a-4c78-b767-33605ff5376f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5dce4ed0-c8a1-4608-890e-27c694662fcc"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0223badf-6fc5-4e74-ad72-6be1b020e50d">
    <rdfs:label>High plasma cholesterol level*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003107</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1849a663-fe16-46eb-8ba7-6037709410d9">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4ccf4b53-05f7-4447-9ba0-696f6dceea9c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ac32890-329c-45d7-910c-55cf1f265521"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e080ae2c-6b09-469f-9e22-6e5c15fa50cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0207b78-4438-48c8-897e-99c01ef3c4e1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c59bb06-5f30-4c85-8c1f-f20a906130bd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>high protein diet</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/472f50b0-3a16-410c-a56e-18934f175dac">
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9f68006-8c4a-459a-9c81-c0fa4cc8d991"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f171d3c-689a-4a00-ada7-99eaf2456ae2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f69dedc9-fad2-4f24-9fd3-4224db8a7c53"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ab1856f-78c3-4185-a10b-d41f8f24b370">
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa0fa85d-c534-420b-b467-a2c66a60d7f8">
    <obo:RO_0000056>
      <obo:DDIEM_0000006 rdf:about="http://ddiem.phenomebrowser.net/25bcbdf8-336c-4881-9002-a518d13db0f4">
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20a8c434-e12f-4b91-a804-1004c9ddb95d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a44f7c7-8e70-43bf-abf3-506f515d2ff4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70d82e9f-d56f-4788-a9f0-21afba63f518"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6910c134-f058-49d0-a330-bce1474152e4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f026a32-9bc7-49bd-8bef-582a9bf204cb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/693cf238-c112-4f4f-9a15-6b2814adb8ce"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdcbb130-8453-48c0-85d3-e6ace3f3e84f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000006>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c30e7ecd-324e-41aa-9669-a7f5aaa2d3b1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <dc:identifier>DB00016</dc:identifier>
    <rdfs:label>Erythropoietin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e9ca709-296d-4a2b-8708-882539d60ba8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
    <dc:identifier>DB01956</dc:identifier>
    <rdfs:label>Taurine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/84f0156a-8766-466d-9c63-ba1f04610fb4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5da881df-440a-4701-963a-be46e7762bb1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b77bd08b-05c1-46f3-bde8-c16fa84be21b"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82d09855-326b-42db-81c5-06d7f36b7f42"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f495e800-ae1b-4440-89e1-2ba68f7a969c">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3cc3078a-d4e1-40b7-8cc2-b97869967007">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7f5bb53-486e-4772-a4b5-20d11dab8d12"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/edc3b9ae-0e4d-449b-9de7-25a46520582f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/112881bb-19e0-476d-976e-489b042c60cc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39377296-46cb-473a-8595-3e7ffe1a91fc"/>
    <rdfs:label>Starch, corn</rdfs:label>
    <dc:identifier>DB11599</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac51f2be-17af-43b9-9e14-f3aed50bda8d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3a78267-1c36-4b7c-bf3d-9386ccf4c719"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4a37813f-861f-4c4d-ad33-1dbb31d04c52">
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ab5796f-7cd9-4d6d-b96a-26f4cdbafdc4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/621da6f9-ce1d-4107-adf0-24d3d4b42dca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20e4df74-d6b0-45be-85d9-1b8041231043"/>
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a53ea1dd-a02f-4236-b6a3-78626bc181f6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/92a338ba-63b0-4a26-a5a3-0041f01a7503">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71e298aa-bf66-4b21-9252-236134276741">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <rdfs:label>Tremor</rdfs:label>
        <dc:identifier>HP:0001337</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08ee4870-7d09-42d1-8a92-3082b19ae22b">
        <rdfs:label>Rigidity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
        <dc:identifier>HP:0002063</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bc38a80-a018-450c-986e-aef2e3378232">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Axial dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
        <dc:identifier>HP:0002530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad23c817-48fc-461e-afb0-40d653988546"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be749a8d-3165-4fa3-a66e-9ccc9c9ec548">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:label>Gait abnormality</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/57f11abc-52e6-4671-bb07-356d8654f0b6"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/653a7597-6bc8-45da-a2b5-954483137308"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8143c0f5-7474-4e6e-a765-02e63e321dc7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ccc73daa-435d-41c6-85e7-c696f7fc2015">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69189f15-4d3d-4921-83aa-767f78bd98c6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/281fac5c-99e2-4811-a697-97cf0ecf90be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8652022</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfa1cf36-4169-4073-8251-5626a544fae7">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
    <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
    <dc:identifier>HP:0006670*</dc:identifier>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b67edfe0-bd14-43ae-a8f5-115de4219932">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75da2aa9-415a-43a0-b82b-5022c5023a23">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
        <rdfs:label>ventricular hypertrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001714</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c12eddc9-debf-423c-be73-f621a7d5cff7">
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/678019ac-2528-415e-a80b-77bfdba97b33">
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030872</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99e1e5a5-5a64-49db-8aa0-552bf1cfed1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/091c65c5-d448-4d3a-be52-894dbaf544c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa4766b4-c881-4665-babf-74d054744f25">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfa1cf36-4169-4073-8251-5626a544fae7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61c51e8c-dfab-439c-905a-e1d4b5d5949c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001897</dc:identifier>
    <rdfs:label>Normocytic anemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbed34d3-b91a-4f12-b309-3935795959fc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9de719a6-948b-46ca-b8f1-2ae494640e0b"/>
    <rdfs:label>Somatotropin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c06f6f45-9196-497a-a91d-9f57f9f5e1a1"/>
    <dc:identifier>DB00052</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c911426f-aa95-4347-aaba-df87d34fa9d3">
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7856377b-4a7c-4098-9c1c-7219d5cb99c1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ba25f0d-c5f9-4c75-874d-2767e9823775"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ead683cf-3d68-45d0-b551-0af4631f7bd5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b7803489-8666-491d-ad24-8bd13446e06a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b98539c-499f-473d-b5ff-6074492a3864"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ead683cf-3d68-45d0-b551-0af4631f7bd5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a988dc80-b286-45e3-99e0-2d75d96cdc85"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6af3de4d-ca87-4f84-b60d-889bef52fabe"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ca1088-4f09-4b79-af93-db6df0bc32ab">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>behavioral disability</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dcf5035-9215-4280-9e38-fb8356f91908">
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:label>Poor intelligibility</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0e9a2c99-b559-42d7-9c4a-80d9b6e77652">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b24dc23a-d107-4993-97ed-6a6a28ffa45a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/421f306e-1407-4c0a-be47-917772015308"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca02729e-8d41-46d2-a327-c27b252ff6e3">
        <dc:identifier>HP:0012133*</dc:identifier>
        <rdfs:label>Decreased red blood cell production</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fc9435a-3626-499f-be2f-46b07e600ff5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>low heamoglobin leval</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c880212b-4fd1-4e2e-8490-245f44ef4374">
        <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
        <dc:identifier>HP:0010876*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/453357aa-9269-4500-9c89-5ca8072f863e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b68eef9a-5c7d-4d5f-83aa-80fe3bc733ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb421ffa-343a-4777-ab66-b9be4f8a8c8f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22181c8d-bec0-409d-94b2-51d364454b5e">
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>High serum triglyceride</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ef3cb2e-781e-4ebf-baac-4889cd3565e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/293ece2a-1ccf-4bd7-8444-d49a1e2a0722">
        <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd22afac-e60d-4e73-9060-6db3fa36ee60">
        <dc:identifier>HP:0031798</dc:identifier>
        <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d19cc96b-c076-446e-ac2c-2fb1a930c7de">
        <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7eb77978-4c3d-4798-b222-cb86f8575f07">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2388f92b-4d80-420b-9db3-d667e20692ab"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
    <dc:identifier>DB01626</dc:identifier>
    <rdfs:label>Pargyline</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9da58d03-2feb-46d9-bfd6-fe0d9393cd88">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b8614b8-ec8b-46bd-8822-c80ae08ecabc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010978</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bce4d8db-49c0-4574-9824-58eac5799fea"/>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/a8bf06c6-0544-4f6e-88cf-0098486aeadb">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9414260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d8ad924-a7a3-4ab2-9256-f6c785e19a42">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a82526be-730e-472a-802e-74126a46284e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fb7d6f4-4e90-4338-94d9-92f048f579f8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:label>Abnormal enzyme,coenzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012379</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e25a8c9f-0b20-4867-819c-451b485e465d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85022841-e1d4-4e8f-a94e-e69e5da1bd89"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b56a07ea-7ab2-488c-88ce-7b8dfb232405">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84886372-3abf-4f01-89b0-dad8ccbaea8e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63600574-5939-423f-9eae-77308fb7c043"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eff1d7de-9ac1-44b0-959a-2ce70907124f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/246221d2-0e4b-4573-aefa-d0f165ec4f01">
        <rdfs:label>Low Hemoglobin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0020062</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37ed6861-97e9-4679-a53d-8e461dfb9120">
        <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
        <dc:identifier>HP:0025548</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b7d4f2b-70ac-4c3c-a605-209d19c822a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
    <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/57f11abc-52e6-4671-bb07-356d8654f0b6"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e562297b-6fbe-4001-ba87-227bb6d5dcea">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9106956b-adf4-4601-a673-dd9dbcedc690">
        <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee52cb3d-ddbd-4ff2-a549-bd9fe0bd224a"/>
        <rdfs:label>Beta carotene</rdfs:label>
        <dc:identifier>DB06755</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e1b44e4-050c-408d-8533-c47c2da0d526">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:label>Fluid retention</rdfs:label>
    <dc:identifier>HP:0000969</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0338bf0f-04ac-49f3-bde9-bce48384e7b8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e242f4dd-471f-4bea-b315-3bcc694c786c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c8e0c69c-03ba-4f7e-b368-d7f43b53e5ad">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/542bb41c-e2a7-426e-bb06-a250909139a7">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>mitochondrial dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f8a94454-7d13-43b8-897a-5bbc8cb2fe30">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4193ebff-1c0e-4ca8-b0a1-cdf367246326"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34b3039b-743e-462c-afeb-b1c83ac79c38"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa4d31e5-85c1-4df3-a7b9-6521a8d729f6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/61738226-940c-4032-9b20-6b7785a7ec2c"/>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c72c235-828b-44fa-ac65-5d4ce86ce1da">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:label>Disease progression(Retinopathy)</rdfs:label>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82f15497-358f-4d61-9aa7-777e090e5d4b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4c4720b-6ce9-451a-912e-b31ee07fd3bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a11d61b6-383d-4c44-9911-d858c4f50d7e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2496678-525b-4531-bea7-8dedf68fde78"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761646f2-2887-4446-a926-718fdcf7506d"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a82526be-730e-472a-802e-74126a46284e">
    <rdfs:label>Gene therapy *</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8bf06c6-0544-4f6e-88cf-0098486aeadb"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/169d5002-c1aa-49eb-8829-5f5c79f28714">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
    <dc:identifier>HP:0008282*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8d35c9da-c43c-4292-9d62-f0300c21aa5b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94c1c28c-bb8b-48cd-8c77-0d8ec0f004c4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80f08790-c7b0-44eb-8412-d47ff1c41c32">
        <rdfs:label>Seizure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cdc779f-2222-447b-bfe5-fd2842f6abe7">
        <rdfs:label>Subcortical calcification</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <dc:identifier>HP:0007346</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffab81d7-8c41-4dac-b946-2ce44be2fdfc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
        <dc:identifier>HP:0002135</dc:identifier>
        <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5f22d2eb-6e25-48a3-8d40-b14ad4d5f597">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/337c6e31-c163-43c0-b315-9fc57c8b8ab6"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca12d92b-3c7f-41d9-b801-bb87cc46a877">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a6dadbb-0d0c-4086-b6fc-b54d9732c24a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a95183c-0737-4268-a062-55546bc4b3d2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>epilepsy</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82b02591-5b2c-4b8f-a8a7-530f10d2a1e9">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
        <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
        <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6c6159fb-6620-41e0-8f02-2d7473b76114"/>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6dee938-32c1-4b21-a5bf-82a69abd3047">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a109f753-6190-4e9c-b475-8c317c687e5d">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e28450f-d656-426c-bca9-2d6375a01cc4"/>
        <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e713697-62b9-4414-a5c7-e6a4dd396849">
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/d94653b3-5fdf-441e-aea9-074e45a3255b">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d0155bc4-c988-4bba-852a-e031143e37f3"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e0145ad3-66b8-40ed-9534-a465f50825bf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c35494e9-1b56-4c31-b5eb-c1e81902960e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low intracellular cysteine*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <dc:identifier>HP:0010918</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f59ee7e-8590-4c29-b5de-a49ab93c662b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GSH deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
        <dc:identifier>HP:0003343</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eda1e2d4-e130-4e3b-a798-fecfddc6d474"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4fdc8ca-6d71-4104-bce9-952ca17be277">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b656a6f-e087-4d04-b153-e61fc565a3e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0dc22536-dec0-40c6-8ce7-e0b9f15153bc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad5a90ce-5b59-4a8e-bf14-37a884c4fab4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee47b75c-55d0-448f-b65f-79cd153d270d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c0d08f4-fec7-4688-9aa3-ca588c8c8d24"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f300ff0d-d1ea-49da-9109-9eb6f02547f0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
    <rdfs:label>Arthropathy</rdfs:label>
    <dc:identifier>HP:0003040</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/170669a7-966d-42df-9bfa-2a9134c448a7">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40f05195-94ad-4178-895e-532f4e1be6ae"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ff006b3-b38d-443d-bd52-30ccf80daa59">
        <rdfs:label>High α-ketoisocaproate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29fbd61b-c3d5-4ea9-b1f5-2f8695c1404c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cff06d08-b164-466d-991e-cdc6dc5027a3">
        <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
        <dc:identifier>HP:0008344</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/80de7f10-cc5a-4993-a47e-70df32ecd291">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8d939ae-a8c0-41be-b227-c5b8cdf52b45">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9104385a-c8a4-4d8a-b196-ef609151397c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/223360"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/978b33b7-85f3-4989-ac8b-f71f931bdf74"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68ac959c-4055-42ce-8084-448f2751f787">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
    <dc:identifier>MP:0012604*</dc:identifier>
    <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8d3749ad-7c7a-49c2-b424-9d7dac53b31c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/589e1314-d5c3-4fd6-99a6-d4253f40aea4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87922517-9710-43ce-9144-c192f95e2ea4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d15cab86-f8d3-45ff-8eca-5e67384ce317">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arterial pluque</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <dc:identifier>HP:0002621</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c44e4eb-c5bb-4f81-88c9-05694fc40951">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
        <dc:identifier>HP:0031799</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fff3546c-72c5-4ba6-adab-66f36e8169fa">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002633</dc:identifier>
        <rdfs:label>Vasculitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
        <dc:identifier>ECO:00055442</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57622f2f-5d88-4c76-ad4c-8e9d6b1f9d67">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50b1c85b-dc38-4e45-be46-bfec5b9d8fc7"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a93a860a-622f-45be-9bbb-bac0247665d4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Tonic-clonic seizures</rdfs:label>
    <dc:identifier>HP:0002069</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9fed74e3-0942-4bfa-b7df-a37ba07a0255">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6403ef4-9506-4948-9d73-0b5665ebe2cd">
    <dc:identifier>DB01373</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e1494af2-e001-4986-9b26-ae5445715d4f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed965c7c-a22f-47c8-9069-a062d46b1a2d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b743b979-3eb6-42db-8a9b-2b2bd4f89da0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <rdfs:label>Calcium</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ec1aa09-dcaf-47e2-b2a3-57d9ae27f275">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1b693b8-458b-4e68-9c72-20c35e086606">
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:label>Abnormal circulating renin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02082c37-02a7-4bf9-a461-9ff9453bbd5e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bone mass loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f93b89a2-ba25-4e62-817b-704baa6c40c1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0413d6e-88f9-437f-b93e-cd738b566ee6">
        <dc:identifier>HP:0040085</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cf0d49b-812d-4294-b2cd-edfb71838b83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b4a52aa-700b-4d28-9117-32a04b4b0ae1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc965da1-538b-4cc0-bc47-1f806e8abe69">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002275</dc:identifier>
    <rdfs:label>Poor motor coordination</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dcd988e1-650b-4b7d-8558-cb6c034c9413">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7856377b-4a7c-4098-9c1c-7219d5cb99c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/5a544882-c173-45d4-9c32-375e9778ba88">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c008e92-bdbc-4da4-b5f2-e5a17308a9e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39d4be42-29a8-4693-a0d2-55581061aaaa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2614a453-9a64-4d13-9130-40046e14d321"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9cc9b771-e7bb-49da-a361-e2b19a88653c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39233ca4-5065-4138-b67f-6bf1b8af3225"/>
  </obo:DDIEM_0000009>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/302e0ebe-9752-4530-832e-8a39f17371d2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
    <rdfs:label>Heparin</rdfs:label>
    <dc:identifier>DB01109</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91f00429-0d9f-45a0-a26f-b707aba12346"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74d61ab7-b109-47fa-a8e3-b8e83bf97d82">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7e36400f-ec36-42c1-9c7e-e1071c79cd72">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/291c5c36-a20d-46ee-a9a2-832d3e8d6538"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb414df0-aa7f-4167-9c6b-40fc65044831"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69ecd0b2-3f2a-4aed-a7ca-5539cff7cbe3"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606664"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91864125-1d8a-42a4-b6f6-5bc1e61992b8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d240c4b-c51a-4d79-894c-9e0448884eea"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9567066d-180f-42be-a4d3-8e5deb90b283"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94e43cd9-5ea8-4970-9f65-094985e240c8"/>
    <dc:identifier>DB02701</dc:identifier>
    <rdfs:label>Nicotinamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c97b0c04-241b-4037-a06e-f9cd84ac3b17">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
    <dc:identifier>HP:0012647*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6727a087-0d37-4054-b19f-aa0a489d0a6d">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f2d6c33-1594-4f6d-bd43-c656d0ff0459">
        <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <dc:identifier>HP:0008166</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9c51230-0f32-488f-af14-d215b3c69a64">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97f16612-7f2f-4009-9931-f59ac549384f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bea7908a-1714-47d7-95df-0e4ab434c91d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/199e818b-9404-4503-93ce-778cdec23608">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1710ea1d-4c04-491e-ba4d-407b4526e2c2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ec3f5b9-0dfa-4de5-b299-9ccedebd31dd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypertriglycemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0223badf-6fc5-4e74-ad72-6be1b020e50d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1853b34-646d-4e00-9f7e-6a31a88926dc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29773783</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8cf391f-d2dc-49e4-a4ac-ff0693666695"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1dd8b433-4a35-4c40-b74a-577476b4ca87">
    <rdfs:label>Teriparatide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa3c4959-fb61-4794-a3dc-118b63405f64"/>
    <dc:identifier>DB06285</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d5c8b208-20aa-4428-ab9c-d086cacfeae4">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24a5e2b9-77d8-41d3-a055-b1385b1c5e95"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/258fb8b1-9731-4599-aaab-573faf32abbb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated liver iron concentration</rdfs:label>
        <dc:identifier>HP:0040134</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5a12960-09ac-4645-b077-528b0fad28f1">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/41a5d529-4558-4c79-8f3a-c2705ada9fb3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e6a373b-4cf2-498e-8e60-415be29b725d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b1805ec-144d-42bc-850f-8f3b80a625c1"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c6e4e043-596b-4e64-9e82-55c54e94b0e4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e6a373b-4cf2-498e-8e60-415be29b725d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38cc663d-a9b6-4b79-a08c-e3845c405c0c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00083</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/695d6186-306e-466a-8975-82a172410a9a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20c8bacd-e697-4032-aa51-36b2b2e204db"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57968767-9be5-4f8a-a2d7-09c04931b5a4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e6a373b-4cf2-498e-8e60-415be29b725d"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/36e2779b-782d-421e-969d-b2ae30020d92">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc1965a5-6a1b-4bb3-b3d1-9f9d2f41398a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae92a597-b0f2-4c71-b100-705af3496f52">
        <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
        <dc:identifier>HP:0000491</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c334f704-108d-4345-a7a2-a81dc05ff4ae"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec9710cb-dd42-485a-858b-0537049236c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e372a006-5ba6-4a5a-93e6-6ea42c7bc070"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb3c3d2a-872d-44c6-a4c3-c488c3fcb197">
    <dc:identifier>C07</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a1e1da2-1eda-4d8e-a182-9f08a18bcc61"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d4119c5-90db-4ef1-9bbe-ad5db91d0fe4"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
    <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cb430c2-23de-41c6-94ae-0fdbc388538c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f38485f-aefa-43d3-aaa7-e1122f508c15">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <dc:identifier>DB14307</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4548f60a-652b-4724-a5b8-a8a7bfaf7f15">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27589827</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/522b01cb-1ce1-4c87-9af2-033f2e3d1215"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f3fed4b-71a8-48fd-9e4b-29f96a5127bf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Green tea leaf</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a864e066-6bce-4622-b066-86fc145fdbe2">
    <rdfs:label>Curcumin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/500881b2-c335-4438-9382-a059696d4d50"/>
    <dc:identifier>DB11672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/384f7619-85da-438f-8479-639da52ed3ee">
    <dc:identifier>DB00181</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2668928b-d7dc-4b4c-8223-9687137c947a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a11d61b6-383d-4c44-9911-d858c4f50d7e"/>
    <rdfs:label>Baclofen</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1fd0da5-4800-4447-a754-09261de4eacd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:label>dysarthria</rdfs:label>
    <dc:identifier>HP:0001260</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c0711bf-17ff-44fa-8b09-071b48674862"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/381bc135-a348-4823-bfaa-199a6a414055">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c02e1102-df74-44ae-a7d1-c5306efd56a3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5a37f706-17f5-44aa-a6fd-9ec6b940956b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6423bd6-9981-4fc5-b8fe-b6ecde58bc28"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9174fbf-d714-43cb-8e4c-ab3becd9b018"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/911d575a-7739-41c6-8b93-336d0aa9dc4b"/>
    <dc:identifier>DB00126</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be7a2826-36ba-4d25-92ae-d533212e244d"/>
    <rdfs:label>Ascorbic acid</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7b93b17-c356-4831-8c99-4e5ff59095e3">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/940034c6-2aa8-48ef-88a7-178f48cd2b8f"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1cc2056-8c3a-4477-a512-998561db5df8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29c5e071-19ce-4666-932f-e7032b2a01dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc0e9872-40dc-40cb-a03b-c27dfdd35963"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51589918-6964-4c52-9bf5-93c236235525">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db5aa5d1-c529-423c-9f27-00b6b4c392a8">
        <rdfs:label>Spirapril</rdfs:label>
        <dc:identifier>DB01348</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1715c6b-bb47-40ea-90b3-faebaaa0b63c"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/26dff49c-e13a-448b-96a6-6df7c92aad3c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b573315f-9044-458c-b7a1-e9abad52ea5d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>production of toxic intermediates</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6a51e84-d980-4c5d-819a-1fd483359515">
        <rdfs:label>synthesis of atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7bda4ff-43ac-4d08-94f6-b49d730d4442">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cirrhosis</rdfs:label>
        <dc:identifier>HP:0001394</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/724e96f0-c04a-4620-b2a2-346fa97ce236"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92275ab2-c104-4847-a3eb-78e418dd3b1a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8115d455-f08e-4211-98b3-83c30576d742"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5aeea5a3-aa01-494d-871a-95cf01d33f05">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/864ead78-9b61-4cf6-a158-92a34804b1ad"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1f2616a-e551-4bd8-934a-791e484fca4a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/039c6dc0-fc3d-443a-8063-3b966f2da389">
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:label>Defected bile flow</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f058755-3909-4d65-b6c0-1182e805f028">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bile flow defect</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04df27a0-27b1-4e2c-8330-690cebefcaaa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97186fce-fb19-4bc0-80d5-2ebb29c1a533">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccaa81d5-c0bd-45a5-943b-1a13fecc7dcf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4547f680-0e64-40ab-9689-27b5de761284">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa004478-1d82-465a-8e92-b9ad17c194cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b421b57e-6b9a-4ef3-be55-5f7c36d1a815">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad0c1f46-b777-48a0-9a63-73883b20ba34"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c5b0da0-927b-4e02-a6be-2b289870799a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b12a7b3-101c-44b0-a5db-6d4d7f1db132"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/362c6efc-146c-4ccd-a0e1-61012d142962">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8258ee6-8859-4a4b-8460-82f92a490496"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
    <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0fda910b-6cbd-431e-979f-9e964fd98fdc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/255f85bc-f601-4b5d-b18e-2d6e3dbced82">
        <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
        <dc:identifier>HP:0001112</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebdd6e09-1ad1-4330-93a5-7e96d8349e09"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e86429f7-20b3-4039-8cff-5e86629540d2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0760208d-3ee5-4180-bcb3-2b96399a374f">
        <rdfs:label>Retinal thickness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000630</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000630</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed557427-fd30-411e-8ffc-70203a5e7cb0">
    <dc:identifier>DB05386</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a416e053-e5b4-4fb5-abd7-ef2d88724404"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <rdfs:label>Regramostim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6e0f1ac-12f4-4b84-8934-8ab18fe6c7a2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56f48263-f396-41d7-85fd-729cfa337c57"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
    <dc:identifier>DB00533</dc:identifier>
    <rdfs:label>Rofecoxib</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1a4f9b46-1cca-4167-a725-4bb7e29c0ea4">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20bc603d-01d5-45fd-96f1-f0bf04d7c20d"/>
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/130b91ce-f38a-4219-86e8-18807d0a4dd5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0b804aa-3094-4931-9e15-1ed9b7b94088"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14b0e1a9-cb44-4896-a0ff-cb6f9f875a5d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/144e9daf-f024-43a2-a812-591fbedd32a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a5ad17f-0a89-4ef8-be5f-240699045ec2">
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:label>high serum phenylalanine</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad401cfa-e479-454d-aaad-c64cb13b04c1">
    <dc:identifier>DB00213</dc:identifier>
    <rdfs:label>Pantoprazole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea58721a-792a-4195-81d0-b92d74a00a93"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2547200-263d-4261-ba80-33e0fed01c59">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b919d1a0-f190-47f4-ba78-76633115b0ee">
        <rdfs:label>Zonisamide</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69368856-e12b-49a9-97e4-5a7bd9b6c3b2"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39c356cd-997e-4517-b6dc-511aa97ca72f"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
        <dc:identifier>DB00909</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e3bfa76-f354-48e9-ae6d-1f4d5ecade8c"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/322a2426-1a16-4c90-881d-2656ac034101"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b883ce2e-1794-44ae-82d5-8b4bbeb87118"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b33a91f6-1921-4821-a467-96d8faef59cc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2401373d-3c37-4e11-83e0-c7cad03837b5"/>
    <rdfs:label>Idebenone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/362c6efc-146c-4ccd-a0e1-61012d142962"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d2f2d1ca-e981-43b0-b1ec-c16a49bc5bea">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebdd6e09-1ad1-4330-93a5-7e96d8349e09"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75b8d31a-4537-4daa-909b-01b9cf86cd4e"/>
    <dc:identifier>DB09081</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f010fd17-4ff0-4956-ba7b-36f83e178517">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a4d4ffd-00d4-479b-a9e5-174f3ae62ffe"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2f8aa26a-108b-487f-87f6-0ebb118fd9ed">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a434aa2f-bc21-4687-aff9-54065ff3a190"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ae45e9b-8879-41ef-accb-716f23db625a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b18fd3d5-7b82-4240-adef-f90a5eaef9ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf53c2f5-ba22-4eee-b15f-fc4ff34bc57b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/76a1a4e6-3433-4d5f-b655-5ee581aafbbf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c0f20af-5569-4b2d-b831-6f73c584b897"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d656d29e-ef63-47d6-814c-f14006f97404"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
  </obo:DDIEM_0000011>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ef61a08-6517-4f8f-be6b-37245e6a491e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fd91f47-5fdf-44b9-b966-0d38b5b5b05e">
        <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11214439-a035-4716-b471-551493af1957"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/07ecb5a6-214a-47e7-8433-58b38eb21ea3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28688703-ac46-472d-9674-a22ab8804521">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccdd7715-411a-44d2-9335-8a7911c0f259"/>
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d7573b25-4116-4a05-baa0-e663948d7764">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95b28e5c-6b0c-45fe-b207-b6c782676f30"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c34f7dd-4ee8-4f24-8fd7-4afdf7023609"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ee26c24-b54b-454b-bb49-ca4e7c99fe95"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0d0a9d2-9097-4632-993b-feaf6843c392"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB09341</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd79cf47-81fa-4ea8-9be1-6c6d1d9a55a3">
    <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
    <dc:identifier>HP:0012212</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f1db320-c93a-429c-a0a1-ac08bcb52a05">
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:label>Abnormal liver function test</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea2acbe7-b2b6-4380-94bb-50f5b23c1790">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04b163dc-e9e8-4f07-9a05-998d4545f847">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3022cf45-094f-45a9-952e-6489e1f48b36"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/951ba527-6108-4dcc-a88d-bc6b8fdd5234"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pegvaliase</rdfs:label>
    <dc:identifier>DB12839</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18fa833e-3ed9-4c1d-b17c-b4ca8a8e0719">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <dc:identifier>DB00742</dc:identifier>
    <rdfs:label>Mannitol</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ce32b18f-3237-4f36-a05a-922f37ac20a9">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82e51566-db5f-4652-9d89-3c924b6928c7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f479625-e166-428b-ba7f-da7ffab89117"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86f5df11-c087-41f7-8278-911001167443">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/943ce2e8-933b-4368-b045-06479fc1aa19">
        <dc:identifier>DB02329</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
        <rdfs:label>Carbenoxolone</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50cc893d-b7ea-4b8c-bb96-958b35f32d55"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4072cecb-28ce-4548-b59e-2b64779bd09b">
    <dc:identifier>DB05271</dc:identifier>
    <rdfs:label>Rotigotine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c538a5c-63be-498b-8905-20f71a7b335a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09894aa8-75ee-4975-a8ca-91552ad20733">
    <dc:identifier>HP:0002789</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
    <rdfs:label>tachypnea</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0699683d-5a40-4747-83f4-bc434cb1cf86">
    <rdfs:label>Laronidase</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2b46ebef-426e-4e6c-bbf9-d760412703a4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d1c9e12-2a7d-4156-9889-920cb9caa758"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c891cca0-abbe-4430-94c6-466f7ee5619c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/712ae54b-9f26-47aa-a598-21e20253298f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e1d9244-2924-4d81-a9bf-e17dfc968b17"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b01272b-ab58-4970-92e2-03a05474f1d7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00ab71b8-4d11-4636-9395-a126ac6cc294"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be754f8f-996b-4445-90cc-95341186709d"/>
    <dc:identifier>DB00090</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a0ca1472-8de0-4567-bb4c-6f7e3e335c38">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44a21231-14b5-4a54-a5c5-a1f2e4ad1b20">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study was terminated due to lack of safety</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23c31590-6623-4211-b4a2-7e83a2c83957">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/768f6256-00fa-4315-95ac-6dddf2055f24"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b68eef9a-5c7d-4d5f-83aa-80fe3bc733ad"/>
    <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/0630d680-dc13-4cb2-b95e-a3fa2a228eb1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d4acfe-bfa6-4e86-ba50-efc345afde8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25c9ce39-f6f6-404d-8006-41808a1429ca"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1dbe07e-977f-4633-9d51-ff78fdf8d95b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1ce5e96-2ffe-48d0-a553-974033a4beee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5c4a778d-98a1-4997-8ce3-aaf2424c2745">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/96d28e82-5789-431d-baeb-9dd86315f46b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4b9a4c5-fe02-44fb-85c3-1c7e88f80572">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
        <dc:identifier>HP:0003690</dc:identifier>
        <rdfs:label>Limb muscle weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e71ab154-deb7-4c0b-9fa3-2047490711fb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003738</dc:identifier>
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02105838-7144-4039-969b-e1e510d1891f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57ca153b-5f0d-4b35-a561-24e3a7b4991c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bb6b9c4-3ccb-4732-b6cf-9642beafa170">
        <dc:identifier>HP:0003394</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
        <rdfs:label>Muscle cramps</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08fad2df-4f59-47a9-a381-10af07fbb706"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98087a41-e4da-4051-830f-17494bcdd4ff">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebbff019-c444-493b-98ea-b3d2d8a408cf"/>
    <dc:identifier>DB00435</dc:identifier>
    <rdfs:label>Nitric Oxide</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f36d1639-051d-464d-a8c6-c21a24bcb10e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f94b92c-579d-46ec-9148-9ff2851d115e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c171519e-ac14-43aa-8831-2d0809ca2c77">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84cb189e-8fd1-4f82-b8fa-4462d4f48469">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b8dc229-a96d-44c5-9af4-e3feb7b6c4c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad2a18db-07dc-45e8-95c6-df1fd4eb5314">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
        <rdfs:label>Abdominal pain</rdfs:label>
        <dc:identifier>HP:0002027</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4721c16b-f622-438a-838b-23ceb880169a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f297d08f-b85d-4629-b41d-46389c280bf7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Photosenstivity</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e1b44e4-050c-408d-8533-c47c2da0d526"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f1db320-c93a-429c-a0a1-ac08bcb52a05"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aea39317-e81d-488e-b091-d29db57e5c11">
        <rdfs:label>Hepatotoxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d52cfbef-b88d-44c7-9b07-ec36e56d42ba">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08c48d66-25c1-470c-8934-da656f3a66e7">
        <rdfs:label>Acidemia</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3dd3086-aade-4b72-8978-ebd0a93b9499">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cec2c303-c912-4852-a6ac-f896a20f5bb6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/701aa5ad-a054-457e-b370-1be013523860">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b27b7bd-3058-4b8e-bed5-1bac6b65ff3f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/161f8ff5-f46c-4432-a47b-01312be2f9a5">
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:label>Myoclonic epilepsy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39a1b78f-fdbb-41cd-a9b4-db75f04306fd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef3c4fc8-4963-4008-8eb8-50e710959f5e"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/603d3a40-62ff-47ee-94b3-b28cb87dc332">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8abe4196-2063-4d29-a353-0b573a997aa2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8729189c-09e7-459a-b295-6f9bb4c7e827"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7b15968-4012-4671-92fd-c5ae0e8c6b11"/>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f70d751-e19f-45cf-9d5b-79f8688844b6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0ad31f9-90e7-4950-ba60-6e469e03e009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/cdb5de97-e110-4b8e-b4c2-08d613d1f5a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb3f2a33-8365-436c-be24-acd5e92c47f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37a4e4f3-76dd-4d02-a61a-5314029ab838">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001019</dc:identifier>
        <rdfs:label>Exfoliative erythema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e3da404-4c59-41cc-a418-55fb9aa2e230">
        <rdfs:label>Chronic diarrhea</rdfs:label>
        <dc:identifier>HP:0002028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c0373c0-bc77-4cb0-a185-43dc83db9b24"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16ba1113-e039-49eb-b987-7666b07bbc5b"/>
        <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
        <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a318a291-eff1-45a1-a78f-606bacc086ec">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bccb94b7-126e-4da9-a19a-6454c8a97e53"/>
    <dc:identifier>DB00232</dc:identifier>
    <rdfs:label>Methyclothiazide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13a049a0-371a-4a73-9a7d-9e00c0e0435a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>membrane fluidity alterations</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
    <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
    <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
    <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d5d9e9d7-30c8-4c03-b2fc-76c3e0da0e8e"/>
    <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77055033-fc03-4aea-8a00-08aab7555aab">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2564494-e585-476a-aa72-0050020d997b">
    <dc:identifier>DB09269</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/842c00fc-a946-42d0-bbe6-8cb7d1a170ee">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eaee23a-479b-431b-9194-b821c3f34ef8"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a11e8fb4-7de8-423c-bcb8-a9843f80be4b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <rdfs:label>Phenylacetic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/337674a3-bfca-448d-94d4-fab663a6d43c">
    <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
    <dc:identifier>HP:0010473</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c8b2220f-16cc-42bd-9842-6cbb2d8ff0ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a3b68a7-49b6-401e-b4c5-7b2a2fe74a10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ceb34f04-df30-4ec3-83c2-d63ce9d19d18"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d997f098-b4ec-4a1e-bc99-62db1bbe3fb6">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/575ee4ef-43d5-4345-b092-da3b01fbe103">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f43c21bd-e70f-4e78-889b-287abacc4aa2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79e9c0c0-4d9d-42d5-9802-1200fdb138d0">
        <rdfs:label>high fasting triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/28625882-751d-4057-aa48-1a878a25f74c">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44a5315a-0d2e-4994-9434-18dbb27492bd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/824fc419-f0af-4f35-b707-1aee10028a5b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67fecefa-f78d-4a95-9722-fcf6f70d06b5">
        <rdfs:label>Low HDL-C  level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a2e7bc1-f88e-44df-bd72-7b17a3edcbd8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/570fecd0-0830-4bb0-bc1b-bdd9a09bcba8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a72d0a47-5276-4f2b-b323-ad6070857899"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c04c52f-e877-4888-a645-b87c791c96f7">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ad11d51b-6a81-435e-bc63-80088aa368e3">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26930d1e-93c5-4bb1-8ff2-aefae5582e7e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7f7fd4b-d737-441e-aa0a-f4d6ffee23b0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59032ac1-82e5-4ac2-b4b0-218381c3eec0"/>
    <dc:identifier>DB00635</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <rdfs:label>Prednisone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ac2407c6-7b8a-4599-9c01-af5c7cd14986">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3e9c668-c9ec-4bbf-9905-a21b85d331c7"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1fd0da5-4800-4447-a754-09261de4eacd"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7f7fd4b-d737-441e-aa0a-f4d6ffee23b0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2acb0386-421f-4d3b-bcac-20a8cc3fd629"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3843832-8012-4575-85d0-cff725767972"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cc9b9617-b1d4-46e3-8b45-25311a3b3c42">
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cd0155c-5601-4665-973d-fabae59517e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1c76aaf-dff1-4a6a-9577-67ba58a43404"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ea17686-8a5a-4956-bc05-45ad93306723"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c132989-fd6b-48d7-a905-ff7e65c39236"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbd91ad5-01fd-40c7-b2aa-c13cc9c80d13"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7f7fd4b-d737-441e-aa0a-f4d6ffee23b0"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c93dcb5-1603-4fd3-86c9-56d1f7eb8ab1">
    <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7351b8cd-eb23-4400-9da9-8957edc64f57">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b2a0ffc-36ed-49a4-88f4-1a6007b4a7e7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6748a8a9-26ca-471c-b9ca-76c17e1fed41">
        <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12837870</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e6a373b-4cf2-498e-8e60-415be29b725d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5a12960-09ac-4645-b077-528b0fad28f1"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5b87b515-9338-4fbe-9bd0-144026c22e8f">
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0a97028-d71f-47d8-b2c1-f9f4dd84e713"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1be26cf-2765-44ef-8ab8-4bef5d9b4ce0">
        <dc:identifier>HP:0010978</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal immune function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4de342e-cd52-4433-91de-b0e80b3dc53a"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf677c87-611c-4e31-817f-54a794c126cf"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80091ee7-4b2f-4860-81a9-3f89d11e786c"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/45dcd73e-4507-4269-96d0-20bd5da53166"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a112f64-6214-42a9-a32f-69fc39c2df5e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39ead54c-0807-437a-b37e-079836932ab0"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81aa90f2-d6a3-4674-8779-d171f014a1b8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cdbe31be-e8e3-49a5-8924-77c2833be04e"/>
  </rdf:Alt>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/27e554e2-5675-4f83-b870-5464cf99f940">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/750879c9-36da-4305-83ad-91fa20d47cb3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d2944e6-b66f-4116-b012-e290152dfad0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83ce4649-686e-4b78-8a62-e623f7d6ce10"/>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a1cfa32-f793-46d2-b0d0-19fed95c3a00"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14503488-8e0f-4d17-b13c-40b3ffd51094">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
        <dc:identifier>HP:0001649</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tachycardia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abe9b423-01a7-4f82-b701-005382c16d6a"/>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8d0b08e6-d67c-4c80-9715-bbcbfef77d5b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4f5f4c4-8a00-45b4-9ebf-9cdb2d206234"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02046f8a-116c-4133-b04f-009cf6668f67">
    <rdfs:label>Low quality of life</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdae8d81-c824-4197-b1b9-f3eb24b99969">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001947</dc:identifier>
    <rdfs:label>Renal tubular acidosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3e9c668-c9ec-4bbf-9905-a21b85d331c7">
    <rdfs:label>dysphagia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
    <dc:identifier>HP:0002015</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5bd72ffc-e6e0-4596-a98a-ff35e00237ae">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1a147aac-3c28-48c2-98e4-48beb0d4a738">
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9928ff0-0934-499b-b14a-764923c979cd"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/579909d7-f3be-4795-9afb-291e2cd073de"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Isocarboxazid</rdfs:label>
    <dc:identifier>DB01247</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ad6c42b2-682b-4fbc-ac5f-2c40ed7e5bb3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a8ddd187-877a-4715-af0d-3c0cce19f5c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc75a8f8-b97a-4ca0-a4c8-a61f7bcfbdbe">
        <rdfs:label>Self-mutilation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000742</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f79cd8f4-2f6e-4b6b-9e71-48cf36821161">
    <rdfs:label>Abnormal cardiac function</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2da825fa-b4e1-4d45-baa5-6d8d99b05242">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>low physical activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/274313fe-17fe-4938-8e45-b85e6e609e26">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aea08f6b-4d1b-4af9-8e1e-8931b54348e9">
        <dc:identifier>HP:0003158</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced urinary osmolality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/085290cd-6810-4174-afe1-2c7557090a29">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum osmolality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7ab7278-fe8a-40cf-a981-95072c5275a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c30d5ff3-fee4-4574-8dcb-5ef97cd9f889">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20629f0d-c4e7-467b-bf36-f5980b615570"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6b3dc13-a2b9-4923-b7fa-5d9423377b5b">
    <rdfs:label>Amitriptyline</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/a4c76be8-5ebb-41e9-9158-0f017edab27c">
        <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22b3a342-67a9-4936-9ef5-367e0f0fe5af"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12f555c1-d719-4441-b75d-fab5bfccb673"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <dc:identifier>DB00321</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70c9243b-30d6-4314-b71f-c240af5f486d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26dff49c-e13a-448b-96a6-6df7c92aad3c"/>
    <rdfs:label>Cholic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6d386d4d-a786-4561-98e2-a29aff3886d7">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8517b0d-5195-488b-a9b2-1d4b028600b0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92275ab2-c104-4847-a3eb-78e418dd3b1a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6a51e84-d980-4c5d-819a-1fd483359515"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3558e4e-0e52-4ae9-84f2-14d49db046fd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42222e21-5a43-4e04-bf92-3af8ce9b2893"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8341ab2b-bd3e-4933-a45f-ce376b9fd2a2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5d5f306-24f8-4562-a333-fbf4f597e874"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71769896-0c61-40cb-af49-2fa44d9fdf07"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59a49a7a-6ebd-4238-85ad-1922ed2f0c76"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11924e7d-8d53-4172-9382-0ae49701c5ed"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4962946c-5a58-4ff1-b4b7-1305149da523"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/752ad2cf-a506-4c62-aabc-a2b2a4396113"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1c95050-6768-41f6-b710-9756f6344674"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f058755-3909-4d65-b6c0-1182e805f028"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB02659</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fb2f5e26-62b4-4db1-8c25-2920b6aff824">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
        <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
        <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/57f11abc-52e6-4671-bb07-356d8654f0b6"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8143c0f5-7474-4e6e-a765-02e63e321dc7"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/af11a3fa-7927-41ab-bac2-8383a0c45289">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9fe53061-9628-4db3-8e49-a3f20ee71e1e"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6106a1aa-4532-4cd1-9d0c-02c202290512"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c41bb84b-cb67-49cb-9b16-e5f39664f75f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/067e07c9-752b-4cfd-9a2c-d8da25a61dc8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a37813f-861f-4c4d-ad33-1dbb31d04c52"/>
    <dc:identifier>DB00688</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9e1bd737-05b5-4728-a55b-5eb38ff6a3a6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc1c288e-319c-474c-85bf-37add63ce866"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0db80b99-7a2e-4e2d-b45f-1a518ab80701">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40476a54-a25b-4d57-a4da-da6bde80bfca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a313a22-a82a-4c00-a523-b9a6f5e510f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b487683e-060e-427e-a108-a97207771a3a"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f98fa39a-835e-4c16-86a4-04006e37049c">
    <rdfs:label>Mecasermin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <dc:identifier>DB01277</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2f87641c-dc94-40ef-ba74-26c237534da8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60f0664f-3a9c-42a3-923e-f938f269ac2b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca4285a9-2acd-4d14-96b3-1dd76d225963"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec3bf318-6127-4b34-8ea3-2d194325c96d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/576f6f52-b193-4113-bf88-17397e3b670d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44b5dcab-3013-49d6-b7fa-d2a37380f43e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/212b2ada-857b-40dc-aa17-a47d38cce7ed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/285f062d-8058-496d-b147-a529ef771840"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd481a73-0be7-4cdf-b09e-41a6c2c476cb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e7afffe-a8a9-42e2-bc5e-5871c30b7dc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6af25ab2-0fa8-4764-bad4-231449be3ad2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2b96b44-1a12-4164-aafe-92498fc61adf"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2dffed7c-b148-4fdc-9859-11b8c4c25858">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29134618</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/974ceed6-752b-4a8c-af83-729883e290a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8279242-f879-4372-acd6-b3e4f9be728e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f38c3766-7d03-4b0f-ae98-bc4e52a94c89">
    <dc:identifier>HP:0001976</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e65a306-8deb-4861-9b05-4bf960a5ba65">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cd63027-c89f-4128-9410-6fc7b3f8de77"/>
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5f87b2bd-23b1-42db-b5d9-a28b22f235a3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff1d3dff-9377-436d-91d2-0e695701cf63"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8cced984-7f4b-4545-a0b5-6487534aded3"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/11214439-a035-4716-b471-551493af1957">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77572f95-a377-40e2-994b-ff93ed5b77a4">
        <rdfs:label>Atherosclerosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <dc:identifier>HP:0002621</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ef61a08-6517-4f8f-be6b-37245e6a491e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/929ddfce-e9b5-433c-9f34-b29e2e0b0c2d">
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5649611e-8d25-4c8d-868d-29a992567aac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
        <dc:identifier>HP:0005346</dc:identifier>
        <rdfs:label>Abnormal facial expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e87994b9-7dbe-4b10-aaf2-7d5a4af6e4d4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e9812a29-a7ea-4beb-9203-d3d17e760244">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/816c8e1d-2987-49f6-ad88-18ccd84fed9f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
        <dc:identifier>HP:0011118*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2070d376-4349-4abb-8d62-42626964ef14"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ead2c2e-fb03-4168-9632-4970b2ba4301">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <dc:identifier>HP:0012649</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Inflammation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68ac959c-4055-42ce-8084-448f2751f787"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7d078d6-4d75-4894-ac50-0b93b6f6595a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025460</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
        <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8375ec9-727a-438b-a67c-1c9af17c9564">
    <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd3a8f78-e073-4ce5-b098-3e38c49b6e2a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/03ccf189-088c-4578-a852-342472c8971f"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b9d98c3-92c4-46c3-b51c-96e74b2eea9e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/769a5b93-a64d-4557-aa7a-0b2b1cc2abaa"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <dc:identifier>DB01606</dc:identifier>
    <rdfs:label>Tazobactam</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ac69551-2e84-42d7-905c-d1aa02bb95a8">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4924f0b3-770e-48b8-80f0-b1971a5e065d"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9853cddd-5ace-47dc-b227-f1fa361abbf2"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f9142bf6-78b5-440c-a18c-63b73f76b53c">
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/957ea850-5f08-4c0c-9a5c-9809aa439f42"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/788c92fc-4f6f-4922-9acc-8066852c3959"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90c59b02-58f1-4223-bc8e-e448e33821b2">
        <rdfs:label>Abnormal walking distance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7b2f758-369a-4c16-8264-5514c830ea24">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
        <dc:identifier>HP:0011023</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33d14774-08e8-4920-a6e1-3f25c10daf29">
        <dc:identifier>HP:0012514</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
        <rdfs:label>Lower limb pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fab9ffe9-af73-4d10-bd0e-af16a6114bfb"/>
    <rdfs:label>CYSTATHIONINURIA</rdfs:label>
    <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
    <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a18fd961-0b1e-420c-a5be-aa3316522cd1">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee5e972c-c80d-4109-a3c2-deb22225a9b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d79b7572-dca1-4302-8060-0da1888f886e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f815294f-2dc0-4dca-8f18-e26c87406497">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a137c2bc-19c7-4753-9dae-0ef20e5b2478">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b03948c-8579-49be-b008-b7e5bcbd40a6"/>
    <rdfs:label>Biotin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2f102c9-62ed-4179-91f0-02af725530d2"/>
    <dc:identifier>DB00121</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae4d79b4-71ab-4c21-8f8c-2042dac66ce8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73e21795-ef72-48bc-82dd-4a7e70530cf4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/757d8457-253b-4344-a742-f15b4580c478">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8de71a3e-fff6-4021-b46f-b1d59a492a64"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/271e529c-eecc-4985-88dc-d558e78b66c5">
    <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003119*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/074ebc5e-cb5c-429d-a496-fd68db9e02ca">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4365afe2-b922-4a90-944c-86491c5700f3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Abnormal muscle physiology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/267c69f5-0489-4bcd-8a94-0fca4497f3f7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002180</dc:identifier>
    <rdfs:label>Neurodegeneration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b77bd08b-05c1-46f3-bde8-c16fa84be21b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>mitochondrial toxicity*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
    <dc:identifier>HP:0012103</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ef600696-0f0f-4f43-807f-ea99f2d0c97a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b4a52aa-700b-4d28-9117-32a04b4b0ae1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e167778-e7bb-48fe-b5e6-d79c735a7e86"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31b21ef7-fe1a-4863-9a03-286ce3849b68">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:label>Lack of energy</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1660351f-e1ff-44ad-b6b5-5d54f98decf4">
    <rdfs:label>DTX401</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e51e03d1-1650-4fb0-9edb-b85a0b9cf3ba"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf0a02bf-e136-4a1f-bb96-5be791936a54">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b3f607a-c1e9-48f6-8bf9-e534ed6a6164"/>
    <rdfs:label>Trolox ornithylamide hydrochloride</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b6d6c0c-76fa-420b-99ab-56a2117e85ab">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/4904e5d5-8ff5-4e0b-a980-04e93654d69c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c0f3448-55c6-40da-91f7-272f0c7a3453"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e62206b-5fe5-4755-bc7f-4dc856de60a4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e03f7d1-6e75-4406-985e-72ba1f75d64b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1fa3d38-9d50-4726-8306-9de1046f9737"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/20663f3f-fb5b-4ff8-94e5-75ad3f3ef638">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f337e5b3-fed2-4343-ba86-3b6f7ff7a8d1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB06151</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e7cd28c4-5adf-41ff-92a2-518a6f2f3f29">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e1d370d-8d96-456d-83b6-1d2c5857b442"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7ef780b-8c77-4f45-add6-1a59f17f7c0d"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7216f6e7-e9b3-429a-86be-5bb527a65a5e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e0f6449-3880-49d5-a102-bab619ad917f"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9812a29-a7ea-4beb-9203-d3d17e760244"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e9011ba5-7236-48a8-8295-60369c25b68f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c84e3f9-2311-4a15-a659-428c47c15ea0">
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46578862-b762-4d82-aebc-68385141bca1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4f248a2-a76f-4d1a-afbb-691b2eda3688">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d2f98fbe-0d1b-4cde-a647-85c7351d315f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d01467e-6c0b-4718-8897-ea4bffada29d">
        <dc:identifier>HP:0009830</dc:identifier>
        <rdfs:label>neuropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68cace00-c7ca-4c67-afec-eaf6632b7376"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7416c766-61ef-49a5-a1f8-5569fece4e0f">
    <dc:identifier>HP:0001931</dc:identifier>
    <rdfs:label>hypochromic anemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
    <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
    <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dfd2654d-bd41-4a0e-9031-bf9f3a359f0b"/>
    <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c8503aa3-8e6e-46a3-8ac5-07b30f99997b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:comment>Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/974ceed6-752b-4a8c-af83-729883e290a3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2f8cde2-5e3b-48b0-8f7c-687c9e5d46b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15bf221b-60ba-4d67-836b-ca573981a749"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7f0ce2a-9219-4243-b672-43be0926e445">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <dc:identifier>HP:0000964*</dc:identifier>
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60f0664f-3a9c-42a3-923e-f938f269ac2b">
    <dc:identifier>HP:0008189</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low insulin senstivity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fbea12d0-6736-428a-9472-6bd0a961bb57">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79f4ce58-31b8-47a5-89b8-7e8bfa8fe8dc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low COX content and activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27dfc365-3b68-431d-a31e-c69710dddc22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c41d1ca-c3c1-45a1-b78f-8c6c39d98ef9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9da9c21a-fb7d-429c-a703-2887faf9b1bb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidotic crises</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8c5dedb3-c66a-4232-8ab4-02eda2579475">
    <dc:identifier>DB09043</dc:identifier>
    <rdfs:label>Albiglutide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01be7229-0928-411c-bc80-4141b3adb846"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e0f6449-3880-49d5-a102-bab619ad917f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004396</dc:identifier>
    <rdfs:label>decreased appetite</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ceb47a87-bbe8-44b2-9adb-015382445cde"/>
    <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
    <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82ef51ab-413e-425a-8eb1-4559c1a14bbc">
    <rdfs:label>Vigabatrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28625882-751d-4057-aa48-1a878a25f74c"/>
    <dc:identifier>DB01080</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/15a05cab-cada-4481-a27e-bcff0969e859">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa712af7-e3c0-47a9-b686-96cb62447853"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
        <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5eff083-3e2d-44db-99af-48f49b66dedb"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44a5315a-0d2e-4994-9434-18dbb27492bd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5aef24b1-5aac-497e-809b-27939d2533b0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5c2d33da-2275-4c88-adcc-e1595c34f109">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44a5315a-0d2e-4994-9434-18dbb27492bd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3e92349-7fd9-4f5d-ab4c-83e640056bb4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012187</dc:identifier>
    <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/61be528f-3e48-4f59-bae0-89c94da355d8">
    <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
    <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39b04aab-00dd-4a31-b1c4-c5b34d83c649">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fff26291-df7a-473c-9ee7-b9acae135599"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c8c3e15-01b4-44c2-bcea-23249cca1f1b">
        <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d4220ab-3052-44ee-ba5c-b2a0b482709b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <dc:identifier>HP:0003455</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated long chain fatty acids</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3fe5ec64-4075-40ca-83ea-536b8cb2fa1e">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29b5e153-dbc3-4107-8a12-d9f574eaeae0">
        <rdfs:label>abnormal muscle function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a33e6da-d7fb-4079-848a-32c550f144d0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46bfea4c-f35c-419f-8ce3-ab6ca8a39e92"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0f54b3c-6493-4e4d-8ce0-109dbb762dd2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20eb230b-a8f4-48ec-87f6-a6c0a36fd29e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81c123a6-27bc-4293-a597-55c3e368647e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
    <dc:identifier>DB00755</dc:identifier>
    <rdfs:label>Tretinoin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fe80e64-c673-40b3-8936-5db9001dd731">
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0b607a9-35fe-447d-af94-fb8cbfd64b6f"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cc68eeea-6ce5-4d68-b06d-bda5cd722f09">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf9c3579-829c-4b05-8b36-b2f107a57cbb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c2508d4-96d3-4836-a722-a5a6bfb01d8f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7416c766-61ef-49a5-a1f8-5569fece4e0f"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cc954f65-3f85-465f-aa72-c1a2da1f69a2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8a94454-7d13-43b8-897a-5bbc8cb2fe30"/>
    <dc:identifier>DB03756</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
    <rdfs:label>Doconexent</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16c4873c-9708-4fc5-93e9-314300d8ffa0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c76b2ed3-ba23-48f5-bf11-2e1dd82658f7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7b8e702-026d-4af5-a6a8-aa320f831296"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5c02220-e825-433f-976d-332beeb58793"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5507210c-58a6-4543-9599-1f854ffdbabf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <rdfs:comment></rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
    <dc:identifier>DB00603</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4dafe218-1563-41c7-a334-7d135211b9a2">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/387d86bf-c1e2-4eb6-82a4-5f09a5efae71">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <rdfs:label>Diabetes</rdfs:label>
        <dc:identifier>HP:0000819</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36a64e0d-80cb-428c-89af-584dac7a5514">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c93dcac0-1441-4743-a859-7c2e5f22916c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67a3029a-5cb7-4f0e-b433-841dc42f874d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
    <rdfs:label>Abnormal muscle function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91e4e1b6-f1c3-4ca6-8740-a8f18c96e34e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/219c8f85-0b8a-46dd-9cdd-3ced94554b73"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <rdfs:label>Methotrexate</rdfs:label>
    <dc:identifier>DB00563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b27c09ab-daf7-4f0d-ad7f-f0d85f3d769e">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6ffbb590-e63d-4e50-8f4d-62e3047cde8a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95dcd614-02e6-4486-b9f9-496ea1e14ec0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1dde6e3-ce97-414e-8509-14a50cdd5b2e"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0562cf9c-86d0-434c-b7bd-6ba141c5bc8d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
    <dc:identifier>DB00311</dc:identifier>
    <rdfs:label>Ethoxzolamide</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ed57a27b-26db-430a-a6f0-07885e86e9ae">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5efd8659-0332-42b5-b053-51721e981b07">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
        <rdfs:label>abnormal central vision</rdfs:label>
        <dc:identifier>HP:0000504</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d18f3e22-236e-4f46-881f-bd35c955805d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16f02065-7df3-426b-9819-8ef7cfcc6e32"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11dd961c-eb5b-4a40-9232-ce433a3bf299">
        <rdfs:label>decreased visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67e60a99-3db1-4ec5-ad9d-59989e514530">
        <rdfs:label>choroidal neovascularization</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011506</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ee52cb3d-ddbd-4ff2-a549-bd9fe0bd224a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e562297b-6fbe-4001-ba87-227bb6d5dcea"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c46e9be1-69eb-479e-af0b-cd7002357062">
        <rdfs:label>Pain in the skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
        <dc:identifier>HP:0025280*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ef2fb8a-5084-4011-88e1-29ef1f456ca4">
        <rdfs:label>intolerance to sunlight</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07f74a62-af43-40e0-b999-bbb040cb85cd">
    <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
    <dc:identifier>HP:0200125</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/312d5ac3-1528-4019-84a3-e413bc585aa0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/848b2440-1975-447f-af9e-d3024e2b700f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/779e32a7-c8d9-4c6e-ad27-55f2f7dd82f1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1b59104-b79c-41e5-9917-4ed69a831e68">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a6401806-94dc-4513-96e9-c974e24a4610">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f0b1994-98a6-473b-8a2d-5082d0c1f2a2"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cbd12dea-a3cb-4069-8423-8d5eba26988e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB06667</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b341e30-d294-486b-9e57-bf1d5f4452b4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4568f246-fa19-4629-abd9-8134f74d7063">
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:label>failure to thrive</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/084b175f-ea7b-4df2-b38e-1021fd1340ea">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac20ab01-ed81-4091-912d-00f7550c694a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3904e018-4ed7-4b0a-9ceb-bc0a336ddd59">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/103e40c2-60a4-4836-beaa-65ca66899050"/>
        <rdfs:label>Sobetirome</rdfs:label>
        <dc:identifier>DB07425</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/ee3f1f54-ca18-4f7e-834e-7c6ebb41d7a3">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
        <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e77c9979-a509-440b-9681-4f05fa5a4848"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c0f3448-55c6-40da-91f7-272f0c7a3453"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4578be36-caeb-4826-a921-1334afcd1b12">
        <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fasting ketogenesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dee7343c-2cd5-4832-a43f-b6d0349b1154"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b3d3a10-8146-4ab0-bc02-375c305fe3f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/03bf4ff3-a43e-45d3-9025-8cf69f16a6ab">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3cfd7359-7987-443b-adf3-99d2b9e66c4d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7bac2d8c-6b8f-4f3c-8eeb-ad1ac3a71fd1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ff19fb1-c464-4802-85d0-c621f20d3471"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf1cecc2-c750-47fb-84d1-4fc2706a89a2">
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c1ce3f3-20be-4bb5-8a6c-b52ce6fab9e7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7dd43eea-93fd-4614-85f8-2877aebc7c87"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45315acb-7543-4ab2-95c3-200ed34fbdde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be74836d-8773-4a8d-b04c-1470f9b9b41d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8922ec2e-2776-4edb-9ec4-24b4beece02d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3e7805d-642f-43f6-bbf7-dc85a702c41a"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b8dc229-a96d-44c5-9af4-e3feb7b6c4c1">
    <rdfs:label>Activated charcoal</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
    <dc:identifier>DB09278</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c171519e-ac14-43aa-8831-2d0809ca2c77"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/18219654-4cfa-42f7-8d42-fa450c3a3882">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4932623e-dd5b-4154-a1bf-64e329857c25">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
        <dc:identifier>HP:0011943</dc:identifier>
        <rdfs:label>abnormal thiosulfates level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c3e8b5-2e39-4d04-9dc1-93ae45c463b2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17a46edf-0e35-4ff7-a28f-bcbcfbd2e26f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/826c7c2c-684e-43b8-8f7d-e23fa2684fb1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/4b8a5640-a9a2-407c-a28e-d06b5ed65e01">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/750879c9-36da-4305-83ad-91fa20d47cb3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83a65119-3951-47d2-95c7-bff1fa41a1fa"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79799b99-d7ed-4d14-b588-d730f07cffc6">
    <rdfs:label>low hemoglobin concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001931</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/965a6a19-a15e-4da3-a0d3-a2543a2363c6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>diarrhea</rdfs:label>
    <dc:identifier>HP:0002014</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/16b55569-a005-4722-b55e-d97914107236">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/188247e4-5120-480a-80dc-7d6d8808112a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f1e66361-0d85-468f-ab77-47b5c324b49e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e7750db-d274-44af-94bd-d7ad1573e631">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged kidney</rdfs:label>
        <dc:identifier>HP:0000105</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/328f49d5-5253-458a-a5eb-dc353f75bcb9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac21895b-0a51-4a67-b7a4-40f0c6029d97">
        <rdfs:label>Hyperuricemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6e8f21d-3e6e-458c-b81e-30e2859d50fa"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c05298ab-bf18-4bd3-95f1-5be4d9ec867d">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49330057-438d-4411-a3cc-47354b5563b6">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0df992b1-0841-484f-8f7e-71fea0500654"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa712af7-e3c0-47a9-b686-96cb62447853">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Focal seizures</rdfs:label>
    <dc:identifier>HP:0007359</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30c4f430-adcc-4dae-9b7f-d14a7c8c1c74">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <dc:identifier>DB00480</dc:identifier>
    <rdfs:label>Lenalidomide</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e114e67e-592e-4fa1-bbfc-e4046ece8daa">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34d4a636-3ecb-4e11-b973-620d98452ce8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55e71b38-7a93-48e1-8fe4-8fc14bf153c4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4884f69b-ea57-4fd5-941e-49ef2f94659f">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9853cddd-5ace-47dc-b227-f1fa361abbf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/712c497f-9e15-4f10-aaee-61cc8f290f69"/>
    <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6af03e60-df2a-40d7-839f-4bc0df44e447">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3945ae38-ce22-4ca1-a495-ab67320a071f"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a0fd5b3c-6c13-41f8-8bd4-af02bc113cbf">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6910fb8-4b16-4a97-be57-973c06b71db3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a427794-7154-43d6-9744-ce9a3ee40e3a"/>
        <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa0acee5-5240-4751-b230-d609fb71a2c4"/>
    <dc:identifier>DB00166</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/103e40c2-60a4-4836-beaa-65ca66899050">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d4220ab-3052-44ee-ba5c-b2a0b482709b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac20ab01-ed81-4091-912d-00f7550c694a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/55abcf5c-b815-4d79-bb1c-10154a9411ac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
        <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/90fd04d0-4c32-4881-877d-d3a7b502531d"/>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6928bbbb-5afb-4d32-b0be-0a7edaeb9d52">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:label>Osteopenia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8228a571-8c35-4ef9-acd1-9d24cc416cd5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0a97028-d71f-47d8-b2c1-f9f4dd84e713"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ff705a8-6fb0-493f-99fd-fc521950adbf">
        <dc:identifier>HP:0002718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:label>Recurrent bacterial infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f98a68fe-81b5-4b30-b0d6-c047f419301c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a6e1596-0cfb-4f2a-9070-0db9724194df"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a8cd6c6-373b-4455-a30d-0b787ed5bc7b"/>
    <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d79b7572-dca1-4302-8060-0da1888f886e">
    <dc:identifier>DB04263</dc:identifier>
    <rdfs:label>Geneticin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a18fd961-0b1e-420c-a5be-aa3316522cd1"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/57ad8b34-c532-4407-81c8-8fcce3cc029a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/16691ac2-486d-4866-89dd-f3bb31e4913e"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1099973f-f586-401d-925c-b13f97c12400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9d35f2e3-d8ba-42ef-a051-ace9cbde3d85">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ebce5da-c96e-455b-836c-b0f8013b0ff3"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72c86a28-fdc4-4c68-9ee1-7b152cf494d5"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e93b573f-3323-49b5-8073-8738251012fd">
        <rdfs:label>Muscle inflammation</rdfs:label>
        <dc:identifier>HP:0100614</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bce4d8db-49c0-4574-9824-58eac5799fea"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ba8c5de0-3fbd-4523-87a6-a73781c0122f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3505b172-ef95-4925-9b3b-3af60824264c">
        <rdfs:label>Hepatic steatosis</rdfs:label>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6545cce-5143-4e76-a862-91520ff9caa7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b5df7d27-e3d1-497c-90d9-ab98ba8de06b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b7512ab-48c9-4b0c-92bb-b7dfbd49f8bd">
    <rdfs:label>Abnormal Fukutin function</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4eedeab4-47b6-4891-925d-98d9fa161b23">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1627f28c-8cbd-4c90-9fa1-a5bf0725fc7e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de0b4e3e-4b43-420e-b7c9-95a3c36d0fa1"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6010639-5f18-48ff-a8fb-fb8e771f3d34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c83dd151-4558-427a-a250-27d613395c1a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ef9d6f4-eba3-4855-b168-a33c009bf410"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab6de101-019a-4f23-8f51-f7f4f3aba61e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66708463-d067-40fd-8357-9445fadd8621"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58779253-0f78-4d9a-9302-286e0d687218"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05e776aa-7bcd-4566-906a-5dae174ab386"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>L-Glutamine</rdfs:label>
    <dc:identifier>DB00130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7002f2f5-bdfe-4092-bd78-024ddb138642"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c1ba74e-e2d6-45f7-9246-4b21ee76a63b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
    <dc:identifier>HP:0003077*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/654e5fd3-65b6-4b0a-ade9-5901b581b2b0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfb2e9f0-315e-4d2b-9878-a0a615d72ce8"/>
    <rdfs:label>Urea</rdfs:label>
    <dc:identifier>DB03904</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e89de4fa-fb27-4a37-8e4c-0911bc4d2bee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13ad5633-0063-4be2-97c7-daa825eae156"/>
    <dc:identifier>DB12528</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27aa38df-078a-4112-9599-a56ef34af1ab">
    <rdfs:label>N-acetylmannosamine</rdfs:label>
    <dc:identifier>DB12536</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3308f77-192b-48a1-83f1-57e6dea4beed"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cf8f5157-6483-4e79-bf26-8a35057f8f35">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb8a2d32-234d-46ca-8d1b-2ab3e5164c5c"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
        <dc:identifier>ECO:0005242</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e03bd0cf-5420-4e7b-ac62-1818fd446306">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003676*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1a3c599f-834b-4867-93a7-5c652b3597cb"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c04b197-4a19-48f3-8d51-1fa76201cae3"/>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a3fdd025-07b4-49d4-917b-4c72023dd189">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6fe400e9-1715-4228-b2cf-e4c6a4abac27"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <rdfs:label>Bromocriptine</rdfs:label>
    <dc:identifier>DB01200</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5bdda515-ee70-4d30-b17a-02604bbf39e7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9f2e2da-c196-4012-9fea-4ec61c02bec0"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28c4664c-877f-422e-a084-17bdbaba35be"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300818"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/159b6bee-1129-4eb7-9aec-8db33500a234">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b7512ab-48c9-4b0c-92bb-b7dfbd49f8bd"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afebc4b0-5573-408c-8c91-0660522bf0fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c324bab5-5322-4291-9ed9-5a3e8665ce1a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a12d7982-5f40-4f2a-a881-cf8e3278f027">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92c1f9c2-bb6e-4903-b241-7f70cf04e0da">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011042</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36cd2e49-a76d-44e7-aa97-f29c5b481cb2">
    <rdfs:label>Brain damage</rdfs:label>
    <dc:identifier>HP:0001298</dc:identifier>
    <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6aa952e5-d723-4652-9566-b7474681d7bd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:label>dysarthric speech</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001260</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2411279-4411-446c-b680-a2b7f59fe6d3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
    <dc:identifier>HP:0002540</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>loss of ambulation</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5da237c-4a7d-4595-928e-a98d8f19a5c8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/468f3ad3-ddcb-4d9e-8e1e-63b40741f014">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/160481f9-64e0-4449-8710-6317916271f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d21d5bbc-f9a2-4f4f-9eeb-98b0247d86f8">
        <rdfs:label>Fat malabsorption</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fcc84f0b-e476-433d-ac57-567fc408fbfc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/12dc60e7-80a2-4e56-aa87-c8141f184145">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/546111a0-ffb5-467a-80fb-64d5ea82292b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/373f66d9-a13d-47fe-9e82-cf58fad42e5d"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Olanzapine</rdfs:label>
    <dc:identifier>DB00334</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed2e0576-aa23-4451-9bf8-6e06d558df53"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/871e6c38-e930-4c8a-98fa-0d3a33795acc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6be854a-77b2-420a-9803-21a548e1a1b4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1687da6a-f2f7-4da4-9e61-42445bb3d818">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000155</ddiem:url>
        <rdfs:label>Oral ulceration</rdfs:label>
        <dc:identifier>HP:0000155</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f63372ca-1f17-438f-b039-e1e7ca8c4692"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50eea66a-0e0b-490f-8d9d-4e10308286bd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7219853-e288-44b9-ac8d-fa421a562592"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/18772f79-1bfe-45fd-ae31-40ffea23cdf5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/226dc85b-71e5-4b9a-b9d4-004dc884a2f3">
    <dc:identifier>DB00244</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3da865d-8813-48b4-b954-c07cc72c1977"/>
    <rdfs:label>Mesalazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09801dd2-f331-406d-a419-b28faaa79b11">
    <dc:identifier>HP:0002066*</dc:identifier>
    <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a81ec3d0-5c74-4572-8845-b7267fdbfefa">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>decrease muscle strenght</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb939cf0-5739-49c3-b8f5-5e998c42e094">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
    <rdfs:label>Lamotrigine</rdfs:label>
    <dc:identifier>DB00555</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24b9fe89-ab2e-4d0f-a408-8a4fb415eb67"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11c3b432-88ce-45c5-a3dc-9df00c4a9abc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bf353dd5-4e3c-41c4-9763-816223784dfc">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22452ff9-1234-4184-828e-588a7c621284"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a2e2080-4fd7-4a11-bf57-f87bdf46718d"/>
    <rdfs:label>Phenytoin</rdfs:label>
    <dc:identifier>DB00252</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a3d29f5-1d69-4860-bf8b-12da3f8e9560">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <dc:identifier>HP:0004359*</dc:identifier>
    <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e82b1eea-e53a-43dd-a255-d520d5c67876"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
    <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f43f426c-8948-482f-b533-abd0bf51ead6">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c45f29b-6b46-4081-ae8b-c1e6d64f3707"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b7d3801-92af-465e-b782-330e1151d94c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f273e556-3e08-47f1-8f4b-9cc699aac63e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/416151cd-7f42-4bbf-beee-0a2ecf0098e0">
    <rdfs:label>Vitamin K insufficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc6f46cc-6425-47d2-8aa2-1a18388533d2">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000407</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
    <rdfs:label>Sensorineural hearing impairment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf871e8e-deb3-4f89-bdac-a8e6682d32f7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High triglyceride levels</rdfs:label>
    <dc:identifier>HP:0002155</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f5a87c2-748f-42b4-91ed-abe59d660161">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <dc:identifier>B05BB01</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5604ec00-cbb8-4eec-bf05-fc35a1103237"/>
    <rdfs:label>electrolytes</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0702b3e-cae8-420d-bbb1-f4b2a93b193e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <rdfs:label>High calcium excretion in urine</rdfs:label>
    <dc:identifier>HP:0002150</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/055356ef-893d-4301-a19a-9fe97849d663">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3505b172-ef95-4925-9b3b-3af60824264c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46819907-b8c9-4870-81b2-c3f189c603c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e2e2ac5-0561-451f-87ee-ee6cbedca4a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c1ba74e-e2d6-45f7-9246-4b21ee76a63b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78a623a5-7061-4b3f-9d29-9329c4c7ff7f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased physical function</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee09af5d-92e4-4a92-a4fb-bc4dac2df994">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012759</dc:identifier>
    <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7e9e714-8348-4f0d-9a98-34461848590e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6887625-4072-42c3-9a99-ef42adcc7e45"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f010fd17-4ff0-4956-ba7b-36f83e178517"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/074ebc5e-cb5c-429d-a496-fd68db9e02ca"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc4f5013-6f2c-4f33-8b00-995ee5fe79ae"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7351b8cd-eb23-4400-9da9-8957edc64f57"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee3f1f54-ca18-4f7e-834e-7c6ebb41d7a3"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8d8223b3-51a3-4759-a56b-f2366cbcccdf">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f81cccb-039d-4b0a-9ac2-7da9cc83c2f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67689a9d-11d7-4584-a378-42cc4294e2e1"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df2340b2-4c0a-4cbb-a0d9-bee250574b2b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07f74a62-af43-40e0-b999-bbb040cb85cd"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad3d195d-d295-408a-9aa3-5fa9a41b870b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aaac5823-0eec-4a59-82b8-ad352858f662"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c05298ab-bf18-4bd3-95f1-5be4d9ec867d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82f15497-358f-4d61-9aa7-777e090e5d4b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3015242-72c9-43c5-9000-e82e7782e26c"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/15b411a4-0eca-4bb7-890c-3367f05c261e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b77badf1-490b-4450-b8eb-eaec56ae16cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8e0c69c-03ba-4f7e-b368-d7f43b53e5ad"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bbb880ff-f364-465a-b8d2-42ff6caf8b50"/>
    <rdfs:label>Levocarnitine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3bd06f1-2988-4ea2-a1a1-2ea013b1655e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9c11633-c55c-4ba8-86f3-a3920713a868"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09db3881-b71a-4378-897b-c0b0d8caea95"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9465de3-d486-41f6-ba6b-573af71d1f2d"/>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a36891a0-976a-48a1-b541-93988929cf96"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/951b8733-91f4-4fb0-893c-742760f7e1cb"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51216c86-d1d5-497b-ae7e-9b138b9004d2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65071a8d-089e-4141-837f-82df778cf2d7"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39c356cd-997e-4517-b6dc-511aa97ca72f">
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f0817ca5-d2f8-4e12-82f0-8a3fbc3568f3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70670ed7-41cd-4f20-927f-9aa1d0824cac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f17a14d7-38ba-4d74-941e-3c8fc6425919">
    <rdfs:label>Topiramate</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ba99f7b-1222-4afd-b02e-c1431cd048b5">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e242f4dd-471f-4bea-b315-3bcc694c786c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0338bf0f-04ac-49f3-bde9-bce48384e7b8"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/11be0db5-4baa-4198-914a-d431988ce981">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e242f4dd-471f-4bea-b315-3bcc694c786c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00273</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ba25f0d-c5f9-4c75-874d-2767e9823775">
    <rdfs:label>growth impairment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b0c94736-4dc2-4ebf-a222-c820423f4ab7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00c0e7c4-b51b-4ed7-877d-78886d5404d5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccb129fb-55d3-40f2-8fe3-9bcd70aef4b1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c0f3448-55c6-40da-91f7-272f0c7a3453"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/781d0ffa-6ad8-4078-ae3b-6c48396f8146"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05586586-02f9-4bf4-b89a-668cd24590ba"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82dac0d3-ea0c-4ad6-baa1-a586f681fbf1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2378314-0500-4ade-9431-b6963b97e434">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0020582</dc:identifier>
        <rdfs:label>High cermaide level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fbfa96a9-9c76-448f-93f4-cb1080983019"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4cd58258-4314-4298-b97b-e7b70a8fc1fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b528d009-e5df-4592-9d77-571f7e02cec0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c97b0c04-241b-4037-a06e-f9cd84ac3b17"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3230a364-c6f6-47df-b1ed-d51d5aa79fb8">
    <dc:identifier>HP:0003434</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/45967b27-5978-40c4-ad7f-30c47354de8e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdf872e4-5b6d-4e62-8339-0a78eabb88db"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/124e885f-713a-4299-bc51-fcc167476b65"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef0e79f7-214c-46ed-8ab7-f80ed8a00e86">
        <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6f4c18ee-4d2e-44be-9f3f-d09b8cfd11ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8341ab2b-bd3e-4933-a45f-ce376b9fd2a2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/38e20b40-f738-410e-b7b9-a19fd84e33c4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13d8d4f0-3381-4a2c-854a-19ed8afffed7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <rdfs:label>Potassium chloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4580544-607c-412e-80fd-9ecbc91f450b"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/be04ab60-7af6-42ca-8b2c-69bd9f65e05e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3018468c-8874-4249-8b0a-1bad6e0990e4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e985268-e1d2-4de2-9c39-7cd81f7c090c"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00761</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/126e2271-6af9-4f43-b9c3-e5b40d392abe"/>
    <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d125601-5fa0-4b8c-a5ef-adeef056ac84">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <dc:identifier>DB14992</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcae384b-d864-4818-a7d3-bb4b9b339341"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/198eabed-68d8-4a7a-9eac-56b9bbc1cdec"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b18fd3d5-7b82-4240-adef-f90a5eaef9ce">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f8aa26a-108b-487f-87f6-0ebb118fd9ed"/>
    <rdfs:label>Fluoxetine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <dc:identifier>DB00472</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/26ac2237-b845-41ea-8a4e-70a35ec03bb2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c89b5f0-bad6-4309-af1c-299deada88de">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/945ba616-8dd4-4b5d-91d0-4661e64a91e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d863766-1d8b-4bc2-9c7d-0623e132231f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa8c47a9-149e-4fa3-8af9-2f432c6b9955"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3896da61-237a-4a6e-b8a0-04b348a5ab60">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c4ae2a57-857a-46df-a657-96ad70bad77f">
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9174fbf-d714-43cb-8e4c-ab3becd9b018"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fe4e4d0-d249-4351-bb66-3a326d9f7c52"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Selenium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <dc:identifier>DB11135</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f9aec8e6-b356-41ca-bb5b-7d7ea6bb2444">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e05183c2-be3a-4191-a658-95b37c5af81b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1270e636-6354-47b6-9c2d-c4a15f3af99f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/594bdfeb-8f98-4e2e-b936-611c24bfb501">
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fb7c1fb-e113-4192-95be-258270468a14">
    <rdfs:label>high serum alkaline phosphatase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
    <dc:identifier>HP:0003155</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c346dbe3-d7fb-4d1c-abda-be0f486d57a8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e0cd14-5985-45e5-86aa-6ffcf41f5349"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/882eaa4e-adad-4b36-850f-07749026ec83">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004348</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:label>abnormality in bone mineral density</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20c1d857-a57a-4c08-9c94-3884d21891a3">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/46cfe9b0-129a-4ab6-ade6-a685db6b16c1">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/feacfbb5-4e9b-45b7-910b-1ac09672625e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9352005-d816-4afd-a85d-e2047e8ad0d2"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d138e27f-1ff6-4d25-b4de-42e5669536f5"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64cde555-e0df-48f9-a38c-290c2cbb35ed"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Digoxin</rdfs:label>
    <dc:identifier>DB00390</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d60f6998-40c5-4a3d-9546-0a2372f8f73e">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0b804aa-3094-4931-9e15-1ed9b7b94088"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de14a043-acc9-453b-8f31-c61516efc038"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d98e258-d2af-499e-8667-ea180f382f06"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bee94aa0-8e3c-427e-975b-2f2406c82a96"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d59ec338-3aad-4ccb-8a0c-0a71115ef5e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83ae0923-0cfc-4436-94c2-324cda6a6286">
    <rdfs:label>Abnormal aPTT level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
    <dc:identifier>HP:0003645</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/57899c5c-06e1-408e-ae60-57d61d29712f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2077cea-ef6d-4e20-8937-9c0db8c12b6a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa2697b4-a942-4b9d-80eb-2225264b9349">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:label>Abnormal growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a6439bd-5199-4555-ac1a-8210a87a7162">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c80b7f7-58ed-41fb-9815-98014e8b731c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96d6edf8-e71f-4567-a42d-8630bd4edd6e"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/119c12f9-491d-4c3c-bffa-839d8638c9d1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/914f28dd-fe46-411c-9ec2-af18679b8656">
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2cac432-d41f-49ce-8c20-e5b1927644f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c1288fd-280d-4142-a074-d3655c3b3ed2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/517e8b4e-3c1d-4b6f-a8a6-d34b24318e2c"/>
    <rdfs:label>Deferasirox</rdfs:label>
    <dc:identifier>DB01609</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d2664ea-a56c-43d1-af34-d5cff7936baf">
    <dc:identifier>HP:0012379</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low enzyme activity</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e1cf0e6f-7b37-438c-84e3-35b0e2ebce34">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aeba6a9b-28e9-4072-9e40-283dbfa4d051"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09894aa8-75ee-4975-a8ca-91552ad20733"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/afebc4b0-5573-408c-8c91-0660522bf0fe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4248451-4fb4-40fa-9a9d-6a55e3797201">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>congestive cardiac failure</rdfs:label>
        <dc:identifier>HP:0001635</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b1715c6b-bb47-40ea-90b3-faebaaa0b63c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62dfe729-f632-4fb4-aa6f-27cd29ff4381">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <rdfs:label>Albuminuria</rdfs:label>
        <dc:identifier>HP:0012592</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6b4ff2c-4685-4fbd-a160-183e23b418c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000100</dc:identifier>
        <rdfs:label>glomerular proteinuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51589918-6964-4c52-9bf5-93c236235525"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c552c7a5-1e97-4211-92ac-4d58151b3f33">
    <rdfs:label>Entacapone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/689e9398-aeba-4666-9c9c-bf8863ef7773"/>
    <dc:identifier>DB00494</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b04f7fca-a11e-445b-9177-ff033af4c9ee">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7f0ce2a-9219-4243-b672-43be0926e445"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f04cd077-b78c-4203-9bc3-181da1ee4180">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb3a3f7b-3ef7-406d-afaf-dc8a7fd7d848"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a79a0bf-3fdf-48ee-922d-98eeb1f32306">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/575d20d1-0903-4a66-8cee-19d18ffb5788">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203700"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b8869ab-5925-4ccb-9928-ce3645571eed"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b2941a2-111a-457d-8195-98f1f88f5e4a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <rdfs:comment></rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB14513</dc:identifier>
    <rdfs:label>Magnesium</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9c26edfe-1385-4b11-9ceb-20cc73de6bde">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce2507e1-cede-4a83-a35e-d3a26bb01414"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b8869ab-5925-4ccb-9928-ce3645571eed"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcff4682-2bdc-4600-bbef-7e839681b937"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9d4cce0-ad34-4d4d-85c6-c148e1de9ee5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4746237f-9249-4997-aa03-b9fac374182b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/842d0f00-ad26-412e-8060-be10004c3627">
    <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
    <dc:identifier>DB09449</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43190f8a-aa17-4032-b9aa-19d2b68c85ee"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1899252-f981-49de-bdd5-f25ce8bed343">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001609</dc:identifier>
    <rdfs:label>Hoarseness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4dbad90-711b-448e-9c6e-fff83622eed1">
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ee990e6-7589-4998-bcc2-d430b9cae67a"/>
    <dc:identifier>DB00098</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/940fad52-df38-4266-b6d6-8664b9a562ef">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <dc:identifier>DB05294</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/183ca1ae-ebde-4526-bf15-227e9ee7bb2c"/>
    <rdfs:label>Vandetanib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84281e82-9642-4c9c-9ce2-671fd70ea0a7">
    <dc:identifier>HP:0012446</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>depletion of cerebral folate</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/24ffcaa1-49dd-4756-90a2-94f5cfd375a6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d23823b-b7c4-49b0-82dd-49f7521b9ca0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
        <dc:identifier>HP:0000713</dc:identifier>
        <rdfs:label>Agitation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70f4670f-1b73-425d-9082-f6ee68f96f09">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized convulsion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6271480d-6ea3-461d-b8bc-2ad63f5121cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c5049d9-68fd-444d-b649-213e608b78af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9fa545e-f290-4cd8-850c-a6bbf3363c39">
        <rdfs:label>Complex partial seizure</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17657a04-f4bc-45e7-9159-ef0bb4fcbdd7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01008385-242d-4754-93d7-8b9d054ce51a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c9ae306-d5ba-400e-a0a3-a2ccfcbb2142"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ccd62e4-a383-4dda-bb49-ae57e6080709">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e27ec53-e128-4573-9a1f-ed88e7e899f5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b626206-f74a-46a1-82d6-c176c2849574"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1be26cf-2765-44ef-8ab8-4bef5d9b4ce0"/>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62a448cd-0fb6-4b1a-bd6f-4874d7134713">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
        <dc:identifier>HP:0002960</dc:identifier>
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/586d41f9-7d24-4799-bd0a-a2df3062fa23">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001433</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5db3dd2b-df91-4515-8d6e-445228297f2a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
        <rdfs:label>lymphopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001888</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/772ed99c-e3be-4556-a853-49f1e49b405a">
        <dc:identifier>HP:0001879</dc:identifier>
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00cab11c-25cb-41fe-9469-f88e458be120">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a83ece3e-726c-45bc-8d48-65cb79409a1b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e77207bc-9540-45ec-b4bf-4a757797ea84">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd528ef4-43a0-4624-803a-a7b09556ac4e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d2f98fbe-0d1b-4cde-a647-85c7351d315f">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/03c6e56d-e964-42d2-84f3-581a9b2c650a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fe06818-6cf2-4033-bcd4-cd41eff404f9"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d98e258-d2af-499e-8667-ea180f382f06"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4f248a2-a76f-4d1a-afbb-691b2eda3688"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89f1f16b-0922-45ed-8348-5e1195dbbd89"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18916634-1d56-4631-a4f0-d9c6793edba0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/389a2d19-8099-45f8-9451-291833764f1f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abaef7f9-fee4-4eff-bb3a-cdea12fc33c5"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a91b3cff-149f-4275-a9f3-fd726433b721"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
    <dc:identifier>DB00053</dc:identifier>
    <rdfs:label>Imiglucerase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69a59261-e518-4aee-9d66-e01a44a6bb41">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/49556541-2524-416b-a2d7-f9b4bb66318d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dcb855f-9fd0-4592-8511-cedd4951dc91"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9df2f1e7-6363-4dee-b754-042bba2d9ca4"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50052a8b-d901-4983-a3b8-61283f4f239b"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/212b2ada-857b-40dc-aa17-a47d38cce7ed">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal circulating GH level</rdfs:label>
    <dc:identifier>HP:0032367</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b743b979-3eb6-42db-8a9b-2b2bd4f89da0">
    <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18a24340-2f71-431a-b6cc-ec2400a32e56">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Periodontitis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
    <dc:identifier>HP:0000704</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46bfea4c-f35c-419f-8ce3-ab6ca8a39e92">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fe5ec64-4075-40ca-83ea-536b8cb2fa1e"/>
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0308b14e-1781-4b5a-9285-713f37a0564e">
    <rdfs:label>Decreased cellular ATP level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011925*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
    <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b872fe3d-0243-47c9-b742-cb2d379cf60b"/>
    <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
    <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/36a74143-212e-4a2a-856e-058a33609373">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5586569</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0fe1f90c-7952-482a-894d-8da7638c9f22"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d2664ea-a56c-43d1-af34-d5cff7936baf"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2cb7b9b9-a08d-4c1c-b58c-8514a2ea2a12">
    <dc:identifier>DB02952</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02952</ddiem:url>
    <rdfs:label>Alpha-Aminoisobutyric Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f8d20bf-0f45-4b4d-8cf9-24a438b8b856"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c60a132d-982b-48f9-af9b-bcd06249fd49">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/161f8ff5-f46c-4432-a47b-01312be2f9a5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b41dd322-dc57-41a5-aa35-8cfdd9da8645">
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e0cffde-c726-412c-91ea-0b70406b76cb"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/638c9e56-e17c-4000-81ba-5deb96d73fca"/>
    <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c905bca-df71-46d4-8582-bf77a292e95b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36a64e0d-80cb-428c-89af-584dac7a5514"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/224d56e5-492c-4504-87ad-a8c75e0b6451"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f02a66a-4158-47e3-86ba-4780b9e4b43b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <rdfs:label>Insulin Aspart</rdfs:label>
    <dc:identifier>DB01306</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/131f41e7-b924-4ac2-9bf8-405fb553c720">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6e059043-e82c-40b1-9293-1d624c8b0e3c"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fff26291-df7a-473c-9ee7-b9acae135599">
    <dc:identifier>CHEBI_15724</dc:identifier>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61be528f-3e48-4f59-bae0-89c94da355d8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e40457e4-82ae-4b67-a8f9-7449ae9ee98a">
    <rdfs:label>Bleeding tendency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001892</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e2e2ac5-0561-451f-87ee-ee6cbedca4a6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
    <dc:identifier>DB05990</dc:identifier>
    <rdfs:label>Obeticholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/055356ef-893d-4301-a19a-9fe97849d663"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3ff602a-d056-4fbc-b024-60ac45e7a566">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
    <rdfs:label>Triamcinolone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/60f594e4-596c-4407-889b-0f21670cf79b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d57ec92d-3f6b-44b2-b229-ea03494637c4"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed02ed35-5f67-4704-a3c7-ae938c7a0a38"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8258ee6-8859-4a4b-8460-82f92a490496"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db5ea088-7d7f-4afe-beac-18e2f7568779"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00620</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b47b6600-51f6-4256-bce9-8bb15111eef8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79d23ee4-951b-4415-bae1-4c58b8975cf1">
        <rdfs:label>abnormal muscle strenght</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79f66877-7a7d-4abe-856c-8a89db85a5e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a87366d-bcf6-4be0-87c6-f21776851a3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/069fbe0b-51bc-4db6-9ebf-9fac22a8e69e">
        <rdfs:label>Muscle atrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
        <dc:identifier>HP:0003797</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b8587f1-a0be-4aaa-a721-e7a7b5c4ee8d">
    <rdfs:label>Iron</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/967b6781-70f6-499b-8b2b-dcac97d4f278"/>
    <dc:identifier>DB01592</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/df49dced-b5bc-4ed4-b8a6-a82f5855fcd0">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63600574-5939-423f-9eae-77308fb7c043"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65b92dc9-0380-4699-af8d-48ddf7aa09fe"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d775e5e-ca0e-4139-8d5b-5ec5f276c500"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c52bd00-d51e-429f-b8c6-61f7cf8bf8e0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
    <rdfs:label>Synovitis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100769</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/de560661-f85a-4d51-8d5d-5e0f46b108cb">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8cf391f-d2dc-49e4-a4ac-ff0693666695"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac690927-7f34-42de-9c13-1ed32b9a53ff"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55257229-024d-4cdb-8245-003656463477"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1853b34-646d-4e00-9f7e-6a31a88926dc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ceb34f04-df30-4ec3-83c2-d63ce9d19d18">
    <dc:identifier>DB13961</dc:identifier>
    <rdfs:label>Fish oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8b2220f-16cc-42bd-9842-6cbb2d8ff0ea"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78eeeb2d-f5ea-49d9-8998-c7d47fcef259">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
    <dc:identifier>HP:0003800</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41307c6a-3c8a-4674-8f0b-fab9b4690586">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/940034c6-2aa8-48ef-88a7-178f48cd2b8f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f300ff0d-d1ea-49da-9109-9eb6f02547f0"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aab584af-dad5-4721-9024-51db1c56871e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5d7e22e-1845-4f62-a6b6-9966053bc20b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57901a4c-89a5-464b-a7c8-315cade5b476"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e27bef0a-4769-4678-b1a8-1d6cc96bbb3a">
    <dc:identifier>DB00695</dc:identifier>
    <rdfs:label>Furosemide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0269237-11a5-42b4-a850-da0c29d47028"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c440df4a-0480-40e1-afb4-3ad70941cfed">
    <dc:identifier>DB00230</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/406e8f34-702d-460f-9bad-057b5e279110"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
    <rdfs:label>Pregabalin</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc2d46e0-fedd-4e6a-b93a-f4ad3c5fc158">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5785c771-9aa2-4757-8854-dc3f8bd5ed80">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4f525f7-fbc7-474d-91be-98512380706c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b74f86a1-da57-49bf-87fb-a312cc864575">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7704294-2e4a-4f4f-b4b1-898c2e124155"/>
    <dc:identifier>DB00700)</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/27488456-4089-4d90-9d8e-55e61a2c157c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99468ffd-ab61-4f95-9ace-93c1dbe0a10a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2411279-4411-446c-b680-a2b7f59fe6d3"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca44c2e7-dce6-4b2e-bffc-92a6f74114d5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c049725e-3e34-48b3-8223-01445ac76b91"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4208be5-9b6b-4cc8-8cf4-40c56514a447">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bcd1c44a-27ed-4bf1-9499-a577805f922c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc1c288e-319c-474c-85bf-37add63ce866"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d67b18b6-1433-4f36-8e40-10c85a37c159">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d35c9da-c43c-4292-9d62-f0300c21aa5b"/>
    <dc:identifier>DB03256</dc:identifier>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef6661b5-18af-4a5e-8242-8bffad2edab9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3d14ab35-f83e-4db7-97a8-79e2aeacb3f4">
    <dc:identifier>CHEBI_32362</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/57ef4141-6117-420f-8818-b457d3914e20">
        <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18715265-eba3-4742-bdf9-69df63ebd818"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e20ba084-e661-40f5-ba17-1d60530697ff"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b50ea348-11f0-4baa-8c04-0f08b5b1ea18"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>enanthate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/480d7dd3-e940-41a1-9742-827d77d11b29">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec8f9cc6-26d2-486a-adf8-bb04b9b36f0e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0396009-f894-4b95-9cc2-03efccf86ba7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <dc:identifier>HP:0007166</dc:identifier>
        <rdfs:label>Paroxysmal movements</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42b075da-bf2a-4b8a-ace7-09dd2a569604"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e0549be-76c4-4b2f-a539-8cff85fdbee2">
    <dc:identifier>DB04272</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18af33b0-6038-4d3e-b97f-7603fe765f21"/>
    <rdfs:label>Citric acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/989e27b5-dbf6-4dd2-8e0a-2395a3b99b20">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4de342e-cd52-4433-91de-b0e80b3dc53a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fbf16b1-bd00-4836-aad8-3175a886294f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76e0094d-401e-4db9-a37e-aa44bba99f9b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a23641b-b158-4f87-80c9-9cfa4227fb89"/>
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <dc:identifier>DB05481</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/369f80e8-0218-4b3b-aa7c-668aa5e790d7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e8897f6-ee4c-44d9-b428-853e2308aa5f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Poor swallowing</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e2d3c1e-1f48-4fec-9f19-29feb30b46e9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/267c69f5-0489-4bcd-8a94-0fca4497f3f7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c072f54-5164-4e61-9ff1-0caa64c4f944"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e465867-56d2-42d1-9545-a82f0b55de35"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f57403-df90-4f0d-81be-15c632eb28c9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/120e24a1-1697-4931-abad-19009164bf5f">
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b93d9aad-455e-43c4-9efa-ea519674782c">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79bb2d20-b24c-4edd-ae9d-f9413f62f490">
        <rdfs:label>Liver injury</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001392</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd36b117-5889-445e-9f21-a34ae47d5ad9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ea325eb-dc8f-4d5e-aa40-44ec43eb9568"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f3fed4b-71a8-48fd-9e4b-29f96a5127bf">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Oxidative Stress</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9874a620-7905-4043-bba7-c3d20861d6df">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9bc2caf3-d766-448c-ab49-39de43df8820"/>
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <dc:identifier>DB00028</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/989e27b5-dbf6-4dd2-8e0a-2395a3b99b20"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ef6e618-bc9b-4df3-9a42-7834e389031b">
    <dc:identifier>HP:0001336*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20a8c434-e12f-4b91-a804-1004c9ddb95d">
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:label>Tiredness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/faa1166c-f63c-4f8c-a869-0e4b4fd39ac2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44ef5dc1-ed91-4829-90ef-0386fdfe0d7a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/826c7c2c-684e-43b8-8f7d-e23fa2684fb1">
    <dc:identifier>DB00994</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18219654-4cfa-42f7-8d42-fa450c3a3882"/>
    <rdfs:label>Neomycin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/674b9f6c-ebc5-4551-9739-2e42928edd0e">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/05bcb2a2-9818-44ed-ba18-f7a121eb6a47">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0308b14e-1781-4b5a-9285-713f37a0564e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e74675a-45dc-45cb-8141-cc1fce47ec79"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/beb55732-e16e-4532-bf2b-a7913f8b4e2e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>mitochonic acid 5</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcff4682-2bdc-4600-bbef-7e839681b937">
    <rdfs:label>chondrocalcinosis</rdfs:label>
    <dc:identifier>HP:0000934</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be0218ab-0972-4faf-88fc-70a31cc05e1f">
    <rdfs:label>somnolence</rdfs:label>
    <dc:identifier>HP:0002360</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ec3da2d9-f809-47a3-b732-2718aa977e6c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0712c827-745c-4c9b-beca-8f0989e29155">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
        <dc:identifier>HP:0011021</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c235001a-2c04-41e2-b880-cf733f3c5a84">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37645918-1166-470d-a8d5-335d1413d230"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c5049d9-68fd-444d-b649-213e608b78af">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24ffcaa1-49dd-4756-90a2-94f5cfd375a6"/>
    <dc:identifier>N05A</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edc3b9ae-0e4d-449b-9de7-25a46520582f">
    <dc:identifier>HP:0012051</dc:identifier>
    <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fad6a25-c4a6-40ac-a5a9-ff7ebebcab2e">
    <dc:identifier>DB06742</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e496ca02-2dd4-4036-be32-b470aaac638c"/>
    <rdfs:label>Ambroxol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/864990f6-75c6-4744-9c54-a0bdc12317d7">
    <rdfs:label>hepcidin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d413ed93-0d1e-428b-8ad4-367e1caeb217">
        <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aeac07e6-a1dd-40ee-bb5b-0bdaff38e9c4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a796ef1-9b90-4f03-a961-b78062765b20"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eef612b-6951-4a4e-87c4-4c9e7573c23d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001954</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <rdfs:label>Periodic fever</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d240c4b-c51a-4d79-894c-9e0448884eea">
    <dc:identifier>HP:0001397</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:label>Liver steatosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1eba47ae-bb49-49de-9d02-15b1c1f6e676">
    <dc:identifier>HP:0003117</dc:identifier>
    <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a20c914d-e086-42de-91f7-6c02932cb399">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8258ee6-8859-4a4b-8460-82f92a490496"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f1082ca-8b3b-4554-a871-4a340d754ee1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e31e96a8-c108-476d-b3b2-ee0b6ab4ea11"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d54cc7a0-c93c-4f5b-902a-1dabead051d5">
    <rdfs:label>Potassium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25e46988-79e7-49b5-aec3-5fdd7a279543"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcf1bcf2-9396-4160-9ef5-96d6c50c2ed4"/>
    <dc:identifier>DB14500</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a7c3d486-e0e0-43a0-9e24-88e21573f3f7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9cdb42a-47e1-4ccb-ab92-33fdd69c2739"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95dcd614-02e6-4486-b9f9-496ea1e14ec0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06210e55-bff7-4bc7-b02c-884d4aba3692">
        <rdfs:label>Diclofenac</rdfs:label>
        <dc:identifier>DB00586</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ffbb590-e63d-4e50-8f4d-62e3047cde8a"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3b044bd-9a4f-4b8b-b788-49dfa171838b">
    <dc:identifier>DB00988</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bccb94b7-126e-4da9-a19a-6454c8a97e53"/>
    <rdfs:label>Dopamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f9cbb444-1650-47d5-873a-b38145e6c12d">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36a64e0d-80cb-428c-89af-584dac7a5514"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/224d56e5-492c-4504-87ad-a8c75e0b6451"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de9456de-d6c0-4ebd-b1de-5dd6a3315800">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Neurological abormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9df2f1e7-6363-4dee-b754-042bba2d9ca4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69a59261-e518-4aee-9d66-e01a44a6bb41"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ddff2732-ed80-4221-ad2c-865a888bf107">
    <dc:identifier>DB15146</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/369f80e8-0218-4b3b-aa7c-668aa5e790d7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fffdba44-3f5d-4a38-a0f0-94664499a742"/>
    <rdfs:label>Adrabetadex</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdcbb130-8453-48c0-85d3-e6ace3f3e84f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
    <dc:identifier>HP:0003287</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ff4585b-cd1a-466b-b5f5-4e1bad3da91b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4236cb1-8278-4015-b261-ab1702692f44"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/759b4096-4463-4a90-9084-e1a642cf785f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oedema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44b94d85-e5b6-4938-a9e8-82af89e4e418">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
    <dc:identifier>DB14872</dc:identifier>
    <rdfs:label>Lucerastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4bd52c70-dd8a-45f4-8506-fcbae5b8c171"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55d1ae0c-f123-42de-9007-d42ac09a4b82">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cb430c2-23de-41c6-94ae-0fdbc388538c"/>
    <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
    <dc:identifier>C09CA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a1e1da2-1eda-4d8e-a182-9f08a18bcc61"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90751f57-ade9-4028-b6a6-c7c0229dc0ba">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:label>Increased total cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a1e191f-d281-4842-9b65-c6c383146d79">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/edbd47b6-8af6-40a0-b3e1-37722bcde58e"/>
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
    <dc:identifier>DB02209</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b3ddf17-92fa-4ef9-89b7-d850129c98b9">
    <dc:identifier>HP:0000924*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
    <rdfs:label>pathology in many somatic tissues</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aac83d34-7ca9-4360-930d-935e500ab565">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5542bb3b-9334-4584-9a07-579a2d20348a">
        <rdfs:label>failure-to-thrive</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78a623a5-7061-4b3f-9d29-9329c4c7ff7f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcfcff93-0d81-4acf-8cbe-cbc4733db396"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/117018a7-cdbd-4ac6-8fb7-29c5b6a91dce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000164</dc:identifier>
        <rdfs:label>Dental Defects</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f2c5e89a-ae0b-498f-9f69-ae3399a3d04d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d18f90b0-157b-44bd-9626-386b3e6cd7aa">
        <rdfs:label>deteriorating pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/032df2ea-8f44-4047-a789-33dfaf87afac">
    <rdfs:label>CoCarbs + HPro</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/412e84c2-0e33-4ff5-bfd7-de0eb575dd5b"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/788e221e-f08b-4611-bdec-9426af209e64">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/882eaa4e-adad-4b36-850f-07749026ec83"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/668ac7e3-bb05-46c1-98f9-94d2b8e166fa">
        <dc:identifier>HP:0100712</dc:identifier>
        <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28e37015-a3ef-4cc0-9f60-e8752e6394cb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca223bb0-7449-4cf3-b8ed-28d6fc0977da"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d98e258-d2af-499e-8667-ea180f382f06"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53f59901-6e1b-4358-b343-714961d0a95e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93d502d7-b27b-44f7-9f09-e499cd0ba21f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/586d41f9-7d24-4799-bd0a-a2df3062fa23"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/626268b5-55ca-4151-b297-17e5681dd483">
        <rdfs:label>growth faliure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9311daf0-d5d2-40a8-ba88-a4e489209bf8">
    <rdfs:label>movement disability</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a8a6041-8771-47c3-b734-87b4ef0bc9dd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b7eb557-8acc-486b-b3fc-5327e3e6f00a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <rdfs:label>Sodium acetate</rdfs:label>
    <dc:identifier>DB09395</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/702d613b-dba7-4ff1-8f61-63ff2e930383">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44b31820-3377-421d-9c4e-52b53c466ba3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f094167a-d363-4c82-90fd-1dcb1ed4f0f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b595838c-95f9-4ae8-8e51-1ac51ebcdf72"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79799b99-d7ed-4d14-b588-d730f07cffc6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/76df5688-e96e-4d2c-850a-4284b4baa6c5">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68ae8306-3ee0-4edc-8903-6196de543e50">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e83a08a-e74d-485d-bd80-7fb50125c91d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38dcc8f2-1217-40c8-8ed5-847fda32fa35">
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Imapired muscle function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbd91ad5-01fd-40c7-b2aa-c13cc9c80d13">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
    <rdfs:label>erythroid progenitor depletion</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025034*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/016a7678-b52c-4844-8cb5-7b86453fc9b3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b65d65d1-c903-4b12-9888-49feb3f34e0b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67a75e0e-2b73-40af-a1a3-4132037cf793"/>
    <dc:identifier>DB00035</dc:identifier>
    <rdfs:label>Desmopressin</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6eccaa9-2c1d-4848-9a37-63ae63c52e5f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c56e884b-3b79-4efa-aa8a-d898b933d841">
        <dc:identifier>DB14098</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
        <rdfs:label>Cobalamin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0aeae111-9299-464a-a749-f977a1865f80"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ececf35-f7be-41a2-88ab-9cac06109db8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfa2d9ac-86b6-4cfb-bc42-bd884d0bad06"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd2661c4-5b84-4f09-aca3-cb2efd6cd628"/>
    <rdfs:label>Niacin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec4e055a-252a-4952-8a5b-2309417a096b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e75749d9-59af-4366-a6b1-cc4d0bda8a12"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdb5de97-e110-4b8e-b4c2-08d613d1f5a0"/>
    <dc:identifier>DB00627</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c67b1a43-8284-4554-a454-c01dd0311a35">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4924f0b3-770e-48b8-80f0-b1971a5e065d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7ab7278-fe8a-40cf-a981-95072c5275a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ae142b0-1a2e-4ab0-bee2-ca5eefea7cde">
        <dc:identifier>HP:0003158</dc:identifier>
        <rdfs:label>Hyposthenuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/69b4d3a0-eb56-4454-99e5-535ef165c3f6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8279242-f879-4372-acd6-b3e4f9be728e"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7416c766-61ef-49a5-a1f8-5569fece4e0f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20629f0d-c4e7-467b-bf36-f5980b615570">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/274313fe-17fe-4938-8e45-b85e6e609e26"/>
    <dc:identifier>DB00808</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
    <rdfs:label>Indapamide</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/69ed908f-3aff-4431-bab4-e074384911ac">
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4f5f4c4-8a00-45b4-9ebf-9cdb2d206234"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c324bab5-5322-4291-9ed9-5a3e8665ce1a">
    <dc:identifier>C03</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/159b6bee-1129-4eb7-9aec-8db33500a234"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a1e1da2-1eda-4d8e-a182-9f08a18bcc61"/>
    <rdfs:label>DIURETICS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1cf0e6f-7b37-438c-84e3-35b0e2ebce34"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/272b3a9b-8911-4d37-a3cc-4bf106f5c3e2">
    <dc:identifier>DB14502</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43190f8a-aa17-4032-b9aa-19d2b68c85ee"/>
    <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b98539c-499f-473d-b5ff-6074492a3864">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
    <rdfs:label>low phosphate reabsorption</rdfs:label>
    <dc:identifier>HP:0000117</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fb875973-5a97-4555-ab40-c4dc2a5fe412">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f51a759-304e-400b-913f-1d0ba7043841"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c52293df-7b6f-48d4-93ab-c6f3b3e71544">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/623ac604-ede5-4c9c-8f22-3eda8be7b25f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/581a1cdd-8d7e-48a0-abf3-d565b419af71">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/989a7864-2b5b-41d7-8ddf-20b4a6c75b54">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low cell autofluorescence</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64b2ffad-b17e-491d-bcfc-f69e79526e31">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da65f7f9-f4ac-4ef5-93d5-7a0330978c75"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
    <dc:identifier>DB09154</dc:identifier>
    <rdfs:label>Sodium citrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a02cb601-5777-4efa-88f8-940ec9a69b60"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50052a8b-d901-4983-a3b8-61283f4f239b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pathogenic exon trapping</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17c944f6-2f0f-46af-bf54-2efd87f4b744">
    <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
    <dc:identifier>HP:0012217</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d078ab5c-d8f3-47f9-abb7-404765599454">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
    <dc:identifier>DB02745</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20f6ea7d-5a00-491c-9e81-92db3cdb2c14"/>
    <rdfs:label>Uridine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23713b1b-0f3e-47e0-99ea-f00077cebb46">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/836fd8b3-67d3-404c-b1c5-3a3dc348035c"/>
    <dc:identifier>DB14751</dc:identifier>
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c283793a-21f6-4939-beba-3bbb79c31156">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
    <dc:identifier>DB00404</dc:identifier>
    <rdfs:label>Alprazolam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10f51280-bccc-4b12-979c-9b0dd8297a4b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d198b6f-cfd2-4b08-8ab9-f5214d9c550f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60b21848-c7d1-4cfc-8797-66a4066bb6fa"/>
    <dc:identifier>DB14104</dc:identifier>
    <rdfs:label>Linoleic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ec196a87-9b4a-49a3-ac2a-8b1f892b4f7d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ef5b4f9-9e23-419a-8ba2-fca8c9e4332a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <rdfs:label>Abnormal Folate level</rdfs:label>
        <dc:identifier>HP:0040087</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f24d42f-0f06-40a1-a9d1-bf3110a912e0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd357210-31eb-4b68-b593-9420ea6572e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/daec4adc-742e-4a81-8cd1-312433474fca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f10c4080-a06e-4239-96fa-8f9ec15e4e5a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef4f2d2d-1a30-4b35-9f6f-e5504410191d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22538ae6-697f-4d47-9ad7-877cd7e931a7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/654e5fd3-65b6-4b0a-ade9-5901b581b2b0"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1bc7290-045b-431f-a2e9-5d4c42f113e0">
    <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9ca3717-53d2-420c-a67d-9695786a1460">
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3ddfad2-75a5-4f31-b61b-956bf9f2f65f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
    <dc:identifier>DB09115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/185d2c34-b2d1-43be-8d48-83fe2f7788e7">
    <dc:identifier>HP:0012656</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>dopamine deficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fd16d4f-0aa0-44c0-8b96-48ef733aa77a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ER-associated degradation of R8L</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f6e9d31-8317-4540-914f-b51796cf432c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fd7583e-4f48-473f-af51-b526ff36da81"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
    <rdfs:label>Lithium citrate</rdfs:label>
    <dc:identifier>DB14507</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ddcacb9-219c-4332-a767-7fdccda88c79">
    <rdfs:label>Cinacalcet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/848bb669-678b-4251-827b-fb25543f70da"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f13a9a86-45e3-43f5-9bcb-25cb515ee6b7"/>
    <dc:identifier>DB01012</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79ce5118-e2dc-4639-b731-118b60ec05c8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/848bf089-28e5-4b89-abcb-d033fb3c5004">
    <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cbcfe40b-428b-4dce-9ba0-e6ed816c68fb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df49dced-b5bc-4ed4-b8a6-a82f5855fcd0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b56a07ea-7ab2-488c-88ce-7b8dfb232405"/>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <dc:identifier>DB00115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97f7937f-95f2-4996-96d6-aeccd683833f">
    <rdfs:label>Perampanel</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1e3e00e-73fb-479f-a488-c54d1dffabf4"/>
    <dc:identifier>DB08883</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3f5d92e-5df7-42df-bef0-fde8cc430b16">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f386b78c-23db-4cf2-9914-1e82522c3459"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
    <rdfs:label>Protoporphyrin</rdfs:label>
    <dc:identifier>DB02285</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2e8971d3-0901-413f-b0f6-acfd10f6fc48">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6928bbbb-5afb-4d32-b0be-0a7edaeb9d52"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85ff1ce1-5d2e-4ce0-8f08-c579a15b0963"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/443afe04-fbdd-4e87-ace6-b742f3d2eb5d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51400d4e-fd44-4bf2-ab37-45e38c5bd9b8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <dc:identifier>DB12907</dc:identifier>
    <rdfs:label>Mannose</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9484536-ff3f-4c99-a972-e0f1e38df021">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c9f1cb65-6945-4506-b0f7-6157fb868ece">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb8c555-9810-4574-b0ec-742fc823f727"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93df6250-51e6-4392-b962-2610724c2060"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40fbb7ce-061d-45a2-967d-17af70710222"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcd988e1-650b-4b7d-8558-cb6c034c9413"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85dd1957-9026-4470-ba9d-c96c48ebbb63"/>
    <dc:identifier>DB11094</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff5d0d5e-94bf-4fda-a037-058aa1f53036"/>
    <rdfs:label>Vitamin D</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cba554e-e28a-4996-b366-6ab1f8ec68a3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19c832bf-e792-44c5-9e63-50bef39e295c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f337e5b3-fed2-4343-ba86-3b6f7ff7a8d1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high Lactic acid</rdfs:label>
    <dc:identifier>HP:0003648</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6da43da-0f50-4d08-8bea-e68d0192da36">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
    <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004295</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e99e2cd8-25c8-4414-a790-aab94858ff57">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8d2cf1f-2b0e-4845-a907-b99c47a30b56"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb2f5e26-62b4-4db1-8c25-2920b6aff824"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/480d7dd3-e940-41a1-9742-827d77d11b29"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a766eeb4-5d5f-4f68-ad02-d262ed12d174"/>
    <rdfs:label>Levodopa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abcfe6aa-96c3-48f7-9138-45af9ec8acc9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92a338ba-63b0-4a26-a5a3-0041f01a7503"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/11e33c9c-7dee-4ae8-92d5-05d886bbaefc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/912ccdd2-d7a5-4713-ac85-c3f6bf335bd9"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55abcf5c-b815-4d79-bb1c-10154a9411ac"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb875973-5a97-4555-ab40-c4dc2a5fe412"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/929ddfce-e9b5-433c-9f34-b29e2e0b0c2d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4d7b9d0d-a40a-494c-98a7-7a5591a68582"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c4a71cb-fbad-48ab-b199-0af7f6e2899f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/568044ac-bb9e-42fb-a904-08e6681be9b9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38e20b40-f738-410e-b7b9-a19fd84e33c4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82b02591-5b2c-4b8f-a8a7-530f10d2a1e9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19d7d03d-1ee7-4f79-89c6-15a309d1e572">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
    <dc:identifier>MP:0004144</dc:identifier>
    <rdfs:label>Drawing inabiliity</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0aeae111-9299-464a-a749-f977a1865f80">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0ad31f9-90e7-4950-ba60-6e469e03e009"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c66812f4-41d6-42ca-b73c-7045638b4a31"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54ed2876-6bb0-48ca-bf12-a2576d0eb0b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4685c12-a2da-4959-8915-4b146d3fc729"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02b465bf-63d0-4ace-b38b-638f03228c36">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
        <dc:identifier>HP:0000952</dc:identifier>
        <rdfs:label>Jaundice</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cd3d990-717c-43b9-a3b6-bc7d312fa194"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4243631c-ef63-4b85-9f07-f3db62cb5185"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8748323-14e7-4d2a-bd99-c77eda2b7bb2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6eccaa9-2c1d-4848-9a37-63ae63c52e5f"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4215d1db-358e-4134-887b-d20a9213edd8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/26ff010c-d0b8-4111-9223-49e33b85a7b2">
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67a3029a-5cb7-4f0e-b433-841dc42f874d"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6bbc605-8547-4c4a-b3a4-4cf19f74a4ef"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3bf2a44f-0e88-469a-8e12-07cf091b95c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3161359c-fd5b-4e8e-8133-6c172323afcf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b6fe60a-d11c-40f0-81f7-09f22a00b23f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>NO revealed clinical benefit</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f57e66c5-b168-4b7a-8248-696aee255429">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002354</dc:identifier>
    <rdfs:label>working spatial memory impairment*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5c02220-e825-433f-976d-332beeb58793">
    <rdfs:label>Amenorrhea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
    <dc:identifier>HP:0000141</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc03fd6a-09ee-427b-a9f0-516cc2ad8ffd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87859c13-3933-4f32-b961-1eb07c0758b4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f273e556-3e08-47f1-8f4b-9cc699aac63e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f43f426c-8948-482f-b533-abd0bf51ead6"/>
    <rdfs:label>Piracetam</rdfs:label>
    <dc:identifier>DB09210</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d573f998-b7a0-4a2f-bed4-5cb0eee23ff6"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5b81977-1026-4920-b8ec-b19d45abe55d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f79400f0-9f93-49a7-9aba-ded42df3cdc5"/>
    <dc:identifier>DB00734</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad6c42b2-682b-4fbc-ac5f-2c40ed7e5bb3"/>
    <rdfs:label>Risperidone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b22c6b72-9a23-4ba9-981d-b8c901347054">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c6d45e2-5ff3-4f14-9b1b-fe7080ce9945">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33b3a5b0-9bc2-422e-9367-f3fe6052f384">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b3bd77d-a095-4900-9cfe-4d0e294a1ad2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf871e8e-deb3-4f89-bdac-a8e6682d32f7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220d396f-5441-4c9e-8730-98f68d8abd1f"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
    <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
    <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3ca01151-5955-49e0-badc-49529b568b62"/>
    <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c2e1a6e-e01e-42f5-8ca2-c48e26be728f">
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f26f9e0c-0b80-4ee0-b2ac-39f79d26493d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5f6a25d-3858-42a1-a948-680bbd08e3fe">
    <dc:identifier>DB00067</dc:identifier>
    <rdfs:label>Vasopressin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92bfc802-cefc-436a-8551-64735a79b1ae"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c894d5a-a6d7-462c-aa8a-84a781320954">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurological damage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6699aeb-0b4d-4246-9ca9-e48a8b083f1f">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f4dd1290-dc45-493b-b3cc-71b42c5541be">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d3e1b55-e283-4ccf-8695-bdbf23408062"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c4657e7-abe9-4b55-ac73-7603babe48a0"/>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aabf3241-6f82-4993-8a30-2f22d1fb2fe6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c6c5f3c-9420-4ea2-ae5a-ceb5b99c9e05"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c19e0d9-9cbb-492a-be26-bf9ca7adc16d">
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/62841848-33bd-4576-a4d4-800ac2aac937"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d781882-017a-49aa-b104-3a3475f731f9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:label>photosensitivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/84e60def-792d-427b-b25e-6d02c8a20974">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9872a869-6f3e-4e3e-827b-9eb46e918d2e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec196a87-9b4a-49a3-ac2a-8b1f892b4f7d"/>
    <dc:identifier>DB00200</dc:identifier>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/63bccc21-dca1-4356-9170-c8f1f39edf53">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95987c02-5e1b-4b6a-80cf-75e3b9e914f0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236270"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10d01746-99c4-4d11-b82d-c0e7a92ae5de"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08dc00f5-1e70-43f9-93bf-bd5eac7ea12e">
    <dc:identifier>HP:0025464</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:label>Increased ROS formation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df1561a7-31b5-4146-b68f-29c7b50788c0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000867</dc:identifier>
    <rdfs:label>Hyperparathyrodism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97f16612-7f2f-4009-9931-f59ac549384f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6727a087-0d37-4054-b19f-aa0a489d0a6d"/>
    <rdfs:label>β-galactosidase:RTB lectin fusion</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ab1db91-3d28-4743-a93a-bd292829be67">
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67c8b290-f3e2-48a6-923b-d429ffc67771"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fec1ab7-7402-4bf4-85ef-553f9bd95269">
    <rdfs:label>impairment of reference</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63db562d-65f1-4289-8888-45998e57d8d8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfeeab3f-d0bc-4dd7-b75e-71305de0dc30"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
    <dc:identifier>DB14933</dc:identifier>
    <rdfs:label>Nicotinamide riboside</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0bb31518-3cb3-4f61-9ae5-3a943a768c03">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3e2b581-2a6c-4ec1-8b38-9fb59f5a3698"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6fd16c71-5001-4383-95dc-b77e57583ce8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10b3716f-4e02-46f4-8d5d-ca484e8f7821"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df1561a7-31b5-4146-b68f-29c7b50788c0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/caf6c9a0-dad4-4cf1-adf3-b274abcbec9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4507c8d4-3124-431e-8efe-ce41976df63a">
        <rdfs:label>Renal rickets</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002748</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10b3716f-4e02-46f4-8d5d-ca484e8f7821">
    <rdfs:label>Calcitriol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bb31518-3cb3-4f61-9ae5-3a943a768c03"/>
    <dc:identifier>DB00136</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7460bef3-f45d-46e0-a620-d66f6762ae39">
    <rdfs:label>Metformin</rdfs:label>
    <dc:identifier>DB00331</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d3d2d71-3fda-40d3-904b-2ec35ac795bb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82e48dee-2447-488a-8640-10799898ab3b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c05b774-5815-4837-a117-7c4835780cf2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0155bc4-c988-4bba-852a-e031143e37f3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e713697-62b9-4414-a5c7-e6a4dd396849"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4f1ff45-5d8e-457e-a4c0-4fc77fa13686">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
    <dc:identifier>HP:0100660</dc:identifier>
    <rdfs:label>Dyskinesia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57718ed9-3dab-406c-8a4a-92ca2ed6c1b5">
    <rdfs:label>Voice tremor</rdfs:label>
    <dc:identifier>HP:0012477</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50d81e36-0412-41ee-966b-b617de613d06">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/484ad0c2-ebc5-4b89-975f-cb84d50f5d66"/>
    <rdfs:label>Pantothenic acid</rdfs:label>
    <dc:identifier>DB01783</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e8010c6-f0cb-4ee7-ab89-314ba7de3c6b">
    <rdfs:label>Atorvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eda3185d-7e9e-4870-8bbd-d3f4aefb8a0c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52d97a32-a0cf-4f3b-84a0-8966d1355905"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0ca1472-8de0-4567-bb4c-6f7e3e335c38"/>
    <dc:identifier>DB01076</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/453357aa-9269-4500-9c89-5ca8072f863e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0305f18-0148-4229-a2f1-5b52d608c801">
    <rdfs:label>Clonic contractions</rdfs:label>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c34f7dd-4ee8-4f24-8fd7-4afdf7023609">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
    <rdfs:label>Mild attack</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012825</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/713774a5-508b-418f-9ac2-a3ceccb7093c">
    <rdfs:label>High total homocysteine level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010919</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5ddc351-5e9b-41dd-ad09-11a303935c05">
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82cee9c3-b8b4-4ac9-a01f-40b42b09764e">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b3ddf17-92fa-4ef9-89b7-d850129c98b9"/>
        <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a238452-e3b7-4a03-afb7-6069784faf16"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/084b175f-ea7b-4df2-b38e-1021fd1340ea"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f49597d1-6dd8-4a00-82b1-1df17f8194aa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bd95760-5b97-4f54-bb4c-fce37e6b0add"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0213378b-ec3a-4ce5-8e22-50ac1facd733">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51e4964a-6c81-41c9-aa16-5a859fd16c49">
        <rdfs:label>spastic bladder</rdfs:label>
        <dc:identifier>HP:0005340</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bce4d8db-49c0-4574-9824-58eac5799fea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cdcb604a-d92c-4ba9-944e-b662de77f535">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49c4c321-e075-4740-98b2-96df934560a0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d53155ab-f869-4fc4-8144-1a8f505ef449">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/84df06e5-faf4-4524-ba6f-6a2d62df2390"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1f17e5e-e065-4dd3-87db-358b397d6a84">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9a18144-aa0e-4a91-a18f-0331883a1265">
    <dc:identifier>DB00650</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0999a499-d883-4e3b-b945-6d138363a41c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4b9ed28-7b15-461d-a628-861ddb1e6e8d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84281e82-9642-4c9c-9ce2-671fd70ea0a7"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85127325-6910-4ae0-b3d7-9832f3179060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/272899b4-c7ee-4cdc-acb8-ed7ff75470a8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d36b969a-2a42-4490-b0a8-b0fd229dc1ea"/>
    <rdfs:label>Leucovorin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e5dd289-dfc1-43e6-afeb-72d048a39822"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79d2c91b-49d1-4bbd-98fb-630557ba73e7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8069ebd1-b0ce-45df-9d25-5b9fea65d85f">
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92029b44-5811-4ac6-85dc-aeb2eb1b91b3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4ed0799-9fe1-494a-83cc-7c388dedddab"/>
    <dc:identifier>DB03085</dc:identifier>
    <rdfs:label>Glycolic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe9f7cf7-f1a2-4f2a-93a0-aa45a052515d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9731920-9cd3-408b-8a55-b33ef75f386e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/788e221e-f08b-4611-bdec-9426af209e64"/>
    <dc:identifier>DB06720</dc:identifier>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/c54d909c-5d11-44a8-a10a-f9e1a7989d2e">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6f767462-a6fe-4748-a6d1-0d31f9c2751f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ca922d8-0894-43e7-bcba-c32e50cf4eb6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d52fab0-167d-44cb-9f8c-7e870667f86e"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
    <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d9bbcc6-fb37-466a-ac09-67d06bfbb400"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/933d5ac4-c22f-4e87-a0ee-6ad509fe7501"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/50cc893d-b7ea-4b8c-bb96-958b35f32d55">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13a049a0-371a-4a73-9a7d-9e00c0e0435a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86f5df11-c087-41f7-8278-911001167443"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/989a7864-2b5b-41d7-8ddf-20b4a6c75b54"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/900813d3-3af1-497c-9193-8f1269c59345"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54706848-68ec-484f-b14f-f3e3170ca547">
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39593b8d-673e-403e-98b5-9e4d6a8e6d3a">
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccc73daa-435d-41c6-85e7-c696f7fc2015"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <dc:identifier>DB08809</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/572f8c07-abf0-4cde-b972-6b9deb5e389d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
    <rdfs:label>acute arthritis</rdfs:label>
    <dc:identifier>HP:0001369</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4e42178-c14e-4742-9557-429b509c0c49">
    <dc:identifier>HP:0000712</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
    <rdfs:label>emotional disturbances</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9dd94e8d-477b-40bb-9b33-46639078da3b">
    <dc:identifier>DB06756</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99f126c5-be24-4aa8-a5e7-4222ce280b15"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a57092c-86de-4ca6-857e-28772d21aac4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <rdfs:label>Glycine betaine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/546111a0-ffb5-467a-80fb-64d5ea82292b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>behavioural disturbance</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d66936f9-34da-47c7-bdab-6cc064c1159e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23a82ca0-83cd-4875-9679-1ffa7cde62c3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9011ba5-7236-48a8-8295-60369c25b68f"/>
    <dc:identifier>DB00419</dc:identifier>
    <rdfs:label>Miglustat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f00f365-9121-4009-923f-68fc1acfd253">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ac69551-2e84-42d7-905c-d1aa02bb95a8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4884f69b-ea57-4fd5-941e-49ef2f94659f"/>
    <dc:identifier>DB11133</dc:identifier>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e20ba084-e661-40f5-ba17-1d60530697ff">
    <rdfs:label>Exercise-induced muscle cramps</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003710</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003710</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b9aedef-78a6-41f2-866f-4589c6c96f76">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
    <rdfs:label>Polythiazide</rdfs:label>
    <dc:identifier>DB01324</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19444866-9e00-493e-b450-ccca1f6eac02"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ff4585b-cd1a-466b-b5f5-4e1bad3da91b"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ed0e888c-b5ad-4ca5-a817-b4116c70ec11">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ad7ce27-895d-420f-9201-ca91c7530759"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a15cbdb5-04b0-4f13-b531-82401673498a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df63ba58-0239-4638-9e89-cde02ba46fce">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18a24340-2f71-431a-b6cc-ec2400a32e56"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/759fb870-5d35-47d8-80a0-b27ea8a0f707"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b3bd77d-a095-4900-9cfe-4d0e294a1ad2">
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
    <dc:identifier>DB08834</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b22c6b72-9a23-4ba9-981d-b8c901347054"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dcfea03e-b22d-4e97-9290-9e6b3ec00f74">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6045059-dc2f-41ea-a50f-441b0e1ff9d5"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
        <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11583ad2-b42a-488b-843b-14d0604652db">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d71ca39-1fe7-4b7e-ba0d-de58238263d0"/>
    <dc:identifier>DB11635</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
    <rdfs:label>Tocofersolan</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a24546a1-f507-4d8e-99c1-52a0bcde2cb2">
    <dc:identifier>DB00020</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c54d909c-5d11-44a8-a10a-f9e1a7989d2e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0a0c87a-21e6-4e95-981a-cddd0d34a277"/>
    <rdfs:label>Sargramostim</rdfs:label>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/fd29b728-f3ce-4b56-baf2-a2ff7fef2ebf">
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7f4432e-a8b8-4632-a7f1-4db53c659bd0"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ad58dac-22de-42d4-8e3c-281141877225">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f72d3f21-e3f3-499f-a58b-d5d1160a3c06"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6e8f21d-3e6e-458c-b81e-30e2859d50fa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9236654-157b-4e3d-894d-fd49a7c9ea60">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76e0a75c-3744-4de0-bc45-24b2e00f1232">
    <rdfs:label>Elevated Phe level in blood</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89f1f16b-0922-45ed-8348-5e1195dbbd89">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001744</dc:identifier>
    <rdfs:label>splenomegaly</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92bb383b-c113-4fda-a7dc-23858e82e7c2">
    <rdfs:label>Clofibrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c67b1a43-8284-4554-a454-c01dd0311a35"/>
    <dc:identifier>DB00636</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fac5b7b-2b0c-423f-8acf-3e72c0b59958"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccaed853-7e79-4b6c-9607-57c17bc7eb68"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebf51c0e-01c1-4fa0-8e23-b4721c47b7d4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aac83d34-7ca9-4360-930d-935e500ab565"/>
    <rdfs:label>Asfotase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc8d99c8-e564-4c3d-ab53-76af59998e46"/>
    <dc:identifier>DB09105</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4080e804-813d-462c-947f-4f81bcd7c92e"/>
    <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3161359c-fd5b-4e8e-8133-6c172323afcf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26ff010c-d0b8-4111-9223-49e33b85a7b2"/>
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce433fa3-9b45-4edf-9fc8-5c32065569ab">
    <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
    <dc:identifier>HP:0009124*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed941595-baab-4b89-b44d-199d60b14966">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mislocalization of R8L</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bc25e2f1-a2ee-4894-9867-4c34ebde86d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8279242-f879-4372-acd6-b3e4f9be728e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/974ceed6-752b-4a8c-af83-729883e290a3"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdb79641-2c71-44ea-9584-ad9e178b7ee3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56b0f634-89b5-4c0c-b934-5e4be955d7b3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84c45b5a-fa7f-4ef2-b0de-04b31cf764ea"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <dc:identifier>DB00125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bbb880ff-f364-465a-b8d2-42ff6caf8b50"/>
    <rdfs:label>L-Arginine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/805b0c25-db23-403d-953a-701bae9041af"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13fb59a9-ccb1-497f-b0e8-1ef816572849">
    <rdfs:label>Ethosuximide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ca0c8a6-09b9-4f2b-a698-141b3d0cac10"/>
    <dc:identifier>DB00593</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0879b21f-614d-4678-900e-f7dcd4439b08">
    <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22b3a342-67a9-4936-9ef5-367e0f0fe5af">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffdb152a-6e33-4904-a571-ac0fce877f26">
    <rdfs:label>Cerebral palsy</rdfs:label>
    <dc:identifier>HP:0100021</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
    <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ea3f653-a1d2-4a77-b86f-7441ff3c0679">
    <dc:identifier>HP:0000962</dc:identifier>
    <rdfs:label>hyperkeratosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8de71a3e-fff6-4021-b46f-b1d59a492a64">
    <rdfs:label>Propranolol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae4d79b4-71ab-4c21-8f8c-2042dac66ce8"/>
    <dc:identifier>DB00571</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b65b0f63-f5e0-43b9-959b-554e885dfbe7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfad9467-235f-4097-b0cd-30a513452510"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
    <rdfs:label>Ramipril</rdfs:label>
    <dc:identifier>DB00178</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/444001c5-5b09-4239-acb4-fd8a379c0508">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
    <dc:identifier>DB08826</dc:identifier>
    <rdfs:label>Deferiprone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5c8b208-20aa-4428-ab9c-d086cacfeae4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ee8c85e-1583-4dd6-9fc8-1288fb99a4eb"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b1805ec-144d-42bc-850f-8f3b80a625c1">
    <rdfs:label>abnormal muscular co-contraction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001257</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b2941a2-111a-457d-8195-98f1f88f5e4a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Status epilepticus</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/510b7e23-86cd-481e-aa31-895b61b69bcf">
    <dc:identifier>HP:0001251*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
    <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58779253-0f78-4d9a-9302-286e0d687218">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal EEG results</rdfs:label>
    <dc:identifier>HP:0002353</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6d113f1-8fde-4f4e-a9d4-4e7e878d84f9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5749ddbb-9278-4634-8cad-bf7f2519a40e"/>
    <dc:identifier>DB00073</dc:identifier>
    <rdfs:label>Rituximab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eefad780-2898-495f-8a40-f845e3ae406d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <dc:identifier>HP:0001336</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>myoclonuic Jerk</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
    <rdfs:label>SALLA DISEASE; SD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/638c9e56-e17c-4000-81ba-5deb96d73fca"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
    <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b8fb632-3b0f-4d45-a300-082171e26c4a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <dc:identifier>DB00060</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3f11d42-366a-4744-bc82-8fd64fae1bdc"/>
    <rdfs:label>Interferon beta-1a</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2bcf374d-3e7c-4810-b8b3-be17578619cf">
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30581c38-52d4-4110-8f71-7e3b9205c29c"/>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/04459c8d-d6eb-42bc-bd60-3fc550c5bcc6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c243b4c-cdf1-4487-b45d-dba6fe74ed83"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a833785d-8550-49b1-9139-67417330062b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d163a896-211e-41c7-8f83-4310b5852d69"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/484d2f22-7a19-4640-b407-e0a2afb226bd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4063ab12-3106-4b7a-8ba8-928ac25fcbd7"/>
    <rdfs:label>Pamidronic acid</rdfs:label>
    <dc:identifier>DB00282</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8039f557-75d6-40bb-85bc-6add97b55e54">
    <dc:identifier>DB00091</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ee990e6-7589-4998-bcc2-d430b9cae67a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9fce680-d351-4bac-9b95-9cf5466fd71d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e8971d3-0901-413f-b0f6-acfd10f6fc48"/>
    <rdfs:label>Ciclosporin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
    <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
    <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/38791c4a-8a8d-4ebe-8ff9-a569ac494caa"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28261de0-93f6-4110-a31f-2c30cecce574">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fb3780e-463c-4af3-94d1-0125a00f583a"/>
    <dc:identifier>CHEBI_32030</dc:identifier>
    <rdfs:label>Kaliumbromid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a957ab3-a844-44a3-b5b8-0739871eb84d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c5d56e7-ea8c-4e2e-be89-054711177353"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2c888c6e-a989-4b3b-bcaa-c763cf221d90"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <dc:identifier>DB00776</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f36d1639-051d-464d-a8c6-c21a24bcb10e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b96c9d3-0d27-4860-ba55-6aa8ccdf8d7d">
    <rdfs:label>Ursadiol</rdfs:label>
    <dc:identifier>DB14555</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bff9a640-4b5b-459f-9d5e-9ff8f723ed6f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35b63325-3d68-4ea8-a36d-6c09cd9947b6">
    <rdfs:label>Self-injurious behaviour</rdfs:label>
    <dc:identifier>HP:0100716</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7a78fc4-f4ed-4a80-9510-c5577905ecea">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36a74143-212e-4a2a-856e-058a33609373"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fcc0d0c7-668f-489f-bd70-0296e036dfa1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/402e5ed0-da52-474d-8a2e-5adbcf25c70f"/>
    <dc:identifier>DB00114</dc:identifier>
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf1c1786-0ddf-4d62-873c-90b0f9a94d49">
    <dc:identifier>DB00235</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bccb94b7-126e-4da9-a19a-6454c8a97e53"/>
    <rdfs:label>Milrinone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59a49a7a-6ebd-4238-85ad-1922ed2f0c76">
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>biochemical abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c4b236f-e128-47b2-bcb2-77f054e178b1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1bcd57e-0912-462b-b998-7f4577e1c78e"/>
    <rdfs:label>Uridine triacetate</rdfs:label>
    <dc:identifier>DB09144</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64145cff-ea9b-46f5-8b95-81a58e9a735e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/239fd360-f723-4de0-b629-f0a438f22ca7">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7ab7278-fe8a-40cf-a981-95072c5275a1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e0672d1-671b-471c-9b86-c0bbe29daaac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad449995-36d6-4713-bbcb-11482a689160"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1270e636-6354-47b6-9c2d-c4a15f3af99f">
    <dc:identifier>DB04552</dc:identifier>
    <rdfs:label>Niflumic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9aec8e6-b356-41ca-bb5b-7d7ea6bb2444"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e0ecad2f-2d46-49a7-9753-3effb3aac820">
    <dc:identifier>DB04844</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
    <rdfs:label>Tetrabenazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ad9c126-b87b-4d83-b02c-1de979831e09"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99bfd0cb-67b8-483f-916b-8616cc88592e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9c2980b-35aa-4179-93d8-96324805547c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2572d05e-c84d-4979-ae87-4c1e2a44c83a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
    <dc:identifier>HP:0003678*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1ab17b0-b5a1-43b0-913c-c3791f538787">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Self-injurious Behavior</rdfs:label>
    <dc:identifier>HP:0100716</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a91b3cff-149f-4275-a9f3-fd726433b721">
    <dc:identifier>HP:0001903*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>primary low heamoglobin level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/825974d0-2398-47a4-a126-7203c4b29f27">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/badf6cd9-0688-405b-976b-1d4400e6b3e9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0c00bd7-1088-4639-8266-704afb1c21ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e0cd14-5985-45e5-86aa-6ffcf41f5349"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47e91f80-c98b-4095-b99a-d4b3cf5a1361">
    <rdfs:label>pruritus</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000989</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce96fc90-1137-46a9-ad89-efd7961eda39">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
    <rdfs:label>Duloxetine</rdfs:label>
    <dc:identifier>DB00476</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0457a024-ffb9-4f87-b6ff-08cfbc296a6f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37dd416c-49d9-4c5e-84b4-69d5163c73b0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
    <dc:identifier>HP:0001138</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Optic nerve damage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/29c5e071-19ce-4666-932f-e7032b2a01dd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7b93b17-c356-4831-8c99-4e5ff59095e3"/>
    <rdfs:label>Anakinra</rdfs:label>
    <dc:identifier>DB00026</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f6c78f8-1ca6-45fa-b86e-45095946af83"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4916d40-ba9d-42cc-a732-393c59ddc093">
    <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
    <dc:identifier>HP:0040006*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d762b50-5889-4441-873f-724d99262f87">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3bfe3db-3cd7-43db-9e1b-3ceb20c76b3d"/>
    <dc:identifier>A11</dc:identifier>
    <rdfs:label>VITAMINS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27b3846b-0c64-4102-bcbe-6477445cec93">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/91b5fc0d-f7eb-4b14-ba25-7872cd3f3f96">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46998788-06d0-4277-b746-27cad1d171b4"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5decf862-1b87-4ada-a567-420634fbbb81"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
    <dc:identifier>A11E</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ac32890-329c-45d7-910c-55cf1f265521">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1849a663-fe16-46eb-8ba7-6037709410d9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c08dc99d-f730-41c1-9faa-2c3800395be3">
    <rdfs:label>Benazepril</rdfs:label>
    <dc:identifier>DB00542</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19886453-377a-4eb7-825b-71944bcc9e81"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/931e0f15-33b0-418a-a8c5-9b2f79461f4b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lower extremity weakness</rdfs:label>
    <dc:identifier>HP:0007340</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10ee8be4-d0ae-4bc5-98ff-271f9474ca33">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/815d6577-1046-4862-b2af-d40c9826ff93"/>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <dc:identifier>DB06819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d0b08e6-d67c-4c80-9715-bbcbfef77d5b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69ed908f-3aff-4431-bab4-e074384911ac"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80565c9a-d7e3-4783-963d-fde4ee618312"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bd95760-5b97-4f54-bb4c-fce37e6b0add">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04067a75-ce89-4798-ba27-66acd0193aa0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e71a71b-eedc-490b-8e57-37b78888c721"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1710ea1d-4c04-491e-ba4d-407b4526e2c2">
    <rdfs:label>Sebelipase alfa</rdfs:label>
    <dc:identifier>DB11563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bea7908a-1714-47d7-95df-0e4ab434c91d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36288ad9-08d2-486b-8c57-ed0691e10236">
    <rdfs:label>abnormal nucleotide sugars</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
    <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
    <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4144eb9-2864-4f46-8570-f20820491415"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/160481f9-64e0-4449-8710-6317916271f9">
    <dc:identifier>DB09422</dc:identifier>
    <rdfs:label>Soybean oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5da237c-4a7d-4595-928e-a98d8f19a5c8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a148142d-0094-4a0c-91d2-db92caed7108">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
    <rdfs:label>Cardiomyopathy</rdfs:label>
    <dc:identifier>HP:0001638</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91864125-1d8a-42a4-b6f6-5bc1e61992b8">
    <rdfs:label>Fatty liver</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001397</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdbd47f8-f6dc-4b74-9fc4-cb23cf3dc984">
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d23eda5c-77b7-4c35-a537-a8019626e248"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <dc:identifier>DB09539</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8abe4196-2063-4d29-a353-0b573a997aa2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39a1b78f-fdbb-41cd-a9b4-db75f04306fd"/>
    <dc:identifier>DB12890</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
    <rdfs:label>Dihydrexidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f41de4bb-1c87-4f2a-bb0f-2dd69d5acc2d">
    <rdfs:label>Tempol</rdfs:label>
    <dc:identifier>DB12449</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf8f5157-6483-4e79-bf26-8a35057f8f35"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b656a6f-e087-4d04-b153-e61fc565a3e1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0145ad3-66b8-40ed-9534-a465f50825bf"/>
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8517b0d-5195-488b-a9b2-1d4b028600b0">
    <dc:identifier>HP:0002630*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5d9663c-98b1-4e4d-8f08-1b43f323977f">
    <rdfs:label>hemolytic anemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001878</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1dddc903-ae4e-48f1-9fa0-7bb43fae4043">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1257e5a2-d206-4a97-ba9a-b2197358badc"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4ee7b93-882c-42f4-ae14-61f083171d42">
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f172ac76-4755-4558-a27d-9e4998b914fc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b7c586b-1d9e-4026-8bb4-15742394cec4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/934780db-650f-45d9-8050-4d0a8f585cfc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
    <rdfs:label>Phosphorus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d37204cd-77b5-448b-b50d-28a650a4c8d1"/>
    <dc:identifier>DB14151</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d96dbf1-925c-4507-8b02-3e2553e8667d">
    <rdfs:label>Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85eedb92-29c6-4d09-a1a2-49203c78650b"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6e28450f-d656-426c-bca9-2d6375a01cc4">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6dee938-32c1-4b21-a5bf-82a69abd3047"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a5d0739-a54d-453d-8690-c4646f8b75d7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00ab71b8-4d11-4636-9395-a126ac6cc294">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
    <dc:identifier>HP:0001376</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ba3e26ad-21ea-41aa-80d5-f423e78148d2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26930d1e-93c5-4bb1-8ff2-aefae5582e7e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/18772f79-1bfe-45fd-ae31-40ffea23cdf5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c635aec2-e9ec-4cc3-a5ff-0e19835c7104">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e03f7d1-6e75-4406-985e-72ba1f75d64b">
    <dc:identifier>HP:0000518</dc:identifier>
    <rdfs:label>Cataract</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16f02065-7df3-426b-9819-8ef7cfcc6e32">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
    <dc:identifier>DB00112</dc:identifier>
    <rdfs:label>Bevacizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed57a27b-26db-430a-a6f0-07885e86e9ae"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9aa67007-d512-4e1c-b5bb-a77f4bee8565">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55e71b38-7a93-48e1-8fe4-8fc14bf153c4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1058a72d-8d22-4f91-841a-ae0d18db50c2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/625f5b76-5afe-47b5-8878-8635730a0b67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa004478-1d82-465a-8e92-b9ad17c194cf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04df27a0-27b1-4e2c-8330-690cebefcaaa"/>
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <dc:identifier>DB14002</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f7d139b6-8d86-4582-ab27-985f7c07e0d7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/105a7e7e-92ac-4248-9270-d5d6e17077c8">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4fd1e269-5ac2-440d-b925-5ce9f1c6929b"/>
        <dc:identifier>M01AX</dc:identifier>
        <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f5af3f7-2689-4f0e-bd81-d22b586ee254">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4981803-6f5d-46ac-aaa6-3c643a5655a1">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/184bd0d2-5379-4b29-b565-5c46ed4f5fe8"/>
        <dc:identifier>DB02691</dc:identifier>
        <rdfs:label>Glycocholic acid</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f885fd4e-17b2-473a-92e9-c75939831f6b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <rdfs:label>Eculizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bdda515-ee70-4d30-b17a-02604bbf39e7"/>
    <dc:identifier>DB01257</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f072b7e-102a-4f79-a309-60cba72e39fc"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/415ae071-acd8-429e-aa91-737e235e6a3e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e96950c0-d49b-4c49-8dff-bea38e3c71f3"/>
    <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
    <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2614a453-9a64-4d13-9130-40046e14d321">
    <rdfs:label>Arginine-restricted diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a544882-c173-45d4-9c32-375e9778ba88"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41eeee59-8c4e-4975-86ea-32c5fcae05db">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a988dc80-b286-45e3-99e0-2d75d96cdc85">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>retarded growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50b1c85b-dc38-4e45-be46-bfec5b9d8fc7">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/589e1314-d5c3-4fd6-99a6-d4253f40aea4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cd0155c-5601-4665-973d-fabae59517e3">
    <dc:identifier>HP:0001903</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low hb level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81c03bb5-d6e9-4421-800d-1f7bd572a53e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75a2c86f-d7c4-4f72-9e17-a4e749ce35cd"/>
    <rdfs:label>Prokinetic agents</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6937c442-9575-4bef-a4d5-5d096f116059">
    <rdfs:label>CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21353248-18d3-41cd-8f21-d6ea01f36578">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4ef804c-a655-43e9-a685-2f550df41f1e"/>
    <rdfs:label>Fenofibric acid</rdfs:label>
    <dc:identifier>DB13873</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae37504e-7ae2-41fa-9987-9685dcadd9dc"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07b22438-d150-4bce-8ecb-cf58accd691e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c80b7f7-58ed-41fb-9815-98014e8b731c">
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57899c5c-06e1-408e-ae60-57d61d29712f"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/184bd0d2-5379-4b29-b565-5c46ed4f5fe8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8115d455-f08e-4211-98b3-83c30576d742"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1dbe07e-977f-4633-9d51-ff78fdf8d95b"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f5af3f7-2689-4f0e-bd81-d22b586ee254"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6817b284-c31c-4e04-b20c-9d2ee8ba7cbd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11e043a1-c61b-42e9-af96-a404e06d9315"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd481a73-0be7-4cdf-b09e-41a6c2c476cb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031034</dc:identifier>
    <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a343e3b-cdfb-4b7c-96b4-1e59481cb0c8">
    <rdfs:label>Elevated prostaglandin E2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
    <dc:identifier>HP:0003566</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/536eea0b-4bcc-4164-b189-46f0c09637dd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor eye contect</rdfs:label>
    <dc:identifier>HP:0000817</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bcf9be3c-31d4-4af1-a5e4-6c9769e2deb1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef600696-0f0f-4f43-807f-ea99f2d0c97a"/>
    <dc:identifier>DB01197</dc:identifier>
    <rdfs:label>Captopril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0269237-11a5-42b4-a850-da0c29d47028"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d416e1a-1d14-4dc0-a52b-29c0fcf4f0c6"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5c78d6b-0ef4-4e9a-b50a-289240c40019">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d35f2e3-d8ba-42ef-a051-ace9cbde3d85"/>
    <rdfs:label>Amcinonide</rdfs:label>
    <dc:identifier>DB00288</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8817cc30-1283-403b-b0da-6be4356d1d32"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9da58d03-2feb-46d9-bfd6-fe0d9393cd88"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0213378b-ec3a-4ce5-8e22-50ac1facd733"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e372a006-5ba6-4a5a-93e6-6ea42c7bc070">
    <dc:identifier>DB00065</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36e2779b-782d-421e-969d-b2ae30020d92"/>
    <rdfs:label>Infliximab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/709ef93f-dcef-4da9-a02b-3f6fb0a08e30">
    <rdfs:label>AAV9-TAZ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3dd497a-2389-4e14-b72c-72879ec985b4"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5846b0b-20e0-406d-a26c-5cdae435ac6e">
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
    <dc:identifier>DB13257</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc867f93-8c69-481d-bb3f-4a484cb24938"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62c7731c-eb30-4f7b-b6e8-632ee13fc2e1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/53a45212-68ff-4f9e-8aad-6ce3fd526760"/>
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6492a1af-250c-4ede-bbfe-2eb1e13032e2">
    <dc:identifier>DB04540</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5091d2f6-c7d1-4071-963b-44111db38163"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <rdfs:label>Cholesterol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2d1bc1d-a096-4b40-8503-2ef5faf9d8fc"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9a909fbc-8c2e-4320-8057-ec317ae95ab5">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f07d186f-945a-4b0f-abd3-55e7616146ce"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09801dd2-f331-406d-a419-b28faaa79b11"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/659f450b-0a09-4a53-ade0-af5818393dae">
    <dc:identifier>DB01914</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76ebd45c-ce25-4ada-bca4-d266b950c93f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c346dbe3-d7fb-4d1c-abda-be0f486d57a8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/badf6cd9-0688-405b-976b-1d4400e6b3e9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <rdfs:label>D-glucose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b9ae963-08a4-4be1-b790-32293698f671"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1c95050-6768-41f6-b710-9756f6344674">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed21356e-8167-4f27-8b79-6240ab7556b4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0762cea-19fe-4c69-b4aa-cf442e8dd343"/>
    <rdfs:label>Etanercept</rdfs:label>
    <dc:identifier>DB00005</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f77e8cde-39e1-47a8-acdd-d86c2485a195">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2dd67d26-5557-4391-bcd0-a0477ff128e9">
        <dc:identifier>CHEBI_84293</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86d74820-b80e-4fbb-aaa5-db28571bb30d"/>
        <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69ecd0b2-3f2a-4aed-a7ca-5539cff7cbe3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DNA hypermethylation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/788e89e7-67f3-4bb0-8e8b-497a76f5d262">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002180</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae50881a-e1ec-4031-818b-0a61093de809">
    <rdfs:label>Mucosal lesions</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be0fa6ab-a63a-4f73-aab3-2ae07f84d3b7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8831d90-6a07-4f12-82fd-de4c6c9291cd"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4f73c6e-55bd-4e39-8e10-776eefb18458">
    <dc:identifier>DB00145</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d2910be-ef3f-4c8f-91c4-9af3be719958"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04459c8d-d6eb-42bc-bd60-3fc550c5bcc6"/>
    <rdfs:label>Glycine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c689f8f0-3a53-4e90-aff4-165b557df696">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008897</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
    <rdfs:label>Growth impairment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/551f3e45-a42c-4190-b3de-a205a77672fb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfd42121-f28e-415b-b2fc-a26aec660d39"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c4bf98d-9965-44b8-99f2-0ec3e966f8b8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <rdfs:label>Elamipretide</rdfs:label>
    <dc:identifier>DB11981</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e1d9244-2924-4d81-a9bf-e17dfc968b17">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
    <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010535*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/315c1d5c-3442-4a21-9a5e-cb1c378c0c49">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <rdfs:label>Deferoxamine</rdfs:label>
    <dc:identifier>DB00746</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6389689d-b085-4b7e-ab42-509569728b9c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc25e2f1-a2ee-4894-9867-4c34ebde86d8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69b4d3a0-eb56-4454-99e5-535ef165c3f6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2dffed7c-b148-4fdc-9859-11b8c4c25858"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b77badf1-490b-4450-b8eb-eaec56ae16cd">
    <dc:identifier>HP:0012120</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High urinary malonic acid</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f098221-f297-454e-8634-aa7435638885">
    <dc:identifier>DB01026</dc:identifier>
    <rdfs:label>Ketoconazole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b31c10a-4cbd-4ec5-b970-8164e16d02ad"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/809e0771-24b0-415c-95af-cb89cfcb5d85">
    <rdfs:label>Cholestyramine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de560661-f85a-4d51-8d5d-5e0f46b108cb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0538677-fe56-4b1c-a3bd-33ef3d3d3a46"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <dc:identifier>DB01432</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87b09f7d-7bab-42a5-b5f2-ab5a5f68e7f6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18f1e9da-febd-4584-94fc-52afe435ab11"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4fd1e269-5ac2-440d-b925-5ce9f1c6929b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7d139b6-8d86-4582-ab27-985f7c07e0d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a343e3b-cdfb-4b7c-96b4-1e59481cb0c8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cf0d49b-812d-4294-b2cd-edfb71838b83"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0702b3e-cae8-420d-bbb1-f4b2a93b193e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3252bb1b-5ef5-41dd-ac63-046d28bffbfb">
    <dc:identifier>DB00158</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c30e7ecd-324e-41aa-9669-a7f5aaa2d3b1"/>
    <rdfs:label>Folic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92e791d6-c064-4879-bab5-3e33b6af62a6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000870</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
    <rdfs:label>hyperprolactinemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5d5f306-24f8-4562-a333-fbf4f597e874">
    <dc:identifier>HP:0001396</dc:identifier>
    <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b27404b6-c013-4752-b731-14a7cb51e31c">
    <dc:identifier>DB01403</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9eb5c914-ace3-46d8-a01c-50f414b07428"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
    <rdfs:label>Methotrimeprazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb3a3f7b-3ef7-406d-afaf-dc8a7fd7d848">
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b04f7fca-a11e-445b-9177-ff033af4c9ee"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
    <dc:identifier>D07A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fd14756-0ddb-42e4-a98c-ec0aaeba5414">
    <dc:identifier>DB09046</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9eea98c7-9917-4d56-96ea-02db4edcf1ff"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <rdfs:label>Metreleptin</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/579909d7-f3be-4795-9afb-291e2cd073de">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5bd72ffc-e6e0-4596-a98a-ff35e00237ae"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11c5178c-cb49-46ee-8223-62b2eca1e3e7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3a3d21a-6d97-4c80-82ed-9a994534ef87"/>
    <rdfs:label>Progesterone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <dc:identifier>DB00396</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/742562eb-550e-4a39-bd14-16cefbaedd94">
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:label>Poor fine motor skills</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f120e42d-da2f-4eae-86fc-63c0a00782fb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7c3d486-e0e0-43a0-9e24-88e21573f3f7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/524b37eb-fb89-438e-8b86-fbd61eeab40a"/>
    <dc:identifier>DB00152</dc:identifier>
    <rdfs:label>Thiamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9eaaceca-5e11-48ba-8bea-50f66c95d96e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f648156-7dcf-4ba8-ac6b-799690de8335"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c35cdf76-d420-4aed-9849-6640abe339b9"/>
    <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c918b3b-0a8e-4c7a-a0a3-22c9227bd6b1"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c6527af5-309f-4409-81df-1d4d7a7e5b49">
    <dc:identifier>DB00051</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3ec7470-3f3e-47a6-a4e8-d7ba8a8d3dbf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
    <rdfs:label>Adalimumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec274b29-ada1-4f6d-89a5-8062deac3b42">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <dc:identifier>CHEBI_28384</dc:identifier>
    <rdfs:label>vitamine K</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76a1a4e6-3433-4d5f-b655-5ee581aafbbf"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5007472b-7929-4ede-8077-ea22dcba4b2d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3cda9a7c-4195-46b4-aeeb-fa154f5ed765"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7bac2d8c-6b8f-4f3c-8eeb-ad1ac3a71fd1">
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/03bf4ff3-a43e-45d3-9025-8cf69f16a6ab"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ee2de93-7cf3-440d-a2a1-3f566aa62b97">
    <rdfs:label>pseudoexon activation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c83dd151-4558-427a-a250-27d613395c1a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low brain glutamine concentration</rdfs:label>
    <dc:identifier>HP:0030980</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3558e4e-0e52-4ae9-84f2-14d49db046fd">
    <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0684c11-652c-49c0-8ab1-018f86873082">
    <rdfs:label>Increased intraabdominal fat</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008993</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d3e1b55-e283-4ccf-8695-bdbf23408062">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6699aeb-0b4d-4246-9ca9-e48a8b083f1f"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d268d2e3-6689-4991-be52-9786e8189ac9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dc17b85-81ec-43b8-9a16-6c5154c3deeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f4193862-dc1d-4813-8973-d9b13cc36420"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a83ece3e-726c-45bc-8d48-65cb79409a1b">
    <rdfs:label>Elapegademase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ccd62e4-a383-4dda-bb49-ae57e6080709"/>
    <dc:identifier>DB14712</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62e2a7dc-da9e-4d8a-b7a2-4c99431dc28a">
    <dc:identifier>HP:0009051</dc:identifier>
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/091c65c5-d448-4d3a-be52-894dbaf544c0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b67edfe0-bd14-43ae-a8f5-115de4219932"/>
    <rdfs:label>Gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e886d96-d44e-4da6-96c0-27ba6b292083">
    <dc:identifier>A11EB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d6b15e8-ba02-46a0-bcb4-18a2b50adaa4"/>
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4bc5e92c-2ef1-49cd-9de3-6a6cd9ababbd">
    <dc:identifier>DB13178</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c540cf98-a177-4980-82c0-99a675d57899"/>
    <rdfs:label>Inositol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66555cbf-be75-4823-8b38-b9a95994e93d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f6b112f-e830-4e59-85ca-e48839270f06"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/efd010d3-5776-4ad8-b4bf-24ea6e3504e6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50e50643-02ec-4f98-8635-c4e5f98613cd"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63c6f556-cb8f-4184-9506-d2b2ffa985ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87738124-6203-4cd1-a2d2-64fb7367a478"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/960f5da2-3ce8-4b4a-a100-ce025192d84d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/768f6256-00fa-4315-95ac-6dddf2055f24">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0ca1472-8de0-4567-bb4c-6f7e3e335c38"/>
    <rdfs:label>Torcetrapib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
    <dc:identifier>DB06281</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57ca153b-5f0d-4b35-a561-24e3a7b4991c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c4a778d-98a1-4997-8ce3-aaf2424c2745"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
    <dc:identifier>DB02053</dc:identifier>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e31f96f0-4571-4e93-b497-af7b909b1dd9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
    <dc:identifier>DB01234</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ec1aa09-dcaf-47e2-b2a3-57d9ae27f275"/>
    <rdfs:label>Dexamethasone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0407d98e-d400-4395-b2e3-c567e9cb32e5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15adf047-c5d9-4885-9923-f8e1ee399144">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012048</dc:identifier>
    <rdfs:label>oromandibular dystonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/421f306e-1407-4c0a-be47-917772015308">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e9a2c99-b559-42d7-9c4a-80d9b6e77652"/>
    <rdfs:label>L-Leucine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <dc:identifier>DB00149</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5decf862-1b87-4ada-a567-420634fbbb81">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27b3846b-0c64-4102-bcbe-6477445cec93"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3bcdf09d-f719-47f0-9994-d50d62220e8c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb3c3d2a-872d-44c6-a4c3-c488c3fcb197"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13c0194f-2eaf-4645-81f1-2d8fc08a4556"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55d1ae0c-f123-42de-9007-d42ac09a4b82"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0504fe4-54e2-4e57-a3f7-b5ae0596c9e1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03d5cbeb-614e-47a6-a2be-225512f1e1c2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <dc:identifier>HP:0003141</dc:identifier>
    <rdfs:label>Increased LDL cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f0b06eb-6a80-49d5-b703-5d69dc9e8332">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/694c96c6-fe34-4c3e-ac80-84652c8538a4"/>
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/26ea1afe-b428-4479-874b-684bb6276366">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe1d4a23-66cb-476f-b9d4-9cf5a2ef5f30">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/761742a5-e395-4fd1-9bc6-a049422d5f2f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cf0d49b-812d-4294-b2cd-edfb71838b83"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40fbb7ce-061d-45a2-967d-17af70710222">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/822d1ce5-a6fe-442d-a0ca-31e4ef9c2340">
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>skin photosensitivity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87c5bdae-dd64-4855-aab1-870fd8421496">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51ae0d3d-5359-47c8-9919-093479caef4f"/>
    <dc:identifier>DB01323</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38bc3b4e-59cd-4ee4-949c-d4ea20b3c94c">
    <dc:identifier>HP:0002098</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
    <rdfs:label>Noctornal difficulty breathing</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00552f93-b336-43b9-ad11-3d8aba3d4fcd">
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
    <dc:identifier>DB08830</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/872e0d49-4de4-4df9-938f-85cfdecef9e1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bcb9ebeb-0434-4e84-ac36-4b412f349022">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
    <rdfs:label>Vitamin K</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d6b15e8-ba02-46a0-bcb4-18a2b50adaa4"/>
    <dc:identifier>B02BA</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6db6567e-3a5b-4448-82cf-e6afaa389b70">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d33ceb0e-5068-45db-81de-48f46c856414"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f03809f7-614f-4891-9a7d-df0f556bc12e"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c891cca0-abbe-4430-94c6-466f7ee5619c">
    <dc:identifier>HP:0002111</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
    <rdfs:label>Low Forced Vital Capacity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9cdd8b81-2773-45f5-8593-f85deb05efbb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b4d02e75-0f50-4e7a-9f2a-117b73861ae8"/>
    <rdfs:label>Diazoxide</rdfs:label>
    <dc:identifier>DB01119</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b16a507f-1975-4657-abf8-0c8d7efb2a64"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb66e84f-1ecb-4d13-9ea8-1b0597ec69be"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b528d009-e5df-4592-9d77-571f7e02cec0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0c94736-4dc2-4ebf-a222-c820423f4ab7"/>
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b0f8901-2fcf-4688-b0c7-e9474b5cfbf4">
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfa1c6c3-c637-44b1-8fb0-322f666ed8f0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1c76aaf-dff1-4a6a-9577-67ba58a43404">
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low quality of ife</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1b9d3f3e-35b1-42dd-91c1-a9454ba74886">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97d01c92-7e50-405f-98f6-b0618f228962">
        <rdfs:label>Skin papules</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200034</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/247100"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae50881a-e1ec-4031-818b-0a61093de809"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/759fb870-5d35-47d8-80a0-b27ea8a0f707"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e34ca3-c9dc-44fe-88b3-24b968627e3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6fdcac6c-fefd-4b0f-97eb-3b8f5661588a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ea3f653-a1d2-4a77-b86f-7441ff3c0679"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d915c73-9b88-43d1-b407-061c2542667a">
        <dc:identifier>HP:0001072</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
        <rdfs:label>Elbow skin thickening</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1899252-f981-49de-bdd5-f25ce8bed343"/>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/951ba527-6108-4dcc-a88d-bc6b8fdd5234">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea2acbe7-b2b6-4380-94bb-50f5b23c1790"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db780100-48b8-4f1c-bcb7-dac436992a7c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:label>Growth failure</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38cc663d-a9b6-4b79-a08c-e3845c405c0c">
    <rdfs:label>Delayed motor development</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001270</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e27d7aee-d9b7-49bd-8adc-b8a5851a16f5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b8fb632-3b0f-4d45-a300-082171e26c4a"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
    <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3f95a537-e6f3-4e57-b5ee-a53b3ac22cb2"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb414df0-aa7f-4167-9c6b-40fc65044831">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
    <dc:identifier>HP:0001395</dc:identifier>
    <rdfs:label>Liver fibrosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad449995-36d6-4713-bbcb-11482a689160">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/239fd360-f723-4de0-b629-f0a438f22ca7"/>
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/100133a0-a779-49aa-885e-fa73db7d77d5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
    <rdfs:label>high EMA levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003219</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15bf221b-60ba-4d67-836b-ca573981a749">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8503aa3-8e6e-46a3-8ac5-07b30f99997b"/>
    <rdfs:label>flavanols</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bcd1c44a-27ed-4bf1-9499-a577805f922c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27488456-4089-4d90-9d8e-55e61a2c157c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
    <dc:identifier>DB13173</dc:identifier>
    <rdfs:label>Cerliponase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a87366d-bcf6-4be0-87c6-f21776851a3d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b47b6600-51f6-4256-bce9-8bb15111eef8"/>
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46a5137a-db77-493a-802c-0f95ccf03121">
    <rdfs:label>NA</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0630d680-dc13-4cb2-b95e-a3fa2a228eb1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cec2c303-c912-4852-a6ac-f896a20f5bb6">
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d52cfbef-b88d-44c7-9b07-ec36e56d42ba"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
    <dc:identifier>DB04075</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4f525f7-fbc7-474d-91be-98512380706c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc2d46e0-fedd-4e6a-b93a-f4ad3c5fc158"/>
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9528f1e4-5278-4b15-a09a-f147400f4dc2">
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
    <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
    <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b9c18a3-80f4-4ddf-a0cc-6c7fe703bfd4">
    <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5163fb2c-b239-4f61-a211-35e765c5ebd1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8c40fa1-326e-4ff6-80e9-f6aeec263a14">
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <dc:identifier>B01A</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cb430c2-23de-41c6-94ae-0fdbc388538c"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03c79ed7-ba82-4199-8408-d462449832a3">
    <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
    <dc:identifier>HP:0003119*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a15d7b5-fd32-4628-b670-76a0e80385d1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a3604a8-1255-42a8-82fc-7b9a970a42cf"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/df919f49-3ade-4c53-870c-3030f6b3b8a0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b4910613-b779-40a4-875f-0680e61307f3"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec3bf318-6127-4b34-8ea3-2d194325c96d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Body fat composition</rdfs:label>
    <dc:identifier>HP:0025521</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f094167a-d363-4c82-90fd-1dcb1ed4f0f6">
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/702d613b-dba7-4ff1-8f61-63ff2e930383"/>
    <dc:identifier>DB00034</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/404d3b0c-129c-4716-b10b-9bf1ce0ef09f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b06f75b6-75d8-4109-b103-81d2fadf1408"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62fc0890-926f-45a7-a205-4c3e8203d156">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <dc:identifier>HP:0003141</dc:identifier>
    <rdfs:label>High LDL level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42222e21-5a43-4e04-bf92-3af8ce9b2893">
    <rdfs:label>Atypical bile acid synthesis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/009d2391-c9d4-485d-8311-ba2c66f5634a">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
    <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
    <dc:identifier>HP:0000114</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21f75252-1218-4d3e-8c1d-0b47ec583b5e">
    <dc:identifier>H02</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ea429f5-894c-40ed-b783-285a73e675fd"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d7f22cb-aafd-40ba-8188-516d34de955d">
    <rdfs:label>GNT0003</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec3a69fe-24fa-44b8-b596-5d29c0bd82c1"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4cb5e280-2ee9-4904-b837-319be38c9697">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f57ddc9e-0e01-436b-9023-050d36a2139f"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/abfa4010-e8b8-4a4a-a4d7-41ee95b7a290">
    <dc:identifier>DB04159</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8359b919-4238-4a66-9ce2-c70c4240cc51"/>
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f479625-e166-428b-ba7f-da7ffab89117">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18fa833e-3ed9-4c1d-b17c-b4ca8a8e0719"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2acb0386-421f-4d3b-bcac-20a8cc3fd629">
    <rdfs:label>Inflammatory myopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
    <dc:identifier>HP:0009071</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af48ea38-6f9f-4779-a118-1e3f01616b8a">
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e106d3e-a31b-47cb-982a-4c41bd375195"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20c8bacd-e697-4032-aa51-36b2b2e204db">
    <rdfs:label>esotropia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
    <dc:identifier>HP:0000565</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d13dc500-7e7a-49ce-b60d-77b7816f2b90">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <rdfs:label>Velmanase alfa</rdfs:label>
    <dc:identifier>DB12374</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fbab007-7147-480d-add4-ef9293776132"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/794b6d21-9ced-449a-9d18-2339967b7569">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003470</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
    <rdfs:label>paralysis</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1baf68e0-2b40-4757-a23e-fe717d97fbf1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c966759-5ac8-4644-beff-a6e39d00583d"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db5ea088-7d7f-4afe-beac-18e2f7568779">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3ff602a-d056-4fbc-b024-60ac45e7a566"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/178fa760-653f-4128-8292-365a6959f888">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d60f6998-40c5-4a3d-9546-0a2372f8f73e"/>
    <dc:identifier>DB09039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c1ea9fd-6553-45d7-a8e4-0b73e867d520"/>
    <rdfs:label>Eliglustat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a4f9b46-1cca-4167-a725-4bb7e29c0ea4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1e66361-0d85-468f-ab77-47b5c324b49e">
    <rdfs:label>Ad-mG6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16b55569-a005-4722-b55e-d97914107236"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d138e27f-1ff6-4d25-b4de-42e5669536f5">
    <dc:identifier>HP:0005180</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
    <rdfs:label>Tricusped incompetence</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d8a29b0-8749-4071-9dff-030edd754ebc">
    <rdfs:label>Nitisinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45967b27-5978-40c4-ad7f-30c47354de8e"/>
    <dc:identifier>DB00348</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a5fe535-92a2-477c-b637-a2a59a4a1431"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9104385a-c8a4-4d8a-b196-ef609151397c">
    <rdfs:label>Droxidopa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80de7f10-cc5a-4993-a47e-70df32ecd291"/>
    <dc:identifier>DB06262</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3701a85-4c01-4a93-824f-e064599150ad">
    <rdfs:label>GNeo-IDUA</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf9cee23-a145-4f93-8d93-21661b1a0823"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e22e363-df78-4cd6-96f3-35a01c7f3995">
    <rdfs:label>Ad-hBUGT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3dc2f810-90fc-4702-be64-d04d65d86105"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4cf289c-0942-40bd-b727-ac0c8f1c3377">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04b4e5fb-18bc-4fa2-981b-9e1c0139faa4"/>
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f10c4080-a06e-4239-96fa-8f9ec15e4e5a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <dc:identifier>DB04789</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec196a87-9b4a-49a3-ac2a-8b1f892b4f7d"/>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/988595fb-e4ac-4acf-aaa5-b2dcb5ee9264">
    <dc:identifier>DB01345</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82b1318b-e7e6-4f3d-aa1e-20153aa336e3"/>
    <rdfs:label>Potassium cation</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d54f5745-b829-4f45-b65d-82888977d9ed">
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ba8050b-857f-4c2a-93d7-6935845dc4da"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b12a7b3-101c-44b0-a5db-6d4d7f1db132">
    <rdfs:label>rhPBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b421b57e-6b9a-4ef3-be55-5f7c36d1a815"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49e4db8e-1bc1-4fda-935d-d13afc1f0eb9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b469820-2834-48ee-b878-9ef99c217f2d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65b6cbf4-086d-4d11-8412-098f7aa6d4f9">
    <rdfs:label>Increased muscle lipid droplets</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
    <dc:identifier>HP:0012240</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fdbde11-f97d-4c4e-b378-732dc301a98c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c8817a9-5b3b-4d8d-8c8e-9ad708570a37">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2adb602d-58ad-4012-89b4-80cc6301bb11"/>
    <dc:identifier>DB01037</dc:identifier>
    <rdfs:label>Selegiline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed02ed35-5f67-4704-a3c7-ae938c7a0a38">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
    <rdfs:label>Macular cystoid changes</rdfs:label>
    <dc:identifier>HP:0008028</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fdb7e71-2d3a-4970-bc5c-bbe300074873">
    <dc:identifier>DB11859</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f0d5323-86d6-47dc-a7f2-6b45a76ff399"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc772cc2-d1b0-499a-b110-bf023399b3bf"/>
    <rdfs:label>Brexanolone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31f668dc-98ac-4363-8901-18d0ad71d7b0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d30c0e7c-e1bb-4651-95f9-968c0246a621"/>
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e62206b-5fe5-4755-bc7f-4dc856de60a4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
    <dc:identifier>HP:0000144</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95b28e5c-6b0c-45fe-b207-b6c782676f30">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
    <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
    <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c40278ae-f7c8-47d7-a421-86fa2bb5cf5d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1195d345-36e6-4bc1-807a-fe5c9eaa4f4b"/>
    <rdfs:label>Acetazolamide</rdfs:label>
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a909fbc-8c2e-4320-8057-ec317ae95ab5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24baa860-b133-4eb4-a6b8-637567cf116a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c5810f1-3d81-4a0e-90ef-9c55a49e9368"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21a0a2bd-b1c1-470b-9102-db383532621f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18b9aca0-10a8-4bf5-b249-0b6f1b78cbe8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c63881ce-2f87-4f6d-97b4-812360f03d9e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <dc:identifier>DB03485</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdc8944f-1ec3-437c-8fbc-6a7e9dbb9739">
    <rdfs:label> Softeners, emollients</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0614d83-a96b-446e-8015-75801db39e63"/>
    <dc:identifier>A06AA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8613f4e-f451-48f5-9e30-4b87d04158bb"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2c2ec5c-acdc-43b0-9a20-2db51a19fb7a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lack of strenght</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2cd83c1d-5fa4-4f5e-86d8-71fb1907b654">
    <dc:identifier>DB6756</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8398c62d-e6a5-4990-9683-a68506807ace"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15a212a6-ea9e-42db-a92b-0aa6338cf755">
    <rdfs:label>rAAV-PPCR</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d445503b-7f44-4148-a16d-af0f4dbdaf43"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a6dadbb-0d0c-4086-b6fc-b54d9732c24a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f22d2eb-6e25-48a3-8d40-b14ad4d5f597"/>
    <rdfs:label>Pyridoxal</rdfs:label>
    <dc:identifier>DB00147</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3640013-ffe4-43ef-9d1a-6affaf5cb20f">
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcfa2626-1da7-4b99-9607-bf86ade6357c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f43c21bd-e70f-4e78-889b-287abacc4aa2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d997f098-b4ec-4a1e-bc99-62db1bbe3fb6"/>
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bca8777-c157-40db-9088-f0b4c62e323e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003141</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b60061f0-0c82-4eff-9f16-3bee1afd24b7">
    <dc:identifier>DB00996</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
    <rdfs:label>Gabapentin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e7bfcbb-4a58-4774-a5b1-f40b4b5faeef"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8922ec2e-2776-4edb-9ec4-24b4beece02d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low expression of AGA enzyme</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/554bb998-00a1-4006-9571-69ef0c9eed50">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/777c2e92-2aad-4c55-8961-5abaacb14eb6"/>
    <rdfs:label>AT342</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c62d88af-ceac-4cab-bca7-671d55bbf537">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0db60fa5-cd49-4996-bc7d-fd61f1805710"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c359364-1b06-4b03-aa33-cf3edd3f9456">
    <rdfs:label>Gene Therapy ??</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/addabc34-d272-485f-8149-34c5400baa6f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/abb067ac-67dc-4801-a7d3-3bb8de44eb10">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <dc:identifier>M02AA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a61f6173-faf8-4e99-a98a-bda61602da3d"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ecabf769-c260-4e67-9eba-5c2f583cd11e">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d6ed35-c802-4b08-8d75-15ded88c2739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b49ffae-c7f4-4237-afa4-faf2678ff99c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6910c134-f058-49d0-a330-bce1474152e4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low Frataxin expression level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a313a22-a82a-4c00-a523-b9a6f5e510f7">
    <rdfs:label>AAV-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e1bd737-05b5-4728-a55b-5eb38ff6a3a6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/761742a5-e395-4fd1-9bc6-a049422d5f2f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26ea1afe-b428-4479-874b-684bb6276366"/>
    <dc:identifier>DB11098</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d09ee8f-6922-4960-bf21-6a752c3f75ba">
    <dc:identifier>HP:0002719</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/192e1f89-67d4-4c46-989e-d3a4d1976f0c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
    <rdfs:label>Cystathioninuria</rdfs:label>
    <dc:identifier>HP:0003153</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8c6d91c8-9f20-4214-ba6f-82847778ae98">
    <dc:identifier>DB00829</dc:identifier>
    <rdfs:label>Diazepam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10f51280-bccc-4b12-979c-9b0dd8297a4b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ea0cd8f-a26b-475c-9d74-50bab9a39ee1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
    <dc:identifier>HP:0040126</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low level of serum B12</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9144e907-8706-47e0-8dd3-0dfd43cad2fe">
    <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/366faf9d-f79d-4bf5-8a0f-f2331afcc5df">
    <rdfs:label>Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6df842d-010a-48f8-8aca-3623a7b24a39"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90910d1f-e837-4741-bde5-078058707f43">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
    <rdfs:label>Fructose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c75998c-c981-485f-8b60-d2b3d4b9ccc3"/>
    <dc:identifier>DB04173</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b5df7d27-e3d1-497c-90d9-ab98ba8de06b">
    <rdfs:label>Gemcabene</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba8c5de0-3fbd-4523-87a6-a73781c0122f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
    <dc:identifier>DB05123</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46998788-06d0-4277-b746-27cad1d171b4">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of the nervous system</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53823a91-b8ed-4511-949a-4c5a5bee0a69">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myositis</rdfs:label>
    <dc:identifier>HP:0100614</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0647d761-4e9a-4d13-ad5a-bbb60eb7e857">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3e6b400-f94a-4a94-93c5-58ac2c2b9530"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a798e4a0-d223-4d96-bc8d-42439e75dccb"/>
    <dc:identifier>DB00119</dc:identifier>
    <rdfs:label>Pyruvic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a916d2db-2388-4f37-a476-ee45d65dd7f1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52b96535-8df7-43a7-8632-c37d5e922731">
    <dc:identifier>DB09125</dc:identifier>
    <rdfs:label>Potassium Citrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d14403b-c1df-4be2-888d-556ee9487b03"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abe34805-a98d-4003-805e-89b21d52bf66"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0277a778-4e11-4c5f-a793-18de640d6580">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:label>steatohepatitis</rdfs:label>
    <dc:identifier>HP:0001397</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7a12cea-f87a-4090-90ae-a29a1308e12d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e8e5139c-3a56-4a3d-aee7-545e77fcecb1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6cc7c450-9f5d-46f9-93c4-b2e2278b5301">
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e433554-1c46-4575-983b-c4acc8c9c8f8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1299b1e9-50b6-4d3e-9548-bb273d2cbe39">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Rhabdomyolysis</rdfs:label>
    <dc:identifier>HP:0003201</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b2ed23d-5526-476d-a490-2f9ad5328dd9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <rdfs:label>Probenecid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31e62928-1423-4277-920b-d8e9498a6e7c"/>
    <dc:identifier>DB01032</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67f3522f-9284-4115-bd93-598795419e78"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/646d5e2b-1bcb-49ba-9353-3b8468c9d26b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <rdfs:label>Filgrastim</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8228a571-8c35-4ef9-acd1-9d24cc416cd5"/>
    <dc:identifier>DB00099</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82e48dee-2447-488a-8640-10799898ab3b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7460bef3-f45d-46e0-a620-d66f6762ae39"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92fab497-b94b-4987-b62d-3ccf90765599">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d268d2e3-6689-4991-be52-9786e8189ac9"/>
    <dc:identifier>DB00123</dc:identifier>
    <rdfs:label>L-Lysine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bbb880ff-f364-465a-b8d2-42ff6caf8b50"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fe5143f-aab7-496c-8590-710ec9080c82"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6bcf96fe-2dba-49c7-8830-e96f0f4f80a4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b2c7ee9-c064-493b-a792-a7e5874a1b77"/>
    <rdfs:label>Copper Histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be74836d-8773-4a8d-b04c-1470f9b9b41d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/094c0311-da78-4612-91de-d981c1cbc062">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29c5e071-19ce-4666-932f-e7032b2a01dd"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/473933d5-7110-4622-a688-d4009306269b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8dcb855f-9fd0-4592-8511-cedd4951dc91">
    <dc:identifier>HP:0030098</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
    <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6fbb2f46-d13c-4d60-8e8b-7fb3010a5318">
    <rdfs:label>Hemin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27e554e2-5675-4f83-b870-5464cf99f940"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b8a5640-a9a2-407c-a28e-d06b5ed65e01"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <dc:identifier>DB03404</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/894dc9ab-6c2b-440c-9467-92cc857be941"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca753c3d-70a8-49f8-8044-2dacd24e81fb">
    <rdfs:label>Flumazenil</rdfs:label>
    <dc:identifier>DB01205</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f078f53c-bf3e-4629-9197-210c723bf907"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17755cd5-891e-47e3-99a7-6239be5d827b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fc1d9ae-da2b-42d7-897a-b9bf057be5f7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a72d0a47-5276-4f2b-b323-ad6070857899">
    <rdfs:label>r LCAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/824fc419-f0af-4f35-b707-1aee10028a5b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/84df06e5-faf4-4524-ba6f-6a2d62df2390">
    <dc:identifier>CHEBI_26537</dc:identifier>
    <rdfs:label>retinoid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdcb604a-d92c-4ba9-944e-b662de77f535"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/307686bb-57ca-4d50-a98a-487a668290ef">
    <rdfs:label>Modified Atkins diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61cf57a9-a429-49ce-8962-e51a8f4f3e41"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87738124-6203-4cd1-a2d2-64fb7367a478">
    <rdfs:label>Benzbromarone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/efd010d3-5776-4ad8-b4bf-24ea6e3504e6"/>
    <dc:identifier>DB12319</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bbb7d36-88cd-4e61-8193-cc85cecd2baf">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>movement disorders</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fe9af0f-a3dc-4c8e-8c32-90dd83cd2cb1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6366d67c-e46e-478b-bbc5-280ce45dcbfa"/>
    <dc:identifier>DB01039</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <rdfs:label>Fenofibrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45a37aac-b5cf-484a-ab8a-4f0b94a40d34"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c96e27d8-c8db-4135-ab3f-df80de672f4e"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5507210c-58a6-4543-9599-1f854ffdbabf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16c4873c-9708-4fc5-93e9-314300d8ffa0"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
  </owl:Class>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/beb55732-e16e-4532-bf2b-a7913f8b4e2e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/674b9f6c-ebc5-4551-9739-2e42928edd0e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f2fd615-70f6-4f29-a7ed-06dfa469c419">
    <rdfs:label>AAV-treated βgal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85f57dbc-0054-4de4-8479-0dfa4554b9cd"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ea30a72-e1ba-4890-8af5-cb94932589b9">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
    <dc:identifier>(DB00328</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7704294-2e4a-4f4f-b4b1-898c2e124155"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d7986ec-fde4-4fbc-92fa-e5caf2d2ec7f">
    <rdfs:label>High serum amyloid A protein</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/189c0e94-a048-44b2-9083-d87f9391c52e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b27404b6-c013-4752-b731-14a7cb51e31c"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec5b2926-d2b3-4a71-9e5a-5aa470987fd2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6819f9b0-f387-4198-955c-608e244c861c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83d948d0-a338-48c6-a6a8-3af5719e230b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
    <dc:identifier>HP:0012120</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3e7805d-642f-43f6-bbf7-dc85a702c41a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05e776aa-7bcd-4566-906a-5dae174ab386">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0030980*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
    <rdfs:label>Low CSF glutamine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/40dae991-fa2a-4980-91df-3868ffed377e">
    <rdfs:label>Spironolactone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25e46988-79e7-49b5-aec3-5fdd7a279543"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <dc:identifier>DB00421</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57054856-12ea-48c0-b291-c77f0530d37d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9b188aa-ee0c-4c76-92b9-749ec2075076"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0adb1513-3e8a-4492-bb9e-f78851334d66">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6af9477-1036-48a8-99da-6bc1339e028c"/>
    <rdfs:label>(5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3022cf45-094f-45a9-952e-6489e1f48b36">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/074576ef-d393-45b6-ad56-3c75dbe6951d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccfeae75-51d7-4b8a-a8e9-998f25558615"/>
    <rdfs:label>Carbamazepine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
    <dc:identifier>DB00564</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f87b2bd-23b1-42db-b5d9-a28b22f235a3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ac582d3-3915-4643-98b1-dd75096bba66">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a36891a0-976a-48a1-b541-93988929cf96"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <dc:identifier>DB03147</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/522b01cb-1ce1-4c87-9af2-033f2e3d1215">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f38485f-aefa-43d3-aaa7-e1122f508c15"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f8eb2b8-a291-4d7d-bfed-557982bc589d">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
    <rdfs:label>decreased cholesterol absorption</rdfs:label>
    <dc:identifier>MP:0002647</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e7e52af-3c06-47ad-90e5-3d90c2f7c4ab">
    <rdfs:label>GNE gene lipoplex</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3149fe0-9d4e-47ce-a292-829ae8850a89"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6010639-5f18-48ff-a8fb-fb8e771f3d34">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
    <dc:identifier>HP:0010903</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c14f5c20-57b6-43f1-ad6c-81ee43c10210">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
    <rdfs:label>abnormal interactivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012433</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e3ddb8a-9258-47a5-ae66-cc6152612d25">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c8a912b-4150-4aed-9505-7451806908d0"/>
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5afc6b51-4df3-4197-85bc-9eabfa5b8171">
    <dc:identifier>DB0084</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bccb94b7-126e-4da9-a19a-6454c8a97e53"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5265beb7-9b99-4af5-973b-c2c9850e810a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43b56c30-9b9a-469b-aeeb-355555e3281d"/>
    <rdfs:label>Ezetimibe</rdfs:label>
    <dc:identifier>DB00973</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69904507-70c2-4c52-92bf-7e4d10436203">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High calcium excretion</rdfs:label>
    <dc:identifier>HP:0002150</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c93dcac0-1441-4743-a859-7c2e5f22916c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4dafe218-1563-41c7-a334-7d135211b9a2"/>
    <rdfs:label>Insulin Human</rdfs:label>
    <dc:identifier>DB00030</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9cbb444-1650-47d5-873a-b38145e6c12d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c905bca-df71-46d4-8582-bf77a292e95b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26bf68a3-72aa-446c-ae84-4025f00c1151">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <dc:identifier>CHEBI_25548</dc:identifier>
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fb42dc8-c4b8-429a-8bf3-2906825c474a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7bdedc3-59e7-4d38-9f52-241ecbd2e743">
    <rdfs:label>Chlorpromazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7c2f4fc-8973-40c5-a242-6ee222bd1e76"/>
    <dc:identifier>DB00477</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71cbb69d-ad23-4e39-9d5b-f35e752acb61">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39a80636-48f2-4660-9caa-ffeaf00931ca"/>
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c36a8ac-2f4d-4a9c-83e8-ea5a24c5e83a">
    <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d5483f1-8894-483b-bed8-96ea36188465">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15c27fb9-82f5-40ee-a95f-4783a7a455ea"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
    <rdfs:label>Gentamicin C1a</rdfs:label>
    <dc:identifier>DB04729</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbdab353-c3cc-4229-8f2f-51c8d2750540">
    <dc:identifier>DB00594</dc:identifier>
    <rdfs:label>Amiloride</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7704294-2e4a-4f4f-b4b1-898c2e124155"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4962946c-5a58-4ff1-b4b7-1305149da523">
    <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d785342d-f514-4a31-8a36-152fba2aed4b">
    <dc:identifier>HP:0004305</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <rdfs:label>Involuntary movement</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3d239f8-c2a1-4e73-97b7-46d42541c917">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6db6567e-3a5b-4448-82cf-e6afaa389b70"/>
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c029371-342f-4b10-8a6f-48147aa11476">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
    <rdfs:label>Atrial fibrillation</rdfs:label>
    <dc:identifier>HP:0005110</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5540dfb8-33cc-41cd-8f5f-aba57a2879cd">
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2907d2d-bca1-4331-81bc-e57e84f2ea0b"/>
    <dc:identifier>DB00999</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b75f3665-afa2-4d86-b02c-8763d46f4f68">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e8010c6-f0cb-4ee7-ab89-314ba7de3c6b"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5fce2dc-c9a7-4fed-a813-b450a283809b"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16a4eb31-c7fb-407f-9ee6-dcf8246ccd66"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1532c9ac-c4d3-4e92-b309-989078f38dc8">
    <rdfs:label>Colchicine</rdfs:label>
    <dc:identifier>DB01394</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2269f67a-84a8-4624-b9f5-fcf0502975c5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c41d1ca-c3c1-45a1-b78f-8c6c39d98ef9">
    <rdfs:label>Methylene blue</rdfs:label>
    <dc:identifier>DB09241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbea12d0-6736-428a-9472-6bd0a961bb57"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ddb5457-0b57-4d3f-a0a2-733f98cee623">
    <rdfs:label>Nifedipine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2d23b9d-e40f-4d63-94cf-ff53a8800622"/>
    <dc:identifier>DB01115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37645918-1166-470d-a8d5-335d1413d230">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec3da2d9-f809-47a3-b732-2718aa977e6c"/>
    <dc:identifier>DB00393</dc:identifier>
    <rdfs:label>Nimodipine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc875ae8-5230-4987-9085-583a5129a466">
    <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000166</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e05ab7c-7cb1-42a7-b87a-70691c171948">
    <rdfs:label>Increased liver enzyme activities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31ce3532-6caf-48de-9f7a-79a81fd4814c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a86435b-0804-42af-81b6-2368132a1e46"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e83a08a-e74d-485d-bd80-7fb50125c91d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76df5688-e96e-4d2c-850a-4284b4baa6c5"/>
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0d0a9d2-9097-4632-993b-feaf6843c392">
    <dc:identifier>HP:0010472</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/625f5b76-5afe-47b5-8878-8635730a0b67">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9aa67007-d512-4e1c-b5bb-a77f4bee8565"/>
    <dc:identifier>DB00111</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
    <rdfs:label>Daclizumab</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d199e02-8238-423e-bc65-a0036086ca14">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/635b3114-1d55-486e-9b03-24111916ed9d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7a898c4-4ec7-4dc4-914b-cc357cd7723b">
    <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a407695d-5afe-49e2-b805-aa3d77334057">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011227</dc:identifier>
    <rdfs:label>Elevated C-reactive protein</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65db7ed2-82ed-49d8-8052-a9562f13c7b6">
    <rdfs:label>Chloroquine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
    <dc:identifier>DB00608</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cba06df1-4032-4b4b-ba29-b0b616e26a52"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9928ff0-0934-499b-b14a-764923c979cd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
    <rdfs:label>Low dopamine level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012656</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
    <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/68b1c89f-9634-499e-ad0a-b718a71dcf8c"/>
    <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
    <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e080ae2c-6b09-469f-9e22-6e5c15fa50cd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>delayed growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a906de9e-0742-4713-9e22-4815088d152a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3eb233a-5e80-44e3-96a6-fb61dbe44e67"/>
    <dc:identifier>DB00129</dc:identifier>
    <rdfs:label>Ornithine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d143412-aa22-4c28-bf71-16fa590e5d0f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb3c3d2a-872d-44c6-a4c3-c488c3fcb197"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/150eef7d-b4d3-447d-b667-74620d84df0f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/473933d5-7110-4622-a688-d4009306269b"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ae9671f-60cc-4781-ad76-221dab2d3e20">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/caadfa09-bcd3-4b5a-a755-dc69ac2c9c09"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b9c4068-5de1-4a7c-a28c-1b6dba5c53d8">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <dc:identifier>HP:0011123</dc:identifier>
    <rdfs:label>Dermatitis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5d7e22e-1845-4f62-a6b6-9966053bc20b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41307c6a-3c8a-4674-8f0b-fab9b4690586"/>
    <dc:identifier>DB01611</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d863766-1d8b-4bc2-9c7d-0623e132231f">
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26ac2237-b845-41ea-8a4e-70a35ec03bb2"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e20bcf83-2125-4883-baae-987cddb82d89">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f66227f-e495-4c07-bb30-9572c4f214f1"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34d4a636-3ecb-4e11-b973-620d98452ce8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30c4f430-adcc-4dae-9b7f-d14a7c8c1c74"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea71e02c-ab70-455b-87a8-895ccde42719">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f6b3546-80a4-42a1-bbe8-8591c409c072"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6066d4d-d859-4c8c-82d6-e27a78dd03c7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>fiber necrosis</rdfs:label>
    <dc:identifier>HP:0003713</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e31e96a8-c108-476d-b3b2-ee0b6ab4ea11">
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a20c914d-e086-42de-91f7-6c02932cb399"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f72d3f21-e3f3-499f-a58b-d5d1160a3c06">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd29b728-f3ce-4b56-baf2-a2ff7fef2ebf"/>
    <rdfs:label>AAV-cG6PGH</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a238452-e3b7-4a03-afb7-6069784faf16">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5ddc351-5e9b-41dd-ad09-11a303935c05"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/389a2d19-8099-45f8-9451-291833764f1f">
    <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6230162f-c85c-41bc-b5e5-28152d08ae4f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/697739e9-98f8-416d-aefd-e8f72e4258f8"/>
    <dc:identifier>DB13191</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d497ca35-e2ba-4273-ab5c-8927b378f9f2"/>
    <rdfs:label>Phosphocreatine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe0fb7be-5eb0-4e9e-944e-f5c381100017">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a80e40f1-4502-4d80-930c-08386254f431"/>
    <rdfs:label>Amantadine</rdfs:label>
    <dc:identifier>DB00915</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d0d95af-6381-4430-9722-2f8a02532824"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba0f235f-84f2-4ae3-a9d7-5bc0cee7266e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97097396-8992-405f-a2b2-85e4ed42bdf9"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbb8a55c-de4c-4517-bb44-2e567aff6b69">
    <dc:identifier>HP:0003117*</dc:identifier>
    <rdfs:label>Serotonin deficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12f555c1-d719-4441-b75d-fab5bfccb673">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6b3dc13-a2b9-4923-b7fa-5d9423377b5b"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26bc56ea-aa15-4415-93fd-725fdc83131a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53d9c15a-653a-4c2c-9423-d23272e2f2c7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c14d6e7-4d93-4639-b11f-cb2149721697">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/682f1bb8-5917-480f-8971-d1950b1ae182"/>
    <rdfs:label>Pioglitazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
    <dc:identifier>DB01132</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/827e5f5f-85db-4967-a9f2-003e8dd73d6e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13302134-1249-4064-838b-f110d9206624"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bf7b990-d74c-49fb-9f57-b69c7993994c">
    <dc:identifier>HP:0004325</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low weight,growth</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06f8b658-2452-4c2c-9b76-c4e71838c744">
    <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a84c2898-ce2d-42e1-875f-e0c2801c03b6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d2866732-89bb-41e5-8d14-7d6bd278991d"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4ea69d6-d1bc-465b-aeba-27d6aecb4b58">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/797c5fed-670b-43ee-83ec-ac23d7dbfb1b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c09afd6-f880-424a-9641-d6a0e1a759ab">
    <dc:identifier>HP:0025303</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
    <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39ead54c-0807-437a-b37e-079836932ab0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <dc:identifier>DB00061</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5b87b515-9338-4fbe-9bd0-144026c22e8f"/>
    <rdfs:label>Pegademase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ec75377-48d8-41d3-bc55-8398f4f93af4">
    <dc:identifier>DB01233</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7dcbc81b-4f42-462f-91a7-5232789950b6"/>
    <rdfs:label>Metoclopramide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f0b1994-98a6-473b-8a2d-5082d0c1f2a2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Trial is no longer available</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7dd43eea-93fd-4614-85f8-2877aebc7c87">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf1cecc2-c750-47fb-84d1-4fc2706a89a2"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23d00816-d18e-41a2-b1ef-b0b31fc4c137">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7865902b-4e2e-4b4a-81fb-5be375eb9cfd"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c2508d4-96d3-4836-a722-a5a6bfb01d8f">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <dc:identifier>CHEBI_2786</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc68eeea-6ce5-4d68-b06d-bda5cd722f09"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b7694e5-8bc0-4ce1-b4bf-77f59565ac2a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8f73202-9d9e-40a6-8c2f-32575e328ed0"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a11e8fb4-7de8-423c-bcb8-a9843f80be4b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2564494-e585-476a-aa72-0050020d997b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28e9b592-5fe6-47b3-b3a5-cd152ee01cec">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>frequent hospital admission</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7653f9ed-b787-4ad4-b6e2-584a949e5b92">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
    <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
    <dc:identifier>HP:0003645</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12bce9fb-3ea1-4f9d-a168-a13fbb08a766">
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37b10c5b-0941-43da-97df-1a0455763c3c"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a2b4cca-97cd-4a05-97b9-472bdbb02384">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07e1be15-2b50-4c00-a5fd-6fcb3b76507b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e659ba26-e82e-4864-b787-ca8d7935cada">
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4fc085ef-dddf-4167-92c7-d13634f19540"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45315acb-7543-4ab2-95c3-200ed34fbdde">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brain lysosomal storage disease</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b60c549-72d7-45c8-874d-4330e033606a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c124e8f-cbe9-4e52-801f-4148e0b355cd"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08e57b06-1bb3-4d47-b973-c742024f24de">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b742e52d-1188-4cd8-9b1e-ca6d1dd09a78"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5bc31c1-c693-4d0d-ab5b-fde0c753ba4d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80462ebf-f5e9-4eb9-be8e-97b21c8ded02">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/578fcb98-ef9b-4db0-89d8-dbb0e7d55178"/>
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31deefad-ab88-4f9b-b375-fc017dbfc430">
    <dc:identifier>HP:0040306</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>decreased male libido</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2d2a7b4-a914-48b2-9fd8-0706c3cc520f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e9c538ca-4ac3-48ad-9b9c-3720abb25e32"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0562cf9c-86d0-434c-b7bd-6ba141c5bc8d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b27c09ab-daf7-4f0d-ad7f-f0d85f3d769e"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e2af13a-5b31-492a-a9df-2c0089009e69">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36a92f46-075b-4b53-90be-a703f2f31e24"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e456d8a9-a329-4174-9fb3-80db0d8574c0">
    <rdfs:label>Retrovirus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da37d10e-0146-4ba7-a751-a7c1d2a452c0"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/429e2b1a-2d0f-4df2-9240-f77fbc845b0d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b4e0925-c27b-4368-9893-ae24836c1313"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b50ea348-11f0-4baa-8c04-0f08b5b1ea18">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3d14ab35-f83e-4db7-97a8-79e2aeacb3f4"/>
  </rdf:Alt>
</rdf:RDF>
